0001171843-24-001239.txt : 20240307 0001171843-24-001239.hdr.sgml : 20240307 20240307170004 ACCESSION NUMBER: 0001171843-24-001239 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 117 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HARVARD BIOSCIENCE INC CENTRAL INDEX KEY: 0001123494 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043306140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33957 FILM NUMBER: 24731053 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL RD CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: 5088938999 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD CITY: HOLLISTON STATE: MA ZIP: 01746 10-K 1 hboi20231231_10k.htm FORM 10-K hboi20231231_10k.htm
0001123494 HARVARD BIOSCIENCE INC false --12-31 FY 2023 November 23, 2023 James Green Chairman, President and Chief Executive Officer true false 240,000 false false January 21, 2024 0.01 0.01 5,000,000 5,000,000 0.01 0.01 80,000,000 80,000,000 43,394,509 43,394,509 42,081,707 42,081,707 137 566 0 0 0 60 4 15 0 0 1 4 0 0 0 0 0 Weighted average life in years as of September 30, 2022 Updated dimension from: "Debt Securities [Member]". 00011234942023-01-012023-12-31 iso4217:USD 00011234942023-06-30 xbrli:shares 00011234942024-03-01 thunderdome:item 00011234942023-11-232023-12-31 00011234942023-12-31 00011234942022-12-31 iso4217:USDxbrli:shares 00011234942022-01-012022-12-31 0001123494us-gaap:CommonStockMember2021-12-31 0001123494us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001123494us-gaap:RetainedEarningsMember2021-12-31 0001123494us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 00011234942021-12-31 0001123494us-gaap:CommonStockMember2022-01-012022-12-31 0001123494us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0001123494us-gaap:RetainedEarningsMember2022-01-012022-12-31 0001123494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0001123494us-gaap:CommonStockMember2022-12-31 0001123494us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001123494us-gaap:RetainedEarningsMember2022-12-31 0001123494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001123494us-gaap:CommonStockMember2023-01-012023-12-31 0001123494us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-31 0001123494us-gaap:RetainedEarningsMember2023-01-012023-12-31 0001123494us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-31 0001123494us-gaap:CommonStockMember2023-12-31 0001123494us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001123494us-gaap:RetainedEarningsMember2023-12-31 0001123494us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 xbrli:pure utr:Y 0001123494us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2023-12-31 0001123494us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2023-12-31 0001123494hbio:ComputerEquipmentAndSoftwareMembersrt:MinimumMember2023-12-31 0001123494hbio:ComputerEquipmentAndSoftwareMembersrt:MaximumMember2023-12-31 0001123494us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-12-31 0001123494us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2023-12-31 utr:D 0001123494srt:MinimumMember2023-01-012023-12-31 0001123494srt:MaximumMember2023-01-012023-12-31 0001123494srt:MinimumMember2023-12-31 0001123494srt:MaximumMember2023-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2023-01-012023-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-01-012023-12-31 0001123494srt:RestatementAdjustmentMember2022-01-012022-12-31 0001123494srt:RestatementAdjustmentMember2021-01-012021-12-31 0001123494srt:RestatementAdjustmentMember2022-12-31 0001123494us-gaap:AccumulatedTranslationAdjustmentMember2021-12-31 0001123494us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-31 0001123494us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-31 0001123494us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-31 0001123494us-gaap:AccumulatedTranslationAdjustmentMember2022-12-31 0001123494us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-31 0001123494us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-31 0001123494us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-31 0001123494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-31 0001123494us-gaap:AccumulatedTranslationAdjustmentMember2023-12-31 0001123494us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-31 0001123494us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-31 0001123494hbio:DistributionAgreementscustomerRelationshipsMember2023-12-31 0001123494hbio:DistributionAgreementscustomerRelationshipsMember2022-12-31 0001123494hbio:ExistingTechnologyAndSoftwareDevelopmentMember2023-12-31 0001123494hbio:ExistingTechnologyAndSoftwareDevelopmentMember2022-12-31 0001123494hbio:TradeNamesAndPatentsMember2023-12-31 0001123494hbio:TradeNamesAndPatentsMember2022-12-31 0001123494us-gaap:MachineryAndEquipmentMember2023-12-31 0001123494us-gaap:MachineryAndEquipmentMember2022-12-31 0001123494hbio:ComputerEquipmentAndSoftwareMember2023-12-31 0001123494hbio:ComputerEquipmentAndSoftwareMember2022-12-31 0001123494us-gaap:LeaseholdImprovementsMember2023-12-31 0001123494us-gaap:LeaseholdImprovementsMember2022-12-31 0001123494us-gaap:FurnitureAndFixturesMember2023-12-31 0001123494us-gaap:FurnitureAndFixturesMember2022-12-31 0001123494us-gaap:AutomobilesMember2023-12-31 0001123494us-gaap:AutomobilesMember2022-12-31 0001123494country:US2023-12-31 0001123494country:US2022-12-31 0001123494country:DE2023-12-31 0001123494country:DE2022-12-31 0001123494hbio:RestOfTheWorldMember2023-12-31 0001123494hbio:RestOfTheWorldMember2022-12-31 0001123494hbio:CostOfRevenuesMember2021-12-31 0001123494us-gaap:EmployeeSeveranceMember2021-12-31 0001123494us-gaap:OtherRestructuringMember2021-12-31 0001123494hbio:CostOfRevenuesMember2022-01-012022-12-31 0001123494us-gaap:EmployeeSeveranceMember2022-01-012022-12-31 0001123494us-gaap:OtherRestructuringMember2022-01-012022-12-31 0001123494hbio:CostOfRevenuesMember2022-12-31 0001123494us-gaap:EmployeeSeveranceMember2022-12-31 0001123494us-gaap:OtherRestructuringMember2022-12-31 0001123494hbio:CostOfRevenuesMember2023-01-012023-12-31 0001123494us-gaap:EmployeeSeveranceMember2023-01-012023-12-31 0001123494us-gaap:OtherRestructuringMember2023-01-012023-12-31 0001123494hbio:CostOfRevenuesMember2023-12-31 0001123494us-gaap:EmployeeSeveranceMember2023-12-31 0001123494us-gaap:OtherRestructuringMember2023-12-31 0001123494us-gaap:PensionPlansDefinedBenefitMember2023-12-31 0001123494us-gaap:PensionPlansDefinedBenefitMember2022-12-31 0001123494us-gaap:OtherNoncurrentLiabilitiesMember2023-12-31 0001123494us-gaap:OtherNoncurrentLiabilitiesMember2022-12-31 0001123494us-gaap:DomesticCorporateDebtSecuritiesMember2023-12-31 0001123494us-gaap:DomesticCorporateDebtSecuritiesMember2022-12-31 0001123494us-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-31 0001123494us-gaap:DefinedBenefitPlanEquitySecuritiesMember2022-12-31 0001123494us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-31 0001123494us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-31 0001123494hbio:OtherPlanAssetsMember2023-12-31 0001123494hbio:OtherPlanAssetsMember2022-12-31 0001123494us-gaap:FairValueInputsLevel1Member2023-12-31 0001123494us-gaap:FairValueInputsLevel1Member2022-12-31 0001123494us-gaap:FairValueInputsLevel2Member2023-12-31 0001123494us-gaap:FairValueInputsLevel2Member2022-12-31 0001123494us-gaap:FairValueInputsLevel3Member2023-12-31 0001123494us-gaap:FairValueInputsLevel3Member2022-12-31 0001123494hbio:TermLoanMember2023-12-31 0001123494hbio:TermLoanMember2022-12-31 0001123494us-gaap:LineOfCreditMember2023-12-31 0001123494us-gaap:LineOfCreditMember2022-12-31 0001123494hbio:TheCreditAgreementMemberhbio:TheLendersMemberhbio:TermLoanMember2020-12-22 0001123494us-gaap:RevolvingCreditFacilityMemberhbio:TheCreditAgreementMemberhbio:TheLendersMember2020-12-22 0001123494us-gaap:LetterOfCreditMemberhbio:TheCreditAgreementMemberhbio:TheLendersMember2020-12-22 0001123494hbio:SwinglineLoanFacilityMemberhbio:TheCreditAgreementMemberhbio:TheLendersMember2020-12-22 0001123494hbio:TheCreditAgreementMember2020-12-22 0001123494us-gaap:RevolvingCreditFacilityMemberhbio:TheCreditAgreementMember2023-12-31 0001123494hbio:TheCreditAgreementMemberhbio:SecuredOvernightFinancingRateSofrMember2023-12-31 0001123494hbio:TheCreditAgreementMemberus-gaap:BaseRateMember2023-12-31 0001123494hbio:TheCreditAgreementMemberhbio:TheSOFRLoanAndPricingGridCreditAgreementMembersrt:MinimumMemberhbio:SecuredOvernightFinancingRateSofrMember2023-01-012023-12-31 0001123494hbio:TheCreditAgreementMembersrt:MaximumMemberhbio:SecuredOvernightFinancingRateSofrMember2023-01-012023-12-31 0001123494hbio:TheCreditAgreementMembersrt:MinimumMemberhbio:TheABRLoanMember2023-01-012023-12-31 0001123494hbio:TheCreditAgreementMembersrt:MaximumMemberhbio:TheABRLoanMember2023-01-012023-12-31 0001123494hbio:TheCreditAgreementMember2023-01-012023-12-31 0001123494hbio:TheCreditAgreementMember2022-01-012022-12-31 0001123494hbio:TheCreditAgreementMember2023-12-31 0001123494hbio:TheCreditAgreementMember2022-12-31 0001123494us-gaap:InterestRateSwapMember2023-12-31 0001123494us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001123494us-gaap:CostOfSalesMemberus-gaap:SegmentContinuingOperationsMember2023-01-012023-12-31 0001123494us-gaap:CostOfSalesMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-12-31 0001123494us-gaap:SellingAndMarketingExpenseMemberus-gaap:SegmentContinuingOperationsMember2023-01-012023-12-31 0001123494us-gaap:SellingAndMarketingExpenseMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-12-31 0001123494us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:SegmentContinuingOperationsMember2023-01-012023-12-31 0001123494us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-12-31 0001123494us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:SegmentContinuingOperationsMember2023-01-012023-12-31 0001123494us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-12-31 0001123494hbio:TwentyTwentyOneIncentivePlanMember2023-12-31 0001123494us-gaap:EmployeeStockOptionMemberhbio:BlackScholesOptionPricingModelMember2023-01-012023-12-31 0001123494us-gaap:EmployeeStockOptionMemberhbio:BlackScholesOptionPricingModelMember2022-01-012022-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0001123494hbio:MarketConditionRestrictedStockUnitsMember2021-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0001123494hbio:MarketConditionRestrictedStockUnitsMember2022-01-012022-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0001123494hbio:MarketConditionRestrictedStockUnitsMember2022-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0001123494hbio:MarketConditionRestrictedStockUnitsMember2023-01-012023-12-31 0001123494us-gaap:RestrictedStockUnitsRSUMember2023-12-31 0001123494hbio:MarketConditionRestrictedStockUnitsMember2023-12-31 00011234942023-12-312023-12-31 00011234942022-12-312022-12-31 0001123494hbio:EmployeeStockPurchasePlanMember2023-12-31 0001123494hbio:InstrumentsEquipmentSoftwareAndAccessoriesMember2023-01-012023-12-31 0001123494hbio:InstrumentsEquipmentSoftwareAndAccessoriesMember2022-01-012022-12-31 0001123494hbio:ServiceMaintenanceAndWarrantyContractsMember2023-01-012023-12-31 0001123494hbio:ServiceMaintenanceAndWarrantyContractsMember2022-01-012022-12-31 0001123494us-gaap:TransferredAtPointInTimeMember2023-01-012023-12-31 0001123494us-gaap:TransferredAtPointInTimeMember2022-01-012022-12-31 0001123494us-gaap:TransferredOverTimeMember2023-01-012023-12-31 0001123494us-gaap:TransferredOverTimeMember2022-01-012022-12-31 0001123494country:US2023-01-012023-12-31 0001123494country:US2022-01-012022-12-31 0001123494srt:EuropeMember2023-01-012023-12-31 0001123494srt:EuropeMember2022-01-012022-12-31 0001123494hbio:GreaterChinaMember2023-01-012023-12-31 0001123494hbio:GreaterChinaMember2022-01-012022-12-31 0001123494hbio:RestOfTheWorldMember2023-01-012023-12-31 0001123494hbio:RestOfTheWorldMember2022-01-012022-12-31 0001123494us-gaap:ServiceMember2023-12-31 0001123494us-gaap:ServiceMember2022-12-31 0001123494us-gaap:ServiceMember2023-01-012023-12-31 0001123494us-gaap:ServiceMember2021-12-31 0001123494us-gaap:ServiceMember2022-01-012022-12-31 0001123494hbio:CustomerAdvancesMember2023-12-31 0001123494hbio:CustomerAdvancesMember2022-12-31 0001123494hbio:CustomerAdvancesMember2023-01-012023-12-31 0001123494hbio:CustomerAdvancesMember2021-12-31 0001123494hbio:CustomerAdvancesMember2022-01-012022-12-31 0001123494us-gaap:StateAndLocalJurisdictionMemberhbio:ExpireBetween2024And2043Member2023-12-31 0001123494us-gaap:ForeignCountryMember2023-12-31 0001123494hbio:Expire2024Member2023-12-31 0001123494us-gaap:ForeignCountryMemberus-gaap:ResearchMember2023-12-31 0001123494srt:SubsidiariesMemberus-gaap:NonUsMember2023-12-31 0001123494srt:SubsidiariesMemberus-gaap:NonUsMember2022-12-31 0001123494srt:DirectorMemberhbio:IndemnificationAgreementsMember2023-12-31 0001123494hbio:CaseInSuffolkSuperiorCourtMemberus-gaap:ConvertiblePreferredStockMember2022-06-102022-06-10 00011234942022-06-10 0001123494hbio:HarvardApparatusRegenerativeTechnologyIncHartMember2023-12-31 0001123494hbio:HarvardApparatusRegenerativeTechnologyIncHartMember2023-01-012023-12-31 0001123494us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhbio:HoeferProductLineMember2023-02-17 0001123494us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhbio:HoeferProductLineMember2023-02-172023-02-17 0001123494hbio:ProgramsEstablishedToOffsetTheImpactOfCOVIDMember2023-01-012023-12-31 0001123494hbio:ProgramsEstablishedToOffsetTheImpactOfCOVIDMember2022-01-012022-12-31 0001123494hbio:PaycheckProtectionProgramCaresActMemberus-gaap:SubsequentEventMember2024-02-012024-02-29 0001123494hbio:BlackScholesOptionPricingModelMember2023-01-012023-12-31
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-K

 

☒

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 

For the fiscal year ended December 31, 2023

or

 

☐

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from         to

 

Commission File Number 001-33957

 

 

HARVARD BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

04-3306140

(State or other jurisdiction of Incorporation or organization)

(I.R.S. Employer Identification No.)

 

84 October Hill Road, Holliston, Massachusetts 01746

(Address of Principal Executive Offices, including zip code)

 

(508) 893-8999

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

HBIO

The Nasdaq Global Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

 
Table of Contents

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐

Accelerated filer ☒

  

Non-accelerated filer ☐

Smaller reporting company ☒

  
 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐  No ☒

 

The aggregate market value of shares of voting common equity held by non-affiliates of the registrant as of June 30, 2023 was approximately $219.4 million based on the closing sales price of the registrant’s common stock, par value $0.01 per share on that date. At March 1, 2024, there were 43,399,291 shares of the registrant’s common stock issued and outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the Company’s definitive Proxy Statement in connection with the 2024 Annual Meeting of Stockholders (the “Proxy Statement”), to be filed within 120 days after the end of the Registrant’s fiscal year, are incorporated by reference into Part III of this Form 10-K. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.

 

 

 

 

 

 

 

 

 

 

 

 
Table of Contents

 

 

HARVARD BIOSCIENCE, INC.

TABLE OF CONTENTS

ANNUAL REPORT ON FORM 10-K

For the Year Ended December 31, 2023

INDEX

 

   

Page

PART I

  

1
       
 

Item 1.

Business

1
 

Item 1A.

Risk Factors

7
 

Item 1B.

Unresolved Staff Comments

15
 

Item 1C.

Cybersecurity

15
 

Item 2.

Properties

15
 

Item 3.

Legal Proceedings

16
 

Item 4.

Mine Safety Disclosures

16
       

PART II

  

16
       
 

Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

16
 

Item 6.

[Reserved]

16
 

Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

17
 

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

21
 

Item 8.

Financial Statements and Supplementary Data

21
 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

21
 

Item 9A.

Controls and Procedures

21
 

Item 9B.

Other Information

24
 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

24
     

PART III

  

24
       
 

Item 10.

Directors, Executive Officers and Corporate Governance

24
 

Item 11.

Executive Compensation

24
 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

24
 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

24
 

Item 14.

Principal Accounting Fees and Services

24
       

PART IV

  

24
     
 

Item 15.

Exhibits, Financial Statement Schedules

24
 

Item 16.

Form 10-K Summary

24
       
   

Signatures

  
       
   

Exhibit Index

  
       

 

 

 
Table of Contents

 

 

This Annual Report on Form 10-K contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), each as amended. The forward-looking statements are principally, but not exclusively, contained in “Item 1: Business” and “Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations, our business strategy, our ability to raise capital or borrow funds to consummate acquisitions and the availability of attractive acquisition candidates, our expectations regarding future costs of product revenues, our anticipated compliance with the covenants contained in our credit facility, the adequacy of our financial resources and our plans, objectives, expectations and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “seek,” “expects,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “think,” “strategy,” “potential,” “objectives,” “optimistic,” “new,” “goal” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in detail under the heading “Item 1A. Risk Factors” beginning on page 7 of this Annual Report on Form 10-K. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Bioscience, Inc. is referred to herein as “we,” “our,” “us,” and “the Company.”

 

PART I

 

Item 1.

Business.

 

Overview

 

Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.

 

Our History and Strategy

 

Our business began in 1901, under the name Harvard Apparatus. It was founded by Dr. William T. Porter, a Professor of Physiology at Harvard Medical School and a pioneer of physiology education. We have grown over the years with the development and evolution of modern life science research and education. Our early inventions included ventilators based on Dr. Porter’s design, the mechanical syringe pump for drug infusion in the 1950s, and the microprocessor-controlled syringe pump in the 1980s.

 

In 1996, a group of investors acquired a majority of the then existing business of our predecessor, Harvard Apparatus, Inc. Following this acquisition, our focus was redirected to acquiring complementary companies with innovative technologies while continuing to grow the existing business through internal product development. Harvard Bioscience, Inc. was incorporated in the State of Delaware in September 2000 and became the successor entity to Harvard Apparatus, Inc. by merger in November 2000.

 

From 1996 to 2018, we completed multiple business or product line acquisitions related to our continuing operations. In 2018, we acquired Data Sciences International, Inc. (“DSI”), a global leader in products, services and solutions focused on preclinical testing. The DSI product portfolio, which is largely complementary to our cellular and molecular technology (“CMT”) product portfolio, expanded our product portfolio to address the continuum from research and discovery to preclinical testing with principal applications in pharmaceutical and therapy testing.

 

During 2021, we completed a restructuring program to improve operational efficiency and reduce costs which entailed consolidating and downsizing several sites and reducing headcount in Europe and North America. During 2022, we reviewed our business and product portfolio and identified opportunities to rationalize our product portfolio, improve our cost structure and  optimize our sales organization. In connection with this review, we identified certain non-strategic products for discontinuation and further reduced our headcount in Europe and North America. We believe that these actions will allow us to focus on product opportunities that drive sustainable revenue growth with attractive gross margins and improved profitability.

 

 

1
Table of Contents

 

Our strategy for driving sustainable revenue growth is focused on four areas. The first is to maintain and strengthen our existing competitive position in the areas of therapy research and pre-clinical testing, which we believe provides a base for expanding our products and technologies to address additional growth opportunities. The second is to expand our product offerings to higher-volume industrial customers such as CROs, biotechnology and pharmaceutical companies, and government laboratories engaged in the development and testing of new therapeutics, where the ability to reduce costs and improve cycle times in pre-clinical testing has the potential to drive additional demand. Third, we are expanding our product offerings for biotechnology and pharmaceutical customers in the field of bioproduction, where we believe there are opportunities to provide innovative products and services that bridge from research and development to production in applications that scale with production volume. Fourth, we are expanding our product offerings for academic, biotechnology, and pharmaceutical customers engaged in therapy, discovery, development and testing, especially in the area of streamlined in vitro testing from cell lines to organoids early in the development cycle.

 

Our Products

 

As noted above, our products, consumables, software and services enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing.

 

We have organized our product line activities into two product families, CMT and Preclinical.

 

Our CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. Our CMT products also have application in the emerging field of bioproduction of pharmaceuticals and therapeutics as well as in in vitro testing of cell lines and organoids in the therapy development. The principal customers for our CMT products include academic and government laboratories, biotechnology and pharmaceutical companies, and CROs.

 

Our Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis for safety and regulatory compliance. Preclinical products are primarily sold to pharmaceutical, biotechnology and CROs, as well as larger academic labs.

 

We sell our products under several brand names, including Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH (“MCS”) and Panlab.

 

Our solutions range from simple to complex, and generally consist of hardware/firmware and software products, augmented with consumables, options, upgrades and post-sales (scientific, installation and data) services. Sales prices of these products and services range typically from $1,000 to over $100,000. Our products include spectrophotometers that analyze light to detect and quantify a wide range of molecules as well as cell analysis and electroporation and electrofusion systems to influence and/or analyze cellular processes. Other products and services focus on tissue and organ responses to new drugs and encompass wireless monitors, and signal acquisition and analysis functionality. We also feature products that monitor physiological processes in living organisms to study behavior. Many of our proprietary products are leaders in their fields. 

 

In addition to our proprietarily manufactured products, we distribute products developed by other manufacturers. These distributed products accounted for approximately 13% and 15% of our revenues for the years ended December 31, 2023 and 2022, respectively. Resale of such products enables us to act as a single source for our customers’ research needs. They consist of a large variety of complementing instruments or accessories as well as consumables used in experiments involving fluid handling, molecular and cell analysis and tissue, organ and animal research.

 

 

2
Table of Contents

 

Below is a description of each product family.

 

Cellular and Molecular Technologies Product Family

 

Our CMT product family includes products designed primarily to support the discovery phase of new drug development. The CMT product family includes the Harvard Apparatus, Biochrom, BTX, Heka, Hugo Sachs, and MCS brands.  CMT products include:

 

 

●

 electroporation and electrofusion instruments, including the bioproduction configuration of our BTX electroporation system, introduced in 2022, which leverages our electroporation technology to bridge from therapy to production in the emerging field of bioproduction;
     
 

●

amino acid analyzers, spectrophotometers, and other equipment which primarily support molecular level testing and research;
     
 

●

high precision syringe and peristaltic infusion pump product lines;
     
 

●

precision scientific measuring instrumentation and equipment in the field of electrophysiology such as: data acquisition systems with custom amplifier configurations for cellular analysis, complete micro electrode array solutions for in vivo recordings and in vitro systems for extracellular recordings; and
     
 

●

our new Mesh MEA™ platform, launched in 2023, builds on our existing micro-electrode array technology to support streamlined in vitro testing from cell lines to organoids early in the therapy development cycle.

 

Our CMT product family made up approximately 49% and 51% of our global revenues for the years ended December 31, 2023 and 2022, respectively.

 

Preclinical Product Family

 

Our Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical product family includes the DSI, Panlab and Buxco brands. It includes:

 

 

●

implantable and externally worn telemetry systems, which are commonly used in research to collect cardiovascular, central nervous system, respiratory, metabolic data;
     
 

●

behavioral products; isolated organ and surgical products, a broad range of instruments and accessories for tissue, organ-based lab research, including surgical products, infusion systems, and behavior research systems;
     
 

●

turn-key respiratory system solutions encompassing plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation;
     
 

●

inhalation and exposure systems providing precise, homogenous aerosol delivery for up to 42 subjects, while integrating respiratory parameters for the ultimate delivered dose system;
     
 

●

powerful GLP-capable data acquisition and analysis systems, capable of integrating third party sensors for a more comprehensive study design; and
     
 

●

our new VivaMars™ behavioral monitoring system, launched in 2023, which is directed to the high throughput testing needs of higher-volume industrial customers such as CROs, biotechnology and pharmaceutical companies, and government laboratories engaged in the development and testing of new therapeutics. 

 

Our Preclinical product family made up approximately 51% and 49% of our global revenues for the years ended December 31, 2023 and 2022, respectively.

 

3
Table of Contents

 

Customers

 

Our end-user customers are primarily research and development scientists and engineers at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, including the United States National Institutes of Health (“NIH”), U.S. Army and CROs. Our pharmaceutical and biotechnology customers include pharmaceutical companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron. Our academic customers include major colleges and universities such as Baylor College of Medicine, Cambridge University, Harvard University, Imperial College of London, Johns Hopkins University, Stanford, the University of California system, University of Pennsylvania, University of Pittsburgh,  University of Texas and Yale University. Our CRO customers include Charles River Laboratories, Labcorp and Wuxi AppTec. We have a wide range of diverse customers worldwide, and no customer accounted for more than 10% of our revenues in 2023.

 

Sales

 

We conduct direct sales and through distributors in the United States, China and major European markets. We sell primarily through distributors in other countries. For the year ended December 31, 2023, revenues from direct sales to end-users represented approximately 65% of our revenues; and revenues from sales of our products through distributors represented approximately 35% of our revenues.

 

Direct Sales

 

We have a global sales organization managing both direct sales and distributors. Our websites and marketing collateral serve as the primary sales tool for our product lines, which includes both proprietary manufactured products and complementary products from various suppliers.

 

Sales through Distributors

 

We engage distributors for the sales of our own branded and private label products in certain areas of the world and for certain product lines.

 

Marketing

 

Our marketing activities encompass product management and marketing communications. Marketing maintains value-proposition based product roadmaps, collaborates with research and development on timing and investment for new products, develops marketing and sales strategies, supports direct and distributor sales activities, and sets the global pricing of our products. Our marketing team also maintains digital presence across the web and social media platforms, creates electronic leads and analyzes opportunities for new product portfolio extensions.

 

Research and Development

 

Our research and development activities are focused primarily on maintaining and strengthening our existing product and technology portfolio and expanding our portfolio to support new opportunities consistent with our growth strategy. We maintain development staff in many of our manufacturing facilities to design and develop new products and to re-engineer existing products to bring them to the next generation. Our research and development expenses were approximately $11.8 million and $12.3 million for the years ended December 31, 2023 and 2022, respectively. We anticipate that we will continue to make investments in research and development activities to advance our position in the industry as a provider of life science equipment, software and services. We plan to continue to pursue a balanced development portfolio strategy of originating new products from internal research and acquiring products and technologies through business and technology acquisitions or collaborations, as appropriate.

 

 

Manufacturing

 

We manufacture and test the majority of our products in our principal manufacturing facilities located in the United States, Germany and Spain. We have considerable manufacturing flexibility at our various facilities, and each facility can manufacture multiple products at the same time. We maintain in-house manufacturing expertise, technologies and resources. We seek to maintain multiple suppliers for key components that are not manufactured in-house, and while some of our products are dependent on sole-source suppliers, we have made investments in new talent in procurement and other functions to reduce exposures related to sole-source suppliers, and are accelerating these efforts given the dynamics of the global supply chain in recent years. Our manufacturing operations primarily involve assembly and testing activities along with some machine-based processes. Going forward we will continue to evaluate our manufacturing facilities and operations in order to optimize our manufacturing footprint.

 

See “Part I, Item 2. Properties” of this report for additional information regarding our manufacturing facilities.

 

4
Table of Contents

 

Competition

 

The markets into which we sell our products are highly competitive, and we expect the intensity of competition to continue or increase. We compete with many companies engaged in developing and selling tools for life science research. Many of our competitors have greater financial, operational, sales and marketing resources and more experience in research and development and commercialization than we have. Moreover, our competitors may have broader product offerings and greater name recognition than we do, and many offer discounts as a competitive tactic. These competitors and other companies may have developed or could in the future develop new technologies that compete with our products, which could render our products obsolete. We cannot provide assurance that we will be able to make the enhancements to our technologies necessary to compete successfully with newly emerging technologies. While we provide a broad selection of differentiated products, we have numerous competitors across our product lines. We believe that we compete favorably with our competitors on the basis of product performance, including quality, reliability, speed, technical support, price and delivery time.

 

We compete with several companies that provide products for life science research including Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, Emka Technologies, Eppendorf AG, Instem plc, Kent Scientific Corporation, Lonza Group Ltd., PerkinElmer, Inc., Thermo Fisher Scientific, Inc. and TSE Systems.

 

We cannot forecast if or when these or other companies may develop competitive products. We expect that other products will compete with our products and potential products based on efficacy, safety, cost and intellectual property positions. While we believe that these will be the primary competitive factors, other factors include, in certain instances, availability of supply, manufacturing, marketing and sales expertise and capability.

 

Seasonality

 

Sales and earnings in our third quarter are usually flat or down from the second quarter primarily because there are a large number of holidays and vacations during such quarter, especially in Europe. Our fourth quarter revenues and earnings are often the highest in any fiscal year compared to the other three quarters, primarily because many of our customers tend to spend budgeted money before their own fiscal year ends.

 

Intellectual Property

 

To establish and protect our proprietary technologies and products, we rely on a combination of patent, copyright, trademark and trade secret laws, as well as confidentiality provisions in our contracts. Patents or patent applications cover certain of our new technologies. Most of our product lines are protected principally by trade names and trade secrets.

 

We have implemented a patent strategy designed to provide us with freedom to operate and facilitate commercialization of our current and future products. Our success depends, to a significant degree, upon our ability to develop proprietary products and technologies. We intend to continue to file patent applications covering new products and technologies where it is appropriate to do so taking into account factors such as the likely scope of coverage, strategic value, and cost.

 

Patents provide some degree of protection for our intellectual property. However, the assertion of patent protection involves complex legal and factual determinations and is therefore uncertain. The scope of any of our issued patents may not be sufficiently broad to offer meaningful protection. In addition, our issued patents or patents licensed to us may be successfully challenged, invalidated, circumvented or unenforceable so that our patent rights would not create an effective competitive barrier. Moreover, the laws of some foreign countries may protect our proprietary rights to a greater or lesser extent than the laws of the United States. In addition, the laws governing patentability and the scope of patent coverage continue to evolve, particularly in areas of interest to us. As a result, there can be no assurance that patents will be issued from any of our patent applications or from applications licensed to us. As a result of these factors, our intellectual property positions bear some degree of uncertainty.

 

We also rely in part on trade secret protection of our intellectual property. We attempt to protect our trade secrets by entering into confidentiality agreements with third parties, employees and consultants. Our employees and consultants also sign agreements requiring that they assign to us their interests in patents and copyrights arising from their work for us. Although many of our United States employees have signed agreements not to compete unfairly with us during their employment and after termination of their employment, through the misuse of confidential information, soliciting employees, soliciting customers and the like, the enforceability of these provisions varies from jurisdiction to jurisdiction and, in some circumstances, they may not be enforceable. In addition, it is possible that these agreements may be breached or invalidated and if so, there may not be an adequate corrective remedy available. Despite the measures we have taken to protect our intellectual property, we cannot provide assurance that third parties will not independently discover or invent competing technologies or reverse engineer our trade secrets or other technologies. Therefore, the measures we are taking to protect our proprietary rights may not be adequate.

 

5
Table of Contents

 

We do not believe that our products infringe on the intellectual property rights of any third party. We cannot assure, however, that third parties will not claim such infringement by us or our licensors with respect to current or future products. We expect that product developers in our market will increasingly be subject to such claims as the number of products and competitors in our market segment grows and the product functionality in different market segments overlaps. In addition, patents on production and business methods are becoming more common and we expect that more patents will be issued in our technical field. Any such claims, with or without merit, could be time-consuming, result in costly litigation and diversion of management’s attention and resources, cause product shipment delays or require us to enter into royalty or licensing agreements. Moreover, such royalty or licensing agreements, if required, may not be on terms advantageous to us, or acceptable at all, which could seriously harm our business or financial condition.

 

“Harvard” is a registered trademark of Harvard University. The marks “Harvard Apparatus” and “Harvard Bioscience” are being used pursuant to a license agreement entered into in December 2002 between us and Harvard University.

 

Government Regulation

 

We are generally not subject to direct governmental regulation other than the laws and regulations generally applicable to businesses in the domestic and foreign jurisdictions in which we operate. In particular, other than our amino acid analyzer product, our current products are not subject to pre-market approval by the United States Food and Drug Administration for use on human clinical patients. In addition, we believe we are materially in compliance with all relevant environmental laws.

 

Employees

 

As of December 31, 2023, we employed 416 employees, which included 391 full-time employees. Some of our employees in Europe have statutory collective bargaining rights. We have never experienced a general work stoppage or strike, and management believes that our relations with our employees are good. Additional information about our employees follows:

 

Country

  

Full-time

    

Part-time

  

United States

     248       9  

Germany

     55       14  

United Kingdom

     35       2  

Spain

     26       -  

China

     17       -  

Rest of World

     10       -  

Total

     391       25  

 

Function

  

Full-time

    

Part-time

  

Manufacturing

     153       6  

Sales and marketing

     135       6  

Research and development

     49       9  

General and administrative

     54       4  

Total

     391       25  

 

We make employment decisions without regard to age, color, national origin, citizenship status, physical or mental disability, race, religion, creed, gender, sex, sexual orientation, gender identity and/or expression, genetic information, marital status, status with regard to public assistance, veteran and military status or any other characteristic protected by federal, state or local law. We take steps to employ and advance in employment qualified protected veterans and qualified individuals with disabilities.

 

Geographic Area

 

Financial information regarding geographic areas in which we operate is provided in Notes 5 and 13 to the Consolidated Financial Statements included in “Part IV, Item 15. Exhibits, Financial Statement Schedules” of this report.

 

Available Information and Website

 

Our website address is www.harvardbioscience.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and exhibits and amendments to those reports filed or furnished with the Securities and Exchange Commission pursuant to Section 13(a) of the Exchange Act are available for review on our website and the Securities and Exchange Commission’s website at www.sec.gov. Any such materials that we file with, or furnish to, the SEC in the future will be available on our website as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information on our website is not incorporated by reference into this Annual Report on Form 10-K.

 

6
Table of Contents

 

Item 1A.

Risk Factors.

 

The following factors should be reviewed carefully, in conjunction with the other information contained in this Annual Report on Form 10-K. As previously discussed, our actual results could differ materially from our forward-looking statements. Our business faces a variety of risks. These risks include those described below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. If any of the events or circumstances described in the following risk factors occur, our business operations, performance and financial condition could be adversely affected, and the trading price of our common stock could decline.

 

Risks Related to Our Industry

 

The life sciences industry is very competitive.

 

We expect to encounter increased competition from both established and development-stage companies that continually enter the market. These include companies developing and marketing life science instruments, systems and lab consumables, health care companies that manufacture laboratory-based tests and analyzers, diagnostic and pharmaceutical companies, analytical instrument companies, and companies developing life science or drug discovery technologies. Currently, our principal competition comes from established companies that provide products that perform many of the same functions for which we market our products. Many of our competitors have substantially greater financial, operational, marketing and technical resources than we do. Moreover, these competitors may offer broader product lines and tactical discounts and may have greater name recognition. In addition, we may face competition from new entrants into the field. We may not have the financial resources, technical expertise or marketing, distribution or support capabilities to compete successfully in the future. In addition, we face changing customer preferences and requirements, including increased customer demand for more environmentally friendly products.

 

The life sciences industry is also subject to rapid technological change and discovery. The development of new or improved products, processes or technologies by other companies may render our products or proposed products obsolete or less competitive. In some instances, our competitors may develop or market products that are more effective or commercially attractive than our current or future products. To meet the evolving needs of customers, we must continually enhance our current products and develop and introduce new products. However, we may experience difficulties that may delay or prevent the successful development, introduction and marketing of new products or product enhancements. In addition, our product lines are based on complex technologies that are subject to change as new technologies are developed and introduced in the marketplace. We may have difficulty in keeping abreast of the changes affecting each of the different markets we serve or intend to serve, and our new products may not be accepted by the marketplace or may generate lower than anticipated revenues. Our failure to develop and introduce products in a timely manner in response to changing technology, market demands, or the requirements of our customers could cause our product sales to decline, and we could experience significant losses.

 

We offer, and plan to continue to offer, a broad range of products and have incurred, and expect to continue to incur, substantial expenses for the development of new products and enhancements to our existing products. The speed of technological change in our market may prevent us from being able to successfully market some or all of our products for the length of time required to recover development costs. Failure to recover the development costs of one or more products or product lines could decrease our profitability or cause us to experience significant losses.

 

A portion of our revenues is derived from customers in the pharmaceutical and biotechnology industries and is subject to the risks faced by those industries. Such risks may adversely affect our financial results.

 

We derive a significant portion of our revenues from pharmaceutical companies, biotechnology companies, and CROs serving these companies. We expect that pharmaceutical companies, biotechnology companies and CROs will continue to be a significant source of our revenues for the foreseeable future, including in our CMT and Preclinical product families. As a result, we are subject to risks and uncertainties that affect the pharmaceutical and biotechnology industries, such as government regulation, ongoing consolidation, uncertainty of technological change, and reductions and delays in research and development expenditures by companies in these industries.

 

In particular, the biotechnology industry is largely dependent on raising capital to fund its operations. If biotechnology companies that are our customers are unable to obtain the financing necessary to purchase our products, our business and results of operations could be adversely affected. In addition, we are dependent, both directly and indirectly, upon general health care spending patterns, particularly in the research and development budgets of the pharmaceutical and biotechnology industries, as well as upon the financial condition and purchasing patterns of various governments and government agencies. As it relates to both the biotechnology and pharmaceutical industries, many companies have significant patents that have expired or are about to expire, which could result in reduced revenues for those companies. If pharmaceutical or biotechnology companies that are our customers suffer reduced revenues as a result of these patent expirations, they may be unable to purchase our products, and our business and results of operations could be adversely affected.

 

7
Table of Contents

 

Changes in governmental regulations may reduce demand for our products, adversely impact our revenues, or increase our expenses.

 

We operate in many markets in which we and our customers must comply with federal, state, local and international regulations. We develop, configure and market our products to meet customer needs created by, and in compliance with, those regulations. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post marketing reporting. We must incur expense and spend time and effort to ensure compliance with these complex regulations. Possible regulatory actions for non-compliance could include warning letters, fines, damages, injunctions, civil penalties, recalls, seizures of our products, and criminal prosecution. These actions could result in, among other things, substantial modifications to our business practices and operations; refunds, recalls, or seizures of our products; a total or partial shutdown of production in one or more of our facilities while we or our suppliers remedy the alleged violation; and withdrawals or suspensions of current products from the market. Any of these events could disrupt our business and have a material adverse effect on our revenues, profitability and financial condition.

 

Risks Related to Our Business

 

Reductions in customers’ research budgets or government funding may adversely affect our business.

 

Many of our customers are universities, government research laboratories, private foundations and other institutions that are dependent on grants from government agencies, such as the NIH, for funding. These customers represent a significant source of our revenue. Research and development spending by our customers may fluctuate based on spending priorities and general economic conditions. The level of government funding for research and development is unpredictable. In the past, NIH grants have been frozen or otherwise made unavailable for extended periods or directed to certain products. Reductions or delays in governmental spending could cause customers to delay or forego purchases of our products. If government funding necessary for the purchase of our products were to decrease, our business and results of operations could be materially, adversely affected. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.

 

Our business is subject to economic, political and other risks associated with international revenues and operations.

 

We manufacture and sell our products worldwide and as a result, our business is subject to risks associated with doing business internationally. A substantial amount of our revenues is derived from international operations, and we anticipate that a significant portion of our sales will continue to come from outside the United States in the future. We anticipate that revenues from international operations will likely continue to increase as a result of our efforts to expand our business in markets abroad. In addition, a number of our manufacturing facilities and suppliers are located outside the United States.

 

Our foreign operations subject us to certain risks, including: effects of fluctuations in foreign currency exchange rates; the impact of local economic conditions; fluctuations or reductions in economic growth in overseas markets including Asia and Europe; local product preferences and seasonality and product requirements; local difficulty to effectively establish and expand our business and operations in international markets; disruptions of capital and trading markets; restrictions and potentially negative tax implications of transfer of capital across borders; differing labor regulations; other factors beyond our control, including potential political instability, terrorism, acts of war, natural disasters and diseases, including COVID-19 discussed below; unexpected changes and increased enforcement of regulatory requirements and various state, federal and international, intellectual property, environmental, antitrust, anti-corruption, fraud and abuse (including anti-kickback and false claims laws) and employment laws; interruption to transportation flows for delivery of parts to us and finished goods to our customers; and laws and regulations on foreign investment in the United States under the jurisdiction of the Committee on Foreign Investment in the United States, or CFIUS, and other agencies, including the Foreign Investment Risk Review Modernization Act, or FIRRMA, adopted in August 2018.

 

A small percentage of our products are subject to export control regulations administered by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”) and by the Export Administration Regulations administered by the U.S. Department of Commerce’s Bureau of Industry and Security (“BIS”). Based on the nature of the product, its ultimate end use and country of destination, we are sometimes subject to foreign assets control and economic sanctions regulations administered by OFAC, which restrict or prohibit our ability to transact with certain foreign countries, certain individuals and entities identified on the Treasury Department’s “Denied Parties List.” Under the OFAC regulations, the sale or transfer of certain equipment to a location outside the United States may require prior approval in the form of an export license issued by the BIS or the U.S. Department of State’s Directorate of Defense Trade Controls. Some potential international transactions may also be restricted or prohibited based on the location, nationality or identity of the potential end user, customer or other parties to the transaction or may require prior authorization in the form of an OFAC license. These risks may be exacerbated by geopolitical tensions in various regions of the world such as China, the Asia-Pacific region and the Middle East. Any delay in obtaining required governmental approvals could affect our ability to conclude a sale or timely commence a project, and the failure to comply with all such controls could result in criminal and/or civil penalties. These international transactions may otherwise be subject to tariffs and import/export restrictions from the United States or other governments.

 

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social and political conditions. In order to continue to succeed in our international sales strategy, we must continue developing and implementing policies and strategies that are effective in each location where we do business, which could negatively affect our profitability.  

 

8
Table of Contents

 

Rising inflation and interest rates could negatively impact our revenues, profitability and borrowing costs. In addition, if our costs increase and we are not able to correspondingly adjust our commercial relationships to account for this increase, our net income would be adversely affected, and the adverse impact may be material.

 

Inflation rates, particularly in the U.S., have increased recently to levels not seen in years. Sustained or increased inflation may result in decreased demand for our products, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised interest rates in response to concerns about inflation. Increases in interest rates have had, and could continue to have, a material impact on our borrowing costs. In an inflationary environment, we may be unable to raise the sales prices of our products at or above the rate at which our costs increase, which could reduce our profit margins and have a material adverse effect on our financial results and net income. We also may experience lower than expected sales if there is a decrease in spending on products in our industry in general or a negative reaction to our pricing. A reduction in our revenue would be detrimental to our profitability and financial condition and could also have an adverse impact on our future growth.

 

We have substantial debt and other financial obligations, and we may incur even more debt. Any failure to meet our debt and other financial obligations or maintain compliance with related covenants could harm our business, financial condition and results of operations.

 

Our credit agreement provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility (collectively, the “Credit Agreement”) and will mature on December 22, 2025. As of December 31, 2023, we had outstanding borrowings of $37.1 million under the Credit Agreement.

 

Pursuant to the terms of the Credit Agreement, we are subject to various covenants, including negative covenants that restrict our ability to engage in certain transactions, which may limit our ability to respond to changing business and economic conditions. Such negative covenants include, among other things, limitations on our ability and the ability of our subsidiaries to incur debt or liens, make investments (including acquisitions), sell assets, and pay dividends on our capital stock. In addition, the Credit Agreement contains certain financial covenants, including a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio, each of which will be tested at the end of each fiscal quarter of the Company.

 

If we are not able to maintain compliance with the covenants under the Credit Agreement, as amended, or are unsuccessful in obtaining waivers or amendments for any covenant defaults in the future, in addition to other actions our lenders may require, the amounts outstanding under the Credit Agreement may become immediately due and payable. This immediate payment may negatively impact our financial condition. In addition, any failure to make scheduled payments of interest and principal on our outstanding indebtedness would likely harm our ability to incur additional indebtedness on acceptable terms. Our cash flow and capital resources may be insufficient to pay interest and principal on our debt in the future. If that should occur, our capital raising or debt restructuring measures may be unsuccessful or inadequate to meet our scheduled debt service obligations, which could cause us to default on our obligations and further impair our liquidity.

 

Further, based upon our actual performance levels, our covenants relating to leverage and fixed charges could limit our ability to incur additional debt, which could hinder our ability to execute our current business strategy.

 

Our ability to make scheduled payments on our debt and other financial obligations and comply with financial covenants depends on our financial and operating performance. Our financial and operating performance will continue to be subject to prevailing economic conditions and to financial, business and other factors, some of which are beyond our control. Failure within any applicable grace or cure periods to make such payments, comply with the financial covenants, or any other non-financial or restrictive covenant, would create a default under our Credit Agreement. Our cash flow and existing capital resources may be insufficient to repay our debt at maturity, in which such case prior thereto we would have to extend such maturity date, or otherwise repay, refinance and or restructure the obligations under the Credit Agreement, including with proceeds from the sale of assets, and additional equity or debt capital. If we are unsuccessful in obtaining such extension, or entering into such repayment, refinance or restructure prior to maturity, or any other default existed under the Credit Agreement, our lenders could accelerate the indebtedness under the Credit Agreement, foreclose against their collateral or seek other remedies, which would jeopardize our ability to continue our current operations.

 

Ethical concerns surrounding the use of our products and misunderstanding of the nature of our business could adversely affect our ability to develop and sell our existing products and new products.

 

Some of our products may be used in areas of research involving animal research and other techniques presently being explored in the life science industry. These techniques have drawn negative attention in the public forum. Government authorities may regulate or prohibit any of these activities. Additionally, the public may disfavor or reject these activities.

 

9
Table of Contents

 

Foreign currency exchange rate fluctuations may have a negative impact on our reported earnings.

 

We are subject to the risks of fluctuating foreign currency exchange rates, which could have an adverse effect on the sales price of our products in foreign markets, as well as the costs and expenses of our foreign subsidiaries. A substantial amount of our revenues is derived from international operations, and we anticipate that a significant portion of revenues will continue to come from outside the United States in the future. As a result, currency fluctuations among the United States dollar, British pound, euro and the other currencies in which we do business have caused and will continue to cause foreign currency translation and transaction gains and losses. We have not used forward exchange contracts to hedge our foreign currency exposures. We attempt to manage foreign currency risk through the matching of assets and liabilities. In the future, we may undertake to manage foreign currency risk through hedging methods, including foreign currency contracts. We recognize foreign currency gains or losses arising from our operations in the period incurred. We cannot guarantee that we will be successful in managing foreign currency risk or in predicting the effects of exchange rate fluctuations upon our future operating results because of the number of currencies involved, the variability of currency exposure and the potential volatility of currency exchange rates. We cannot predict with any certainty changes in foreign currency exchange rates or the degree to which we can address these risks.

 

Failure or inadequacy of our information technology infrastructure or software could adversely affect our day-to-day operations and decision-making processes and have an adverse effect on our performance.

 

We depend on accurate and timely information and numerical data from key software applications to aid our day-to-day business, financial reporting and decision-making and, in many cases, proprietary and custom-designed software is necessary to operate our business.

 

Disruption caused by the failure of these systems, the underlying equipment, or communication networks could delay or otherwise adversely impact day-to-day business and decision making, could make it impossible for us to operate critical equipment, and could have an adverse effect on our performance. Our disaster recovery plans may not fully mitigate the effect of any such disruption. Disruptions could be caused by a variety of factors, such as catastrophic events or weather, power outages, or cyber-attacks on our systems by outside parties.

 

We review our information technology (“IT”) systems regularly to assess and implement opportunities to improve or upgrade our enterprise resource planning (“ERP”) or other information systems required to operate our business effectively. Our ERP systems are critical to our ability to accurately maintain books and records, record transactions, provide important information to our management and prepare our financial statements. The implementation of any IT systems, including ERP systems, has required in the past, and may continue to require, the investment of significant financial and human resources. In addition, we may not be able to successfully complete the implementation of the ERP systems without experiencing difficulties. Any disruptions, delays or deficiencies in the design and implementation of any IT system, including ERP systems could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business.

 

An information security incident, including a cybersecurity breach, could have a negative impact on our business or reputation.

 

To meet business objectives, we rely on both internal IT systems and networks, and those of third parties and their vendors, to process and store sensitive data, including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection. The extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of these IT systems and networks, and the confidentiality, integrity, and availability of our sensitive data. We continually assess these threats and make investments to increase internal protection, detection, and response capabilities, as well as ensure our third-party providers have the required capabilities and controls to address this risk. While we have been, and may continue to be, subject to cybersecurity risks and incidents related to our business, to date, we have not experienced any material impact to the business or operations resulting from information or cybersecurity incidents; however, because of the frequently evolving tactics adopted by threat actors, along with the increased volume and sophistication of attacks by such threat actors, there is the potential for us to be materially adversely impacted in the future. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Additionally, the California Consumer Privacy Act of 2018 (the “CCPA”), which became effective on January 1, 2020, provides private rights of action for data breaches and requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices and allow consumers to opt out of certain data sharing with third parties. Compliance with the CCPA and other current and future applicable privacy, cybersecurity and related laws can be costly and time-consuming. Significant capital investments and other expenditures could also be required to remedy cybersecurity problems and prevent future breaches, including costs associated with additional security technologies, personnel, experts and credit monitoring services for those whose data has been breached. These costs, which could be material, could adversely impact our results of operations in the period in which they are incurred and may not meaningfully limit the success of future attempts to breach our information technology systems.

 

We may be unable to renew leases or enter into new leases on favorable terms.

 

Our facilities are located in leased premises. Several of our leases will expire in 2024 and we may be unable to renew such leases or enter into new leases on favorable terms and conditions or at all. A significant rise in real estate prices or real property taxes could also result in an increase in lease cost, and thereby negatively impacting the Company’s results of operations and cash flow. As a result, we may incur additional costs including increased rent and other costs related to our renegotiation of lease terms for our facilities or for a new lease in a desirable location.

 

10
Table of Contents

 

We may incur additional restructuring costs or not realize the expected benefits of our initiatives to reduce operating expenses in the future.

 

We may not be able to implement all of the actions that we intend to take in the restructuring of our operations, and we may not be able to fully realize the expected benefits from such realignment and restructuring plans or other similar restructurings in the future. In addition, we may incur additional restructuring costs in implementing such realignment and restructuring plans or other similar future plans in excess of our expectations. The implementation of our restructuring efforts, including the reduction of our workforce, may not improve our operational and cost structure or result in greater efficiency of our organization; and we may not be able to support sustainable revenue growth and profitability following such restructurings.

 

If we are not able to manage our growth, our operating profits may be adversely impacted.

 

Our success will depend on the expansion of our operations through organic growth, and we may execute acquisitions in the future to augment this growth. Effective growth management will place increased demands on our management team, operational and financial resources and expertise. To manage growth, we must optimize our operational, financial and management processes and systems, and information technology infrastructure and hire and train additional qualified personnel. While we are currently in the process of evaluating potential improvements to and consolidation of many of our processes and systems, we may not be able to implement these changes in an efficient or timely manner. Failure to manage our growth effectively, including failure to improve our systems and processes timely or efficiently, could impair our ability to generate revenues or could cause our expenses to increase more rapidly than revenues, resulting in operating losses or reduced profitability.

 

We may incur a variety of costs in connection with acquisitions we may seek to consummate in the future, and we may never realize the anticipated benefits of our acquisitions due in part to difficulties integrating the businesses, operations and product lines.

 

Our business strategy has historically included the acquisition of businesses, technologies, services or products that we believe are a strategic fit with our business. If we were to undertake future acquisitions, the process of integrating the acquired business, technology, service and/or product(s) may result in unforeseen operating difficulties and expenditures and potentially absorb significant management attention that would otherwise be available for ongoing development of our business. Moreover, we may fail to realize the anticipated benefits of an acquisition as rapidly as expected, or at all. Such transactions are inherently risky, and any such recent or future acquisitions could reduce stockholders’ ownership, cause us to incur debt, expose us to future liabilities and result in amortization expenses related to intangible assets with definite lives, which may adversely impact our ability to undertake future acquisitions on substantially similar terms. We may also incur significant expenditures in anticipation of an acquisition that is never realized.

 

Our ability to achieve the benefits of acquisitions depends in part on the integration and leveraging of technology, operations, sales and marketing channels and personnel. Integration is a complex, time-consuming and expensive process and may disrupt our business if not completed in a timely and efficient manner. We may have difficulty successfully integrating acquired businesses, and their domestic and foreign operations or product lines, and as a result, we may not realize any of the anticipated benefits of the acquisitions we make. We cannot assure that our growth rate will equal the growth rates that have been experienced by us, and these other acquired companies, respectively, operating as separate companies in the past.

 

Failure to raise additional capital or generate the significant capital necessary to expand our operations, invest in new products, or pursue acquisitions or other business development opportunities could reduce our ability to compete and result in less revenues.

 

We anticipate that our financial resources, which include available cash, cash generated from operations, and debt and equity capacity, will be sufficient to finance operations and capital expenditures for at least the next twelve months. However, this expectation is premised on the current operating plan, which may change as a result of many factors, including market acceptance of new products and future opportunities with collaborators. Consequently, we may need additional funding sooner than anticipated. In addition, our borrowings under the Credit Agreement may not be sufficient to support our pursuit of potential acquisitions or other business development opportunities. In such case, our inability to raise sufficient capital on favorable terms and in a timely manner (if at all) could seriously harm our business, product development, and acquisition efforts. In addition, our Credit Agreement contains various negative covenants that, among other things, restrict our ability to incur additional indebtedness and make acquisitions for aggregate consideration in excess of $5.0 million. If future financing is not available or is not available on acceptable terms, we may have to alter our operations or change our business strategy. We cannot assure you that the capital required to fund operations, or our acquisition strategy will be available in the future.

 

 

11
Table of Contents

 

If we fail to retain key personnel and hire, train and retain qualified employees, we may not be able to compete effectively, which could result in reduced revenue or increased costs.

 

Our success is highly dependent on the continued services of key management, technical and scientific personnel. Our management and other employees may voluntarily terminate their employment at any time upon short notice. The loss of the services of any member of the senior management team, including the Chief Executive Officer or Chief Financial Officer or any of our  managerial, technical or scientific staff may significantly delay or prevent the achievement of product development, our growth strategies and other business objectives. Our future success will also depend on our ability to identify, recruit and retain additional qualified scientific, technical and managerial personnel. We operate in several geographic locations where labor markets are particularly competitive, including the Boston, Massachusetts and Minneapolis, Minnesota metropolitan areas, England, and Germany where demand for personnel with these skills is extremely high and is likely to remain high. Additionally, the COVID-19 pandemic and other macroeconomic factors have exacerbated these challenges, contributed to a sustained labor shortage, and increased turnover rates. As a result, competition for qualified personnel is intense, particularly in the areas of general management, finance, information technology, engineering and science, and the process of hiring suitably qualified personnel is often lengthy and expensive and may become more expensive in the future. If we are unable to hire and retain a sufficient number of qualified employees, our ability to conduct and expand our business could be seriously reduced.

 

Our success will depend partly on our ability to operate without infringing on or misappropriating the intellectual property rights of others.

 

We may be sued for infringing on the intellectual property rights of others, including the patent rights, trademarks and trade names of third parties. Intellectual property litigation is costly, and the outcome is uncertain. If we do not prevail in any intellectual property litigation, in addition to any damages we might have to pay, we could be required to stop the infringing activity, or obtain a license to or design around the intellectual property in question. If we are unable to obtain a required license on acceptable terms, or are unable to design around any third-party patent, we may be unable to sell some of our products and services, which could result in reduced revenue.

 

Third parties may seek to hold us responsible for Harvard Apparatus Regenerative Technologies, Inc.’s (“HRGN”) (formerly known as Biostage, Inc.) liabilities, including liabilities that HRGN has assumed  from us.

 

Third parties may continue to seek to hold us responsible for HRGN’s liabilities, including any of the liabilities that HRGN agreed to retain or assume in connection with the separation of the HRGN business from our businesses, and related spin-off distribution. For example, in April 2022, we and HRGN entered into a settlement of a litigation relating to injuries allegedly caused by products produced by us and HRGN and utilized in connection with surgeries performed by third parties (the “HRGN Settlement”). The HRGN Settlement resolved and dismissed all claims by and between the parties.

 

Shares of common stock of HRGN held by the Company could fluctuate considerably in value and could become worthless.

 

In connection with the HRGN Settlement, HRGN issued shares of its Series E Convertible Preferred Stock (the “Series E Preferred Stock”) to the Company in satisfaction of $4.0 million of HRGN’s total indemnification obligations to the Company. In April 2023, all of the Series E Preferred Stock we held in HRGN were mandatorily converted into shares of HRGN common stock. As of December 31, 2023, we held shares of HRGN common stock with an estimated fair value of $3.5 million.

 

Due to HRGN’s limited operating history, their overall financial condition, (including whether it can continue as a going concern without additional capital) and the limited trading volume and liquidity of HRGN’s common stock, the value of this investment could fluctuate considerably or become worthless.

 

 

12
Table of Contents

 

 

Risks Related to Our Common Stock

 

Our stock price has fluctuated in the past and could experience substantial declines in the future.

 

The market price of our common stock has experienced significant fluctuations and may become volatile and could decline in the future, perhaps substantially, in response to various factors including, but not limited to:

 

 

●

volatility of the financial markets;
     
 

●

uncertainty regarding the prospects of the domestic and foreign economies;
     
 

●

technological innovations by competitors or in competing technologies;
     
 

●

 revenues and operating results fluctuating or failing to meet our expectations or financial guidance, or the expectations of securities analysts, or investors;
     
 

●

comments of securities analysts and mistakes by or misinterpretation of comments from analysts, downward revisions in securities analysts’ estimates or management guidance;
     
 

●

conditions or trends in the biotechnology and pharmaceutical industries;
     
 

●

announcements of significant acquisitions or financings or strategic partnerships;
     
 

●

non-compliance with the internal control standards pursuant to the Sarbanes-Oxley Act of 2002; and
     
 

●

a decrease in the demand for our common stock.

 

In addition, public stock markets have experienced extreme price and trading volatility. The stock market and the Nasdaq Global Market in general, and the biotechnology and life science tools industry and small cap markets in particular, have experienced significant price and volume fluctuations that at times may have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may further harm the market price of our common stock, regardless of our operating performance. In the past, securities class action litigation has often been instituted following periods of volatility in the market price of a company’s securities. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of management’s attention and resources.

 

If we raise additional funds through the sale of equity or convertible debt or equity-linked securities, existing percentages of ownership in our common stock will be reduced and these transactions may dilute the value of our outstanding common stock.

 

We may raise additional funds through the sale of equity or convertible debt or equity-linked securities to repay our existing indebtedness, implement our acquisition strategy, expand our operations and/or invest in new products. If we raise additional funds through such sales, existing percentages of ownership in our common stock will be reduced and these transactions may dilute the value of our outstanding common stock. We may issue securities that have rights, preferences and privileges senior to our common stock. If we raise additional funds through collaborations or licensing arrangements, we may relinquish rights to certain of our technologies or products, or grant licenses to third parties on terms that are unfavorable.

 

13
Table of Contents

 

General Risks

 

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to military conflicts. Our business, financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, the Middle East or any other geopolitical tensions.

 

U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions globally, including military conflicts (such as the conflict between Russia and Ukraine and the conflicts in Israel and the Middle East). Although the length and impact of these conflicts are highly unpredictable, these conflicts could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, supply chain interruptions, and additional economic and financial sanctions.

 

Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Annual Report on Form 10-K.

 

Epidemics and pandemics such as the COVID-19 pandemic have had, and in the future may have, a material adverse impact on our business.

 

Our operations and financial performance have been, and in the future may be, negatively impacted by public health crises such as the COVID-19 pandemic and other epidemics and pandemics. Such events have caused, and may in the future cause, impacts such as reductions in economic activity (including volatility in demand for our products, services, and solutions, disruptions in global supply chains, and volatility in financial markets). Additionally, we have in the past experienced, and may in the future experience, operational challenges such as workplace disruptions, restrictions on the movement of people, raw materials, and goods (both at our own facilities and at those of our customers and suppliers), global supply chain disruptions, delays or disruptions in orders and order fulfillment, and price inflation.

 

If we incur higher costs as a result of trade policies, treaties, government regulations or tariffs, we may become less profitable.

 

There continues to be uncertainty about the relationship between the United States and foreign countries, including with respect to trade policies, treaties, government regulations and tariffs. We are unable to predict whether or when tariffs will be imposed or the impact of any such future tariff increases.

 

We may be the subject of lawsuits from counterparties to acquisitions and divestitures, including an acquiring company or its stockholders, an acquired company’s previous stockholders, a divested company’s stockholders or our current stockholders.

 

We may be the subject of lawsuits from either an acquiring company or its stockholders, an acquired company’s previous stockholders, a divested company’s stockholders or our current stockholders. Such lawsuits could result from the actions of the acquisition or divestiture target prior to the date of the acquisition or divestiture, from the acquisition or divestiture transaction itself or from actions after the acquisition or divestiture. Defending potential lawsuits could cost us significant expense and detract management’s attention from the operation of the business. Additionally, these lawsuits could result in the cancellation of or the inability to renew certain insurance coverage that would be necessary to protect our assets.

 

Rising commodity and precious metals costs could adversely impact our profitability.

 

Raw material commodities, such as resins, and precious metal commodities, such as platinum, are subject to wide price variations. Increases in the costs of these commodities and the costs of energy, transportation and other necessary services may adversely affect our profit margins if we are unable to pass along any higher costs in the form of price increases or otherwise achieve cost efficiencies such as in manufacturing and distribution.

 

Provisions of Delaware law, or of our charter and bylaws may make a takeover more difficult, which could cause our stock price to decline.

 

Provisions in our certificate of incorporation and bylaws and in the Delaware corporate law may make it difficult and expensive for a third party to pursue a tender offer, change in control or takeover attempt, which is opposed by management and the board of directors. Public stockholders who might desire to participate in such a transaction may not have an opportunity to do so. We have a staggered board of directors that makes it difficult for stockholders to change the composition of the board of directors in any one year. These anti-takeover provisions could substantially impede the ability of public stockholders to change our management and board of directors. Such provisions may also limit the price that investors might be willing to pay for shares of our common stock in the future.

 

14
Table of Contents

 

Item 1B.

Unresolved Staff Comments.

 

None.

 

Item 1C. Cybersecurity.

 

Cybersecurity Risk Management and Strategy

 

We have implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program is an element of and is integrated into our overall enterprise risk management program. Our framework is informed in part by the National Institute of Standards and Technology (NIST) Cybersecurity Framework and International Organization for Standardization 27001 (ISO 27001) Framework, although we have not been audited to, and may not be in compliance with, all technical standards, specifications or requirements under the NIST or ISO 27001 frameworks. Our cybersecurity risk management program includes:

 

  ● risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology (“IT”) environment;
     
  ● a security team that is principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;
     
  ● the use of external service providers, where appropriate, to assess, test, or otherwise assist with aspects of our security controls;
     
  ● cybersecurity awareness training for our employees, incident response personnel, and senior management;
     
  ● assessment of material cybersecurity risks posed by third-party service providers, including risks to employee, customer and financial information; and
     
  ● a cybersecurity incident response protocol that includes procedures for responding to cybersecurity incidents.

 

We have been, and expect to continue to be, subject to cybersecurity risks and incidents related to our business. To date, such risks and incidents have not materially affected our business strategy, results of operations or financial condition. For more information about the cybersecurity risks we face, see Item 1A – Risk Factors.

 

Cybersecurity Governance

 

Our Board considers cybersecurity risk as part of its enterprise risk management oversight function. This oversight includes periodic reports from management, including our Vice President of IT, concerning cybersecurity related risks.

 

Our management team, including our Vice President of IT, is responsible for assessing and managing risks from cybersecurity threats. Our Vice President of IT has extensive information technology and program management experience, including broad experience in corporate and consulting environments across of range of organizations and industries. Where appropriate, she engages external cybersecurity consultants to assist with cybersecurity related matters. Our management team has primary responsibility for our overall cybersecurity risk management program and, under the leadership of our Vice President of IT, supervises both our internal personnel and external cybersecurity consultants. This includes efforts to prevent, detect, mitigate, and remediate cybersecurity risks. These efforts employ information from various sources, such as security tools deployed in our IT environment, internal personnel, external security consultants, and governmental sources.

 

Item 2.

Properties.

 

Our facilities perform manufacturing, research and development, sales and marketing, and administration functions. As of December 31, 2023, we leased the following principal facilities: 

 

       

Approximate

    

Location

  

Description of Facility

  

Square Footage

  

Expiration

Holliston, Massachusetts

  

Manufacturing facility and corporate headquarters

  

83,000

  

2024

New Brighton, Minnesota

  

Manufacturing facility

  

75,000

  

2030

Reutlingen, Germany

  

Manufacturing facility

  

23,000

  

2024

Barcelona, Spain

  

Manufacturing facility

  

16,000

  

2024

March-Hugstetten, Germany

  

Manufacturing facility

  

11,000

  

2024

 

We also lease facilities in Cambridge, England; Kista, Sweden; Beijing, China; and Shanghai, China. We believe our current facilities are adequate for our needs for the foreseeable future.

 

15
Table of Contents

 

Item 3.

Legal Proceedings.

 

For information related to legal proceedings, see the discussion in Note 15 and Note 16 to the Consolidated Financial Statements included in “Part IV, Item 15. Exhibits, Financial Statement Schedules” of this report, which information is incorporated by reference into this Item 3.

 

Item 4.

Mine Safety Disclosures

 

Not Applicable.

 

PART II

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock is quoted on the Nasdaq Global Market under the symbol “HBIO.”

 

Stockholders

 

There were 90 holders of record of our common stock as of March 1, 2024. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies.

 

Dividend Policy

 

We have never declared or paid cash dividends on our common stock in the past and do not intend to pay cash dividends on our common stock in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors our board of directors deems relevant.

 

Item 6.

[Reserved]

 

16
Table of Contents

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward-Looking Statements

 

The following section of this Annual Report on Form 10-K contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Factors that may cause our actual results to differ materially from those in the forward-looking statements include those factors described in “Item 1A. Risk Factors” in this Annual Report on Form 10-K. You should carefully review all of these factors, as well as the comprehensive discussion of forward-looking statements on page 1 of this Annual Report on Form 10-K.

 

Overview

 

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and CROs. With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.

 

Trends and Developments

 

Our business is affected by global and regional economic trends and uncertainties. The global economy has recently experienced increasing uncertainty, including inflationary pressure, rising interest rates, and fluctuations in exchange rates. Our business has also been affected by a recent softening of certain international markets, especially in China and the Asia-Pacific region, the events in Ukraine and the Middle East, as well as delays in government funding for our customers. These developments may lead to additional economic uncertainties.

 

Overall, our results of operations were negatively impacted by the COVID-19 pandemic. However, we experienced a period of increased demand for certain of our products due to increased COVID-19 related research activity during the pandemic, which is unlikely to be repeated. Our business has been affected by a reduced demand from our biotechnology and pharmaceutical company customers, due principally to the increased cost of capital and a reduction in spending following the COVID-19 pandemic.

 

If these trends are prolonged or are more severe, or if the recovery is less robust or takes longer than anticipated, our business, results of operations, and cash flow may be materially impacted.

 

Restructuring Activities

 

On an ongoing basis, we review our business, the global economy, the healthcare industry, and the markets in which we compete to identify operational efficiencies, enhance commercial capabilities and align our cost base and infrastructure with customer needs and our strategic plans.

 

During 2022, we reviewed our business and product portfolio and identified opportunities to rationalize our product portfolio, improve our cost structure and optimize our sales organization. In connection with this review, during the year ended December 31, 2022, we identified certain non-strategic products for discontinuation and recorded  $1.5 million of inventory charges and also recorded $0.9 million in severance expenses in connection with headcount reductions in Europe and North America. During the year ended December 31, 2023, we incurred an additional $0.3 million in inventory charges and $0.1 million in remaining severance and other expenses related to completion of this restructuring program.

 

17
Table of Contents

 

Selected Results of Operations

 

In the table below, we provide an overview of selected operating metrics for the year ended December 31, 2023, compared to the year ended December 31, 2022.

 

   

Year Ended December 31,

 

(dollars in thousands)

  

2023

    

% of revenue

    

2022

    

% of revenue

  

Revenues

   $ 112,250             $ 113,335          

Gross profit

     66,071       58.9 %     60,819       53.7 %

Sales and marketing expenses

     24,108       21.5 %     25,041       22.1 %

General and administrative expenses

     22,780       20.3 %     24,493       21.6 %

Research and development expenses

     11,764       10.5 %     12,329       10.9 %

Amortization of intangible assets

     5,525       4.9 %     6,122       5.4 %

Litigation settlement

     -       -       (233 )     -0.2 %

Interest expense

     3,591       3.2 %     2,548       2.2 %

Unrealized loss on equity securities

     632       0.6 %     -       -  

Income tax expense

     859       0.8 %     337       0.3 %

 

Revenues

 

Revenues decreased $1.0 million, or 1.0%, to $112.3 million for the year ended December 31, 2023, compared to $113.3 million for the year ended December 31, 2022. Revenues included a net decrease of $5.0 million from the discontinuation of non-strategic products, which was largely offset by growth in preclinical product and service revenue. Foreign exchange favorably impacted revenue by $0.7 million during the year ended December 31, 2023.

 

Gross profit

 

Gross profit increased $5.3 million, or 8.6%, to $66.1 million for the year ended December 31, 2023, compared with $60.8 million for the year ended December 31, 2022. Gross margin increased to 58.9% for the year ended December 31, 2023, compared with 53.7% for the year ended December 31, 2022. The increase in gross margin was due primarily to a higher mix of preclinical products, services, and software, which generally have higher gross margins than our other product lines, reduced revenue from lower margin products discontinued during the second half of 2022 and lower cost of sales resulting from restructuring activities related to discontinuing those products. Costs of goods sold for the year ended December 31, 2022, also included a $1.5 million inventory write down related to the discontinuation of certain non-strategic products.

 

Sales and marketing expenses

 

Sales and marketing expenses decreased $0.9 million, or 3.7%, to $24.1 million for the year ended December 31, 2023, compared to $25.0 million for the year ended December 31, 2022. A reduction in salaries due to lower headcount was partially offset by increases in variable compensation.

 

General and administrative expenses

 

General and administrative expenses decreased by $1.7 million, or 7.0%, to $22.8 million for the year ended December 31, 2023, compared with $24.5 million for the year ended December 31, 2022. The decrease was primarily due to reduced consulting costs and severance costs incurred with restructuring activities in the prior period, partially offset by increases in salaries and variable compensation in the current period.

 

Research and development expenses

 

Research and development expenses decreased $0.5 million, or 4.6%, to $11.8 million for the year ended December 31, 2023, compared with $12.3 million for the year ended December 31, 2022. The decrease was primarily due to the capitalization of software development costs. Reduced salaries and consulting costs were offset by increases in variable compensation.

 

Amortization of intangible assets

 

Amortization of intangible assets was $5.5 million for the year ended December 31, 2023, compared to $6.1 million for the year ended December 31, 2022. Amortization expense decreased as certain intangible assets became fully amortized during 2022.

 

18
Table of Contents

 

Litigation settlement

 

During the year ended December 31, 2022, we recorded a net credit of $0.2 million related to the HRGN Settlement consisting of $5.2 million in settlement and legal expenses offset by credits of $5.4 million. The credits consisted of adjustments to the reserve against an indemnification receivable from HRGN to reflect: i) the issuance by HRGN of Series E Convertible Preferred Stock to us on June 10, 2022, in satisfaction of $4.0 million of Biostage’s total indemnification obligations, ii) the payment by HRGN of legal fees associated with the HRGN Settlement, and iii) other accrual adjustments.

 

On April 6, 2023, all of the shares of Convertible Preferred Stock we held in HRGN were mandatorily converted into shares of common stock.

 

Interest expense

 

Interest expense increased $1.1 million, or 40.9%, to $3.6 million for the year ended December 31, 2023, compared with $2.5 million for the year ended December 31, 2022. The increase was the result of higher interest costs in a rising rate environment, which was partially offset by lower average borrowings during the period.

 

Unrealized loss on equity securities

 

In connection with the settlement discussed above, as of December 31, 2023 we held shares of HRGN common stock with an estimated fair value of $3.5 million. During the year ended December 31, 2023, we recorded an unrealized loss of $0.6 million related to these shares. We determine the fair value of our HRGN common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. Due to HRGN’s limited operating history, its overall financial condition and the limited trading volumes and liquidity of its common stock, the value of our investment in this common stock could fluctuate considerably or become worthless.

 

Income tax expense

 

Income tax expense for the year ended December 31, 2023, was $0.9 million compared to $0.3 million for the year ended December 31, 2022. The effective tax rates for the years ended December 31, 2023 and 2022, were (33.5)% and (3.7)%, respectively. The difference between our effective tax rates compared to the U.S. statutory tax rate of 21% was primarily due to the mix of forecasted income or losses in our U.S. and foreign tax jurisdictions, the impact of the employee retention credit, and a Global Intangible Low-Taxed Income inclusion to taxable income. The effective tax rates in both the years ended December 31, 2023 and 2022, were also impacted by changes in valuation allowances associated with our assessment of the likelihood of the recoverability of our deferred tax assets. We have valuation allowances against substantially all of our net operating loss carryforwards and tax credit carryforwards.

 

Liquidity and Capital Resources

 

Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations and our revolving credit facility. Our expected cash outlays relate primarily to cash payments due under our Credit Agreement described below, salaries, inventory, and capital expenditures.

 

As of December 31, 2023, we held cash and cash equivalents of $4.3 million, compared with $4.5 million at December 31, 2022. Borrowings outstanding under our Credit Agreement were $37.1 million and $47.7 million as of December 31, 2023 and 2022, respectively.

 

On December 22, 2020, we entered into a Credit Agreement which provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility both maturing on December 22, 2025 (See Note 9 to the Consolidated Financial Statements included in “Part IV, Item 15. Exhibits, Financial Statement Schedules” of this report). As of December 31, 2023, the weighted average interest rate on our borrowings, inclusive of the effect of our interest rate swaps, was 7.4%, and the available and unused borrowing capacity under the Credit Agreement, as amended, was $10.8 million. Total revolver borrowing capacity is limited by our consolidated net leverage ratio as defined under the Credit Agreement, as amended.

 

Based on our current operating plans, we expect that our available cash, cash generated from current operations and debt capacity will be sufficient to finance current operations and capital expenditures for at least the next 12 months. This assessment includes consideration of our best estimates of the impact of macroeconomic conditions on our financial results described above. Our forecast for the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary as a result of a number of factors.

 

19
Table of Contents

 

Condensed Consolidated Cash Flow Statements

 

        Year Ended December 31,  

(in thousands)

  

2023

    

2022

  

Cash provided by operating activities

   $ 14,028     $ 1,152  

Cash used in investing activities

     (1,799 )     (1,590 )

Cash used in financing activities

     (12,134 )     (2,837 )

Effect of exchange rate changes on cash

     (320 )     (38 )

Decrease in cash and cash equivalents

   $ (225 )   $ (3,313 )

 

Cash provided by operations was $14.0 million and $1.2 million for the years ended December 31, 2023 and 2022, respectively. Cash provided by operating activities for the year ended December 31, 2023 improved due to reductions in our net loss adjusted for non-cash items and increases in deferred revenue for service contracts. During the year ended December 31, 2022, cash used in operations was negatively impacted by the payment of approximately $4.0 million in connection with the HRGN Settlement.

 

Cash used in investing activities was $1.8 million for the year ended December 31, 2023, and primarily consisted of $2.3 million of capital expenditures in manufacturing, information technology infrastructure, and capitalized software costs, offset by $0.5 million from proceeds from the sale our Hoefer product line. Cash used in investing activities was $1.6 million for the year ended December 31, 2022, and primarily consisted of capital expenditures in manufacturing and information technology infrastructure.

 

Cash used in financing activities was $12.1 million for the year ended December 31, 2023. During this period, we made term loan installments payments under the Credit Agreement of $4.1 million, with net payments of $6.4 million under the revolving credit facility. We also received proceeds of $0.9 million from the exercise of stock options and the employee stock purchase plan and paid $2.5 million for taxes related to net share settlement of equity awards.

 

Cash used in financing activities was $2.8 million for the year ended December 31, 2022. During this period, we made term loan payments under the Credit Agreement of $3.2 million, with net borrowings of $1.4 million under the revolving facility. We also received proceeds of $0.6 million from the exercise of stock options and employee stock purchase plan purchases and paid $1.6 million for taxes related to net share settlement of equity awards.

 

Impact of Foreign Currencies

 

Our international operations in some instances operate as a natural hedge as we sell our products in many countries and a substantial portion of our revenues, costs and expenses are denominated in foreign currencies, primarily the euro and the British pound. During the year ended December 31, 2023, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.7 million and an unfavorable effect on expenses of approximately $0.5 million.

 

During the years ended December 31, 2023 and 2022, the translation of foreign currency into U.S. dollars included as a component of comprehensive loss resulted in a gain (loss) of $1.5 million and $(2.6) million, respectively. In addition, the currency exchange rate fluctuations included as a component of net loss resulted in currency losses of $(0.2) million and $(0.4) million during the years ended December 31, 2023 and 2022, respectively.

 

Recent Accounting Pronouncements

 

For information on recent accounting pronouncements impacting our business, see “Recent Accounting Pronouncements” included in Note 2 to the Consolidated Financial Statements included in “Part IV, Item 15. Exhibits, Financial Statement Schedules” of this report.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, investments, income taxes, litigation and other contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

20
Table of Contents

 

We believe the following is one of the more significant judgments and estimates used in the preparation of our consolidated financial statements:

 

Income Taxes and Valuation Allowance

 

We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Our annual tax rate is based on income, statutory tax rates, tax reserve changes and tax planning opportunities available to us in the various jurisdictions in which we operate. We regularly assess the likelihood of tax adjustments in each of the tax jurisdictions in which we have operations and account for the related financial statement implications. We have established tax reserves that we believe are appropriate given the possibility of tax adjustments. Determining the appropriate level of tax reserves requires significant judgment regarding the uncertain application of tax laws. Reserves are adjusted when information becomes available or when an event occurs indicating a change in the reserve is appropriate. Changes in tax reserves could have a material impact on our financial condition or results of operations.

 

Significant judgment is also required in determining the amount of deferred tax assets that will ultimately be realized and any corresponding deferred tax asset valuation allowance. When estimating the necessary valuation allowance, we consider all available evidence for each jurisdiction including historical operating results, estimates of future taxable income and the feasibility of ongoing tax planning strategies. If new information becomes available that would alter our estimate of the amount of deferred tax assets that will ultimately be realized, we adjust the valuation allowance through income tax expense. Changes in the deferred tax asset valuation allowance could have a material impact on our financial condition or results of operations.

 

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk.

 

Not Applicable.

 

Item 8.

Financial Statements and Supplementary Data.

 

The information required by this item is contained in the financial statements referenced in “Part IV, Item 15. Exhibits, Financial Statement Schedules” of this report, which financial statements are appended to this report. An index of those financial statements is found on page F-1.

 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A.

Controls and Procedures.

 

This Report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 9A includes information concerning the controls and control evaluations referred to in those certifications.

 

(a)

Evaluation of Disclosure Controls and Procedures

 

We carried out an evaluation required by the Securities Exchange Act of 1934 (the “1934 Act”), under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the 1934 Act, as of December 31, 2023. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of December 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the 1934 Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

21
Table of Contents

 

(b)

Management’s Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the 1934 Act. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Grant Thornton LLP has independently assessed the effectiveness of our internal control over financial reporting and its report is included below.

 

(c)

Changes in Internal Controls Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the last quarter ended December 31, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

(d)

Limitations on Controls

 

Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

 

 

 

 

 

 

 

 

22
Table of Contents

 

(e)

Report of Independent Registered Public Accounting Firm

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Board of Directors and Stockholders

Harvard Bioscience, Inc.

 

Opinion on internal control over financial reporting

 

We have audited the internal control over financial reporting of Harvard Bioscience, Inc. (a Delaware corporation) and subsidiaries (the “Company”) as of December 31, 2023, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in the 2013 Internal Control—Integrated Framework issued by COSO.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated financial statements of the Company as of and for the year ended December 31, 2023, and our report dated March 7, 2024 expressed an unqualified opinion on those financial statements.

 

Basis for opinion

 

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and limitations of internal control over financial reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

/s/ GRANT THORNTON LLP

 

Hartford, Connecticut

March 7, 2024

 

23
Table of Contents

 

 

Item 9B.

Other Information.

 

On November 23, 2023, James Green, our Chairman, President and Chief Executive Officer, adopted a trading plan intended to satisfy the affirmative defense available under Rule 10b5-1(c) (the “Trading Plan”). The expiration date of the Trading Plan was February 7, 2025. The total number of shares of our common stock (the “Shares”) to be sold under the Trading Plan was a maximum of 240,000. Mr. Green terminated the Trading Plan on January 21, 2024. No Shares were sold under the Trading Plan prior to its termination.

 

 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 

Not applicable.

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance.

 

Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2024 Annual Meeting of Stockholders.

 

Item 11.

Executive Compensation.

 

Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2024 Annual Meeting of Stockholders.

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2024 Annual Meeting of Stockholders.

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

 

Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2024 Annual Meeting of Stockholders.

 

Item 14.

Principal Accounting Fees and Services.

 

Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2024 Annual Meeting of Stockholders.

 

PART IV

 

Item 15.

Exhibits, Financial Statement Schedules.

 

 

(a)

The following documents are filed as part of this Annual Report on Form 10-K or incorporated by reference as indicated:

 

 

(1)

Financial Statements, Schedules, and Exhibits. We have listed our consolidated financial statements filed as part of this annual report in the index to consolidated financial statements on page F-1.

 

 

(2)

Financial Statement Schedules. We have omitted all financial statement schedules because they are not applicable or not required or because we have included the necessary information in our consolidated financial statements or related notes.

 

 

(3)

Exhibits. We have listed the exhibits filed as part of this annual report in the accompanying exhibit index, which follows the signature page to this annual report.

 

Item 16.

Form 10-K Summary.

 

None.

 

24
Table of Contents
 
 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

HARVARD BIOSCIENCE, INC.

 

 

Page

  

Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248)

F-2

  

Consolidated Balance Sheets

F-3

  

Consolidated Statements of Operations

F-4

  

Consolidated Statements of Comprehensive Loss

F-5

  

Consolidated Statements of Stockholders’ Equity

F-6

  

Consolidated Statements of Cash Flows

F-7

  

Notes to Consolidated Financial Statements

F-8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
F-1
Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Board of Directors and Stockholders

Harvard Bioscience, Inc.

 

Opinion on the financial statements

We have audited the accompanying consolidated balance sheets of Harvard Bioscience, Inc. (a Delaware corporation) and subsidiaries (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), and our report dated March 7, 2024, expressed an unqualified opinion.

 

Basis for opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical audit matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

 

/s/ GRANT THORNTON LLP

 

We have served as the Company’s auditor since 2017.

 

Hartford, Connecticut

March 7, 2024

 

F-2
Table of Contents

 

 

HARVARD BIOSCIENCE, INC.

CONSOLIDATED BALANCE SHEETS 

(In thousands, except share and per share data) 

 

  

December 31,

 
  

2023

  

2022

 

Assets

        

Current assets:

        

Cash and cash equivalents

 $4,283  $4,508 

Accounts receivable, net

  16,099   16,705 

Inventories

  24,716   26,439 

Other current assets

  3,940   3,472 

Total current assets

  49,038   51,124 

Property, plant and equipment, net

  3,981   3,366 

Operating lease right-of-use assets

  4,773   5,816 

Goodwill

  57,065   56,260 

Intangible assets, net

  16,036   21,014 

Other long-term assets

  6,473   7,780 

Total assets

 $137,366  $145,360 

Liabilities and Stockholders' Equity

        

Current liabilities:

        

Current portion of long-term debt

 $5,859  $3,811 

Current portion of operating lease liabilities

  1,416   2,135 

Accounts payable

  5,554   6,447 

Contract liabilities

  4,508   3,370 

Other current liabilities

  9,205   7,486 

Total current liabilities

  26,542   23,249 

Long-term debt, net

  30,704   43,013 

Deferred tax liability

  776   590 

Operating lease liabilities

  4,794   5,282 

Other long-term liabilities

  1,476   1,006 

Total liabilities

  64,292   73,140 

Commitments and contingencies - Note 15

          

Stockholders' equity:

        

Preferred stock, par value $0.01 per share, 5,000,000 shares authorized

  -   - 

Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,394,509 shares issued and outstanding at December 31, 2023;  42,081,707 shares issued and outstanding at December 31, 2022

  434   454 

Additional paid-in-capital

  232,435   229,008 

Accumulated deficit

  (145,605)  (142,190)

Accumulated other comprehensive loss

  (14,190)  (15,052)

Total stockholders' equity

  73,074   72,220 

Total liabilities and stockholders' equity

 $137,366  $145,360 

 

See accompanying notes to condensed consolidated financial statements.

 

F-3
Table of Contents

 

 

HARVARD BIOSCIENCE, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(In thousands, except per share data)

 
         
  

Year Ended December 31,

 
  

2023

  

2022

 
         

Revenues

 $112,250  $113,335 

Cost of revenues

  46,179   52,516 

Gross profit

  66,071   60,819 
         

Sales and marketing expenses

  24,108   25,041 

General and administrative expenses

  22,780   24,493 

Research and development expenses

  11,764   12,329 

Amortization of intangible assets

  5,525   6,122 

Litigation settlement - Note 16

  -   (233)

Total operating expenses

  64,177   67,752 
         

Operating income (loss)

  1,894   (6,933)
         

Other (expense) income:

        

Interest expense

  (3,591)  (2,548)

Unrealized loss on equity securities - Note 16

  (632)  - 

Other (expense) income, net

  (227)  302 

Total other expense

  (4,450)  (2,246)
         

Loss before income taxes

  (2,556)  (9,179)

Income tax expense

  859   337 

Net loss

 $(3,415) $(9,516)
         

Loss per share:

        

Basic and diluted loss per share

 $(0.08) $(0.23)
         

Weighted-average common shares:

        

Basic and diluted

  42,420   41,413 

 

See accompanying notes to condensed consolidated financial statements.

 

F-4
Table of Contents

 

 

HARVARD BIOSCIENCE, INC.

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

(In thousands)

 
         
  

Year Ended December 31,

 
  

2023

  

2022

 
         

Net loss

 $(3,415) $(9,516)

Other comprehensive income (loss):

        

Foreign currency translation adjustments

  1,507   (2,614)

Defined benefit pension plans, net of tax benefit of $137 and $566, respectively

  (446)  (2,411)

Derivative instruments qualifying as cash flow hedges, net of tax of $-0-

  (199)  - 

Other comprehensive income (loss)

  862   (5,025)

Comprehensive loss

 $(2,553) $(14,541)

 

See accompanying notes to consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F-5
Table of Contents

 

 

HARVARD BIOSCIENCE, INC.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 

(In thousands)

 
                         
                  

Accumulated

     
  

Number

      

Additional

      

Other

  

Total

 
  

of Shares

  

Common

  

Paid-in

  

Accumulated

  

Comprehensive

  

Stockholders’

 
  

Issued

  

Stock

  

Capital

  

Deficit

  

Loss

  

Equity

 

Balance at December 31, 2021

  41,143  $452  $225,650  $(132,674) $(10,027) $83,401 

Stock option exercises

  40   2   106   -   -   108 

Stock purchase plan

  176   -   469   -   -   469 

Vesting of restricted stock units

  1,135   -   -   -   -   - 

Shares withheld for taxes

  (412)  -   (1,628)  -   -   (1,628)

Stock-based compensation expense

  -   -   4,411   -   -   4,411 

Net loss

  -   -   -   (9,516)  -   (9,516)

Other comprehensive loss

  -   -   -   -   (5,025)  (5,025)

Balance at December 31, 2022

  42,082   454   229,008   (142,190)  (15,052)  72,220 

Stock option exercises

  214   -   506   -   -   506 

Stock purchase plan

  137   -   424   -   -   424 

Vesting of restricted stock units

  1,460   -   -   -   -   - 

Shares withheld for taxes

  (498)  -   (2,523)  -   -   (2,523)

Stock-based compensation expense

  -   -   5,000   -   -   5,000 

Net loss

  -   -   -   (3,415)  -   (3,415)

Other comprehensive income

  -   -   -   -   862   862 

Other adjustments

  -   (20)  20   -   -   - 

Balance at December 31, 2023

  43,395  $434  $232,435  $(145,605) $(14,190) $73,074 

 

See accompanying notes to consolidated financial statements.

 

 

 

 

 

 

 

F-6
Table of Contents

 

 

HARVARD BIOSCIENCE, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(In thousands)

 
         
  

Year Ended December 31,

 
  

2023

  

2022

 

Cash flows from operating activities:

        

Net loss

 $(3,415) $(9,516)

Adjustments to reconcile net loss to net cash provided by operating activities:

        

Depreciation

  1,473   1,453 

Amortization of intangible assets

  5,525   6,122 

Amortization of deferred financing costs

  280   280 

Stock-based compensation expense

  5,000   4,411 

Deferred income taxes and other

  336   (414)

Unrealized loss on equity securities - Note 16

  632   - 

Convertible preferred stock received in litigation settlement - Note 16

  -   (3,900)

Gain on sale of product line

  (403)  - 

Changes in operating assets and liabilities:

        

Accounts receivable

  810   4,780 

Inventories

  1,524   252 

Other assets

  1,651   474 

Accounts payable and other current liabilities

  555   (1,399)
Contract liabilities  1,138   (896)

Other liabilities

  (1,078)  (495)

Net cash provided by operating activities

  14,028   1,152 

Cash flows from investing activities:

        

Additions to property, plant and equipment

  (1,788)  (1,590)

Capitalized software development costs

  (523)  - 

Proceeds from sale of product line

  512   - 

Net cash used in investing activities

  (1,799)  (1,590)

Cash flows from financing activities:

        

Borrowing from revolving line of credit

  4,500   7,800 

Repayment of revolving line of credit

  (10,950)  (6,400)

Repayment of term debt

  (4,091)  (3,186)

Proceeds from exercise of stock options and employee stock purchase plan

  930   577 

Taxes paid related to net share settlement of equity awards

  (2,523)  (1,628)

Net cash used in financing activities

  (12,134)  (2,837)

Effect of exchange rate changes on cash

  (320)  (38)

Decrease in cash and cash equivalents

  (225)  (3,313)

Cash and cash equivalents at beginning of period

  4,508   7,821 

Cash and cash equivalents at end of period

 $4,283  $4,508 

Supplemental disclosures of cash flow information:

     

Cash paid for interest

 $3,795  $2,314 

Cash paid for income taxes, net of refunds

 $207  $534 

 

See accompanying notes to consolidated financial statements.

 

F-7
Table of Contents

 

HARVARD BIOSCIENCE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

1.

Organization

 

Harvard Bioscience, Inc., a Delaware corporation (the “Company”), is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe and China, the Company sells through a combination of direct and distribution channels to customers around the world.
 

2.

Summary of Significant Accounting Policies

 

Principles of Consolidation 

 

The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables. and defined benefit pension obligations. Estimates are also required to evaluate the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash holdings in financial institutions that exceed insured limits for such financial institutions. The Company mitigates this risk by utilizing financial institutions of high credit quality.

 

Approximately 49% of the Company’s cash and cash equivalents at December 31, 2023 was held by the Company’s foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by subsidiaries in the United Kingdom, Germany and Spain.

 

Marketable Equity Securities

 

Equity securities traded in active markets are marked to market at each balance sheet date based on prices as quoted on the relevant stock exchange. Fair value mark-to-market adjustments are recorded as non-operating gains (losses) in the consolidated statement of operations. The Company’s investments in marketable equity securities are classified in the consolidated balance sheet based on the nature of the securities and their availability for use in current operations.

 

Allowance for Expected Credit Losses on Receivables

 

The allowance for expected credit losses on receivables is used to present accounts receivable, net, at an amount that represents the Company’s estimate of the receivables expected to be collected from customers. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written off. The Company estimates the allowance on the basis of specifically identified receivables that are evaluated individually for impairment and an analysis of the remaining receivables determined by reference to past default experience. The Company considers the need to adjust historical information to reflect the extent to which current conditions and reasonable forecasts are expected to differ from the conditions that existed for the historical period considered. Losses on receivables have not historically been significant.

 

Management judgments are used to determine when to charge off uncollectible trade accounts receivable. The Company bases these judgments on the age of the receivable, credit quality of the customer, current economic conditions, and other factors that may affect a customer’s ability and intent to pay. Customers are generally not required to provide collateral for purchases.

 

F- 8
Table of Contents
 

Inventories

 

The Company values inventories at the lower of cost (determined on a first-in, first-out method) or net realizable value. The Company regularly reviews inventory quantities on hand and writes down excess and obsolete inventories to estimated net realizable value if less than cost, based primarily on historical inventory usage and estimated forecast of product demand.

 

Property, Plant and Equipment

 

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

 

Machinery and equipment (years)

3

-

10

Computer equipment and software (years)

3

-

7

Furniture and fixtures (years)

5

-

10

 

Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.

 

Leases

 

The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right for the Company to control the use of the identified property, plant or equipment for a period of time in exchange for consideration. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight-line basis over the lease term.

 

The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets.

 

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the leases’ commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparison to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  The Company uses the flow-through method to account for investment tax credits.  Under this method, the investment tax credits are recognized as a reduction of income tax expense.

 

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. The Company’s policy is to account for Global Intangible Low-Taxed income as a period cost.

 

Foreign Currency

 

The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of  foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in other expense (income), net, in the Company’s consolidated statements of operations.

 

F- 9
Table of Contents
 

Earnings per Share

 

Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.

 

The following table sets forth the computation of basic and diluted earnings per share:

 

  

Year Ended December 31,

 

(in thousands, except per share data)

 

2023

  

2022

 

Net loss

 $(3,415) $(9,516)

Weighted average shares outstanding - basic

  42,420   41,413 

Dilutive effect of equity awards

  -   - 

Weighted average shares outstanding - diluted

  42,420   41,413 

Basic loss per share

 $(0.08) $(0.23)

Diluted loss per share

 $(0.08) $(0.23)

Shares excluded from diluted loss per share due to their anti-dilutive effect

  3,868   3,661 

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) represents the change in equity resulting from items other than shareholder investments and distributions. The Company’s foreign currency translation adjustments, interest rate swap - cash flow hedge and minimum pension liability adjustments are included in AOCI. The components of other comprehensive income are reclassified as net income, net of tax, when the underlying component impacts earnings. Comprehensive income (loss) and the components of AOCI are presented in the accompanying consolidated statements of comprehensive loss and consolidated statements of equity.

 

Revenue Recognition

 

Nature of contracts and customers

 

The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions.

 

The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer customers who incorporate its products into their products under their own brands.

 

Performance obligations

 

The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, software licenses and enhancements, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may contain multiple promises such as delivery of hardware, software, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For contracts with customers that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which does not materially differ from the stated price in the contract. In general, the Company’s list prices are indicative of standalone selling price, and the majority of the Company's contracts have a term of less than one year.

 

Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales of these items are therefore generally recognized at a point in time.

 

F- 10
Table of Contents
 

The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may return an implantable monitor to the Company after use, and if the returned monitor can be reprocessed and resold, they may, in exchange, purchase a replacement implantable monitor of the same model at a lower price than a new monitor. The implantable monitors that are returned by customers are reprocessed and made available for future sale. The initial sale of implantable monitors and subsequent sale of replacement implantable monitors are independent transactions. The Company has no obligation in connection with the initial sale to sell replacement implantable monitors at any future date under any fixed terms and may refuse returned implantable monitors that cannot be recovered or are obsolete. The Company has concluded that the offer to its customers that they may purchase a discounted product in the future is not a material right. 

 

Service revenue consists of installation, training, data analysis and surgeries performed on research animals. Service revenue is recognized when the service is performed. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised and are not a separate performance obligation. Extended warranties relate to warranties that are separately priced and purchased in addition to a standard warranty, and are therefore a separate performance obligation. The Company has made the judgment that the customer benefits as the Company performs over the period of the contract, and therefore revenues from maintenance and warranty contracts are recognized over time. The Company uses the input method to recognize revenue over time, which is generally on a straight-line basis over the service period.

 

For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment.

 

Variable Consideration

 

The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration, and its impact on the Company’s revenue recognition, was not material in any of the periods presented.

 

The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which occurs at the time of shipment or prior to services being performed. Payment terms vary by the type of customers and the products or services offered.

 

Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues.

 

Contract Liabilities

 

The Company records contract liabilities  when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Contract liabilities consist of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Contract liabilities are  generally expected to be recognized within one year.

 

The amounts included in contract liabilities from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not represent a significant financing component as the customer can exercise their discretion as to when they can obtain the products for which they have made a prepayment.

 

Disaggregation of revenue

 

Refer to Note 13 for revenue disaggregated by type and by geographic location as well as further information about the deferred revenue balances.

 

F- 11
Table of Contents
 

Software Development

 

Software development costs for software products to be sold, leased or otherwise marketed that are incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product-by-product basis until the product is available for general release to customers at which time amortization begins.

 

Annual amortization, charged to cost of goods sold, is the amount computed using the ratio that current revenues for a product bear to the total current and anticipated future revenues for that product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product.

 

Intangible Assets

 

Intangible assets are comprised of existing technology, customer contracts and contractual relationships, and other definite-lived intangible assets. Identifiable intangible assets resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by the Company based on the fair value of assets received. Identifiable definite-lived intangible assets are being amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from four to fifteen years.

 

 

Goodwill

 

Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired.

 

For the purpose of its goodwill analysis, the Company has one reporting unit. The Company conducts its annual impairment analysis in the fourth quarter of the fiscal year and more frequently if there is an indicator of impairment. The Company assesses qualitative factors of the reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment indicates a potential impairment, a quantitative analysis is performed. The Company compares the fair value of the reporting unit with its carrying amount. The Company typically estimates fair value using the income approach but will also consider market approaches when appropriate. Under the income approach, the Company uses a discounted cash flows model, which indicates the fair value of the reporting unit based on the present value of the cash flows that the Company expects the reporting unit to generate in the future. The Company's significant estimates in the discounted cash flows model include weighted average cost of capital, long-term rate of growth and profitability of the reporting unit, expected income tax rates and working capital effects. If the carrying amount of a reporting unit exceeds its fair value, goodwill is impaired, and the Company would recognize a loss equal to the excess.

 

The Company evaluated its goodwill for impairment as of October 1, 2023 by performing a qualitative analysis and determined that it was more likely than not that the fair value of the reporting unit exceeded the carrying value.

 

Impairment of Long-Lived Assets

 

The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors which could trigger an impairment review include significant negative industry or economic trends, significant loss of clients, and significant changes in the manner of the Company’s use of the assets or the strategy for its overall business.

 

The recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Cash flow projections are based on trends of historical performance and management’s estimate of future performance. The Company’s estimate of future cash flows requires significant judgment based on historical and anticipated results and are subject to many factors.

 

When the Company determines that the carrying value of the assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, the Company measures the potential impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in its current business model. An impairment loss is recognized only if the carrying amount of the asset is not recoverable and exceeds its fair value. Different assumptions and judgments could materially affect the calculation of the fair value of our assets. For the years ended December 31, 2023 and 2022, the Company concluded that there were no triggering events requiring the Company to assess the recoverability of its long-lived assets.

 

Derivatives

 

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge) and does not use derivative financial instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values.

 

F- 12
Table of Contents
 

The Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

 

By using derivative financial instruments to hedge exposure to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations by the use of cash flow sensitivity analysis, which estimates the expected impact of changes in interest rates on the Company’s future cash flows.

 

Fair Value of Financial Instruments

 

Financial reporting standards define a fair value hierarchy that consists of three levels:

 

 

●

Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

 

 

●

Level 2 includes instruments for which the valuations are based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

 

 

●

Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The carrying values of the Company’s cash and cash equivalents, trade accounts receivable, trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity (Level 2).

 

Stock-based Compensation

 

The Company recognizes compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, and restricted stock units with a market condition. The Company issues awards under the 2021 Incentive Plan (the “2021 Incentive Plan”) and the Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “2000 Incentive Plan” and together with the 2021 Incentive Plan, the “Incentive Plans”), as well as issues shares for employee stock purchases related to its Employee Stock Purchase Plan (as amended, the “ESPP”). The Company issues new shares from its registered but unissued stock pool to satisfy stock option exercises and vesting of the restricted stock units. Stock-based compensation expense is recorded on a straight-line basis over the applicable service period, which ranges from one to four years. The Company has elected as an accounting policy to account for forfeitures for service-based awards as they occur, with no adjustment for estimated forfeitures.

 

The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using a Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables including, but are not limited to, the Company’s expected stock price volatility over the term of the awards, interest rate assumptions, and discounts to adjust for any holding period post-vest restrictions.

 

Preferred Stock

 

The Company’s board of directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The board of directors may exercise this authority without any further approval from stockholders. As of December 31, 2023 and 2022, the Company had no preferred stock issued or outstanding.

 

F- 13
Table of Contents
 

Business Segment Information

 

The Company operates in one segment which involves the design, development, production and distribution of  products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company has a single, company-wide management team that administers all properties as a whole rather than as discrete operating segments. The chief operating decision maker, who is the Company's chief executive officer, measures financial performance as a single enterprise and allocates resources across the Company to maximize profitability, and not on geography, legal entity, or end market basis. The Company operates in a number of countries throughout the world in a variety of product lines. Information regarding product lines and geographic financial information is provided in Note 13, “Revenues” and Note 5, "Balance Sheet Information."

 

Commitments and Contingencies

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. If a loss is reasonably possible and the loss or range of loss can be reasonably estimated, the Company discloses the possible loss. If a loss is probable and the loss or range of loss cannot be reasonably estimated, the Company discloses or states that such an estimate cannot be made. Refer to Note 15 Commitments and Contingencies for additional information. The Company accrues and expenses legal costs associated with contingencies when incurred.

 

Recent Accounting Pronouncements

 

Accounting Pronouncements Adopted in 2023

 

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04), which eliminates the performance of Step 2 from the goodwill impairment test. In performing its annual or interim impairment testing, an entity will instead compare the fair value of the reporting unit with its carrying amount and recognize any impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The Company adopted ASU 2017-04 effective January 1, 2023, with no impact to the consolidated financial statements.

 

In September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU 2016-13 to clarify implementation guidance and to provide transition relief for certain entities. The Company adopted ASU 2016-13 effective January 1, 2023, which resulted in an immaterial impact to the consolidated financial statements.

 

Accounting Pronouncements yet to be Adopted

 

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax, which enhances disclosures related to the effective tax rate reconciliation, income taxes paid, as well as other disclosures. The new standard impacts footnote disclosures and is effective for the Company’s annual financial statements for the year ended December 31, 2025. The Company is currently evaluating the potential impact of adopting ASU 2023-09 will have on the disclosures in its consolidated financial statements.

 

Prior Period Financial Statement Reclassifications

 

During the year ended December 31, 2023, the Company identified immaterial misclassification errors in the financial statement footnote describing the components of AOCI as of December 31, 2022 and 2021. These misclassifications overstated the amount attributed to the defined benefit pension plans, net of tax, by $5.4 million and $5.1 million and understated the amount attributed to foreign currency translation adjustments by $(5.4) million and $(5.1) million as of December 31, 2022 and 2021, respectively. These misclassifications had no impact on total OCI for the year ended December 31, 2022, included in the consolidated statements of comprehensive loss, or the total AOCI included in the consolidated balance sheets as of December 31, 2022, and also had no impact on any of the Company’s previously reported consolidated statements of operations, stockholders’ equity, or cash flows. The correction of these offsetting misclassifications is included in these consolidated financial statements. See Note 3 below for further details.

 

F- 14
Table of Contents
 
 

3.

Accumulated Other Comprehensive Loss

 

Changes in the components of accumulated other comprehensive loss, net of tax, for the years ended December 31, 2023 and 2022, respectively, are as follows:

 

  

Foreign Currency

      

Derivatives

     
  

Translation

  

Defined Benefit

  

Qualifying

     

(in thousands)

 

Adjustments

  

Pension Plans

  

as Hedges

  

Total

 

Balance at December 31, 2021*

 $(8,778) $(1,249) $-  $(10,027)

Other comprehensive loss, net

  (2,614)  (2,411)  -   (5,025)

Balance at December 31, 2022*

  (11,392)  (3,660)  -   (15,052)

Other comprehensive income (loss), net

  1,507   (446)  (199)  862 

Balance at December 31, 2023

 $(9,885) $(4,106) $(199) $(14,190)

 

* See Note 2 – Prior Period Financial Statement Reclassifications

 

 

4.

Goodwill and Intangible Assets

 

The change in the carrying amount of goodwill is as follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Carrying amount at beginning of period

 $56,260  $57,689 

Effect of change in currency translation

  805   (1,429)

Carrying amount at end of period

 $57,065  $56,260 

 

Intangible assets at December 31, 2023 and 2022 consist of the following:

 

      

December 31, 2023

  

December 31, 2022

 

(in thousands)

 

Average

      

Accumulated

          

Accumulated

     

Amortizable intangible assets:

 

Life*

  

Gross

  

Amortization

  

Net

  

Gross

  

Amortization

  

Net

 

Distribution agreements/customer relationships

  6  $16,038  $(9,706) $6,332  $16,124  $(8,727) $7,397 

Existing technology & software development

  2   35,007   (27,029)  7,978   37,549   (26,482)  11,067 

Trade names and patents

  3   7,613   (6,094)  1,519   7,523   (5,197)  2,326 

Total amortizable intangible assets

     $58,658  $(42,829) $15,829  $61,196  $(40,406) $20,790 

Indefinite-lived intangible assets:

              207           224 

Total intangible assets

             $16,036          $21,014 

 

* Weighted average life in years as of December 31, 2023

 

During the year ended December 31, 2023, the Company wrote off approximately $3.7 million of fully amortized intangible assets of certain existing technology and other intangibles related to discontinued product lines. The Company capitalized $0.5 million of software development costs during the year ended December 31, 2023.

 

Intangible asset amortization expense was $5.5 million and $6.1 million for the years ended December 31, 2023 and 2022, respectively. Estimated amortization expense of existing amortizable intangible assets for each of the five succeeding years and thereafter is as follows:

 

(in thousands)

    

2024

 $5,281 

2025

  4,027 

2026

  2,366 

2027

  1,269 

2028

  1,546 

Thereafter

  1,340 

Total

 $15,829 

 

F- 15
Table of Contents
 
 

5.

Balance Sheet Information

 

The following tables provide details of selected balance sheet items as of the periods indicated:

 

Inventories:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Finished goods

 $5,120  $5,223 

Work in process

  4,188   3,776 

Raw materials

  15,408   17,440 

Total

 $24,716  $26,439 

 

Property, Plant and Equipment:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Machinery and equipment

 $8,154  $7,500 

Computer equipment and software

  6,493   6,781 

Leasehold improvements

  2,417   2,507 

Furniture and fixtures

  1,244   1,386 

Automobiles

  58   38 
   18,366   18,212 

Less: accumulated depreciation

  (14,385)  (14,846)

Property, plant and equipment, net

 $3,981  $3,366 

 

Depreciation expense was $1.5 million for each of the years ended December 31, 2023 and 2022. During the year ended December 31, 2023, the Company wrote off approximately $2.0 million of fully depreciated property and equipment from its fixed asset records.

 

Other Current Liabilities:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Compensation

 $3,929  $3,476 

Customer credits

  3,201   2,368 

Professional fees

  499   392 

Warranty costs

  336   268 

Other

  1,240   982 

Total

 $9,205  $7,486 

 

Long-lived Assets by Geographic Area:

 

Long-lived assets by geographic area, which include operating lease right-of-use assets, property, plant and equipment, and amortizable intangible assets, are as follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

United States

 $21,558  $26,051 

Germany

  1,703   2,432 

Rest of the world

  1,322   1,489 

Total long-lived assets

 $24,583  $29,972 

 

F- 16
Table of Contents
 
 

6.

Restructuring and Other Exit Costs

 

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420, Exit or Disposal Cost Obligations, and are discussed below.

 

During the year ended December 31, 2022, the Company reviewed its product portfolio and identified certain non-strategic products for discontinuation and incurred severance expenses in connection with headcount reductions in Europe and North America. The following table summarizes the restructuring activity for the years ended December 31, 2023 and 2022:

 

(in thousands)

 

Inventory Related

  

Severance

  

Other

  

Total

 

Balance at December 31, 2021

 $-  $-  $-  $- 

Restructuring and other exit costs

  1,471   877   46   2,394 

Non-cash charges

  (1,471)  -   -   (1,471)

Cash payments

  -   (241)  (46)  (287)

Balance at December 31, 2022

  -   636   -   636 

Restructuring and other exit costs

  320   42   29   391 

Non-cash charges

  (142)  -   -   (142)

Cash payments

  (94)  (678)  (29)  (801)

Balance at December 31, 2023

 $84  $-  $-  $84 

 

Substantially all of the severance and other costs detailed above have been included as a component of general and administrative expenses, and all inventory-related charges are included in cost of revenues.

 

 

7.

Employee Benefit Plans

 

Employee Retirement Savings Plans

 

The Company sponsors various qualified employee retirement savings plans and makes discretionary contributions to match a certain portion of employee contributions. The Company contributed $1.1 million to these plans for each of the years ended December 31, 2023 and 2022.

 

Employee Pension Plans

 

The Company’s subsidiary in the United Kingdom, Biochrom Ltd., maintains two defined benefit pension plans for its employees. In 2014, these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The Company recognizes the funded status of the pension plans as an asset or liability in the consolidated balance sheets. The funded status equals the difference between the fair value of the plan’s assets and their benefit obligations and has historically measured each year as of December 31. The Company records net period benefit expense (credit) as a component of other expense in the Consolidated Statement of Operations.

 

The components of the Company’s net period benefit expense (credit) were as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Interest cost

 $670  $371 

Expected return on plan assets

  (788)  (818)

Net amortization loss

  328   27 

Net periodic benefit expense (credit)

 $210  $(420)

 

F- 17
Table of Contents
 

The following provides a reconciliation of the changes in the plans’ fair value of assets and benefit obligations for the years ended December 31, 2023 and 2022, and a summary of the funded status as of December 31, 2023 and 2022:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Change in fair value of plan assets:

        

Balance at beginning of year

 $15,576  $27,252 

Actual return on plan assets

  351   (9,098)

Employer contributions

  622   619 

Benefits paid

  (563)  (592)

Currency translation adjustment

  954   (2,605)

Balance at end of year

 $16,940  $15,576 

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Change in benefit obligation:

        

Balance at beginning of year

 $13,263  $22,562 

Interest cost

  665   371 

Actuarial loss (gain)

  479   (6,912)

Benefits paid

  (563)  (592)

Currency translation adjustment

  819   (2,166)

Balance at end of year

 $14,663  $13,263 

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Fair value of plan assets

 $16,940  $15,576 

Benefit obligation

  14,663   13,263 

Net funded status

 $2,277  $2,313 

 

Changes in the actuarial loss (gain) disclosed above are primarily the result of changes in the discount rate and inflation assumptions due to underlying market conditions.

 

The amounts recognized in the consolidated balance sheets consist of:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Other long-term assets

 $2,277  $2,313 

Accumulated other comprehensive loss

  5,909   5,326 

 

The weighted average assumptions used in determining the net pension cost for these plans follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Discount rate

  4.6%  5.0%

Expected return on assets

  5.3%  5.0%

 

The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations.

 

The Company’s mix of pension plan investments among asset classes also affects the long-term expected rate of return on plan assets. As of December 31, 2023, the Company’s actual asset mix approximated its target mix. Differences between actual and expected returns are recognized in the calculation of net periodic pension cost over the average remaining expected future working lifetime, which is approximately 7 years for active plan participants.

 

F- 18
Table of Contents
 

The asset allocations and fair value of the Company’s pension benefits as of December 31, 2023 and 2022, were as follows:

 

(in thousands)

 

2023

  

2022

 

Asset category:

                

Debt securities

 $11,761   69% $11,714   75%

Equity securities

  3,567   21%  3,507   23%

Cash and cash equivalents

  304   2%  185   1%

Other

  1,308   8%  170   1%

Total

 $16,940   100% $15,576   100%

 

(in thousands)

 

2023

  

2022

 

Quoted Prices in Active Markets for Identical Assets (Level 1)

 $304  $185 

Significant Other Observable Inputs (Level 2)

  16,636   15,391 

Significant Other Unobservable Inputs (Level 3)

  -   - 

Total

 $16,940  $15,576 

 

Level 1 assets consist of cash and cash equivalents held in the pension plans. The Level 2 assets primarily consist of investments in private investment funds that are valued using the net asset values provided by the trust or fund, including an insurance contract. Although these funds are not traded in an active market with quoted prices, the investments underlying the net asset value are based on quoted prices.

 

The Company expects to contribute approximately $0.6 million to its pension plans during 2024. The benefits expected to be paid from the pension plans are $0.9 million in 2024, $0.7 million in 2025, $0.8 million in 2026, $1.0 million in 2027 and $0.8 million in 2028. The expected benefits to be paid in the five years from 2029 to 2033 are $5.0 million. The expected benefits are based on the same assumptions used to measure the Company’s benefit obligations at December 31, 2023.

 

 

8.

Leases

 

The Company has noncancelable operating leases for office space, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.

 

The components of lease expense for the years ended December 31, 2023 and 2022, are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Operating lease cost

 $2,013  $1,971 

Short-term lease cost

  199   233 

Sublease income

  (102)  (102)

Total lease cost

 $2,110  $2,102 

 

Supplemental balance sheet information related to the Company’s operating leases was as follows:

 

(in thousands)

 

December 31,

 
  

2023

  

2022

 

Operating lease right-of-use assets

 $4,773  $5,816 
         

Current portion, operating lease liabilities

  1,416   2,135 

Operating lease liabilities, long-term

  4,794   5,282 

Total operating lease liabilities

 $6,210  $7,417 
         

Weighted average remaining lease term (years)

  5.7   6.2 

Weighted average discount rate

  9.5%  9.4%

 

F- 19
Table of Contents
 

Supplemental cash flow information related to the Company’s operating leases was as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Cash paid for amounts included in the measurement of lease liabilities

 $2,367  $2,347 

Right-of-use assets obtained in exchange for lease obligations

  293   295 

 

Future minimum lease payments for operating leases, with initial terms in excess of one year at December 31, 2023, are as follows:

 

Year Ending December 31,

    

(in thousands)

    

2024

  1,938 

2025

  1,166 

2026

  1,060 

2027

  1,047 

2028

  1,057 

Thereafter

  1,926 

Total lease payments

  8,194 

Less imputed interest

  (1,984)

Total operating lease liabilities

 $6,210 

 
 

9.

Long-Term Debt

 

As of December 31, 2023 and 2022, the Company’s borrowings were comprised of the following:

 

(in thousands)

 

December 31, 2023

  

December 31, 2022

 

Long-term debt:

        

Term loan

 $30,723  $34,814 

Revolving line

  6,400   12,850 

Less: unamortized deferred financing costs

  (560)  (840)

Total debt

  36,563   46,824 

Less: current portion of long-term debt

  (6,139)  (4,091)

Current unamortized deferred financing costs

  280   280 

Long-term debt

 $30,704  $43,013 

 

The aggregate amounts of debt maturities are as follows:

 

(in thousands)

    

2024

 $6,139 

2025

  30,984 
  $37,123 

 

On   December 22, 2020, the Company entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A., Wells Fargo Bank, National Association, and Silicon Valley Bank, (together, the “Lenders”). Effective March 27, 2023, all commitments and obligations under the Credit Agreement previously held by Silicon Valley Bank were assumed by First Citizens Bank & Trust Company. The Credit Agreement provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility (including a $10.0 million sub-facility for the issuance of letters of credit and a $10.0 million swingline loan sub-facility) (collectively, the “Credit Facility”). The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s direct, domestic wholly-owned subsidiaries; none of the Company’s direct or indirect foreign subsidiaries has guaranteed the Credit Facility. The Company’s obligations under the Credit Agreement are secured by substantially all of the assets of Harvard Bioscience, Inc. and each guarantor (including all or a portion of the equity interests in certain of the Company’s domestic and foreign subsidiaries). The Credit Facility matures on December 22, 2025. Issuance costs of $1.4 million are amortized over the contractual term to maturity date on a straight-line basis, which approximates the effective interest method. Available and unused borrowing capacity under the revolving line of credit was $10.8 million as of December 31, 2023, based on the Credit Agreement, as amended pursuant to the April 2022 Amendment and November 2022 Amendment as described below. Total revolver borrowing capacity is limited by the consolidated net leverage ratio as defined under the amended Credit Agreement.

 

F- 20
Table of Contents
 

Borrowings under the amended Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement, as amended (a “SOFR Loan”), or (ii) an alternative base rate plus an applicable interest rate margin, each as determined as provided in the Credit Agreement (an “ABR Loan”). SOFR interest under the Credit Agreement is subject to applicable market rates and a floor of 0.50%. The alternative base rate is based on the Citizens Bank prime rate or the federal funds effective rate of the Federal Reserve Bank of New York and is subject to a floor of 1.0%. The applicable interest rate margin varies from 2.0% per annum to 3.25% per annum for SOFR Loans, and from 1.5% per annum to 3.0% per annum for ABR Loans, in each case depending on the Company’s consolidated leverage ratio and is determined in accordance with a pricing grid set forth in the Credit Agreement. Interest on SOFR Loans is payable in arrears on the last day of each applicable interest period, and interest on ABR Loans is payable in arrears at the end of each calendar quarter. There are no prepayment penalties in the event the Company elects to prepay and terminate the Credit Facility prior to its scheduled maturity date, subject to SOFR Loan breakage and redeployment costs in certain circumstances.

 

The effective interest rate on the Company’s borrowings for the years ended December 31, 2023 and 2022, was 8.1% and 5.0%, respectively. The weighted average interest rate as of December 31, 2023, inclusive of the effect of the Company’s interest rate swaps, was 7.4%. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

 

As of December 31, 2023, the term loan amortizes in quarterly installments of $1.0 million with a balloon payment at maturity. Furthermore, within ninety days after the end of the Company’s fiscal year, the term loans may be permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep”, as defined in the agreement; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. As of December 31, 2023, the current portion of long-term debt includes an excess cash flow sweep of $2.1 million to be paid by March 31, 2024. As of December 31, 2022, the current portion of long-term debt included an excess cash flow sweep of $1.1 million which was paid on March 31, 2023. Amounts outstanding under the revolving credit facility can be repaid at any time but are due in full at maturity.

 

The Credit Agreement, as amended, includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement, as amended, also includes customary events of default.

 

In April 2022, the Company entered into an amendment to the Credit Agreement (the “April 2022 Amendment”) which modified, among other things, the financial covenant relating to the consolidated net leverage ratio, and provided consent for the HRGN Settlement (as defined in Note 16). In November 2022, the Company entered into a subsequent amendment to the Credit Agreement which modified, among other things, the financial covenant relating to the consolidated net leverage ratio, and the definition of Consolidated EBITDA used in the calculation of certain financial covenants (the “November 2022 Amendment”). The Company was in compliance with the covenants of the Credit Agreement, as amended, as of December 31, 2023.

 

 

10.

Derivatives

 

On February 28, 2023, the Company entered into an interest rate swap contract to improve the predictability of cash flows from interest payments related to its variable, SOFR-based debt. The swap contract has a notional amount of $27.4 million as of December 31, 2023, and matures on December 22, 2025. This swap contract effectively converts the SOFR-based variable portion of the interest payable under the Credit Agreement into fixed-rate debt at an annual rate of 4.75%. The swap contract does not impact the additional interest related to the applicable interest rate margin as discussed above in Note 9, Long-Term Debt. The swap contract is considered an effective cash flow hedge, and as a result, net gains or losses are reported as a component of OCI in the consolidated financial statements and are reclassified as net income when the underlying hedged interest impacts earnings. An assessment is performed quarterly to evaluate the ongoing hedge effectiveness.

 

The following table presents the notional amount and fair value of the Company’s derivative instrument as of December 31, 2023:

 

(in thousands)

 

December 31, 2023

 

Derivatives Instruments

 

Balance Sheet Classification

 

Notional Amount

  

Fair Value (a)

 

Interest rate swap

 

Other long-term liabilities

 $27,375  $(199)

 

(a) See Note 11 for the fair value measurements related to this financial instrument.  

 

F- 21
Table of Contents
 

The following table summarizes the effect of derivatives designated as cash flow hedging instruments for the year ended December 31, 2023: 

 

  

Year Ended

 

Derivatives Qualifying as Hedges, net of tax (in thousands)

 

December 31, 2023

 

Amount of loss recognized in OCI on derivatives (effective portion)

 $199 

Amounts reclassified from accumulated other comprehensive loss to interest expense

  120 

 
 

11.

Fair Value Measurements

 

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

 

  

Fair Value as of December 31, 2023

 

Assets (Liabilities) (in thousands)

 

Level 1

  

Level 2

  

Level 3

  

Total

 

Equity securities - common stock

 $3,511  $-  $-  $3,511 

Interest rate swap agreements

  -   (199)  -   (199)

 

The Company uses the market approach technique to value its financial assets and liabilities. The Company’s financial assets and liabilities carried at fair value include, when applicable, investments in common stock and derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s investment in common stock of Harvard Apparatus Regenerative Technologies (“HRGN” formerly known as Biostage, Inc.) (see Note 16 for information regarding the HRGN Settlement) was based on the closing price as quoted on the OTCQB Marketplace at the reporting date. The fair value of the Company’s interest rate swap agreements was based on SOFR-yield curves at the reporting date.

 

 

12.

Stock-Based Compensation

 

Stock-based compensation expense for the years ended December 31, 2023 and 2022, is allocated as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Cost of revenues

 $308  $121 

Sales and marketing expenses

  746   557 

General and administrative expenses

  3,560   3,487 

Research and development expenses

  386   246 

Total stock-based compensation expenses

 $5,000  $4,411 

 

As of December 31, 2023, the total compensation costs related to unvested awards not yet recognized is $4.7 million and the weighted average period over which it is expected to be recognized is approximately 1.6 years. During the years ended December 31, 2023 and 2022, the Company did not capitalize any stock-based compensation.

 

Equity Incentive Plans

 

During 2021, the Company’s board of directors and stockholders adopted the 2021 Incentive Plan which authorized additional  shares available for grants to officers, employees, non-employee directors and other key persons of the Company and its subsidiaries. As of December 31, 2023, there were approximately 3.1 million shares available for issuance under the 2021 Incentive Plan.

 

Restricted Stock Units with a Market Condition

 

The Company grants deferred awards of market condition restricted stock units (the “Market Condition RSUs”) to certain members of the Company’s management team. The vesting of the Market Condition RSUs is linked to the achievement of a relative total shareholder return (“TSR”) of the Company’s common stock measured from the earlier of (i) the measurement period as set out in the award agreement or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology or Russell 2000 index and based on a 20-day trading average price) and is subject to a one-year holding period after vesting.

 

For Market Condition RSUs with a measurement period that concluded during the years ended December 31, 2023, the TSR of the Company’s common stock relative to the applicable index resulted in achieving 100% of the target. Market Condition RSUs outstanding as of December 31, 2023 remain subject to a TSR measurement which can result in vesting rates ranging from 0% to 150% of the target number.

 

F- 22
Table of Contents
 

The weighted average assumptions used in the valuation of the Market Condition RSUs granted during the years ended December 31, 2023 and 2022, are as follows:

 

  

2023

  

2022

 

Volatility

  56.8%  62.6%

Risk-free interest rate

  4.6%  2.1%

Correlation coefficient

  41.7%  41.5%

Dividend yield

  -%  -%

Liquidity discount

  14.1%  11.7%

 

The Company used historical volatility to calculate the expected volatility matching the expected holding period. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the award. Additionally, the Company assumes a liquidity discount to adjust the fair value for the one-year holding period post-vest restrictions.

 

Stock-Based Payment Awards

 

RSU and Market Condition RSU activity for  the years ended December 31, 2023 and 2022, is as follows:

 

          

Condition

     
  

Restricted

  

Grant Date

  

Restricted

  

Grant Date

 
  

Stock Units

  

Fair Value

  

Stock Units

  

Fair Value

 

Balance at December 31, 2021

  1,141,164  $3.57   860,155  $3.13 

Granted

  918,870   4.64   320,272   5.08 

Vested

  (733,611)  4.08   (401,308)  2.11 

Cancelled/Forfeited

  (232,622)  4.44   (132,884)  4.21 

Balance at December 31, 2022

  1,093,801  $3.94   646,235  $4.51 

Granted

  1,350,125   2.87   558,958   2.61 

Vested

  (1,144,065)  3.38   (316,210)  4.01 

Cancelled/Forfeited

  (134,865)  3.71   (87,138)  4.64 

Balance at December 31, 2023

  1,164,996  $3.28   801,845  $3.37 

 

Stock option activity for  the years ended December 31, 2023 and 2022, is as follows:

 

  

Number of Options

  

Weighted-Average Exercise Price

  

Weighted-Aveage Remaining Contractual Term (years)

  

Average Intrinsic Value (in thousands)

 

Outstanding at December 31, 2021

  1,404,816  $3.10         

Exercised

  (40,267)  2.64         

Cancelled/Forfeited

  (125,773)  2.77         

Outstanding at December 31, 2022

  1,238,776  $3.15         

Exercised

  (213,644)  2.38         

Cancelled/Forfeited

  (101,065)  2.71         

Outstanding and Exerciseable at December 31, 2023

  924,067  $3.37   3.4  $1,836 

 

The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.35 as of December 31, 2023, which would have been received by the option holders had all option holders exercised their options as of that date. The aggregate intrinsic value of options exercised was $0.6 million and $0.1 million for the years ended December 31, 2023 and 2022, respectively.

 

Employee Stock Purchase Plan (“ESPP”)

 

The Company has an employee stock purchase plan under which eligible employees may purchase a limited number of shares of common stock at a discount of up to 15% of the market value of such stock at pre-determined and plan-defined dates. There were 0.1 million and 0.2 million shares issued under the ESPP during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there were 0.3 million shares available for issuance under the ESPP. 

 

F- 23
Table of Contents
 
 

13.

Revenues

 

The following table represents a disaggregation of revenue from contracts with customers for the years ended December 31, 2023 and 2022:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Instruments, equipment, software and accessories

 $105,716  $108,165 

Service, maintenance and warranty contracts

  6,534   5,170 

Total revenues

 $112,250  $113,335 

 

Revenues by timing of recognition are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Goods and services transferred at a point in time

 $108,558  $111,927 

Goods and services transferred over time

  3,692   1,408 

Total revenues

 $112,250  $113,335 

 

Revenues by geographic destination are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

United States

 $48,205  $49,912 

Europe

  32,801   30,687 

Greater China

  18,488   16,393 

Rest of the world

  12,756   16,343 

Total revenues

 $112,250  $113,335 

 

Contract Liabilities

 

The following tables provide details of contract liabilities as of the periods indicated:

 

  

December 31,

      

December 31,

     

(in thousands)

 

2023

  

2022

  

Change

  

2022

  

2021

  

Change

 

Service contracts

 $2,849  $1,530  $1,319   1,530  $1,976  $(446)

Customer advances

  1,659   1,840   (181)  1,840   2,290   (450)

Total contract liabilities

 $4,508  $3,370  $1,138   3,370  $4,266  $(896)

 

Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service and warranty contracts. During the years ended December 31, 2023 and 2022, the Company recognized revenue of $2.1 million and $2.5 million from contract liabilities existing at December 31, 2022 and 2021, respectively.

 

Provision for Expected Credit Losses on Receivables

 

Activity in the provision for expected losses on receivables is as follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Balance, beginning of period

 $191  $136 

Provision for expected credit losses

  29   62 

Charge-offs and other

  (60)  (7)

Balance, end of period

 $160  $191 

 

Concentrations

 

No customer accounted for more than 10% of the revenues for the years ended December 31, 2023 and 2022, or for more than 10% of net accounts receivable at December 31, 2023 and 2022.

 

F- 24
Table of Contents
 

Warranties

 

Activity in the product warranty accrual is as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Balance at December 31, 2022

 $268  $240 

Expense

  381   408 

Warranty claims

  (313)  (380)

Balance at December 31, 2023

 $336  $268 
 

14.

Income Tax

 

Income tax expense for the years ended December 31, 2023 and 2022, consisted of: 

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Current income tax expense:

        

Federal and state

 $570  $641 

Foreign

  61   194 
   631   835 

Deferred income tax expense (benefit):

        

Federal and state

  132   (468)

Foreign

  96   (30)
   228   (498)

Total income tax expense

 $859  $337 

 

The effective tax rate for the year ended December 31, 2023 was (33.5)% as compared with (3.7)% for the same period in 2022. The difference between the Company’s effective tax rate year over year was primarily attributable to changes in the mix of pre-tax income and losses at individual subsidiaries, and the impact of changes in uncertain tax positions.

 

Income tax expense for the years ended December 31, 2023 and 2022, differed from the amount computed by applying the U.S. federal income tax rate of 21% to pre-tax loss as a result of the following:  

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Income tax benefit computed at federal statutory tax rate

 $(537) $(1,927)

Increase (decrease) in income taxes resulting from:

        

Permanent differences, net

  (89)  375 

Non-deductible executive compensation

  324   346 

Global Intangible Low-Taxed Income (GILTI)

  537   552 

State income taxes, net of federal income tax benefit

  (19)  (295)

Stock-based compensation

  (329)  69 

Tax credits

  (51)  492 

Net operating loss true-ups and expirations

  1,140   431 

Change in reserve for uncertain tax position

  239   688 

Impact of change to prior year tax accruals

  (171)  (232)

Change in valuation allowance allocated to income tax

  631   (102)

Other

  (816)  (60)

Total income tax expense

 $859  $337 

 

F- 25
Table of Contents
 

Income tax expense is based on the following pre-tax (loss) income from operations:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Domestic

 $(2,951) $(9,099)

Foreign

  395   (80)

Total

 $(2,556) $(9,179)

 

The tax effects of temporary differences that give rise to significant components of the deferred tax assets and deferred tax liabilities at December 31, 2023 and 2022, are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Deferred income tax assets:

        

Inventory

 $1,489  $1,696 

Operating loss and credit carryforwards

  11,550   14,883 

Research and development

  3,908   2,000 

Employee retention credit

  1,435   - 

Lease liabilities

  1,317   1,538 

Accrued expenses

  818   621 

Stock compensation

  670   675 

Deferred interest expense

  386   881 

Other assets

  934   726 

Total gross deferred assets

  22,507   23,020 

Less: valuation allowance

  (15,222)  (14,506)

Deferred tax assets

 $7,285  $8,514 
         

Deferred income tax liabilities:

        

Indefinite-lived intangible assets

 $1,964  $1,914 

Definite-lived intangible assets

  3,733   4,875 

Lease right-of-use assets

  959   1,148 

Employee benefit plans

  569   579 

Other liabilities

  400   255 

Total deferred tax liabilities

  7,625   8,771 

Deferred income tax liabilities, net

 $(340) $(257)

 

Deferred income tax assets and liabilities by classification on the consolidated balance sheets were as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Deferred tax assets (included in other long-term assets)

 $436  $333 

Deferred income tax liabilities

  (776)  (590)

Deferred income tax liability, net

 $(340) $(257)

 

At December 31, 2023, the Company had state net operating loss carryforwards of $6.3 million, which expire between 2024 and 2043. The Company had net operating loss carryforwards of $7.8 million in certain foreign jurisdictions which may be carried forward indefinitely, partially offset by valuation allowances. The Company had $7.8 million of research and development tax credit carryforwards which begin to expire in 2024, and are partially offset by a reserve of $0.8 million for uncertain tax positions. The Company had a total of $2.7 million of state investment tax credit carryforwards, research and development tax credit carryforwards, and enterprise zone credit carryforwards, which begin to expire in 2024. In addition, the Company had a total of $0.4 million international R&D credits which begin to expire in 2037. The Internal Revenue Code (“IRC”) limits the amounts of net operating loss carryforwards or credits that a company may use in any one year in the event of a change in ownership under IRC Sections 382 or 383. As a result of various acquisitions in prior years, certain losses and credit carryforwards are subject to these limitations.

 

F- 26
Table of Contents
 

As of December 31, 2023 and 2022, the Company maintained a total valuation allowance of $15.2 million and $14.5 million, respectively, which relates to foreign, federal, and state deferred tax assets in both years. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. The net change in the total valuation allowance for the years ended December 31, 2023 and 2022, was an increase of $0.7 million and a decrease of $0.2 million, respectively. During the year ended December 31, 2023, the Company increased the valuation allowance related to the estimate of realizability of German deferred tax assets and deferred tax assets related to the Employee Retention Credit, offset by the utilization and expiration of certain U.S. federal and state net operating losses and the expiration of certain U.S. credits.

 

As of December 31, 2023 and 2022, cash and cash equivalents held by the Company’s foreign subsidiaries were $2.1 million and $2.6 million, respectively. As of December 31, 2023, the Company has determined the potential income tax and withholding liability related to available cash balances at foreign subsidiaries to be immaterial.

 

A summary of activity of unrecognized tax benefits is as follows:

 

  

(in thousands)

 

Balance at December 31, 2021

 $1,332 

Additions based on tax positions of prior years

  534 

Decreases based on tax positions of prior years

  (34)

Additions based on tax positions of current year

  237 

Other decreases, net

  (86)

Balance at December 31, 2022

  1,983 

Additions based on tax positions of prior years

  13 

Decreases based on tax positions of prior years

  57 

Additions based on tax positions of current year

  245 

Other decreases, net

  (76)

Balance at December 31, 2023

 $2,222 

 

We expect the amount of unrecognized tax benefits to change within the next twelve months, including the release of reserves of approximately $0.4 million. Substantially all of the liability for uncertain tax benefits related to various federal, state and foreign income tax matters would benefit the Company's effective tax rate, if recognized. The Company classifies interest and penalties related to unrecognized tax benefits as a component of income tax expense, which has not been significant during the years ended December 31, 2023 and 2022, respectively.

 

With a few exceptions, the Company is no longer subject to income tax examinations by tax authorities in foreign jurisdictions for the years before 2019. In the U.S., the Company’s net operating loss and tax credit carryforward amounts remain subject to federal and state examination for tax years starting in 2004 as a result of tax losses incurred in prior years. There are currently no pending federal or state tax examinations.
 

15.

Commitments and Contingent Liabilities

 

In April 2022, the Company and HRGN executed a settlement with the plaintiffs in the HRGN Litigation (as defined below), which resolves all claims relating to the litigation as described in Note 16, Litigation Settlement.

 

The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not likely to have a material adverse effect on its business, financial condition, results of operations or cash flow. Although unfavorable outcomes in the proceedings are possible, the Company has not accrued loss contingencies relating to any such matters as they are not considered to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company’s business, financial condition, results of operations and cash flows could be material.

 

In addition, the Company has entered into indemnification agreements with its directors. It is not possible to determine the maximum potential liability amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. The Company has not recorded any liability for costs related to contingent indemnification obligations as of December 31, 2023.

 

The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company is currently undergoing an unclaimed property audit. Based on the current stage of the audits, the Company has not accrued any significant losses related to these audits as of December 31, 2023.

 

F- 27
Table of Contents
 
 

16.

Litigation Settlement

 

In April 2022, the Company and HRGN entered into a settlement of a litigation related to injuries allegedly caused by products produced by the Company and HRGN and utilized in connection with surgeries performed by third parties (the “HRGN Settlement”). The HRGN Settlement resolved and dismissed all claims by and between the parties. HRGN has indemnified the Company for all losses and expenses that the Company incurred in connection with such litigation and settlement.

 

In connection with the HRGN Settlement, in June 2022, HRGN issued 4,000 shares of Series E Convertible Preferred Stock (the “Series E Preferred Stock”) to the Company in satisfaction of $4.0 million of its total indemnification obligations. The Company recorded the Series E Preferred Stock at an estimated fair value of $3.9 million using a Monte Carlo valuation simulation incorporating information from selected guideline companies. As of December 31, 2022, the book value of the shares of Series E Preferred Stock, inclusive of accrued dividends, was $4.1 million and was included in the consolidated balance sheet as a component of other long-term assets.

 

In April 2023, all of the shares of Series E Preferred Stock the Company held in HRGN were mandatorily converted into shares of HRGN common stock.

 

As of December 31, 2023, the Company held shares of HRGN common stock with an estimated fair value of $3.5 million, which are included in the consolidated balance sheet as a component of other long-term assets. During the year ended December 31, 2023, the Company recorded an unrealized loss related to these shares of $(0.6) million, which was recorded as other (expense) income, net, in the consolidated statements of operations. The Company determines the fair value of its HRGN common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. Due to HRGN’s limited operating history, its overall financial condition and the limited trading volumes and liquidity of its common stock, the value of the Company’s investment in this common stock could fluctuate considerably or become worthless.
 

17.

Product Line Disposition

 

On February 17, 2023, the Company completed the disposition of its Hoefer product line for cash consideration of $0.5 million. The carrying value of assets sold was $0.1 million resulting in a gain on disposition of $0.4 million which is recorded in other (expense) income, net, in the consolidated statement of operations for the year ended December 31, 2023. Revenue and gross profit of this disposed product line included in the condensed consolidated statement of operations for the years ended December 31, 2023 and 2022, were not significant.
 

18.

Government Assistance

 

As there is no authoritative guidance under U.S. GAAP on accounting for grants to for profit business entities from government entities, the Company accounts for government assistance by analogy to International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance (IAS 20). Under IAS 20, grants related to income are presented as part of the consolidated statements of operations either as a deduction of the related expense or reported separately in other income.  The Company recognizes government assistance that supplements salaries or research activities as a reduction of the related operating expense over the period for which it is intended to compensate. Government assistance that is not directly related to expense reimbursement or relates to costs incurred in a previous fiscal period is recorded as other income.

 

For the years ended December 31, 2023 and 2022, the Company received $0.2 million and $0.7 million, respectively, under government assistance programs. The majority of the assistance was a result of the Company’s German subsidiaries participating in programs established to offset the negative impact of COVID-19 on profitability, to support employment during the COVID-19 pandemic, and to offset the costs of qualifying research and development activities.

 

In February 2024, the Company received and recorded $3.1 million for the Employee Retention Credit (“ERC”), which was enacted as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES Act”) to provide financial incentives to eligible businesses to retain their workforce through the period of financial hardship resulting from the COVID-19 pandemic.

 

F- 28
Table of Contents
 
 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

HARVARD BIOSCIENCE, INC.
     

 Date: March 7, 2024

By:

/s/ JAMES GREEN
   

James Green
   

Chief Executive Officer

 

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 

 

Signature

  

Title

  

Date
         

/s/ JAMES GREEN

  

Chief Executive Officer and Director

(Principal Executive Officer)

  

March 7, 2024

James Green

        

/s/ JENNIFER COTE

  

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

  

March 7, 2024

Jennifer Cote

        
         

/s/ KATHERINE A. EADE

  

Director

  

March 7, 2024

Katherine A. Eade

        
         

/s/ ALAN EDRICK

  

Director

  

March 7, 2024

Alan Edrick

        
         

/s/ THOMAS W. LOEWALD

  

Director

  

March 7, 2024

Thomas W. Loewald

        
         

/s/ BERTRAND LOY

  

Director

  

March 7, 2024

Bertrand Loy

        

 

 

 

 

 

 

 

F-29
Table of Contents
 

EXHIBIT INDEX

 

The following exhibits are filed as part of this Annual Report on Form 10-K. Where such filing is made by incorporation by reference to a previously filed document, such document is identified.

 

Exhibit

  

Description

  

Method of Filing
         

2.1§

  

Separation and Distribution Agreement between Harvard Bioscience, Inc. and Biostage, Inc. (f/k/a Harvard Apparatus Regenerative Technology, Inc.) dated as of October 31, 2013.

  

Exhibit to the Current Report on Form 8-K filed November 6, 2013, and incorporated by reference thereto.
         

3.1

  

Second Amended and Restated Certificate of Incorporation of Harvard Bioscience, Inc. 

  

Exhibit to the Registration Statement on Form S-1/A (File No. 333-45996) (filed November 9, 2000) and incorporated by reference thereto.
         

3.2

  

Amended and Restated By-laws of Harvard Bioscience, Inc.

  

Exhibit to the Registration Statement on Form S-1/A (File No. 333-45996) (filed November 9, 2000) and incorporated by reference thereto.
         

3.3

  

Amendment No. 1 to Amended and Restated Bylaws of Harvard Bioscience, Inc. (as adopted October 30, 2007).

  

Exhibit to the Current Report on Form 8-K (filed November 1, 2007) and incorporated by reference thereto.
         

4.1

  

Specimen certificate for shares of Common Stock, $0.01 par value, of Harvard Bioscience, Inc.

  

Exhibit to the Registration Statement on Form S-1/A (File No. 333-45996) (filed November 9, 2000) and incorporated by reference thereto.
         

4.2

  

Description of Securities.

  

Exhibit to the Annual Report on Form 10-K (filed March 16, 2020) and incorporated by reference thereto.
         

10.1 #

  

Harvard Bioscience, Inc. Fourth Amended and Restated 2000 Stock Option and Incentive Plan.

  

Exhibit to the Quarterly Report on Form 10-Q filed August 10, 2020, and incorporated by reference thereto. 
         

10.2

  

Harvard Bioscience, Inc. Employee Stock Purchase Plan, as amended.

  

Disclosed as Appendix A to the Proxy Statement on Schedule 14A filed April 7, 2022, and incorporated by reference thereto.
         

10.3

  

Form of Director Indemnification Agreement.

  

Exhibit to the Quarterly Report on Form 10-Q filed May 8, 2020, and incorporated by reference thereto.
         

10.4 +

  

Trademark License Agreement, dated December 19, 2002, by and between Harvard Bioscience, Inc. and President and Fellows of Harvard College.

  

Exhibit to the Annual Report on Form 10-K filed March 9, 2023, and incorporated by reference thereto.
         

10.5 #

  

Form of Incentive Stock Option Agreement (Executive Officers).

  

Exhibit to the Annual Report on Form 10-K filed March 16, 2006, and incorporated by reference thereto.
         

10.6 #

  

Form of Non-Qualified Stock Option Agreement (Executive Officers).

  

Exhibit to the Annual Report on Form 10-K filed March 16, 2006, and incorporated by reference thereto.
         

10.7 #

  

Form of Non-Qualified Stock Option Agreement (Non-Employee Directors).

  

Exhibit to the Annual Report on Form 10-K filed March 16, 2006, and incorporated by reference thereto.
         

10.8 #

  

Form of Deferred Stock Award Agreement.

  

Exhibit to the Annual Report on Form 10-K filed March 16, 2011, and incorporated by reference thereto.
         

10.9 #

  

Form of Market Condition Deferred Stock Award Agreement.

  

Exhibit to the Annual Report on Form 10-K filed March 16, 2020, and incorporated by reference thereto.
         

10.10 #

  

Employment Agreement between Harvard Bioscience, Inc. and James Green.

  

Exhibit to the Current Report on Form 8-K filed July 8, 2019, and incorporated by reference thereto.

 

 
Table of Contents

 

10.11#

  

Employment Agreement between Jennifer Cote and the Company dated June 19, 2023

  

Exhibit to the Current Report on Form 8-K filed June 20, 2023, and incorporated by reference thereto.
         

10.12

  

Consulting Agreement, dated as of March 2, 2020, by and between Harvard Bioscience, Inc. and Chane Graziano.

  

Exhibit to the Current Report on Form 8-K filed March 6, 2020, and incorporated by reference thereto.
         

10.13

  

Credit Agreement dated as of December 22, 2020 among Harvard Bioscience, Inc., as borrower, the lenders party thereto, and Citizens Bank, N.A., as administrative agent.

  

Exhibit to the Current Report on Form 8-K filed December 23, 2020, and incorporated by reference thereto.
         

10.14

  

Pledge and Security Agreement dated as of December 22, 2020 among Harvard Bioscience, Inc., certain of Harvard Bioscience’s direct and indirect subsidiaries and Citizens Bank, N.A., as administrative agent.

  

Exhibit to the Current Report on Form 8-K filed December 23, 2020, and incorporated by reference thereto.
         

10.15

  

First Amendment to Credit Agreement and Amendment to Pledge and Security Agreement, dated April 28, 2022, among Harvard Bioscience, Inc., Citizens Bank, N.A., as the administrative agent, and the lenders party thereto.

  

Exhibit to the Current Report on Form 8-K filed April 28, 2022, and incorporated by reference thereto.
         

10.16

  

Second Amendment to Credit Agreement and Amendment to Pledge and Security Agreement, dated November 8, 2022, among Harvard Bioscience, Inc., Citizens Bank, N.A., as the administrative agent, and the lenders party thereto.

  

Exhibit to the Form 10-Q filed November 9, 2022, and incorporated by reference thereto.
         

10.17

  

Guarantee Agreement dated as of December 22, 2020 among Harvard Bioscience, Inc., certain of Harvard Bioscience’s direct and indirect subsidiaries and Citizens Bank, N.A., as administrative agent.

  

Exhibit to the Current Report on Form 8-K filed December 23, 2020, and incorporated by reference thereto.
         

10.18#

  

Harvard Bioscience, Inc. 2021 Incentive Plan.

  

Exhibit to the Current Report on Form 8-K filed May 19, 2021, and incorporated by reference thereto.
         

10.19#

  

Form of Performance RSU Award Agreement - 2021 Incentive Plan.

  

Exhibit to the Annual Report on Form 10-K filed March 11, 2022, and incorporated by reference thereto.
         

10.20#

  

Form of Time-Based RSU Awards Agreement – 2021 Incentive Plan.

  

Exhibit to the Annual Report on Form 10-K filed March 11, 2022, and incorporated by reference thereto. 
         

10.21#

  

Form of RSU Award for Directors – 2021 Incentive Plan.

  

Exhibit to the Annual Report on Form 10-K filed March 11, 2022, and incorporated by reference thereto.
         

10.22#

  

Separation Agreement and Release between Harvard Bioscience, Inc. and Ken Olson, dated as of January 26, 2022.

  

Exhibit to the Current Report on Form 8-K filed January 28, 2022, and incorporated by reference thereto.
         

10.23#

  

Separation Agreement and Release between Harvard Bioscience, Inc. and Michael Rossi, dated January 18, 2023

  

Exhibit to the Current Report on Form 8-K filed January 19, 2023, and incorporated by reference thereto. 

 

21.1

  

Subsidiaries of the Registrant

  

Filed with this report
         

23.1

  

Consent of Grant Thornton LLP

  

Filed with this report
         

31.1

  

Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

  

Filed with this report
         

31.2

  

Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

  

Filed with this report
         

32.1

  

Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

  

 *

 

 
Table of Contents

 

32.2

  

Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 *
         

97

  

Harvard Bioscience Inc., Dodd-Frank Clawback Policy

  

Filed with this report
         

101.INS

  

Inline XBRL Instance Document

  

Filed with this report
         

101.SCH

  

Inline XBRL Taxonomy Extension Schema Document

  

Filed with this report
         

101.CAL

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document

  

Filed with this report
         

101.DEF

  

Inline XBRL Taxonomy Extension Definition Linkbase Document

  

Filed with this report
         

101.LAB

  

Inline XBRL Taxonomy Extension Label Linkbase Document

  

Filed with this report
         

101.PRE

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document

  

Filed with this report
         

104

  

Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

    

 

 

 

+

Portions of this exhibit have been redacted in compliance with Item 601(b)(10) of Regulation S-K.
   

*

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934
   

#

Management contract or compensatory plan or arrangement.
   

§

The schedules and exhibits have been omitted. A copy of any omitted schedule or exhibit will be furnished to the SEC supplementally upon request.
   
 

The Company will furnish to stockholders a copy of any exhibit without charge upon written request.

 

 

 

 

 

 
EX-21.1 2 ex_632408.htm EXHIBIT 21.1 HTML Editor

EXHIBIT 21.1

 

 

 

Subsidiaries Of Harvard Bioscience, Inc.
   

Name

Jurisdiction

Biochrom Limited

United Kingdom

Biochrom US, Inc.

Delaware, United States

CMA Microdialysis Ab 

Sweden

Data Sciences International, Inc. 

Delaware, United States

Data Sciences (UK) Mn, Ltd.

United Kingdom

Data Sciences Eurl

France

Data Sciences GmbH

Germany

DSI (Shanghai) Trading Co Ltd.

China

Harvard Bioscience (Shanghai) Co. Ltd.

China

Hugo Sachs Elektronik - Harvard Apparatus GmbH

Germany

Multichannel Systems MCS GmbH

Germany

Panlab S.L.

Spain

 

 
 EX-23.1 3 ex_632409.htm EXHIBIT 23.1 HTML Editor

EXHIBIT 23.1

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our reports dated March 7, 2024, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Harvard Bioscience, Inc. on Form 10-K for the year ended December 31, 2023. We consent to the incorporation by reference of said reports in the Registration Statements of Harvard Bioscience, Inc. on Forms S-8 (File No. 333-249943, File No. 333-53848, File No. 333-104544, File No. 333-135418 File No. 333-151003, File No. 333-174476, File No. 333-189175, File No. 333-204760, File No. 333-218497, File No. 333-225365, File No. 333-231825, File No. 333-256295, and File No. 333-265487).

 

/s/ GRANT THORNTON LLP

 

Hartford, Connecticut

March 7, 2024

 

 

 
 EX-31.1 4 ex_632410.htm EXHIBIT 31.1 HTML Editor

EXHIBIT 31.1

 

Certification

 

I, Jennifer Cote, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Harvard Bioscience, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: March 7, 2024

/s/ JENNIFER COTE
 

Jennifer Cote
 

Chief Financial Officer

 

 

 

 

 
 EX-31.2 5 ex_632411.htm EXHIBIT 31.2 HTML Editor

EXHIBIT 31.2

 

Certification

 

I, James Green, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Harvard Bioscience, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: March 7, 2024

/s/ JAMES GREEN
 

James Green
 

Chief Executive Officer

 

 

 

 

 
 EX-32.1 6 ex_632412.htm EXHIBIT 32.1 HTML Editor

EXHIBIT 32.1

 

 

 

CERTIFICATION OF PERIODIC FINANCIAL REPORT

PURSUANT TO 18 U.S.C. SECTION 1350

 

The undersigned officer of Harvard Bioscience, Inc. (the “Company”) hereby certifies to her knowledge that the Company’s annual report on Form 10-K for the year ended December 31, 2023 to which this certification is being furnished as an exhibit (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

Date: March 7, 2024

/s/ JENNIFER COTE
 

Name: Jennifer Cote
 

Title: Chief Financial Officer

 

 

 
 EX-32.2 7 ex_632413.htm EXHIBIT 32.2 HTML Editor

EXHIBIT 32.2

 

 

 

CERTIFICATION OF PERIODIC FINANCIAL REPORT

PURSUANT TO 18 U.S.C. SECTION 1350

 

The undersigned officer of Harvard Bioscience, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s annual report on Form 10-K for the year ended December 31, 2023 to which this certification is being furnished as an exhibit (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

Date: March 7, 2024

/s/ JAMES GREEN
 

Name: James Green
 

Title: Chief Executive Officer

 

 

 
 EX-97 8 ex_632414.htm EXHIBIT 97 HTML Editor

EXHIBIT 97

 

HARVARD BIOSCIENCE, INC. DODD-FRANK CLAWBACK POLICY

 

This document sets forth the Dodd-Frank Clawback Policy (the “Policy”) as adopted by Harvard Bioscience, Inc. (the “Company”) on October 31, 2023. This Policy shall be interpreted to comply with the clawback rules found in 17 C.F.R. §240.10D and the related listing rules of the national securities exchange or national securities association (“Exchange”) on which the Company has listed securities, and, to the extent this Policy is any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.

 

1.  Definitions. 17 C.F.R. §240.10D-1(d) defines the terms “Executive Officer,” “Financial Reporting Measures,” “Incentive-Based Compensation,” and “Received.” As used herein, these terms shall have the same meaning as in that regulation.

 

2.  Application of the Policy. This Policy shall only apply in the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

 

3.  Recovery Period. The Incentive-Based Compensation subject to clawback is the Incentive-Based Compensation Received during the three completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as described in section 2, provided that the person served as an Executive Officer at any time during the performance period applicable to the Incentive-Based Compensation in question. The date that the Company is required to prepare an accounting restatement shall be determined pursuant to 17 C.F.R. §240.10D-1(b)(1)(ii).

 

(a) Notwithstanding the foregoing, the Policy shall only apply if the Incentive-Based Compensation is Received (1) while the Company has a class of securities listed on an Exchange and (2) on or after October 2, 2023.

 

(b) See 17 C.F.R. §240.10D-1(b)(1)(i) for certain circumstances under which the Policy will apply to Incentive-Based Compensation Received during a transition period arising due to a change in the Company’s fiscal year.

 

4.  Erroneously Awarded Compensation. The amount of Incentive-Based Compensation subject to recovery under this Policy (“Erroneously Awarded Compensation”) is the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive Based-Compensation that otherwise would have been Received had it been determined based on the restated amounts and shall be computed without regard to any taxes paid. For Incentive-Based Compensation based on the Company’s stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an accounting restatement: (1) the amount shall be based on a reasonable estimate of the effect of the accounting restatement on the Company’s stock price or total shareholder return upon which the Incentive-Based Compensation was Received; and (2) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange. 

 

5.  The Company shall recover reasonably promptly any Erroneously Awarded Compensation except to the extent that the conditions of paragraphs (a), (b), or (c) below apply. The Compensation Committee of the Board of Directors of the Company (the “Committee”) shall determine the repayment schedule for each amount of Erroneously Awarded Compensation in a manner that complies with this “reasonably promptly” requirement. Such determination shall be consistent with any applicable legal guidance, by the U.S. Securities and Exchange Commission (the “SEC”), judicial opinion, or otherwise. The determination of “reasonably promptly” may vary from case to case and the Committee is authorized to adopt additional rules to further describe what repayment schedules satisfy this requirement.

 

(a) Erroneously Awarded Compensation need not be recovered if the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered and the Committee has made a determination that recovery would be impracticable. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange.

 

(b) Erroneously Awarded Compensation need not be recovered if recovery would violate home country law where that law was adopted prior to November 28, 2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company shall obtain an opinion of home country counsel, acceptable to the Exchange, that recovery would result in such a violation and shall provide such opinion to the Exchange.

 

 
 

 

(c) Erroneously Awarded Compensation need not be recovered if recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.

 

6.  Committee Decisions. Decisions of the Committee with respect to this Policy shall be final, conclusive and binding on all Executive Officers subject to this policy, unless determined to be an abuse of discretion.

 

7.  No Indemnification. Notwithstanding anything to the contrary in any other policy of the Company or any agreement between the Company and an Executive Officer, no Executive Officer shall be indemnified by the Company against the loss of any Erroneously Awarded Compensation or any claims related to the Company’s enforcement of its rights under this Policy.

 

8.  Agreement to Policy by Executive Officers. The Committee shall take reasonable steps to inform Executive Officers of this Policy and obtain their agreement to this Policy, which steps may include the inclusion of this Policy as an attachment to, or reference to this Policy in, any award that is accepted by the Executive Officer, or by reference to the Company’s clawback policies in any plan or arrangement under which an award is provided.

 

9.  Other Recovery Rights. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement (individually or collectively, an “Arrangement”). The Committee may, subject to applicable law and in its sole discretion, seek recovery under such Arrangement of amounts in excess of the amount subject to recovery under this Policy. Notwithstanding the foregoing, there shall be no duplication of recovery of the same Erroneously Awarded Compensation under this Policy, unless required by applicable law.

 

10. Amendments. The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section 10 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or Exchange rule.

 

Adopted: October 31, 2023

 
 EX-101.SCH 9 hbio-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 995454 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 995455 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 995456 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 995457 - Disclosure - Note 4 - Goodwill and Intangible Assets link:calculationLink link:definitionLink link:presentationLink 995458 - Disclosure - Note 5 - Balance Sheet Information link:calculationLink link:definitionLink link:presentationLink 995459 - Disclosure - Note 6 - Restructuring and Other Exit Costs link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Note 7 - Employee Benefit Plans link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 8 - Leases link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 9 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 10 - Derivatives link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 11 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 12 - Stock-Based Compensation link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 13 - Revenues link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 14 - Income Tax link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 15 - Commitments and Contingent Liabilities link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 16 - Litigation Settlement link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 17 - Product Line Disposition link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 18 - Government Assistance link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 4 - Goodwill and Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 5 - Balance Sheet Information (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 6 - Restructuring and Other Exit Costs (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 7 - Employee Benefit Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 8 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 9 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 10 - Derivatives (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 11 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 12 - Stock-Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 13 - Revenues (Tables) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 14 - Income Tax (Tables) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 4 - Goodwill and Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 5 - Balance Sheet Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 5 - Balance Sheet Information - Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 5 - Balance Sheet Information - Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 7 - Employee Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 8 - Leases - Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 8 - Leases - Future Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 9 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 9 - Long-term Debt - Breakdown of Borrowings (Details) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 9 - Long Term Debt - Debt Maturity (Details) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 10 - Derivatives (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 10 - Derivatives - Derivative Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995519 - Disclosure - Note 12 - Stock-Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995520 - Disclosure - Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995521 - Disclosure - Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995522 - Disclosure - Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details) link:calculationLink link:definitionLink link:presentationLink 995523 - Disclosure - Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details) link:calculationLink link:definitionLink link:presentationLink 995524 - Disclosure - Note 13 - Revenues (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995525 - Disclosure - Note 13 - Revenues - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995526 - Disclosure - Note 13 - Revenues - Revenue by Geographic Destination (Details) link:calculationLink link:definitionLink link:presentationLink 995527 - Disclosure - Note 13 - Revenues - Deferred Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995528 - Disclosure - Note 13 - Revenues - Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 995529 - Disclosure - Note 13 - Revenues - Warranties (Details) link:calculationLink link:definitionLink link:presentationLink 995530 - Disclosure - Note 14 - Income Tax (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995531 - Disclosure - Note 14 - Income Tax - Income Tax Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995532 - Disclosure - Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 995533 - Disclosure - Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) link:calculationLink link:definitionLink link:presentationLink 995534 - Disclosure - Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995535 - Disclosure - Note 14 - Income Tax - Unrecognized Tax Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 995536 - Disclosure - Note 15 - Commitments and Contingent Liabilities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995537 - Disclosure - Note 16 - Litigation Settlement (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995538 - Disclosure - Note 17 - Product Line Disposition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995539 - Disclosure - Note 18 - Government Assistance (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 10 hbio-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 hbio-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 hbio-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Interest rate swap us-gaap_DerivativeNotionalAmount Derivative, Notional Amount Case in Suffolk Superior Court [Member] Information regarding case of Suffolk Superior Court. Note To Financial Statement Details Textual hbio_StockIssuedDuringPeriodValueIssuedForSettlement Stock Issued During Period, Value, Issued for Settlement Represent the value of stock issued for settlement. Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Income tax benefit computed at federal statutory tax rate Note 3 - Accumulated Other Comprehensive Loss Risk-free interest rate Note 4 - Goodwill and Intangible Assets Note 5 - Balance Sheet Information Note 6 - Restructuring and Other Exit Costs Note 7 - Employee Benefit Plans Note 8 - Leases Note 9 - Long-term Debt Amortization of intangible assets hbio_AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets including portion attributable to discontinued operations, not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Income Tax Disclosure [Text Block] Note 10 - Derivatives Note 11 - Fair Value Measurements Note 12 - Stock-Based Compensation Note 13 - Revenues Volatility Note 14 - Income Tax us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Schedule of Debt [Table Text Block] Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) Other current liabilities Total Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Defined benefit pension plans, net of tax benefit of $137 and $566, respectively Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) Distribution Agreements/Customer Relationships [Member] Represents distribution agreements or customer relationships. Note 5 - Balance Sheet Information - Inventories (Details) Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) Note 5 - Balance Sheet Information - Other Current Liabilities (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details) Schedule of Stock Options Roll Forward [Table Text Block] Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) Service, Maintenance, and Warranty Contracts [Member] Represents service, maintenance, and warranty contracts. Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) Debt Security, Corporate, US [Member] Instruments, Equipment, Software, and Accessories [Member] Represents instruments, equipment, software, and accessories. Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details) Rest of the World [Member] Represents the rest of the world. Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details) Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) Customer Advances [Member] Represents customer advances. Restricted Stock Units, Vested, Grant Date Fair Value, Balance (in dollars per share) Note 8 - Leases - Lease Expense (Details) Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) Litigation settlement - Note 16 Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Restricted Stock Units, Cancelled / Forfeited in Period (in shares) Note 8 - Leases - Future Minimum Lease Payments (Details) Note 9 - Long-term Debt - Breakdown of Borrowings (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Restricted Stock Units Outstanding , Balance (in shares) Restricted Stock Units Outstanding , Balance (in shares) Note 9 - Long Term Debt - Debt Maturity (Details) Schedule of Derivative Instruments [Table Text Block] Note 10 - Derivatives - Derivative Instruments (Details) Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Restricted Stock Units, Granted in Period (in shares) Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Restricted Stock Units, Vested in Period (in shares) Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details) Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details) Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details) us-gaap_LongTermDebtCurrent Less: current portion of long-term debt Note 13 - Revenues - Disaggregation of Revenue (Details) Note 13 - Revenues - Revenue by Geographic Destination (Details) Note 13 - Revenues - Deferred Revenue (Details) Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Note 13 - Revenues - Allowance for Doubtful Accounts (Details) Paycheck Protection Program CARES Act [Member] Represents loan designed to provide funds for small businesses to keep their employees on the payroll. Note 13 - Revenues - Warranties (Details) Note 14 - Income Tax - Income Tax Expense (Details) Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) Note 14 - Income Tax - Unrecognized Tax Benefits (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Market Condition Restricted Stock Units [Member] Represents information related to market condition restricted stock units. Notes To Financial Statements Notes To Financial Statements [Abstract] hbio_ResearchAndDevelopmentTaxCreditCarryforwardsOffsetByReserveForUncertainTaxPositions Research and Development Tax Credit Carryforwards Offset by Reserve for Uncertain Tax Positions The amount of research and development tax credit carryforwards offset by reserve for uncertain tax positions. Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Schedule of Changes in Projected Benefit Obligations [Table Text Block] Outstanding and Exerciseable at December 31, 2023 (Year) Outstanding and Exerciseable at December 31, 2023 Schedule of Costs of Retirement Plans [Table Text Block] Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Defined Benefit Plan, Assumptions [Table Text Block] Equity securities - common stock Schedule of Allocation of Plan Assets [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding at December 31, 2021 (in dollars per share) Outstanding at December 31, 2022 (in dollars per share) Current portion of long-term debt hbio_EffectiveIncomeTaxRateReconciliationChangeInReserveForUncertainTaxPositionAmount Change in reserve for uncertain tax position Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in reserve for uncertain tax position. Cancelled/Forfeited (in dollars per share) Permanent differences, net, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences, net. Contract liabilities Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) Correlation coefficient The correlation coefficient assumption that is used in valuing an option on its own shares. Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) Black Scholes Option Pricing Model [Member] Represents Black Scholes Option-pricing model. Exercised (in dollars per share) Definite-lived intangible assets hbio_DeferredTaxLiabilitiesDefiniteLivedIntangibleAssets Amount of deferred tax liability attributable to taxable temporary differences from definite lived intangible assets. Compensation us-gaap_EmployeeRelatedLiabilitiesCurrent Indefinite-lived intangible assets hbio_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets Amount of deferred tax liability attributable to taxable temporary differences from indefinite lived intangible assets. Term Loan [Member] Represents information related to term loan. Derivatives and Fair Value [Text Block] Pension Plan [Member] Lessee, Operating Leases [Text Block] Operating loss and credit carryforwards hbio_DeferredTaxAssetsOperatingLossAndTaxCreditsCarryforwards Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss and tax credits carryforwards. Accounts payable Property, Plant and Equipment, Useful Lives [Table Text Block] Tabular disclosure of useful lives of property, plant and equipment. Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding at December 31, 2021 (in shares) Outstanding at December 31, 2022 (in shares) hbio_DebtInstrumentQuarterlyPaymentThereafter Debt Instrument, Quarterly Payment, Thereafter Amount of the required quarterly payments including both interest and principal payments thereafter Retirement Plan Type [Axis] Retirement Plan Type [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Options, Cancelled / Forfeited in Period (in shares) Credit Facility [Axis] Credit Facility [Domain] Other us-gaap_OtherAccruedLiabilitiesCurrent us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names and Patents [Member] Information pertaining to trade names and patents. Warranty costs us-gaap_ProductWarrantyAccrualClassifiedCurrent us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Professional fees us-gaap_AccruedProfessionalFeesCurrent us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date us-gaap_PaymentsToAcquireIntangibleAssets Capitalized software development costs us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Dilutive effect of equity awards (in shares) hbio_DeferredIncomeTaxExpenseBenefitIncludingDiscontinuedOperation Deferred income taxes and other Represents deferred income tax expense (benefit) including discontinued operations. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property, plant and equipment us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) hbio_MinimumVestingRateOfTheTargetedShareholderReturnPercentage Minimum Vesting Rate of the Targeted Shareholder Return, Percentage Represents the minimum percentage vesting rate percentage of the targeted shareholder return. Other Plan Assets [Member] Represents information related to other plan assets. Weighted-average common shares: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Equity Securities, FV-NI, Unrealized Gain (Loss) Cash paid for income taxes, net of refunds Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] us-gaap_Assets Total assets us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Disposal Group, Including Discontinued Operation, Assets Plan Name [Axis] hbio_MaximumVestingRateOfTheTargetedShareholderReturnPercentage Maximum Vesting Rate of the Targeted Shareholder Return, Percentage Represents the maximum vesting rate percentage of the targeted shareholder return. Shareholders' Equity and Share-Based Payments [Text Block] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_SubleaseIncome Sublease income Legal Matters and Contingencies [Text Block] Deferred tax assets (included in other long-term assets) hbio_WriteoffOfFullyAmortizedIntangibleAssetsRelatedToExistingTechnologyAndDiscontinuedProductLines Write-off of Fully Amortized Intangible Assets Related to Existing Technology and Discontinued Product Lines Represents the amount of write off of fully amortized intangible assets related to existing technology and discontinued product lines. Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] hbio_EmployeeStockOwnershipPlanSharesAvailableForIssuance Employee Stock Ownership Plan, Shares Available for Issuance (in shares) Number of shares available for issuance under an employee stock ownership plan. Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Shares withheld for taxes Lease right-of-use assets hbio_DeferredTaxLiabilitiesOperatingLeases Amount of deferred tax liability attributable to taxable temporary differences from operating leases. Lease liabilities hbio_DeferredTaxAssetsOperatingLeases Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating leases. Liquidity discount The liquidity discount given to holders that is used in valuing an option on its own shares. hbio_VestingRateOfTheTargetedShareholderReturn Vesting Rate of the Targeted Shareholder Return Represents the vesting rate percentage of the targeted shareholder return. Business Description and Basis of Presentation [Text Block] Award Type [Domain] Expire 2024 [Member] Represents expiration in 2023. Expire between 2024 and 2043 [Member] Represents the expiration date between 2024 and 2043. Award Type [Axis] Net loss Net loss Net loss Warranty claims The claims relating to the standard product warranty accrual. The Credit Agreement [Member] Information pertaining to the credit agreement. us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Total amortizable intangible assets Finite-Lived Intangible Assets, Net Total Total intangible assets, Net Intangible assets, net The Lenders [Member] Information pertaining to the lenders. Restricted Stock Units (RSUs) [Member] Finite-Lived Intangible Assets, Gross hbio_UnrecognizedTaxBenefitsOtherIncreaseDecrease Other decreases, net The amount of increase/(decrease) in unrecognized tax benefits resulting from other decreases. Employee benefit plans hbio_DeferredTaxLiabilitiesEmployeeBenefitPlans Amount of deferred tax liability attributable to taxable temporary differences from employee benefit plans. Swingline Loan Facility [Member] Information pertaining to the swingline loan sub-facility. hbio_StockIssuedDuringPeriodSharesIssuedForSettlement Stock Issued During Period, Shares, Issued For Settlement (in shares) Amount of stock shares issued during period for settlement. Share-Based Payment Arrangement, Option [Member] Employee retention credit hbio_DeferredTaxAssetsEmployeeRetentionCredit Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee retention credits. The ABR Loan [Member] Information pertaining to the ABR loan. hbio_PreferredStockBookValueInclusiveOfAccruedDividends Preferred Stock, Book Value, Inclusive of Accrued Dividends Represents the book value of preferred stock inclusive of accrued dividends. Effect of change in currency translation Greater China [Member] Represents greater China. The SOFR Loan and Pricing Grid Credit Agreement [Member] Information pertaining to the SOFR loan and pricing grid credit agreement. Programs Established to Offset the Impact of COVID [Member] Represents the programs established to offset the negative impact of COVID. hbio_DebtInstrumentInterestRateStateFloorPercentage Debt Instrument, Interest Rate, State Floor Percentage Represents the stated floor percentage rate. Net operating loss true-ups and expirations Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to net operating loss true-ups and expirations. Indefinite-lived intangible assets: Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation Property, plant and equipment, net Property, plant and equipment, net Goodwill Carrying amount Carrying amount Property, Plant and Equipment, Gross Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Non-deductible executive compensation Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for executive compensation. Existing Technology and Software Development [Member] Represents existing technology and software development. Derivative Instrument [Axis] Derivative Contract [Domain] Cash flows from investing activities: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Equity Securities without Readily Determinable Fair Value, Amount Loss per share: Other liabilities Accounts payable and other current liabilities Letter of Credit [Member] Line of Credit [Member] Income tax expense Total income tax expense (benefit) Tax GERMANY us-gaap_OperatingExpenses Total operating expenses us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost Tax Benefit General and administrative expenses Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Defined Benefit Plan, Fair Value of Plan Assets Defined Benefit Plan, Fair Value of Plan Assets, Balance Defined Benefit Plan, Fair Value of Plan Assets, Balance Share-based compensation us-gaap_AllocatedShareBasedCompensationExpense Benefit obligation Defined Benefit Plan, Benefit Obligation, Balance Defined Benefit Plan, Benefit Obligation, Balance us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Employer contributions us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo Defined Benefit Plan, Expected Future Benefit Payment, Year Two us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree Defined Benefit Plan, Expected Future Benefit Payment, Year Three us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour Defined Benefit Plan, Expected Future Benefit Payment, Year Four us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive Defined Benefit Plan, Expected Future Benefit Payment, Year Five Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss City Area Code us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths Defined Benefit Plan, Expected Future Benefit Payment, Year One Use of Estimates, Policy [Policy Text Block] us-gaap_GainLossOnSaleOfBusiness Gain (Loss) on Disposition of Business Gain on sale of product line New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] Expected return on assets Contract liabilities us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred Revenue, change Balance (in shares) Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) us-gaap_PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding (in shares) Financing Receivable, Allowance for Credit Loss [Table Text Block] Other adjustments Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Discount rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_LeaseCost Total lease cost Weighted average discount rate us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease cost Lease, Cost [Table Text Block] Document Period End Date Right-of-use assets obtained in exchange for lease obligations Weighted average remaining lease term (years) (Year) us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Entity File Number Entity Emerging Growth Company us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet Other long-term assets Net funded status Document Type Entity Small Business Actual return on plan assets us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets Entity Shell Company us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid Benefits paid Document Information [Line Items] Document Information [Table] Service [Member] Currency translation adjustment us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss Entity Public Float Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Restructuring and other exit costs us-gaap_RestructuringCharges Entity Voluntary Filers Entity Well-known Seasoned Issuer Actuarial loss (gain) us-gaap_CapitalizedComputerSoftwareNet Capitalized Computer Software, Net Variable Rate [Domain] us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation Currency translation adjustment us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss Variable Rate [Axis] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Unrealized loss on equity securities - Note 16 Unrealized loss on equity securities - Note 16 ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of intangible assets Amortization of Intangible Assets Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] us-gaap_AllowanceForDoubtfulAccountsReceivable Balance, beginning of period Balance, end of period ecd_TrdArrIndTitle Trading Arrangement, Individual Title ecd_TrdArrIndName Trading Arrangement, Individual Name ecd_TrdArrTerminationDate Trading Arrangement Termination Date ecd_TrdArrSecuritiesAggAvailAmt Trading Arrangement, Securities Aggregate Available Amount (in shares) Entity Common Stock, Shares Outstanding ecd_TrdArrAdoptionDate Trading Arrangement Adoption Date us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi Convertible preferred stock received in litigation settlement - Note 16 us-gaap_IncreaseDecreaseInOtherCurrentAssets Other assets Long-Term Debt [Text Block] us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses Net amortization loss us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost Net periodic benefit expense (credit) Interest cost Interest cost us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets Expected return on plan assets us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd Line of Credit Facility, Interest Rate During Period Stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Line of Credit Facility, Interest Rate During Period Local Phone Number us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Line of Credit Facility, Remaining Borrowing Capacity Stock option exercises (in shares) Exercised (in shares) us-gaap_TableTextBlock Notes Tables Stock purchase plan Vesting of restricted stock units (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Stock option exercises Vesting of restricted stock units Defined Benefit Plan, Actual Plan Asset Allocations Provision for expected credit losses Options, Granted in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Cancelled/Forfeited (in shares) Sales and marketing expenses Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Raw materials Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Finished goods Work in process UNITED STATES Accumulated deficit Research and development expenses Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Indemnification Agreements [Member] Represents indemnification agreements. Customer credits hbio_ContractWithCustomerLiabilityCustomerAdvancesCurrent Represents current customer advance for contract with customer liabiltiiy. Changes in operating assets and liabilities: hbio_PercentageOfCashAndCashEquivalentsHeldByForeignSubsidiaries Percentage of Cash and Cash Equivalents Held by Foreign Subsidiaries Percentage of cash and cash equivalents held by foreign subsidiaries. hbio_LiabilityForContingentIndemnificationObligations Liability for Contingent Indemnification Obligations Represents liability for contingent indemnification obligations. Amortization of deferred financing costs Defined Benefit Plan, Equity Securities [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Defined Benefit Plan, Plan Assets, Category [Axis] Operating lease liabilities, long-term Operating lease liabilities Schedule of Inventory, Current [Table Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Cash and Cash Equivalents [Member] Total operating lease liabilities us-gaap_OperatingLeaseLiability Subsequent Event Type [Axis] Current portion, operating lease liabilities Current portion of operating lease liabilities Subsequent Event Type [Domain] Retirement Benefits [Text Block] Operating lease right-of-use assets Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less imputed interest us-gaap_DeferredIncomeTaxExpenseBenefit deferred income tax (benefit) expense us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Thereafter 2026 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2027 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2028 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Thereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2025 Fair Value of Financial Instruments, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2026 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2027 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2028 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Valuation Approach and Technique [Axis] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Valuation Approach and Technique [Domain] Segment Reporting, Policy [Policy Text Block] us-gaap_PaymentsForRestructuring Cash payments us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2024 Foreign Currency Transactions and Translations Policy [Policy Text Block] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other long-term assets Stock-based compensation expense Lessee, Leases [Policy Text Block] Finite-Lived Intangible Assets, Weighted Average Useful Life (Year) Finite-Lived Intangible Asset, Useful Life (Year) Earnings Per Share, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Internal Use Software, Policy [Policy Text Block] Depreciation Depreciation us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Shares withheld for taxes (in shares) us-gaap_AssetsCurrent Total current assets Share-Based Payment Arrangement [Policy Text Block] Interest expense Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,394,509 shares issued and outstanding at December 31, 2023; 42,081,707 shares issued and outstanding at December 31, 2022 us-gaap_InvestmentOwnedAtFairValue Investment Owned, Fair Value Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash provided by operating activities: Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Stockholders' Equity, Policy [Policy Text Block] us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Revenue from Contract with Customer [Policy Text Block] Revision of Prior Period [Axis] Revision of Prior Period [Domain] Revision of Prior Period, Adjustment [Member] us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance Less: valuation allowance Statistical Measurement [Domain] Cash paid for amounts included in the measurement of lease liabilities Maximum [Member] Minimum [Member] Commitments and Contingencies, Policy [Policy Text Block] Product and Service [Axis] Other current assets Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Deferred tax assets Statistical Measurement [Axis] Litigation Case [Axis] Litigation Case [Domain] Preferred stock, par value $0.01 per share, 5,000,000 shares authorized us-gaap_PreferredStockSharesIssued Preferred Stock, Shares Issued (in shares) Intangible Assets, Finite-Lived, Policy [Policy Text Block] Cash paid for interest Preferred stock, par value (in dollars per share) Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] us-gaap_NoncurrentAssets Long-Lived Assets Geographical [Axis] Geographical [Domain] Property, Plant and Equipment [Table Text Block] us-gaap_DeferredTaxAssetsGross Total gross deferred assets Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Europe [Member] us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Inventories Total Fair Value, Inputs, Level 3 [Member] Research and development us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment Fair Value Hierarchy and NAV [Domain] Inventory us-gaap_DeferredTaxAssetsInventory Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Other assets us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Accrued expenses us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Property, plant and equipment useful life (Year) Cash flows from operating activities: Statement [Line Items] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] us-gaap_NumberOfOperatingSegments Number of Operating Segments Furniture and Fixtures [Member] Accounts receivable, net us-gaap_StandardProductWarrantyAccrual Balance Balance Stock compensation us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Expense hbio_EffectiveIncomeTaxRateReconciliationTaxCreditAmountDeduction Tax credits Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits. Additional paid-in-capital AOCI Attributable to Parent [Member] Schedule of Product Warranty Liability [Table Text Block] Stockholders' equity: Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Other (expense) income, net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other expense us-gaap_DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards, Total Long-Lived Tangible Asset [Domain] us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research Employee Stock Purchase Plan [Member] Information on Employee Stock Purchase Plan. Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Inventory, Policy [Policy Text Block] Effect of exchange rate changes on cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Decrease in cash and cash equivalents 2021 Incentive Plan [Member] Information on the 2021 Incentive Plan . us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and contingencies - Note 15 Director [Member] hbio_DebtInstrumentCurrentMaturitiesExcessCashFlowSweep Debt Instrument, Current Maturities, Excess Cash Flow Sweep Information on the excess cash flow sweep. Operating income (loss) us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized Other liabilities us-gaap_DeferredTaxLiabilitiesOther us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other (expense) income: us-gaap_DeferredTaxLiabilities Deferred income tax liabilities, net us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Investment, Issuer Name [Domain] Investment, Issuer Name [Axis] us-gaap_GrossProfit Gross profit Base Rate [Member] Cost of revenues Derivatives, Policy [Policy Text Block] Deferred tax liability Deferred income tax liabilities us-gaap_ContractWithCustomerLiability Deferred revenue us-gaap_DerivativeLiabilities Derivative liabilities Subsidiaries [Member] Marketable Securities, Policy [Policy Text Block] Consolidated Entities [Axis] Consolidated Entities [Domain] us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Taxes paid related to net share settlement of equity awards Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Retained Earnings [Member] Total revenues Revenues Proceeds from exercise of stock options and employee stock purchase plan Title of Individual [Domain] Title of Individual [Axis] Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit Federal and state Equity Component [Domain] Total debt us-gaap_LongTermDebt Federal and state us-gaap_CurrentIncomeTaxExpenseBenefit current income tax (benefit) expense Global Intangible Low-Taxed Income (GILTI) Other Noncurrent Liabilities [Member] Foreign us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Total us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes Domestic us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic ICFR Auditor Attestation Flag Comprehensive Income (Loss) Note [Text Block] Other comprehensive income (loss): Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] State and Local Jurisdiction [Member] Timing of Transfer of Good or Service [Domain] us-gaap_DeferredFinanceCostsNet Debt Issuance Costs, Net, Total Less: unamortized deferred financing costs Transferred at Point in Time [Member] Transferred over Time [Member] Automobiles [Member] Income Tax Authority [Axis] Harvard Apparatus Regenerative Technology, Inc. (“HART”) [Member] Represents Harvard Apparatus Regenerative Technology, Inc. (“HART”). Current unamortized deferred financing costs us-gaap_DeferredFinanceCostsCurrentNet Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Foreign Tax Authority [Member] Timing of Transfer of Good or Service [Axis] us-gaap_RepaymentsOfLongTermDebt Repayment of term debt Revenue from Contract with Customer [Text Block] Document Annual Report Machinery and Equipment [Member] Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Entity Incorporation, State or Country Code Long-term debt, gross us-gaap_DebtInstrumentCarryingAmount Long-term Debt, Gross Total us-gaap_UnrecognizedTaxBenefits Balance Balance General and Administrative Expense [Member] us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current Selling and Marketing Expense [Member] us-gaap_GovernmentAssistanceAmount Government Assistance, Amount Additions based on tax positions of prior years Security Exchange Name Decreases based on tax positions of prior years Decreases based on tax positions of prior years Additions based on tax positions of current year Title of 12(b) Security Cost of Sales [Member] hbio_FullyDepreciatedAndDisposedOfPropertyAndEquipmentRemovedFromFixedAssetRecords Fully Depreciated and Disposed of Property and Equipment Removed From Fixed Asset Records The amount of fully depreciated and disposed of property and equipment removed from fixed asset records. Government Assistance [Text Block] Research and Development Expense [Member] Government Assistance, Type [Axis] Government Assistance, Type [Domain] Cost of Revenues [Member] Represents the Cost of Revenues. Income Statement Location [Axis] Income Statement Location [Domain] Supplemental Cash Flow Information Related to Operating Leases [Table Text Block] Tabular disclosure of supplemental cash flow information related to operating leases. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Tax Period [Domain] Operating Activities [Domain] Continuing Operations [Member] Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block] Tabular disclosure of supplemental balance sheet information related to operating leases. Auditor Name Summary of Income Tax Contingencies [Table Text Block] Tax Period [Axis] Operating Activities [Axis] Auditor Firm ID Auditor Location us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount hbio_AccountsReceivableAllowanceForCreditLossChargeoffsAndOtherReoveries Charge-offs and other Amount of charge-offs and other recoveries to allowance for credit loss. us-gaap_SharePrice Share Price (in dollars per share) Research Tax Credit Carryforward [Member] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Shares excluded from diluted loss per share due to their anti-dilutive effect (in shares) us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Weighted average shares outstanding - diluted (in shares) us-gaap_RepaymentsOfLinesOfCredit Repayment of revolving line of credit Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Non-US [Member] us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Borrowing from revolving line of credit Statement [Table] Statement of Financial Position [Abstract] us-gaap_EarningsPerShareDiluted Diluted loss per share (in dollars per share) Basic and diluted (in shares) Weighted average shares outstanding - basic (in shares) us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total Basic and diluted loss per share (in dollars per share) Basic loss per share (in dollars per share) Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Disposal Group, Including Discontinued Operation, Consideration Income Statement [Abstract] Disposal Group Name [Axis] Revenue from External Customers by Geographic Areas [Table Text Block] us-gaap_RestructuringReserve Balance Balance Disposal Group Name [Domain] Long-Lived Assets by Geographic Areas [Table Text Block] us-gaap_RestructuringReserveSettledWithoutCash2 Non-cash charges us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2024 Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2025 Other Current Liabilities [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Other Restructuring [Member] Type of Restructuring [Domain] Employee Severance [Member] Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Costs [Table Text Block] Restructuring Type [Axis] Other Cash flows from financing activities: Secured Overnight Financing Rate (SOFR) [Member] Interest rate based on U.S. Treasury repurchases between banks. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other long-term liabilities Impact of change to prior year tax accruals Change in valuation allowance allocated to income tax Stock-based compensation Interest rate swap us-gaap_DerivativeFairValueOfDerivativeNet Hoefer Product Line [Member] Relating to the Hoefer Product Line. Convertible Preferred Stock [Member] Proceeds from sale of product line Balance Total stockholders' equity Balance Balance Comprehensive Income (Loss) [Policy Text Block] Disclosure of the accounting policy for comprehensive income (loss). Class of Stock [Axis] Class of Stock [Domain] Long-term debt Long-term debt, net hbio_CustomerPaymentsTerm Customer Payments Term (Day) Represents payments term from customers. Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax Amounts reclassified from accumulated other comprehensive loss to interest expense Deferred interest expense us-gaap_DeferredTaxAssetInterestCarryforward Derivative instruments qualifying as cash flow hedges, net of tax of $-0- Interest Rate Swap [Member] Computer Equipment and Software [member] Represents information related to computer equipment and software. Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Amount of loss recognized in OCI on derivatives (effective portion) State income taxes, net of federal income tax benefit, amount Defined Benefit Plan, Plan Assets, Category [Table Text Block] EX-101.PRE 13 hbio-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 01, 2024
Jun. 30, 2023
Document Information [Line Items]      
Entity Central Index Key 0001123494    
Entity Registrant Name HARVARD BIOSCIENCE INC    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 001-33957    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-3306140    
Entity Address, Address Line One 84 October Hill Road    
Entity Address, City or Town Holliston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01746    
City Area Code 508    
Local Phone Number 893-8999    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol HBIO    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 219,400,000
Entity Common Stock, Shares Outstanding   43,399,291  
Auditor Firm ID 248    
Auditor Name GRANT THORNTON LLP    
Auditor Location Hartford, Connecticut    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 4,283 $ 4,508
Accounts receivable, net 16,099 16,705
Inventories 24,716 26,439
Other current assets 3,940 3,472
Total current assets 49,038 51,124
Property, plant and equipment, net 3,981 3,366
Operating lease right-of-use assets 4,773 5,816
Goodwill 57,065 56,260
Intangible assets, net 16,036 21,014
Other long-term assets 6,473 7,780
Total assets 137,366 145,360
Current liabilities:    
Current portion of long-term debt 5,859 3,811
Current portion of operating lease liabilities 1,416 2,135
Accounts payable 5,554 6,447
Contract liabilities 4,508 3,370
Other current liabilities 9,205 7,486
Total current liabilities 26,542 23,249
Long-term debt, net 30,704 43,013
Deferred tax liability 776 590
Operating lease liabilities 4,794 5,282
Other long-term liabilities 1,476 1,006
Total liabilities 64,292 73,140
Commitments and contingencies - Note 15
Stockholders' equity:    
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized 0 0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,394,509 shares issued and outstanding at December 31, 2023; 42,081,707 shares issued and outstanding at December 31, 2022 434 454
Additional paid-in-capital 232,435 229,008
Accumulated deficit (145,605) (142,190)
Accumulated other comprehensive loss (14,190) (15,052)
Total stockholders' equity 73,074 72,220
Total liabilities and stockholders' equity $ 137,366 $ 145,360
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 80,000,000 80,000,000
Common stock, shares issued (in shares) 43,394,509 42,081,707
Common stock, shares outstanding (in shares) 43,394,509 42,081,707
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 112,250 $ 113,335
Cost of revenues 46,179 52,516
Gross profit 66,071 60,819
Sales and marketing expenses 24,108 25,041
General and administrative expenses 22,780 24,493
Research and development expenses 11,764 12,329
Amortization of intangible assets 5,525 6,122
Litigation settlement - Note 16 0 (233)
Total operating expenses 64,177 67,752
Operating income (loss) 1,894 (6,933)
Other (expense) income:    
Interest expense (3,591) (2,548)
Unrealized loss on equity securities - Note 16 (632) 0
Other (expense) income, net (227) 302
Total other expense (4,450) (2,246)
Loss before income taxes (2,556) (9,179)
Income tax expense 859 337
Net loss $ (3,415) $ (9,516)
Loss per share:    
Basic and diluted loss per share (in dollars per share) $ (0.08) $ (0.23)
Weighted-average common shares:    
Basic and diluted (in shares) 42,420 41,413
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Net loss $ (3,415) $ (9,516)
Other comprehensive income (loss):    
Foreign currency translation adjustments 1,507 (2,614)
Defined benefit pension plans, net of tax benefit of $137 and $566, respectively (446) (2,411)
Derivative instruments qualifying as cash flow hedges, net of tax of $-0- (199) 0
Other comprehensive income (loss) 862 (5,025)
Comprehensive loss $ (2,553) $ (14,541)
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Loss (Parentheticals) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Tax Benefit $ 137 $ 566
Tax $ 0 $ 0
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares) 41,143,000        
Balance $ 452 $ 225,650 $ (132,674) $ (10,027) $ 83,401
Balance (in shares) at Dec. 31, 2021 41,143,000        
Balance at Dec. 31, 2021 $ 452 225,650 (132,674) (10,027) $ 83,401
Stock option exercises (in shares) 40,000       40,267
Stock option exercises $ 2 106 0 0 $ 108
Stock purchase plan (in shares) 176,000        
Stock purchase plan $ 0 469 0 0 469
Vesting of restricted stock units (in shares) 1,135,000        
Vesting of restricted stock units $ 0 0 0 0 0
Shares withheld for taxes (in shares) (412,000)        
Shares withheld for taxes $ 0 (1,628) 0 0 (1,628)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 0 4,411 0 0 4,411
Net loss 0 0 (9,516) 0 (9,516)
Other comprehensive loss $ 0 0 0 (5,025) (5,025)
Balance (in shares) 42,082,000        
Balance $ 454 229,008 (142,190) (15,052) 72,220
Balance (in shares) at Dec. 31, 2022 42,082,000        
Balance at Dec. 31, 2022 $ 454 229,008 (142,190) (15,052) $ 72,220
Stock option exercises (in shares) 214,000       213,644
Stock option exercises $ 0 506 0 0 $ 506
Stock purchase plan (in shares) 137,000        
Stock purchase plan $ 0 424 0 0 424
Vesting of restricted stock units (in shares) 1,460,000        
Vesting of restricted stock units $ 0 0 0 0 0
Shares withheld for taxes (in shares) (498,000)        
Shares withheld for taxes $ 0 (2,523) 0 0 (2,523)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 0 5,000 0 0 5,000
Net loss 0 0 (3,415) 0 (3,415)
Other comprehensive loss 0 0 0 862 862
Other adjustments $ (20) 20 0 0 0
Balance (in shares) 43,395,000        
Balance $ 434 $ 232,435 $ (145,605) $ (14,190) $ 73,074
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (3,415) $ (9,516)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 1,473 1,453
Amortization of intangible assets 5,525 6,122
Amortization of deferred financing costs 280 280
Stock-based compensation expense 5,000 4,411
Deferred income taxes and other 336 (414)
Unrealized loss on equity securities - Note 16 632 (0)
Convertible preferred stock received in litigation settlement - Note 16 0 (3,900)
Gain on sale of product line (403) 0
Changes in operating assets and liabilities:    
Accounts receivable 810 4,780
Inventories 1,524 252
Other assets 1,651 474
Accounts payable and other current liabilities 555 (1,399)
Contract liabilities 1,138 (896)
Other liabilities (1,078) (495)
Net cash provided by operating activities 14,028 1,152
Cash flows from investing activities:    
Additions to property, plant and equipment (1,788) (1,590)
Capitalized software development costs (523) 0
Proceeds from sale of product line 512 0
Net cash used in investing activities (1,799) (1,590)
Cash flows from financing activities:    
Borrowing from revolving line of credit 4,500 7,800
Repayment of revolving line of credit (10,950) (6,400)
Repayment of term debt (4,091) (3,186)
Proceeds from exercise of stock options and employee stock purchase plan 930 577
Taxes paid related to net share settlement of equity awards (2,523) (1,628)
Net cash used in financing activities (12,134) (2,837)
Effect of exchange rate changes on cash (320) (38)
Decrease in cash and cash equivalents (225) (3,313)
Cash and cash equivalents at beginning of period 4,508 7,821
Cash and cash equivalents at end of period 4,283 4,508
Cash paid for interest 3,795 2,314
Cash paid for income taxes, net of refunds $ 207 $ 534
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 1 Months Ended 12 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2023
shares
Insider Trading Arr Line Items    
Material Terms of Trading Arrangement [Text Block]  

Item 9B.

Other Information.

 

On November 23, 2023, James Green, our Chairman, President and Chief Executive Officer, adopted a trading plan intended to satisfy the affirmative defense available under Rule 10b5-1(c) (the “Trading Plan”). The expiration date of the Trading Plan was February 7, 2025. The total number of shares of our common stock (the “Shares”) to be sold under the Trading Plan was a maximum of 240,000. Mr. Green terminated the Trading Plan on January 21, 2024. No Shares were sold under the Trading Plan prior to its termination.
Trading Arrangement Adoption Date November 23, 2023  
Trading Arrangement, Individual Name James Green  
Trading Arrangement, Individual Title Chairman, President and Chief Executive Officer  
Rule 10b5-1 Arrangement Adopted [Flag] true  
Non-Rule 10b5-1 Arrangement Adopted [Flag] false  
Trading Arrangement, Securities Aggregate Available Amount (in shares) 240,000 240,000
Rule 10b5-1 Arrangement Terminated [Flag] false  
Non-Rule 10b5-1 Arrangement Terminated [Flag] false  
Trading Arrangement Termination Date January 21, 2024  
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 1 - Organization
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

1.

Organization

 

Harvard Bioscience, Inc., a Delaware corporation (the “Company”), is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe and China, the Company sells through a combination of direct and distribution channels to customers around the world.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

2.

Summary of Significant Accounting Policies

 

Principles of Consolidation 

 

The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables. and defined benefit pension obligations. Estimates are also required to evaluate the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash holdings in financial institutions that exceed insured limits for such financial institutions. The Company mitigates this risk by utilizing financial institutions of high credit quality.

 

Approximately 49% of the Company’s cash and cash equivalents at December 31, 2023 was held by the Company’s foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by subsidiaries in the United Kingdom, Germany and Spain.

 

Marketable Equity Securities

 

Equity securities traded in active markets are marked to market at each balance sheet date based on prices as quoted on the relevant stock exchange. Fair value mark-to-market adjustments are recorded as non-operating gains (losses) in the consolidated statement of operations. The Company’s investments in marketable equity securities are classified in the consolidated balance sheet based on the nature of the securities and their availability for use in current operations.

 

Allowance for Expected Credit Losses on Receivables

 

The allowance for expected credit losses on receivables is used to present accounts receivable, net, at an amount that represents the Company’s estimate of the receivables expected to be collected from customers. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written off. The Company estimates the allowance on the basis of specifically identified receivables that are evaluated individually for impairment and an analysis of the remaining receivables determined by reference to past default experience. The Company considers the need to adjust historical information to reflect the extent to which current conditions and reasonable forecasts are expected to differ from the conditions that existed for the historical period considered. Losses on receivables have not historically been significant.

 

Management judgments are used to determine when to charge off uncollectible trade accounts receivable. The Company bases these judgments on the age of the receivable, credit quality of the customer, current economic conditions, and other factors that may affect a customer’s ability and intent to pay. Customers are generally not required to provide collateral for purchases.

 

Inventories

 

The Company values inventories at the lower of cost (determined on a first-in, first-out method) or net realizable value. The Company regularly reviews inventory quantities on hand and writes down excess and obsolete inventories to estimated net realizable value if less than cost, based primarily on historical inventory usage and estimated forecast of product demand.

 

Property, Plant and Equipment

 

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

 

Machinery and equipment (years)

3

-

10

Computer equipment and software (years)

3

-

7

Furniture and fixtures (years)

5

-

10

 

Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.

 

Leases

 

The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right for the Company to control the use of the identified property, plant or equipment for a period of time in exchange for consideration. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight-line basis over the lease term.

 

The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets.

 

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the leases’ commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparison to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  The Company uses the flow-through method to account for investment tax credits.  Under this method, the investment tax credits are recognized as a reduction of income tax expense.

 

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. The Company’s policy is to account for Global Intangible Low-Taxed income as a period cost.

 

Foreign Currency

 

The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of  foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in other expense (income), net, in the Company’s consolidated statements of operations.

 

Earnings per Share

 

Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.

 

The following table sets forth the computation of basic and diluted earnings per share:

 

  

Year Ended December 31,

 

(in thousands, except per share data)

 

2023

  

2022

 

Net loss

 $(3,415) $(9,516)

Weighted average shares outstanding - basic

  42,420   41,413 

Dilutive effect of equity awards

  -   - 

Weighted average shares outstanding - diluted

  42,420   41,413 

Basic loss per share

 $(0.08) $(0.23)

Diluted loss per share

 $(0.08) $(0.23)

Shares excluded from diluted loss per share due to their anti-dilutive effect

  3,868   3,661 

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) represents the change in equity resulting from items other than shareholder investments and distributions. The Company’s foreign currency translation adjustments, interest rate swap - cash flow hedge and minimum pension liability adjustments are included in AOCI. The components of other comprehensive income are reclassified as net income, net of tax, when the underlying component impacts earnings. Comprehensive income (loss) and the components of AOCI are presented in the accompanying consolidated statements of comprehensive loss and consolidated statements of equity.

 

Revenue Recognition

 

Nature of contracts and customers

 

The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions.

 

The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer customers who incorporate its products into their products under their own brands.

 

Performance obligations

 

The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, software licenses and enhancements, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may contain multiple promises such as delivery of hardware, software, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For contracts with customers that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which does not materially differ from the stated price in the contract. In general, the Company’s list prices are indicative of standalone selling price, and the majority of the Company's contracts have a term of less than one year.

 

Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales of these items are therefore generally recognized at a point in time.

 

The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may return an implantable monitor to the Company after use, and if the returned monitor can be reprocessed and resold, they may, in exchange, purchase a replacement implantable monitor of the same model at a lower price than a new monitor. The implantable monitors that are returned by customers are reprocessed and made available for future sale. The initial sale of implantable monitors and subsequent sale of replacement implantable monitors are independent transactions. The Company has no obligation in connection with the initial sale to sell replacement implantable monitors at any future date under any fixed terms and may refuse returned implantable monitors that cannot be recovered or are obsolete. The Company has concluded that the offer to its customers that they may purchase a discounted product in the future is not a material right. 

 

Service revenue consists of installation, training, data analysis and surgeries performed on research animals. Service revenue is recognized when the service is performed. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised and are not a separate performance obligation. Extended warranties relate to warranties that are separately priced and purchased in addition to a standard warranty, and are therefore a separate performance obligation. The Company has made the judgment that the customer benefits as the Company performs over the period of the contract, and therefore revenues from maintenance and warranty contracts are recognized over time. The Company uses the input method to recognize revenue over time, which is generally on a straight-line basis over the service period.

 

For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment.

 

Variable Consideration

 

The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration, and its impact on the Company’s revenue recognition, was not material in any of the periods presented.

 

The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which occurs at the time of shipment or prior to services being performed. Payment terms vary by the type of customers and the products or services offered.

 

Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues.

 

Contract Liabilities

 

The Company records contract liabilities  when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Contract liabilities consist of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Contract liabilities are  generally expected to be recognized within one year.

 

The amounts included in contract liabilities from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not represent a significant financing component as the customer can exercise their discretion as to when they can obtain the products for which they have made a prepayment.

 

Disaggregation of revenue

 

Refer to Note 13 for revenue disaggregated by type and by geographic location as well as further information about the deferred revenue balances.

 

Software Development

 

Software development costs for software products to be sold, leased or otherwise marketed that are incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product-by-product basis until the product is available for general release to customers at which time amortization begins.

 

Annual amortization, charged to cost of goods sold, is the amount computed using the ratio that current revenues for a product bear to the total current and anticipated future revenues for that product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product.

 

Intangible Assets

 

Intangible assets are comprised of existing technology, customer contracts and contractual relationships, and other definite-lived intangible assets. Identifiable intangible assets resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by the Company based on the fair value of assets received. Identifiable definite-lived intangible assets are being amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from four to fifteen years.

 

 

Goodwill

 

Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired.

 

For the purpose of its goodwill analysis, the Company has one reporting unit. The Company conducts its annual impairment analysis in the fourth quarter of the fiscal year and more frequently if there is an indicator of impairment. The Company assesses qualitative factors of the reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment indicates a potential impairment, a quantitative analysis is performed. The Company compares the fair value of the reporting unit with its carrying amount. The Company typically estimates fair value using the income approach but will also consider market approaches when appropriate. Under the income approach, the Company uses a discounted cash flows model, which indicates the fair value of the reporting unit based on the present value of the cash flows that the Company expects the reporting unit to generate in the future. The Company's significant estimates in the discounted cash flows model include weighted average cost of capital, long-term rate of growth and profitability of the reporting unit, expected income tax rates and working capital effects. If the carrying amount of a reporting unit exceeds its fair value, goodwill is impaired, and the Company would recognize a loss equal to the excess.

 

The Company evaluated its goodwill for impairment as of October 1, 2023 by performing a qualitative analysis and determined that it was more likely than not that the fair value of the reporting unit exceeded the carrying value.

 

Impairment of Long-Lived Assets

 

The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors which could trigger an impairment review include significant negative industry or economic trends, significant loss of clients, and significant changes in the manner of the Company’s use of the assets or the strategy for its overall business.

 

The recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Cash flow projections are based on trends of historical performance and management’s estimate of future performance. The Company’s estimate of future cash flows requires significant judgment based on historical and anticipated results and are subject to many factors.

 

When the Company determines that the carrying value of the assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, the Company measures the potential impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in its current business model. An impairment loss is recognized only if the carrying amount of the asset is not recoverable and exceeds its fair value. Different assumptions and judgments could materially affect the calculation of the fair value of our assets. For the years ended December 31, 2023 and 2022, the Company concluded that there were no triggering events requiring the Company to assess the recoverability of its long-lived assets.

 

Derivatives

 

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge) and does not use derivative financial instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values.

 

The Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

 

By using derivative financial instruments to hedge exposure to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations by the use of cash flow sensitivity analysis, which estimates the expected impact of changes in interest rates on the Company’s future cash flows.

 

Fair Value of Financial Instruments

 

Financial reporting standards define a fair value hierarchy that consists of three levels:

 

 

●

Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

 

 

●

Level 2 includes instruments for which the valuations are based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

 

 

●

Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The carrying values of the Company’s cash and cash equivalents, trade accounts receivable, trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity (Level 2).

 

Stock-based Compensation

 

The Company recognizes compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, and restricted stock units with a market condition. The Company issues awards under the 2021 Incentive Plan (the “2021 Incentive Plan”) and the Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “2000 Incentive Plan” and together with the 2021 Incentive Plan, the “Incentive Plans”), as well as issues shares for employee stock purchases related to its Employee Stock Purchase Plan (as amended, the “ESPP”). The Company issues new shares from its registered but unissued stock pool to satisfy stock option exercises and vesting of the restricted stock units. Stock-based compensation expense is recorded on a straight-line basis over the applicable service period, which ranges from one to four years. The Company has elected as an accounting policy to account for forfeitures for service-based awards as they occur, with no adjustment for estimated forfeitures.

 

The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using a Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables including, but are not limited to, the Company’s expected stock price volatility over the term of the awards, interest rate assumptions, and discounts to adjust for any holding period post-vest restrictions.

 

Preferred Stock

 

The Company’s board of directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The board of directors may exercise this authority without any further approval from stockholders. As of December 31, 2023 and 2022, the Company had no preferred stock issued or outstanding.

 

Business Segment Information

 

The Company operates in one segment which involves the design, development, production and distribution of  products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company has a single, company-wide management team that administers all properties as a whole rather than as discrete operating segments. The chief operating decision maker, who is the Company's chief executive officer, measures financial performance as a single enterprise and allocates resources across the Company to maximize profitability, and not on geography, legal entity, or end market basis. The Company operates in a number of countries throughout the world in a variety of product lines. Information regarding product lines and geographic financial information is provided in Note 13, “Revenues” and Note 5, "Balance Sheet Information."

 

Commitments and Contingencies

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. If a loss is reasonably possible and the loss or range of loss can be reasonably estimated, the Company discloses the possible loss. If a loss is probable and the loss or range of loss cannot be reasonably estimated, the Company discloses or states that such an estimate cannot be made. Refer to Note 15 Commitments and Contingencies for additional information. The Company accrues and expenses legal costs associated with contingencies when incurred.

 

Recent Accounting Pronouncements

 

Accounting Pronouncements Adopted in 2023

 

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04), which eliminates the performance of Step 2 from the goodwill impairment test. In performing its annual or interim impairment testing, an entity will instead compare the fair value of the reporting unit with its carrying amount and recognize any impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The Company adopted ASU 2017-04 effective January 1, 2023, with no impact to the consolidated financial statements.

 

In September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU 2016-13 to clarify implementation guidance and to provide transition relief for certain entities. The Company adopted ASU 2016-13 effective January 1, 2023, which resulted in an immaterial impact to the consolidated financial statements.

 

Accounting Pronouncements yet to be Adopted

 

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax, which enhances disclosures related to the effective tax rate reconciliation, income taxes paid, as well as other disclosures. The new standard impacts footnote disclosures and is effective for the Company’s annual financial statements for the year ended December 31, 2025. The Company is currently evaluating the potential impact of adopting ASU 2023-09 will have on the disclosures in its consolidated financial statements.

 

Prior Period Financial Statement Reclassifications

 

During the year ended December 31, 2023, the Company identified immaterial misclassification errors in the financial statement footnote describing the components of AOCI as of December 31, 2022 and 2021. These misclassifications overstated the amount attributed to the defined benefit pension plans, net of tax, by $5.4 million and $5.1 million and understated the amount attributed to foreign currency translation adjustments by $(5.4) million and $(5.1) million as of December 31, 2022 and 2021, respectively. These misclassifications had no impact on total OCI for the year ended December 31, 2022, included in the consolidated statements of comprehensive loss, or the total AOCI included in the consolidated balance sheets as of December 31, 2022, and also had no impact on any of the Company’s previously reported consolidated statements of operations, stockholders’ equity, or cash flows. The correction of these offsetting misclassifications is included in these consolidated financial statements. See Note 3 below for further details.

 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Accumulated Other Comprehensive Loss
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Comprehensive Income (Loss) Note [Text Block]

3.

Accumulated Other Comprehensive Loss

 

Changes in the components of accumulated other comprehensive loss, net of tax, for the years ended December 31, 2023 and 2022, respectively, are as follows:

 

  

Foreign Currency

      

Derivatives

     
  

Translation

  

Defined Benefit

  

Qualifying

     

(in thousands)

 

Adjustments

  

Pension Plans

  

as Hedges

  

Total

 

Balance at December 31, 2021*

 $(8,778) $(1,249) $-  $(10,027)

Other comprehensive loss, net

  (2,614)  (2,411)  -   (5,025)

Balance at December 31, 2022*

  (11,392)  (3,660)  -   (15,052)

Other comprehensive income (loss), net

  1,507   (446)  (199)  862 

Balance at December 31, 2023

 $(9,885) $(4,106) $(199) $(14,190)

 

* See Note 2 – Prior Period Financial Statement Reclassifications
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

4.

Goodwill and Intangible Assets

 

The change in the carrying amount of goodwill is as follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Carrying amount at beginning of period

 $56,260  $57,689 

Effect of change in currency translation

  805   (1,429)

Carrying amount at end of period

 $57,065  $56,260 

 

Intangible assets at December 31, 2023 and 2022 consist of the following:

 

      

December 31, 2023

  

December 31, 2022

 

(in thousands)

 

Average

      

Accumulated

          

Accumulated

     

Amortizable intangible assets:

 

Life*

  

Gross

  

Amortization

  

Net

  

Gross

  

Amortization

  

Net

 

Distribution agreements/customer relationships

  6  $16,038  $(9,706) $6,332  $16,124  $(8,727) $7,397 

Existing technology & software development

  2   35,007   (27,029)  7,978   37,549   (26,482)  11,067 

Trade names and patents

  3   7,613   (6,094)  1,519   7,523   (5,197)  2,326 

Total amortizable intangible assets

     $58,658  $(42,829) $15,829  $61,196  $(40,406) $20,790 

Indefinite-lived intangible assets:

              207           224 

Total intangible assets

             $16,036          $21,014 

 

* Weighted average life in years as of December 31, 2023

 

During the year ended December 31, 2023, the Company wrote off approximately $3.7 million of fully amortized intangible assets of certain existing technology and other intangibles related to discontinued product lines. The Company capitalized $0.5 million of software development costs during the year ended December 31, 2023.

 

Intangible asset amortization expense was $5.5 million and $6.1 million for the years ended December 31, 2023 and 2022, respectively. Estimated amortization expense of existing amortizable intangible assets for each of the five succeeding years and thereafter is as follows:

 

(in thousands)

    

2024

 $5,281 

2025

  4,027 

2026

  2,366 

2027

  1,269 

2028

  1,546 

Thereafter

  1,340 

Total

 $15,829 

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

5.

Balance Sheet Information

 

The following tables provide details of selected balance sheet items as of the periods indicated:

 

Inventories:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Finished goods

 $5,120  $5,223 

Work in process

  4,188   3,776 

Raw materials

  15,408   17,440 

Total

 $24,716  $26,439 

 

Property, Plant and Equipment:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Machinery and equipment

 $8,154  $7,500 

Computer equipment and software

  6,493   6,781 

Leasehold improvements

  2,417   2,507 

Furniture and fixtures

  1,244   1,386 

Automobiles

  58   38 
   18,366   18,212 

Less: accumulated depreciation

  (14,385)  (14,846)

Property, plant and equipment, net

 $3,981  $3,366 

 

Depreciation expense was $1.5 million for each of the years ended December 31, 2023 and 2022. During the year ended December 31, 2023, the Company wrote off approximately $2.0 million of fully depreciated property and equipment from its fixed asset records.

 

Other Current Liabilities:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Compensation

 $3,929  $3,476 

Customer credits

  3,201   2,368 

Professional fees

  499   392 

Warranty costs

  336   268 

Other

  1,240   982 

Total

 $9,205  $7,486 

 

Long-lived Assets by Geographic Area:

 

Long-lived assets by geographic area, which include operating lease right-of-use assets, property, plant and equipment, and amortizable intangible assets, are as follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

United States

 $21,558  $26,051 

Germany

  1,703   2,432 

Rest of the world

  1,322   1,489 

Total long-lived assets

 $24,583  $29,972 

 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Restructuring and Other Exit Costs
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Restructuring and Related Activities Disclosure [Text Block]

6.

Restructuring and Other Exit Costs

 

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420, Exit or Disposal Cost Obligations, and are discussed below.

 

During the year ended December 31, 2022, the Company reviewed its product portfolio and identified certain non-strategic products for discontinuation and incurred severance expenses in connection with headcount reductions in Europe and North America. The following table summarizes the restructuring activity for the years ended December 31, 2023 and 2022:

 

(in thousands)

 

Inventory Related

  

Severance

  

Other

  

Total

 

Balance at December 31, 2021

 $-  $-  $-  $- 

Restructuring and other exit costs

  1,471   877   46   2,394 

Non-cash charges

  (1,471)  -   -   (1,471)

Cash payments

  -   (241)  (46)  (287)

Balance at December 31, 2022

  -   636   -   636 

Restructuring and other exit costs

  320   42   29   391 

Non-cash charges

  (142)  -   -   (142)

Cash payments

  (94)  (678)  (29)  (801)

Balance at December 31, 2023

 $84  $-  $-  $84 

 

Substantially all of the severance and other costs detailed above have been included as a component of general and administrative expenses, and all inventory-related charges are included in cost of revenues.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Retirement Benefits [Text Block]

7.

Employee Benefit Plans

 

Employee Retirement Savings Plans

 

The Company sponsors various qualified employee retirement savings plans and makes discretionary contributions to match a certain portion of employee contributions. The Company contributed $1.1 million to these plans for each of the years ended December 31, 2023 and 2022.

 

Employee Pension Plans

 

The Company’s subsidiary in the United Kingdom, Biochrom Ltd., maintains two defined benefit pension plans for its employees. In 2014, these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The Company recognizes the funded status of the pension plans as an asset or liability in the consolidated balance sheets. The funded status equals the difference between the fair value of the plan’s assets and their benefit obligations and has historically measured each year as of December 31. The Company records net period benefit expense (credit) as a component of other expense in the Consolidated Statement of Operations.

 

The components of the Company’s net period benefit expense (credit) were as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Interest cost

 $670  $371 

Expected return on plan assets

  (788)  (818)

Net amortization loss

  328   27 

Net periodic benefit expense (credit)

 $210  $(420)

 

The following provides a reconciliation of the changes in the plans’ fair value of assets and benefit obligations for the years ended December 31, 2023 and 2022, and a summary of the funded status as of December 31, 2023 and 2022:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Change in fair value of plan assets:

        

Balance at beginning of year

 $15,576  $27,252 

Actual return on plan assets

  351   (9,098)

Employer contributions

  622   619 

Benefits paid

  (563)  (592)

Currency translation adjustment

  954   (2,605)

Balance at end of year

 $16,940  $15,576 

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Change in benefit obligation:

        

Balance at beginning of year

 $13,263  $22,562 

Interest cost

  665   371 

Actuarial loss (gain)

  479   (6,912)

Benefits paid

  (563)  (592)

Currency translation adjustment

  819   (2,166)

Balance at end of year

 $14,663  $13,263 

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Fair value of plan assets

 $16,940  $15,576 

Benefit obligation

  14,663   13,263 

Net funded status

 $2,277  $2,313 

 

Changes in the actuarial loss (gain) disclosed above are primarily the result of changes in the discount rate and inflation assumptions due to underlying market conditions.

 

The amounts recognized in the consolidated balance sheets consist of:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Other long-term assets

 $2,277  $2,313 

Accumulated other comprehensive loss

  5,909   5,326 

 

The weighted average assumptions used in determining the net pension cost for these plans follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Discount rate

  4.6%  5.0%

Expected return on assets

  5.3%  5.0%

 

The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations.

 

The Company’s mix of pension plan investments among asset classes also affects the long-term expected rate of return on plan assets. As of December 31, 2023, the Company’s actual asset mix approximated its target mix. Differences between actual and expected returns are recognized in the calculation of net periodic pension cost over the average remaining expected future working lifetime, which is approximately 7 years for active plan participants.

 

The asset allocations and fair value of the Company’s pension benefits as of December 31, 2023 and 2022, were as follows:

 

(in thousands)

 

2023

  

2022

 

Asset category:

                

Debt securities

 $11,761   69% $11,714   75%

Equity securities

  3,567   21%  3,507   23%

Cash and cash equivalents

  304   2%  185   1%

Other

  1,308   8%  170   1%

Total

 $16,940   100% $15,576   100%

 

(in thousands)

 

2023

  

2022

 

Quoted Prices in Active Markets for Identical Assets (Level 1)

 $304  $185 

Significant Other Observable Inputs (Level 2)

  16,636   15,391 

Significant Other Unobservable Inputs (Level 3)

  -   - 

Total

 $16,940  $15,576 

 

Level 1 assets consist of cash and cash equivalents held in the pension plans. The Level 2 assets primarily consist of investments in private investment funds that are valued using the net asset values provided by the trust or fund, including an insurance contract. Although these funds are not traded in an active market with quoted prices, the investments underlying the net asset value are based on quoted prices.

 

The Company expects to contribute approximately $0.6 million to its pension plans during 2024. The benefits expected to be paid from the pension plans are $0.9 million in 2024, $0.7 million in 2025, $0.8 million in 2026, $1.0 million in 2027 and $0.8 million in 2028. The expected benefits to be paid in the five years from 2029 to 2033 are $5.0 million. The expected benefits are based on the same assumptions used to measure the Company’s benefit obligations at December 31, 2023.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Leases
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

8.

Leases

 

The Company has noncancelable operating leases for office space, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.

 

The components of lease expense for the years ended December 31, 2023 and 2022, are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Operating lease cost

 $2,013  $1,971 

Short-term lease cost

  199   233 

Sublease income

  (102)  (102)

Total lease cost

 $2,110  $2,102 

 

Supplemental balance sheet information related to the Company’s operating leases was as follows:

 

(in thousands)

 

December 31,

 
  

2023

  

2022

 

Operating lease right-of-use assets

 $4,773  $5,816 
         

Current portion, operating lease liabilities

  1,416   2,135 

Operating lease liabilities, long-term

  4,794   5,282 

Total operating lease liabilities

 $6,210  $7,417 
         

Weighted average remaining lease term (years)

  5.7   6.2 

Weighted average discount rate

  9.5%  9.4%

 

Supplemental cash flow information related to the Company’s operating leases was as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Cash paid for amounts included in the measurement of lease liabilities

 $2,367  $2,347 

Right-of-use assets obtained in exchange for lease obligations

  293   295 

 

Future minimum lease payments for operating leases, with initial terms in excess of one year at December 31, 2023, are as follows:

 

Year Ending December 31,

    

(in thousands)

    

2024

  1,938 

2025

  1,166 

2026

  1,060 

2027

  1,047 

2028

  1,057 

Thereafter

  1,926 

Total lease payments

  8,194 

Less imputed interest

  (1,984)

Total operating lease liabilities

 $6,210 

 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Long-term Debt
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Long-Term Debt [Text Block]

9.

Long-Term Debt

 

As of December 31, 2023 and 2022, the Company’s borrowings were comprised of the following:

 

(in thousands)

 

December 31, 2023

  

December 31, 2022

 

Long-term debt:

        

Term loan

 $30,723  $34,814 

Revolving line

  6,400   12,850 

Less: unamortized deferred financing costs

  (560)  (840)

Total debt

  36,563   46,824 

Less: current portion of long-term debt

  (6,139)  (4,091)

Current unamortized deferred financing costs

  280   280 

Long-term debt

 $30,704  $43,013 

 

The aggregate amounts of debt maturities are as follows:

 

(in thousands)

    

2024

 $6,139 

2025

  30,984 
  $37,123 

 

On   December 22, 2020, the Company entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A., Wells Fargo Bank, National Association, and Silicon Valley Bank, (together, the “Lenders”). Effective March 27, 2023, all commitments and obligations under the Credit Agreement previously held by Silicon Valley Bank were assumed by First Citizens Bank & Trust Company. The Credit Agreement provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility (including a $10.0 million sub-facility for the issuance of letters of credit and a $10.0 million swingline loan sub-facility) (collectively, the “Credit Facility”). The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s direct, domestic wholly-owned subsidiaries; none of the Company’s direct or indirect foreign subsidiaries has guaranteed the Credit Facility. The Company’s obligations under the Credit Agreement are secured by substantially all of the assets of Harvard Bioscience, Inc. and each guarantor (including all or a portion of the equity interests in certain of the Company’s domestic and foreign subsidiaries). The Credit Facility matures on December 22, 2025. Issuance costs of $1.4 million are amortized over the contractual term to maturity date on a straight-line basis, which approximates the effective interest method. Available and unused borrowing capacity under the revolving line of credit was $10.8 million as of December 31, 2023, based on the Credit Agreement, as amended pursuant to the April 2022 Amendment and November 2022 Amendment as described below. Total revolver borrowing capacity is limited by the consolidated net leverage ratio as defined under the amended Credit Agreement.

 

Borrowings under the amended Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement, as amended (a “SOFR Loan”), or (ii) an alternative base rate plus an applicable interest rate margin, each as determined as provided in the Credit Agreement (an “ABR Loan”). SOFR interest under the Credit Agreement is subject to applicable market rates and a floor of 0.50%. The alternative base rate is based on the Citizens Bank prime rate or the federal funds effective rate of the Federal Reserve Bank of New York and is subject to a floor of 1.0%. The applicable interest rate margin varies from 2.0% per annum to 3.25% per annum for SOFR Loans, and from 1.5% per annum to 3.0% per annum for ABR Loans, in each case depending on the Company’s consolidated leverage ratio and is determined in accordance with a pricing grid set forth in the Credit Agreement. Interest on SOFR Loans is payable in arrears on the last day of each applicable interest period, and interest on ABR Loans is payable in arrears at the end of each calendar quarter. There are no prepayment penalties in the event the Company elects to prepay and terminate the Credit Facility prior to its scheduled maturity date, subject to SOFR Loan breakage and redeployment costs in certain circumstances.

 

The effective interest rate on the Company’s borrowings for the years ended December 31, 2023 and 2022, was 8.1% and 5.0%, respectively. The weighted average interest rate as of December 31, 2023, inclusive of the effect of the Company’s interest rate swaps, was 7.4%. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

 

As of December 31, 2023, the term loan amortizes in quarterly installments of $1.0 million with a balloon payment at maturity. Furthermore, within ninety days after the end of the Company’s fiscal year, the term loans may be permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep”, as defined in the agreement; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. As of December 31, 2023, the current portion of long-term debt includes an excess cash flow sweep of $2.1 million to be paid by March 31, 2024. As of December 31, 2022, the current portion of long-term debt included an excess cash flow sweep of $1.1 million which was paid on March 31, 2023. Amounts outstanding under the revolving credit facility can be repaid at any time but are due in full at maturity.

 

The Credit Agreement, as amended, includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement, as amended, also includes customary events of default.

 

In April 2022, the Company entered into an amendment to the Credit Agreement (the “April 2022 Amendment”) which modified, among other things, the financial covenant relating to the consolidated net leverage ratio, and provided consent for the HRGN Settlement (as defined in Note 16). In November 2022, the Company entered into a subsequent amendment to the Credit Agreement which modified, among other things, the financial covenant relating to the consolidated net leverage ratio, and the definition of Consolidated EBITDA used in the calculation of certain financial covenants (the “November 2022 Amendment”). The Company was in compliance with the covenants of the Credit Agreement, as amended, as of December 31, 2023.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Derivatives
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Derivatives and Fair Value [Text Block]

10.

Derivatives

 

On February 28, 2023, the Company entered into an interest rate swap contract to improve the predictability of cash flows from interest payments related to its variable, SOFR-based debt. The swap contract has a notional amount of $27.4 million as of December 31, 2023, and matures on December 22, 2025. This swap contract effectively converts the SOFR-based variable portion of the interest payable under the Credit Agreement into fixed-rate debt at an annual rate of 4.75%. The swap contract does not impact the additional interest related to the applicable interest rate margin as discussed above in Note 9, Long-Term Debt. The swap contract is considered an effective cash flow hedge, and as a result, net gains or losses are reported as a component of OCI in the consolidated financial statements and are reclassified as net income when the underlying hedged interest impacts earnings. An assessment is performed quarterly to evaluate the ongoing hedge effectiveness.

 

The following table presents the notional amount and fair value of the Company’s derivative instrument as of December 31, 2023:

 

(in thousands)

 

December 31, 2023

 

Derivatives Instruments

 

Balance Sheet Classification

 

Notional Amount

  

Fair Value (a)

 

Interest rate swap

 

Other long-term liabilities

 $27,375  $(199)

 

(a) See Note 11 for the fair value measurements related to this financial instrument.  

 

The following table summarizes the effect of derivatives designated as cash flow hedging instruments for the year ended December 31, 2023: 

 

  

Year Ended

 

Derivatives Qualifying as Hedges, net of tax (in thousands)

 

December 31, 2023

 

Amount of loss recognized in OCI on derivatives (effective portion)

 $199 

Amounts reclassified from accumulated other comprehensive loss to interest expense

  120 

 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Fair Value Measurements
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

11.

Fair Value Measurements

 

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

 

  

Fair Value as of December 31, 2023

 

Assets (Liabilities) (in thousands)

 

Level 1

  

Level 2

  

Level 3

  

Total

 

Equity securities - common stock

 $3,511  $-  $-  $3,511 

Interest rate swap agreements

  -   (199)  -   (199)

 

The Company uses the market approach technique to value its financial assets and liabilities. The Company’s financial assets and liabilities carried at fair value include, when applicable, investments in common stock and derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s investment in common stock of Harvard Apparatus Regenerative Technologies (“HRGN” formerly known as Biostage, Inc.) (see Note 16 for information regarding the HRGN Settlement) was based on the closing price as quoted on the OTCQB Marketplace at the reporting date. The fair value of the Company’s interest rate swap agreements was based on SOFR-yield curves at the reporting date.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Shareholders' Equity and Share-Based Payments [Text Block]

12.

Stock-Based Compensation

 

Stock-based compensation expense for the years ended December 31, 2023 and 2022, is allocated as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Cost of revenues

 $308  $121 

Sales and marketing expenses

  746   557 

General and administrative expenses

  3,560   3,487 

Research and development expenses

  386   246 

Total stock-based compensation expenses

 $5,000  $4,411 

 

As of December 31, 2023, the total compensation costs related to unvested awards not yet recognized is $4.7 million and the weighted average period over which it is expected to be recognized is approximately 1.6 years. During the years ended December 31, 2023 and 2022, the Company did not capitalize any stock-based compensation.

 

Equity Incentive Plans

 

During 2021, the Company’s board of directors and stockholders adopted the 2021 Incentive Plan which authorized additional  shares available for grants to officers, employees, non-employee directors and other key persons of the Company and its subsidiaries. As of December 31, 2023, there were approximately 3.1 million shares available for issuance under the 2021 Incentive Plan.

 

Restricted Stock Units with a Market Condition

 

The Company grants deferred awards of market condition restricted stock units (the “Market Condition RSUs”) to certain members of the Company’s management team. The vesting of the Market Condition RSUs is linked to the achievement of a relative total shareholder return (“TSR”) of the Company’s common stock measured from the earlier of (i) the measurement period as set out in the award agreement or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology or Russell 2000 index and based on a 20-day trading average price) and is subject to a one-year holding period after vesting.

 

For Market Condition RSUs with a measurement period that concluded during the years ended December 31, 2023, the TSR of the Company’s common stock relative to the applicable index resulted in achieving 100% of the target. Market Condition RSUs outstanding as of December 31, 2023 remain subject to a TSR measurement which can result in vesting rates ranging from 0% to 150% of the target number.

 

The weighted average assumptions used in the valuation of the Market Condition RSUs granted during the years ended December 31, 2023 and 2022, are as follows:

 

  

2023

  

2022

 

Volatility

  56.8%  62.6%

Risk-free interest rate

  4.6%  2.1%

Correlation coefficient

  41.7%  41.5%

Dividend yield

  -%  -%

Liquidity discount

  14.1%  11.7%

 

The Company used historical volatility to calculate the expected volatility matching the expected holding period. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the award. Additionally, the Company assumes a liquidity discount to adjust the fair value for the one-year holding period post-vest restrictions.

 

Stock-Based Payment Awards

 

RSU and Market Condition RSU activity for  the years ended December 31, 2023 and 2022, is as follows:

 

          

Condition

     
  

Restricted

  

Grant Date

  

Restricted

  

Grant Date

 
  

Stock Units

  

Fair Value

  

Stock Units

  

Fair Value

 

Balance at December 31, 2021

  1,141,164  $3.57   860,155  $3.13 

Granted

  918,870   4.64   320,272   5.08 

Vested

  (733,611)  4.08   (401,308)  2.11 

Cancelled/Forfeited

  (232,622)  4.44   (132,884)  4.21 

Balance at December 31, 2022

  1,093,801  $3.94   646,235  $4.51 

Granted

  1,350,125   2.87   558,958   2.61 

Vested

  (1,144,065)  3.38   (316,210)  4.01 

Cancelled/Forfeited

  (134,865)  3.71   (87,138)  4.64 

Balance at December 31, 2023

  1,164,996  $3.28   801,845  $3.37 

 

Stock option activity for  the years ended December 31, 2023 and 2022, is as follows:

 

  

Number of Options

  

Weighted-Average Exercise Price

  

Weighted-Aveage Remaining Contractual Term (years)

  

Average Intrinsic Value (in thousands)

 

Outstanding at December 31, 2021

  1,404,816  $3.10         

Exercised

  (40,267)  2.64         

Cancelled/Forfeited

  (125,773)  2.77         

Outstanding at December 31, 2022

  1,238,776  $3.15         

Exercised

  (213,644)  2.38         

Cancelled/Forfeited

  (101,065)  2.71         

Outstanding and Exerciseable at December 31, 2023

  924,067  $3.37   3.4  $1,836 

 

The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.35 as of December 31, 2023, which would have been received by the option holders had all option holders exercised their options as of that date. The aggregate intrinsic value of options exercised was $0.6 million and $0.1 million for the years ended December 31, 2023 and 2022, respectively.

 

Employee Stock Purchase Plan (“ESPP”)

 

The Company has an employee stock purchase plan under which eligible employees may purchase a limited number of shares of common stock at a discount of up to 15% of the market value of such stock at pre-determined and plan-defined dates. There were 0.1 million and 0.2 million shares issued under the ESPP during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there were 0.3 million shares available for issuance under the ESPP. 

 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

13.

Revenues

 

The following table represents a disaggregation of revenue from contracts with customers for the years ended December 31, 2023 and 2022:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Instruments, equipment, software and accessories

 $105,716  $108,165 

Service, maintenance and warranty contracts

  6,534   5,170 

Total revenues

 $112,250  $113,335 

 

Revenues by timing of recognition are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Goods and services transferred at a point in time

 $108,558  $111,927 

Goods and services transferred over time

  3,692   1,408 

Total revenues

 $112,250  $113,335 

 

Revenues by geographic destination are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

United States

 $48,205  $49,912 

Europe

  32,801   30,687 

Greater China

  18,488   16,393 

Rest of the world

  12,756   16,343 

Total revenues

 $112,250  $113,335 

 

Contract Liabilities

 

The following tables provide details of contract liabilities as of the periods indicated:

 

  

December 31,

      

December 31,

     

(in thousands)

 

2023

  

2022

  

Change

  

2022

  

2021

  

Change

 

Service contracts

 $2,849  $1,530  $1,319   1,530  $1,976  $(446)

Customer advances

  1,659   1,840   (181)  1,840   2,290   (450)

Total contract liabilities

 $4,508  $3,370  $1,138   3,370  $4,266  $(896)

 

Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service and warranty contracts. During the years ended December 31, 2023 and 2022, the Company recognized revenue of $2.1 million and $2.5 million from contract liabilities existing at December 31, 2022 and 2021, respectively.

 

Provision for Expected Credit Losses on Receivables

 

Activity in the provision for expected losses on receivables is as follows:

 

  

December 31,

 

(in thousands)

 

2023

  

2022

 

Balance, beginning of period

 $191  $136 

Provision for expected credit losses

  29   62 

Charge-offs and other

  (60)  (7)

Balance, end of period

 $160  $191 

 

Concentrations

 

No customer accounted for more than 10% of the revenues for the years ended December 31, 2023 and 2022, or for more than 10% of net accounts receivable at December 31, 2023 and 2022.

 

Warranties

 

Activity in the product warranty accrual is as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Balance at December 31, 2022

 $268  $240 

Expense

  381   408 

Warranty claims

  (313)  (380)

Balance at December 31, 2023

 $336  $268 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

14.

Income Tax

 

Income tax expense for the years ended December 31, 2023 and 2022, consisted of: 

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Current income tax expense:

        

Federal and state

 $570  $641 

Foreign

  61   194 
   631   835 

Deferred income tax expense (benefit):

        

Federal and state

  132   (468)

Foreign

  96   (30)
   228   (498)

Total income tax expense

 $859  $337 

 

The effective tax rate for the year ended December 31, 2023 was (33.5)% as compared with (3.7)% for the same period in 2022. The difference between the Company’s effective tax rate year over year was primarily attributable to changes in the mix of pre-tax income and losses at individual subsidiaries, and the impact of changes in uncertain tax positions.

 

Income tax expense for the years ended December 31, 2023 and 2022, differed from the amount computed by applying the U.S. federal income tax rate of 21% to pre-tax loss as a result of the following:  

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Income tax benefit computed at federal statutory tax rate

 $(537) $(1,927)

Increase (decrease) in income taxes resulting from:

        

Permanent differences, net

  (89)  375 

Non-deductible executive compensation

  324   346 

Global Intangible Low-Taxed Income (GILTI)

  537   552 

State income taxes, net of federal income tax benefit

  (19)  (295)

Stock-based compensation

  (329)  69 

Tax credits

  (51)  492 

Net operating loss true-ups and expirations

  1,140   431 

Change in reserve for uncertain tax position

  239   688 

Impact of change to prior year tax accruals

  (171)  (232)

Change in valuation allowance allocated to income tax

  631   (102)

Other

  (816)  (60)

Total income tax expense

 $859  $337 

 

Income tax expense is based on the following pre-tax (loss) income from operations:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Domestic

 $(2,951) $(9,099)

Foreign

  395   (80)

Total

 $(2,556) $(9,179)

 

The tax effects of temporary differences that give rise to significant components of the deferred tax assets and deferred tax liabilities at December 31, 2023 and 2022, are as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Deferred income tax assets:

        

Inventory

 $1,489  $1,696 

Operating loss and credit carryforwards

  11,550   14,883 

Research and development

  3,908   2,000 

Employee retention credit

  1,435   - 

Lease liabilities

  1,317   1,538 

Accrued expenses

  818   621 

Stock compensation

  670   675 

Deferred interest expense

  386   881 

Other assets

  934   726 

Total gross deferred assets

  22,507   23,020 

Less: valuation allowance

  (15,222)  (14,506)

Deferred tax assets

 $7,285  $8,514 
         

Deferred income tax liabilities:

        

Indefinite-lived intangible assets

 $1,964  $1,914 

Definite-lived intangible assets

  3,733   4,875 

Lease right-of-use assets

  959   1,148 

Employee benefit plans

  569   579 

Other liabilities

  400   255 

Total deferred tax liabilities

  7,625   8,771 

Deferred income tax liabilities, net

 $(340) $(257)

 

Deferred income tax assets and liabilities by classification on the consolidated balance sheets were as follows:

 

  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Deferred tax assets (included in other long-term assets)

 $436  $333 

Deferred income tax liabilities

  (776)  (590)

Deferred income tax liability, net

 $(340) $(257)

 

At December 31, 2023, the Company had state net operating loss carryforwards of $6.3 million, which expire between 2024 and 2043. The Company had net operating loss carryforwards of $7.8 million in certain foreign jurisdictions which may be carried forward indefinitely, partially offset by valuation allowances. The Company had $7.8 million of research and development tax credit carryforwards which begin to expire in 2024, and are partially offset by a reserve of $0.8 million for uncertain tax positions. The Company had a total of $2.7 million of state investment tax credit carryforwards, research and development tax credit carryforwards, and enterprise zone credit carryforwards, which begin to expire in 2024. In addition, the Company had a total of $0.4 million international R&D credits which begin to expire in 2037. The Internal Revenue Code (“IRC”) limits the amounts of net operating loss carryforwards or credits that a company may use in any one year in the event of a change in ownership under IRC Sections 382 or 383. As a result of various acquisitions in prior years, certain losses and credit carryforwards are subject to these limitations.

 

As of December 31, 2023 and 2022, the Company maintained a total valuation allowance of $15.2 million and $14.5 million, respectively, which relates to foreign, federal, and state deferred tax assets in both years. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. The net change in the total valuation allowance for the years ended December 31, 2023 and 2022, was an increase of $0.7 million and a decrease of $0.2 million, respectively. During the year ended December 31, 2023, the Company increased the valuation allowance related to the estimate of realizability of German deferred tax assets and deferred tax assets related to the Employee Retention Credit, offset by the utilization and expiration of certain U.S. federal and state net operating losses and the expiration of certain U.S. credits.

 

As of December 31, 2023 and 2022, cash and cash equivalents held by the Company’s foreign subsidiaries were $2.1 million and $2.6 million, respectively. As of December 31, 2023, the Company has determined the potential income tax and withholding liability related to available cash balances at foreign subsidiaries to be immaterial.

 

A summary of activity of unrecognized tax benefits is as follows:

 

  

(in thousands)

 

Balance at December 31, 2021

 $1,332 

Additions based on tax positions of prior years

  534 

Decreases based on tax positions of prior years

  (34)

Additions based on tax positions of current year

  237 

Other decreases, net

  (86)

Balance at December 31, 2022

  1,983 

Additions based on tax positions of prior years

  13 

Decreases based on tax positions of prior years

  57 

Additions based on tax positions of current year

  245 

Other decreases, net

  (76)

Balance at December 31, 2023

 $2,222 

 

We expect the amount of unrecognized tax benefits to change within the next twelve months, including the release of reserves of approximately $0.4 million. Substantially all of the liability for uncertain tax benefits related to various federal, state and foreign income tax matters would benefit the Company's effective tax rate, if recognized. The Company classifies interest and penalties related to unrecognized tax benefits as a component of income tax expense, which has not been significant during the years ended December 31, 2023 and 2022, respectively.

 

With a few exceptions, the Company is no longer subject to income tax examinations by tax authorities in foreign jurisdictions for the years before 2019. In the U.S., the Company’s net operating loss and tax credit carryforward amounts remain subject to federal and state examination for tax years starting in 2004 as a result of tax losses incurred in prior years. There are currently no pending federal or state tax examinations.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Commitments and Contingent Liabilities
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

15.

Commitments and Contingent Liabilities

 

In April 2022, the Company and HRGN executed a settlement with the plaintiffs in the HRGN Litigation (as defined below), which resolves all claims relating to the litigation as described in Note 16, Litigation Settlement.

 

The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not likely to have a material adverse effect on its business, financial condition, results of operations or cash flow. Although unfavorable outcomes in the proceedings are possible, the Company has not accrued loss contingencies relating to any such matters as they are not considered to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company’s business, financial condition, results of operations and cash flows could be material.

 

In addition, the Company has entered into indemnification agreements with its directors. It is not possible to determine the maximum potential liability amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. The Company has not recorded any liability for costs related to contingent indemnification obligations as of December 31, 2023.

 

The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company is currently undergoing an unclaimed property audit. Based on the current stage of the audits, the Company has not accrued any significant losses related to these audits as of December 31, 2023.

 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Litigation Settlement
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Legal Matters and Contingencies [Text Block]

16.

Litigation Settlement

 

In April 2022, the Company and HRGN entered into a settlement of a litigation related to injuries allegedly caused by products produced by the Company and HRGN and utilized in connection with surgeries performed by third parties (the “HRGN Settlement”). The HRGN Settlement resolved and dismissed all claims by and between the parties. HRGN has indemnified the Company for all losses and expenses that the Company incurred in connection with such litigation and settlement.

 

In connection with the HRGN Settlement, in June 2022, HRGN issued 4,000 shares of Series E Convertible Preferred Stock (the “Series E Preferred Stock”) to the Company in satisfaction of $4.0 million of its total indemnification obligations. The Company recorded the Series E Preferred Stock at an estimated fair value of $3.9 million using a Monte Carlo valuation simulation incorporating information from selected guideline companies. As of December 31, 2022, the book value of the shares of Series E Preferred Stock, inclusive of accrued dividends, was $4.1 million and was included in the consolidated balance sheet as a component of other long-term assets.

 

In April 2023, all of the shares of Series E Preferred Stock the Company held in HRGN were mandatorily converted into shares of HRGN common stock.

 

As of December 31, 2023, the Company held shares of HRGN common stock with an estimated fair value of $3.5 million, which are included in the consolidated balance sheet as a component of other long-term assets. During the year ended December 31, 2023, the Company recorded an unrealized loss related to these shares of $(0.6) million, which was recorded as other (expense) income, net, in the consolidated statements of operations. The Company determines the fair value of its HRGN common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. Due to HRGN’s limited operating history, its overall financial condition and the limited trading volumes and liquidity of its common stock, the value of the Company’s investment in this common stock could fluctuate considerably or become worthless.
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 17 - Product Line Disposition
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

17.

Product Line Disposition

 

On February 17, 2023, the Company completed the disposition of its Hoefer product line for cash consideration of $0.5 million. The carrying value of assets sold was $0.1 million resulting in a gain on disposition of $0.4 million which is recorded in other (expense) income, net, in the consolidated statement of operations for the year ended December 31, 2023. Revenue and gross profit of this disposed product line included in the condensed consolidated statement of operations for the years ended December 31, 2023 and 2022, were not significant.
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 18 - Government Assistance
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Government Assistance [Text Block]

18.

Government Assistance

 

As there is no authoritative guidance under U.S. GAAP on accounting for grants to for profit business entities from government entities, the Company accounts for government assistance by analogy to International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance (IAS 20). Under IAS 20, grants related to income are presented as part of the consolidated statements of operations either as a deduction of the related expense or reported separately in other income.  The Company recognizes government assistance that supplements salaries or research activities as a reduction of the related operating expense over the period for which it is intended to compensate. Government assistance that is not directly related to expense reimbursement or relates to costs incurred in a previous fiscal period is recorded as other income.

 

For the years ended December 31, 2023 and 2022, the Company received $0.2 million and $0.7 million, respectively, under government assistance programs. The majority of the assistance was a result of the Company’s German subsidiaries participating in programs established to offset the negative impact of COVID-19 on profitability, to support employment during the COVID-19 pandemic, and to offset the costs of qualifying research and development activities.

 

In February 2024, the Company received and recorded $3.1 million for the Employee Retention Credit (“ERC”), which was enacted as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES Act”) to provide financial incentives to eligible businesses to retain their workforce through the period of financial hardship resulting from the COVID-19 pandemic.

 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation 

 

The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables. and defined benefit pension obligations. Estimates are also required to evaluate the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash holdings in financial institutions that exceed insured limits for such financial institutions. The Company mitigates this risk by utilizing financial institutions of high credit quality.

 

Approximately 49% of the Company’s cash and cash equivalents at December 31, 2023 was held by the Company’s foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by subsidiaries in the United Kingdom, Germany and Spain.
Marketable Securities, Policy [Policy Text Block]

Marketable Equity Securities

 

Equity securities traded in active markets are marked to market at each balance sheet date based on prices as quoted on the relevant stock exchange. Fair value mark-to-market adjustments are recorded as non-operating gains (losses) in the consolidated statement of operations. The Company’s investments in marketable equity securities are classified in the consolidated balance sheet based on the nature of the securities and their availability for use in current operations.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Allowance for Expected Credit Losses on Receivables

 

The allowance for expected credit losses on receivables is used to present accounts receivable, net, at an amount that represents the Company’s estimate of the receivables expected to be collected from customers. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written off. The Company estimates the allowance on the basis of specifically identified receivables that are evaluated individually for impairment and an analysis of the remaining receivables determined by reference to past default experience. The Company considers the need to adjust historical information to reflect the extent to which current conditions and reasonable forecasts are expected to differ from the conditions that existed for the historical period considered. Losses on receivables have not historically been significant.

 

Management judgments are used to determine when to charge off uncollectible trade accounts receivable. The Company bases these judgments on the age of the receivable, credit quality of the customer, current economic conditions, and other factors that may affect a customer’s ability and intent to pay. Customers are generally not required to provide collateral for purchases.
Inventory, Policy [Policy Text Block]

Inventories

 

The Company values inventories at the lower of cost (determined on a first-in, first-out method) or net realizable value. The Company regularly reviews inventory quantities on hand and writes down excess and obsolete inventories to estimated net realizable value if less than cost, based primarily on historical inventory usage and estimated forecast of product demand.
Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

 

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

 

Machinery and equipment (years)

3

-

10

Computer equipment and software (years)

3

-

7

Furniture and fixtures (years)

5

-

10

 

Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.
Lessee, Leases [Policy Text Block]

Leases

 

The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right for the Company to control the use of the identified property, plant or equipment for a period of time in exchange for consideration. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight-line basis over the lease term.

 

The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets.

 

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the leases’ commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparison to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.
Income Tax, Policy [Policy Text Block]

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  The Company uses the flow-through method to account for investment tax credits.  Under this method, the investment tax credits are recognized as a reduction of income tax expense.

 

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. The Company’s policy is to account for Global Intangible Low-Taxed income as a period cost.
Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

 

The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of  foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in other expense (income), net, in the Company’s consolidated statements of operations.
Earnings Per Share, Policy [Policy Text Block]

Earnings per Share

 

Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.

 

The following table sets forth the computation of basic and diluted earnings per share:

 

  

Year Ended December 31,

 

(in thousands, except per share data)

 

2023

  

2022

 

Net loss

 $(3,415) $(9,516)

Weighted average shares outstanding - basic

  42,420   41,413 

Dilutive effect of equity awards

  -   - 

Weighted average shares outstanding - diluted

  42,420   41,413 

Basic loss per share

 $(0.08) $(0.23)

Diluted loss per share

 $(0.08) $(0.23)

Shares excluded from diluted loss per share due to their anti-dilutive effect

  3,868   3,661 

 
Comprehensive Income (Loss) [Policy Text Block]

Comprehensive Income (Loss)

 

Comprehensive income (loss) represents the change in equity resulting from items other than shareholder investments and distributions. The Company’s foreign currency translation adjustments, interest rate swap - cash flow hedge and minimum pension liability adjustments are included in AOCI. The components of other comprehensive income are reclassified as net income, net of tax, when the underlying component impacts earnings. Comprehensive income (loss) and the components of AOCI are presented in the accompanying consolidated statements of comprehensive loss and consolidated statements of equity.
Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

 

Nature of contracts and customers

 

The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions.

 

The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer customers who incorporate its products into their products under their own brands.

 

Performance obligations

 

The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, software licenses and enhancements, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may contain multiple promises such as delivery of hardware, software, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For contracts with customers that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which does not materially differ from the stated price in the contract. In general, the Company’s list prices are indicative of standalone selling price, and the majority of the Company's contracts have a term of less than one year.

 

Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales of these items are therefore generally recognized at a point in time.

 

The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may return an implantable monitor to the Company after use, and if the returned monitor can be reprocessed and resold, they may, in exchange, purchase a replacement implantable monitor of the same model at a lower price than a new monitor. The implantable monitors that are returned by customers are reprocessed and made available for future sale. The initial sale of implantable monitors and subsequent sale of replacement implantable monitors are independent transactions. The Company has no obligation in connection with the initial sale to sell replacement implantable monitors at any future date under any fixed terms and may refuse returned implantable monitors that cannot be recovered or are obsolete. The Company has concluded that the offer to its customers that they may purchase a discounted product in the future is not a material right. 

 

Service revenue consists of installation, training, data analysis and surgeries performed on research animals. Service revenue is recognized when the service is performed. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised and are not a separate performance obligation. Extended warranties relate to warranties that are separately priced and purchased in addition to a standard warranty, and are therefore a separate performance obligation. The Company has made the judgment that the customer benefits as the Company performs over the period of the contract, and therefore revenues from maintenance and warranty contracts are recognized over time. The Company uses the input method to recognize revenue over time, which is generally on a straight-line basis over the service period.

 

For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment.

 

Variable Consideration

 

The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration, and its impact on the Company’s revenue recognition, was not material in any of the periods presented.

 

The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which occurs at the time of shipment or prior to services being performed. Payment terms vary by the type of customers and the products or services offered.

 

Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues.

 

Contract Liabilities

 

The Company records contract liabilities  when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Contract liabilities consist of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Contract liabilities are  generally expected to be recognized within one year.

 

The amounts included in contract liabilities from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not represent a significant financing component as the customer can exercise their discretion as to when they can obtain the products for which they have made a prepayment.

 

Disaggregation of revenue

 

Refer to Note 13 for revenue disaggregated by type and by geographic location as well as further information about the deferred revenue balances.
Internal Use Software, Policy [Policy Text Block]

Software Development

 

Software development costs for software products to be sold, leased or otherwise marketed that are incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product-by-product basis until the product is available for general release to customers at which time amortization begins.

 

Annual amortization, charged to cost of goods sold, is the amount computed using the ratio that current revenues for a product bear to the total current and anticipated future revenues for that product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

 

Intangible assets are comprised of existing technology, customer contracts and contractual relationships, and other definite-lived intangible assets. Identifiable intangible assets resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by the Company based on the fair value of assets received. Identifiable definite-lived intangible assets are being amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from four to fifteen years.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

 

Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired.

 

For the purpose of its goodwill analysis, the Company has one reporting unit. The Company conducts its annual impairment analysis in the fourth quarter of the fiscal year and more frequently if there is an indicator of impairment. The Company assesses qualitative factors of the reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment indicates a potential impairment, a quantitative analysis is performed. The Company compares the fair value of the reporting unit with its carrying amount. The Company typically estimates fair value using the income approach but will also consider market approaches when appropriate. Under the income approach, the Company uses a discounted cash flows model, which indicates the fair value of the reporting unit based on the present value of the cash flows that the Company expects the reporting unit to generate in the future. The Company's significant estimates in the discounted cash flows model include weighted average cost of capital, long-term rate of growth and profitability of the reporting unit, expected income tax rates and working capital effects. If the carrying amount of a reporting unit exceeds its fair value, goodwill is impaired, and the Company would recognize a loss equal to the excess.

 

The Company evaluated its goodwill for impairment as of October 1, 2023 by performing a qualitative analysis and determined that it was more likely than not that the fair value of the reporting unit exceeded the carrying value.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

 

The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors which could trigger an impairment review include significant negative industry or economic trends, significant loss of clients, and significant changes in the manner of the Company’s use of the assets or the strategy for its overall business.

 

The recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Cash flow projections are based on trends of historical performance and management’s estimate of future performance. The Company’s estimate of future cash flows requires significant judgment based on historical and anticipated results and are subject to many factors.

 

When the Company determines that the carrying value of the assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, the Company measures the potential impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in its current business model. An impairment loss is recognized only if the carrying amount of the asset is not recoverable and exceeds its fair value. Different assumptions and judgments could materially affect the calculation of the fair value of our assets. For the years ended December 31, 2023 and 2022, the Company concluded that there were no triggering events requiring the Company to assess the recoverability of its long-lived assets.
Derivatives, Policy [Policy Text Block]

Derivatives

 

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge) and does not use derivative financial instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values.

 

The Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

 

By using derivative financial instruments to hedge exposure to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations by the use of cash flow sensitivity analysis, which estimates the expected impact of changes in interest rates on the Company’s future cash flows.
Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

Financial reporting standards define a fair value hierarchy that consists of three levels:

 

 

●

Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

 

 

●

Level 2 includes instruments for which the valuations are based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

 

 

●

Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The carrying values of the Company’s cash and cash equivalents, trade accounts receivable, trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity (Level 2).
Share-Based Payment Arrangement [Policy Text Block]

Stock-based Compensation

 

The Company recognizes compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, and restricted stock units with a market condition. The Company issues awards under the 2021 Incentive Plan (the “2021 Incentive Plan”) and the Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “2000 Incentive Plan” and together with the 2021 Incentive Plan, the “Incentive Plans”), as well as issues shares for employee stock purchases related to its Employee Stock Purchase Plan (as amended, the “ESPP”). The Company issues new shares from its registered but unissued stock pool to satisfy stock option exercises and vesting of the restricted stock units. Stock-based compensation expense is recorded on a straight-line basis over the applicable service period, which ranges from one to four years. The Company has elected as an accounting policy to account for forfeitures for service-based awards as they occur, with no adjustment for estimated forfeitures.

 

The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using a Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables including, but are not limited to, the Company’s expected stock price volatility over the term of the awards, interest rate assumptions, and discounts to adjust for any holding period post-vest restrictions.
Stockholders' Equity, Policy [Policy Text Block]

Preferred Stock

 

The Company’s board of directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The board of directors may exercise this authority without any further approval from stockholders. As of December 31, 2023 and 2022, the Company had no preferred stock issued or outstanding.
Segment Reporting, Policy [Policy Text Block]

Business Segment Information

 

The Company operates in one segment which involves the design, development, production and distribution of  products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company has a single, company-wide management team that administers all properties as a whole rather than as discrete operating segments. The chief operating decision maker, who is the Company's chief executive officer, measures financial performance as a single enterprise and allocates resources across the Company to maximize profitability, and not on geography, legal entity, or end market basis. The Company operates in a number of countries throughout the world in a variety of product lines. Information regarding product lines and geographic financial information is provided in Note 13, “Revenues” and Note 5, "Balance Sheet Information."
Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. If a loss is reasonably possible and the loss or range of loss can be reasonably estimated, the Company discloses the possible loss. If a loss is probable and the loss or range of loss cannot be reasonably estimated, the Company discloses or states that such an estimate cannot be made. Refer to Note 15 Commitments and Contingencies for additional information. The Company accrues and expenses legal costs associated with contingencies when incurred.
New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

 

Accounting Pronouncements Adopted in 2023

 

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04), which eliminates the performance of Step 2 from the goodwill impairment test. In performing its annual or interim impairment testing, an entity will instead compare the fair value of the reporting unit with its carrying amount and recognize any impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The Company adopted ASU 2017-04 effective January 1, 2023, with no impact to the consolidated financial statements.

 

In September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU 2016-13 to clarify implementation guidance and to provide transition relief for certain entities. The Company adopted ASU 2016-13 effective January 1, 2023, which resulted in an immaterial impact to the consolidated financial statements.

 

Accounting Pronouncements yet to be Adopted

 

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax, which enhances disclosures related to the effective tax rate reconciliation, income taxes paid, as well as other disclosures. The new standard impacts footnote disclosures and is effective for the Company’s annual financial statements for the year ended December 31, 2025. The Company is currently evaluating the potential impact of adopting ASU 2023-09 will have on the disclosures in its consolidated financial statements.
Reclassification, Comparability Adjustment [Policy Text Block]

Prior Period Financial Statement Reclassifications

 

During the year ended December 31, 2023, the Company identified immaterial misclassification errors in the financial statement footnote describing the components of AOCI as of December 31, 2022 and 2021. These misclassifications overstated the amount attributed to the defined benefit pension plans, net of tax, by $5.4 million and $5.1 million and understated the amount attributed to foreign currency translation adjustments by $(5.4) million and $(5.1) million as of December 31, 2022 and 2021, respectively. These misclassifications had no impact on total OCI for the year ended December 31, 2022, included in the consolidated statements of comprehensive loss, or the total AOCI included in the consolidated balance sheets as of December 31, 2022, and also had no impact on any of the Company’s previously reported consolidated statements of operations, stockholders’ equity, or cash flows. The correction of these offsetting misclassifications is included in these consolidated financial statements. See Note 3 below for further details.
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Property, Plant and Equipment, Useful Lives [Table Text Block]

Machinery and equipment (years)

3

-

10

Computer equipment and software (years)

3

-

7

Furniture and fixtures (years)

5

-

10
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended December 31,

 

(in thousands, except per share data)

 

2023

  

2022

 

Net loss

 $(3,415) $(9,516)

Weighted average shares outstanding - basic

  42,420   41,413 

Dilutive effect of equity awards

  -   - 

Weighted average shares outstanding - diluted

  42,420   41,413 

Basic loss per share

 $(0.08) $(0.23)

Diluted loss per share

 $(0.08) $(0.23)

Shares excluded from diluted loss per share due to their anti-dilutive effect

  3,868   3,661 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Accumulated Other Comprehensive Loss (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
  

Foreign Currency

      

Derivatives

     
  

Translation

  

Defined Benefit

  

Qualifying

     

(in thousands)

 

Adjustments

  

Pension Plans

  

as Hedges

  

Total

 

Balance at December 31, 2021*

 $(8,778) $(1,249) $-  $(10,027)

Other comprehensive loss, net

  (2,614)  (2,411)  -   (5,025)

Balance at December 31, 2022*

  (11,392)  (3,660)  -   (15,052)

Other comprehensive income (loss), net

  1,507   (446)  (199)  862 

Balance at December 31, 2023

 $(9,885) $(4,106) $(199) $(14,190)
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Goodwill [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Carrying amount at beginning of period

 $56,260  $57,689 

Effect of change in currency translation

  805   (1,429)

Carrying amount at end of period

 $57,065  $56,260 
Schedule of Intangible Assets and Goodwill [Table Text Block]
      

December 31, 2023

  

December 31, 2022

 

(in thousands)

 

Average

      

Accumulated

          

Accumulated

     

Amortizable intangible assets:

 

Life*

  

Gross

  

Amortization

  

Net

  

Gross

  

Amortization

  

Net

 

Distribution agreements/customer relationships

  6  $16,038  $(9,706) $6,332  $16,124  $(8,727) $7,397 

Existing technology & software development

  2   35,007   (27,029)  7,978   37,549   (26,482)  11,067 

Trade names and patents

  3   7,613   (6,094)  1,519   7,523   (5,197)  2,326 

Total amortizable intangible assets

     $58,658  $(42,829) $15,829  $61,196  $(40,406) $20,790 

Indefinite-lived intangible assets:

              207           224 

Total intangible assets

             $16,036          $21,014 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

(in thousands)

    

2024

 $5,281 

2025

  4,027 

2026

  2,366 

2027

  1,269 

2028

  1,546 

Thereafter

  1,340 

Total

 $15,829 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Inventory, Current [Table Text Block]

Inventories:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Finished goods

 $5,120  $5,223 

Work in process

  4,188   3,776 

Raw materials

  15,408   17,440 

Total

 $24,716  $26,439 
Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Machinery and equipment

 $8,154  $7,500 

Computer equipment and software

  6,493   6,781 

Leasehold improvements

  2,417   2,507 

Furniture and fixtures

  1,244   1,386 

Automobiles

  58   38 
   18,366   18,212 

Less: accumulated depreciation

  (14,385)  (14,846)

Property, plant and equipment, net

 $3,981  $3,366 
Other Current Liabilities [Table Text Block]

Other Current Liabilities:

 

December 31,

 

(in thousands)

 

2023

  

2022

 

Compensation

 $3,929  $3,476 

Customer credits

  3,201   2,368 

Professional fees

  499   392 

Warranty costs

  336   268 

Other

  1,240   982 

Total

 $9,205  $7,486 
Long-Lived Assets by Geographic Areas [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

United States

 $21,558  $26,051 

Germany

  1,703   2,432 

Rest of the world

  1,322   1,489 

Total long-lived assets

 $24,583  $29,972 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Restructuring and Other Exit Costs (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Restructuring and Related Costs [Table Text Block]

(in thousands)

 

Inventory Related

  

Severance

  

Other

  

Total

 

Balance at December 31, 2021

 $-  $-  $-  $- 

Restructuring and other exit costs

  1,471   877   46   2,394 

Non-cash charges

  (1,471)  -   -   (1,471)

Cash payments

  -   (241)  (46)  (287)

Balance at December 31, 2022

  -   636   -   636 

Restructuring and other exit costs

  320   42   29   391 

Non-cash charges

  (142)  -   -   (142)

Cash payments

  (94)  (678)  (29)  (801)

Balance at December 31, 2023

 $84  $-  $-  $84 
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Costs of Retirement Plans [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Interest cost

 $670  $371 

Expected return on plan assets

  (788)  (818)

Net amortization loss

  328   27 

Net periodic benefit expense (credit)

 $210  $(420)
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Change in fair value of plan assets:

        

Balance at beginning of year

 $15,576  $27,252 

Actual return on plan assets

  351   (9,098)

Employer contributions

  622   619 

Benefits paid

  (563)  (592)

Currency translation adjustment

  954   (2,605)

Balance at end of year

 $16,940  $15,576 
Schedule of Changes in Projected Benefit Obligations [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Change in benefit obligation:

        

Balance at beginning of year

 $13,263  $22,562 

Interest cost

  665   371 

Actuarial loss (gain)

  479   (6,912)

Benefits paid

  (563)  (592)

Currency translation adjustment

  819   (2,166)

Balance at end of year

 $14,663  $13,263 
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Fair value of plan assets

 $16,940  $15,576 

Benefit obligation

  14,663   13,263 

Net funded status

 $2,277  $2,313 
Schedule of Amounts Recognized in Balance Sheet [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Other long-term assets

 $2,277  $2,313 

Accumulated other comprehensive loss

  5,909   5,326 
Defined Benefit Plan, Assumptions [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Discount rate

  4.6%  5.0%

Expected return on assets

  5.3%  5.0%
Schedule of Allocation of Plan Assets [Table Text Block]

(in thousands)

 

2023

  

2022

 

Asset category:

                

Debt securities

 $11,761   69% $11,714   75%

Equity securities

  3,567   21%  3,507   23%

Cash and cash equivalents

  304   2%  185   1%

Other

  1,308   8%  170   1%

Total

 $16,940   100% $15,576   100%
Defined Benefit Plan, Plan Assets, Category [Table Text Block]

(in thousands)

 

2023

  

2022

 

Quoted Prices in Active Markets for Identical Assets (Level 1)

 $304  $185 

Significant Other Observable Inputs (Level 2)

  16,636   15,391 

Significant Other Unobservable Inputs (Level 3)

  -   - 

Total

 $16,940  $15,576 
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Lease, Cost [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Operating lease cost

 $2,013  $1,971 

Short-term lease cost

  199   233 

Sublease income

  (102)  (102)

Total lease cost

 $2,110  $2,102 
Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]

(in thousands)

 

December 31,

 
  

2023

  

2022

 

Operating lease right-of-use assets

 $4,773  $5,816 
         

Current portion, operating lease liabilities

  1,416   2,135 

Operating lease liabilities, long-term

  4,794   5,282 

Total operating lease liabilities

 $6,210  $7,417 
         

Weighted average remaining lease term (years)

  5.7   6.2 

Weighted average discount rate

  9.5%  9.4%
Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Cash paid for amounts included in the measurement of lease liabilities

 $2,367  $2,347 

Right-of-use assets obtained in exchange for lease obligations

  293   295 
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Year Ending December 31,

    

(in thousands)

    

2024

  1,938 

2025

  1,166 

2026

  1,060 

2027

  1,047 

2028

  1,057 

Thereafter

  1,926 

Total lease payments

  8,194 

Less imputed interest

  (1,984)

Total operating lease liabilities

 $6,210 
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Long-term Debt (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Debt [Table Text Block]

(in thousands)

 

December 31, 2023

  

December 31, 2022

 

Long-term debt:

        

Term loan

 $30,723  $34,814 

Revolving line

  6,400   12,850 

Less: unamortized deferred financing costs

  (560)  (840)

Total debt

  36,563   46,824 

Less: current portion of long-term debt

  (6,139)  (4,091)

Current unamortized deferred financing costs

  280   280 

Long-term debt

 $30,704  $43,013 
Schedule of Maturities of Long-Term Debt [Table Text Block]

(in thousands)

    

2024

 $6,139 

2025

  30,984 
  $37,123 
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Derivatives (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Derivative Instruments [Table Text Block]

(in thousands)

 

December 31, 2023

 

Derivatives Instruments

 

Balance Sheet Classification

 

Notional Amount

  

Fair Value (a)

 

Interest rate swap

 

Other long-term liabilities

 $27,375  $(199)
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]
  

Year Ended

 

Derivatives Qualifying as Hedges, net of tax (in thousands)

 

December 31, 2023

 

Amount of loss recognized in OCI on derivatives (effective portion)

 $199 

Amounts reclassified from accumulated other comprehensive loss to interest expense

  120 
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
  

Fair Value as of December 31, 2023

 

Assets (Liabilities) (in thousands)

 

Level 1

  

Level 2

  

Level 3

  

Total

 

Equity securities - common stock

 $3,511  $-  $-  $3,511 

Interest rate swap agreements

  -   (199)  -   (199)
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Cost of revenues

 $308  $121 

Sales and marketing expenses

  746   557 

General and administrative expenses

  3,560   3,487 

Research and development expenses

  386   246 

Total stock-based compensation expenses

 $5,000  $4,411 
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
          

Condition

     
  

Restricted

  

Grant Date

  

Restricted

  

Grant Date

 
  

Stock Units

  

Fair Value

  

Stock Units

  

Fair Value

 

Balance at December 31, 2021

  1,141,164  $3.57   860,155  $3.13 

Granted

  918,870   4.64   320,272   5.08 

Vested

  (733,611)  4.08   (401,308)  2.11 

Cancelled/Forfeited

  (232,622)  4.44   (132,884)  4.21 

Balance at December 31, 2022

  1,093,801  $3.94   646,235  $4.51 

Granted

  1,350,125   2.87   558,958   2.61 

Vested

  (1,144,065)  3.38   (316,210)  4.01 

Cancelled/Forfeited

  (134,865)  3.71   (87,138)  4.64 

Balance at December 31, 2023

  1,164,996  $3.28   801,845  $3.37 
Schedule of Stock Options Roll Forward [Table Text Block]
  

Number of Options

  

Weighted-Average Exercise Price

  

Weighted-Aveage Remaining Contractual Term (years)

  

Average Intrinsic Value (in thousands)

 

Outstanding at December 31, 2021

  1,404,816  $3.10         

Exercised

  (40,267)  2.64         

Cancelled/Forfeited

  (125,773)  2.77         

Outstanding at December 31, 2022

  1,238,776  $3.15         

Exercised

  (213,644)  2.38         

Cancelled/Forfeited

  (101,065)  2.71         

Outstanding and Exerciseable at December 31, 2023

  924,067  $3.37   3.4  $1,836 
Black Scholes Option Pricing Model [Member]  
Notes Tables  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

2023

  

2022

 

Volatility

  56.8%  62.6%

Risk-free interest rate

  4.6%  2.1%

Correlation coefficient

  41.7%  41.5%

Dividend yield

  -%  -%

Liquidity discount

  14.1%  11.7%
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Instruments, equipment, software and accessories

 $105,716  $108,165 

Service, maintenance and warranty contracts

  6,534   5,170 

Total revenues

 $112,250  $113,335 
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Goods and services transferred at a point in time

 $108,558  $111,927 

Goods and services transferred over time

  3,692   1,408 

Total revenues

 $112,250  $113,335 
Revenue from External Customers by Geographic Areas [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

United States

 $48,205  $49,912 

Europe

  32,801   30,687 

Greater China

  18,488   16,393 

Rest of the world

  12,756   16,343 

Total revenues

 $112,250  $113,335 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
  

December 31,

      

December 31,

     

(in thousands)

 

2023

  

2022

  

Change

  

2022

  

2021

  

Change

 

Service contracts

 $2,849  $1,530  $1,319   1,530  $1,976  $(446)

Customer advances

  1,659   1,840   (181)  1,840   2,290   (450)

Total contract liabilities

 $4,508  $3,370  $1,138   3,370  $4,266  $(896)
Financing Receivable, Allowance for Credit Loss [Table Text Block]
  

December 31,

 

(in thousands)

 

2023

  

2022

 

Balance, beginning of period

 $191  $136 

Provision for expected credit losses

  29   62 

Charge-offs and other

  (60)  (7)

Balance, end of period

 $160  $191 
Schedule of Product Warranty Liability [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Balance at December 31, 2022

 $268  $240 

Expense

  381   408 

Warranty claims

  (313)  (380)

Balance at December 31, 2023

 $336  $268 
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Current income tax expense:

        

Federal and state

 $570  $641 

Foreign

  61   194 
   631   835 

Deferred income tax expense (benefit):

        

Federal and state

  132   (468)

Foreign

  96   (30)
   228   (498)

Total income tax expense

 $859  $337 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Income tax benefit computed at federal statutory tax rate

 $(537) $(1,927)

Increase (decrease) in income taxes resulting from:

        

Permanent differences, net

  (89)  375 

Non-deductible executive compensation

  324   346 

Global Intangible Low-Taxed Income (GILTI)

  537   552 

State income taxes, net of federal income tax benefit

  (19)  (295)

Stock-based compensation

  (329)  69 

Tax credits

  (51)  492 

Net operating loss true-ups and expirations

  1,140   431 

Change in reserve for uncertain tax position

  239   688 

Impact of change to prior year tax accruals

  (171)  (232)

Change in valuation allowance allocated to income tax

  631   (102)

Other

  (816)  (60)

Total income tax expense

 $859  $337 
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Domestic

 $(2,951) $(9,099)

Foreign

  395   (80)

Total

 $(2,556) $(9,179)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Deferred income tax assets:

        

Inventory

 $1,489  $1,696 

Operating loss and credit carryforwards

  11,550   14,883 

Research and development

  3,908   2,000 

Employee retention credit

  1,435   - 

Lease liabilities

  1,317   1,538 

Accrued expenses

  818   621 

Stock compensation

  670   675 

Deferred interest expense

  386   881 

Other assets

  934   726 

Total gross deferred assets

  22,507   23,020 

Less: valuation allowance

  (15,222)  (14,506)

Deferred tax assets

 $7,285  $8,514 
         

Deferred income tax liabilities:

        

Indefinite-lived intangible assets

 $1,964  $1,914 

Definite-lived intangible assets

  3,733   4,875 

Lease right-of-use assets

  959   1,148 

Employee benefit plans

  569   579 

Other liabilities

  400   255 

Total deferred tax liabilities

  7,625   8,771 

Deferred income tax liabilities, net

 $(340) $(257)
  

Year Ended December 31,

 

(in thousands)

 

2023

  

2022

 

Deferred tax assets (included in other long-term assets)

 $436  $333 

Deferred income tax liabilities

  (776)  (590)

Deferred income tax liability, net

 $(340) $(257)
Summary of Income Tax Contingencies [Table Text Block]
  

(in thousands)

 

Balance at December 31, 2021

 $1,332 

Additions based on tax positions of prior years

  534 

Decreases based on tax positions of prior years

  (34)

Additions based on tax positions of current year

  237 

Other decreases, net

  (86)

Balance at December 31, 2022

  1,983 

Additions based on tax positions of prior years

  13 

Decreases based on tax positions of prior years

  57 

Additions based on tax positions of current year

  245 

Other decreases, net

  (76)

Balance at December 31, 2023

 $2,222 
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Percentage of Cash and Cash Equivalents Held by Foreign Subsidiaries 49.00%    
Goodwill, Impairment Loss $ 0    
Impairment of Long-Lived Assets Held-for-use $ 0    
Preferred Stock, Shares Authorized (in shares) | shares 5,000,000 5,000,000  
Preferred Stock, Shares Issued (in shares) | shares 0 0  
Preferred Stock, Shares Outstanding (in shares) | shares   0  
Number of Operating Segments 1    
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax $ 446 $ 2,411  
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax 1,507 (2,614)  
Other Comprehensive Income (Loss), Net of Tax 862 (5,025)  
Accumulated Other Comprehensive Income (Loss), Net of Tax $ (14,190) (15,052)  
Revision of Prior Period, Adjustment [Member]      
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax   5,400 $ 5,100
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax   5,400 $ 5,100
Other Comprehensive Income (Loss), Net of Tax   0  
Accumulated Other Comprehensive Income (Loss), Net of Tax   $ 0  
Minimum [Member]      
Customer Payments Term (Day) 0 days    
Finite-Lived Intangible Asset, Useful Life (Year) 4 years    
Minimum [Member] | Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 1 year    
Maximum [Member]      
Customer Payments Term (Day) 60 days    
Finite-Lived Intangible Asset, Useful Life (Year) 15 years    
Maximum [Member] | Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 4 years    
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)
Dec. 31, 2023
Machinery and Equipment [Member] | Minimum [Member]  
Property, plant and equipment useful life (Year) 3 years
Machinery and Equipment [Member] | Maximum [Member]  
Property, plant and equipment useful life (Year) 10 years
Computer Equipment and Software [member] | Minimum [Member]  
Property, plant and equipment useful life (Year) 3 years
Computer Equipment and Software [member] | Maximum [Member]  
Property, plant and equipment useful life (Year) 7 years
Furniture and Fixtures [Member] | Minimum [Member]  
Property, plant and equipment useful life (Year) 5 years
Furniture and Fixtures [Member] | Maximum [Member]  
Property, plant and equipment useful life (Year) 10 years
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Net loss $ (3,415) $ (9,516)
Weighted average shares outstanding - basic (in shares) 42,420 41,413
Dilutive effect of equity awards (in shares) 0 0
Weighted average shares outstanding - diluted (in shares) 42,420 41,413
Basic loss per share (in dollars per share) $ (0.08) $ (0.23)
Diluted loss per share (in dollars per share) $ (0.08) $ (0.23)
Shares excluded from diluted loss per share due to their anti-dilutive effect (in shares) 3,868 3,661
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance $ 72,220 $ 83,401
Other Comprehensive Income (Loss), Net of Tax 862 (5,025)
Balance 73,074 72,220
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance (11,392) (8,778)
Other Comprehensive Income (Loss), Net of Tax 1,507 (2,614)
Balance (9,885) (11,392)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]    
Balance (3,660) (1,249)
Other Comprehensive Income (Loss), Net of Tax (446) (2,411)
Balance (4,106) (3,660)
AOCI Attributable to Parent [Member]    
Balance (15,052) (10,027)
Other Comprehensive Income (Loss), Net of Tax 862 (5,025)
Balance (14,190) $ (15,052)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]    
Other Comprehensive Income (Loss), Net of Tax (199)  
Balance $ (199)  
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Write-off of Fully Amortized Intangible Assets Related to Existing Technology and Discontinued Product Lines $ 3,700  
Capitalized Computer Software, Net 500  
Amortization of Intangible Assets $ 5,525 $ 6,122
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Carrying amount $ 56,260 $ 57,689
Effect of change in currency translation 805 (1,429)
Carrying amount $ 57,065 $ 56,260
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets, Gross $ 58,658 $ 61,196
Total amortizable intangible assets (42,829) (40,406)
Finite-Lived Intangible Assets, Net 15,829 20,790
Indefinite-lived intangible assets: 207 224
Total intangible assets, Net $ 16,036 21,014
Distribution Agreements/Customer Relationships [Member]    
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year) [1] 6 years  
Finite-Lived Intangible Assets, Gross $ 16,038 16,124
Total amortizable intangible assets (9,706) (8,727)
Finite-Lived Intangible Assets, Net $ 6,332 7,397
Existing Technology and Software Development [Member]    
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year) 2 years  
Finite-Lived Intangible Assets, Gross $ 35,007 37,549
Total amortizable intangible assets (27,029) (26,482)
Finite-Lived Intangible Assets, Net $ 7,978 11,067
Trade Names and Patents [Member]    
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year) [1] 3 years  
Finite-Lived Intangible Assets, Gross $ 7,613 7,523
Total amortizable intangible assets (6,094) (5,197)
Finite-Lived Intangible Assets, Net $ 1,519 $ 2,326
[1] Weighted average life in years as of September 30, 2022
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
2024 $ 5,281  
2025 4,027  
2026 2,366  
2027 1,269  
2028 1,546  
Thereafter 1,340  
Total $ 15,829 $ 20,790
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Depreciation $ 1,473 $ 1,453
Fully Depreciated and Disposed of Property and Equipment Removed From Fixed Asset Records $ 2,000  
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information - Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finished goods $ 5,120 $ 5,223
Work in process 4,188 3,776
Raw materials 15,408 17,440
Total $ 24,716 $ 26,439
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment, Gross $ 18,366 $ 18,212
Less: accumulated depreciation (14,385) (14,846)
Property, plant and equipment, net 3,981 3,366
Machinery and Equipment [Member]    
Property, Plant and Equipment, Gross 8,154 7,500
Computer Equipment and Software [member]    
Property, Plant and Equipment, Gross 6,493 6,781
Leasehold Improvements [Member]    
Property, Plant and Equipment, Gross 2,417 2,507
Furniture and Fixtures [Member]    
Property, Plant and Equipment, Gross 1,244 1,386
Automobiles [Member]    
Property, Plant and Equipment, Gross $ 58 $ 38
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Compensation $ 3,929 $ 3,476
Customer credits 3,201 2,368
Professional fees 499 392
Warranty costs 336 268
Other 1,240 982
Total $ 9,205 $ 7,486
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Long-Lived Assets $ 24,583 $ 29,972
UNITED STATES    
Long-Lived Assets 21,558 26,051
GERMANY    
Long-Lived Assets 1,703 2,432
Rest of the World [Member]    
Long-Lived Assets $ 1,322 $ 1,489
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance $ 636 $ 0
Restructuring and other exit costs 391 2,394
Non-cash charges (142) (1,471)
Cash payments (801) (287)
Balance 84 636
Cost of Revenues [Member]    
Balance 0 0
Restructuring and other exit costs 320 1,471
Non-cash charges (142) (1,471)
Cash payments (94) 0
Balance 84 0
Employee Severance [Member]    
Balance 636 0
Restructuring and other exit costs 42 877
Non-cash charges 0 0
Cash payments (678) (241)
Balance 0 636
Other Restructuring [Member]    
Balance 0 0
Restructuring and other exit costs 29 46
Non-cash charges 0 0
Cash payments (29) (46)
Balance $ 0 $ 0
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans (Details Textual)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Defined Contribution Plan, Cost $ 1.1
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 0.6
Defined Benefit Plan, Expected Future Benefit Payment, Year One 0.9
Defined Benefit Plan, Expected Future Benefit Payment, Year Two 0.7
Defined Benefit Plan, Expected Future Benefit Payment, Year Three 0.8
Defined Benefit Plan, Expected Future Benefit Payment, Year Four 1.0
Defined Benefit Plan, Expected Future Benefit Payment, Year Five 0.8
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $ 5.0
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Interest cost $ 665 $ 371
Expected return on plan assets (788) (818)
Net amortization loss 328 27
Net periodic benefit expense (credit) $ 210 $ (420)
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan, Fair Value of Plan Assets, Balance $ 15,576 $ 27,252
Actual return on plan assets 351 (9,098)
Employer contributions 622 619
Benefits paid (563) (592)
Currency translation adjustment 954 (2,605)
Defined Benefit Plan, Fair Value of Plan Assets, Balance $ 16,940 $ 15,576
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan, Benefit Obligation, Balance $ 13,263 $ 22,562  
Interest cost 665 371  
Actuarial loss (gain) 479 (6,912)  
Benefits paid (563) (592)  
Currency translation adjustment 819 (2,166)  
Defined Benefit Plan, Benefit Obligation, Balance 14,663 13,263  
Defined Benefit Plan, Fair Value of Plan Assets 16,940 15,576 $ 27,252
Benefit obligation 14,663 13,263 $ 22,562
Net funded status 5,909 5,326  
Pension Plan [Member]      
Defined Benefit Plan, Benefit Obligation, Balance 13,263    
Defined Benefit Plan, Benefit Obligation, Balance 14,663 13,263  
Defined Benefit Plan, Fair Value of Plan Assets 16,940 15,576  
Benefit obligation 14,663 13,263  
Net funded status $ 2,277 $ 2,313  
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Other long-term assets $ 5,909 $ 5,326
Other Noncurrent Liabilities [Member]    
Other long-term assets $ 2,277 $ 2,313
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Discount rate 4.60% 5.00%
Expected return on assets 5.30% 5.00%
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan, Fair Value of Plan Assets $ 16,940 $ 15,576 $ 27,252
Defined Benefit Plan, Actual Plan Asset Allocations 100.00% 100.00%  
Debt Security, Corporate, US [Member]      
Defined Benefit Plan, Fair Value of Plan Assets [1] $ 11,761 $ 11,714  
Defined Benefit Plan, Actual Plan Asset Allocations 69.00% 75.00%  
Defined Benefit Plan, Equity Securities [Member]      
Defined Benefit Plan, Fair Value of Plan Assets $ 3,567 $ 3,507  
Defined Benefit Plan, Actual Plan Asset Allocations 21.00% 23.00%  
Defined Benefit Plan, Cash and Cash Equivalents [Member]      
Defined Benefit Plan, Fair Value of Plan Assets $ 304 $ 185  
Defined Benefit Plan, Actual Plan Asset Allocations 2.00% 1.00%  
Other Plan Assets [Member]      
Defined Benefit Plan, Fair Value of Plan Assets $ 1,308 $ 170  
Defined Benefit Plan, Actual Plan Asset Allocations 8.00% 1.00%  
[1] Updated dimension from: "Debt Securities [Member]".
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan, Fair Value of Plan Assets $ 16,940 $ 15,576 $ 27,252
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan, Fair Value of Plan Assets 304 185  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan, Fair Value of Plan Assets 16,636 15,391  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan, Fair Value of Plan Assets $ 0 $ 0  
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Leases - Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating lease cost $ 2,013 $ 1,971
Short-term lease cost 199 233
Sublease income (102) (102)
Total lease cost $ 2,110 $ 2,102
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Operating lease right-of-use assets $ 4,773 $ 5,816
Current portion, operating lease liabilities 1,416 2,135
Operating lease liabilities, long-term 4,794 5,282
Total operating lease liabilities $ 6,210 $ 7,417
Weighted average remaining lease term (years) (Year) 5 years 8 months 12 days 6 years 2 months 12 days
Weighted average discount rate 9.50% 9.40%
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities $ 2,367 $ 2,347
Right-of-use assets obtained in exchange for lease obligations $ 293 $ 295
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Leases - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
2024 $ 1,938  
2025 1,166  
2026 1,060  
2027 1,047  
2028 1,057  
Thereafter 1,926  
Total lease payments 8,194  
Less imputed interest (1,984)  
Total operating lease liabilities $ 6,210 $ 7,417
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Long-term Debt (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 22, 2020
Long-term Debt, Gross $ 37,123    
Debt Issuance Costs, Net, Total $ 560 $ 840  
The Credit Agreement [Member]      
Debt Issuance Costs, Net, Total     $ 1,400
Line of Credit Facility, Interest Rate During Period 8.10% 5.00%  
Line of Credit Facility, Interest Rate During Period 7.40%    
Debt Instrument, Quarterly Payment, Thereafter $ 1,000    
Debt Instrument, Current Maturities, Excess Cash Flow Sweep $ 2,100 $ 1,100  
The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member]      
Debt Instrument, Interest Rate, State Floor Percentage 0.50%    
The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member] | Maximum [Member]      
Debt Instrument, Basis Spread on Variable Rate 3.25%    
The Credit Agreement [Member] | Base Rate [Member]      
Debt Instrument, Interest Rate, State Floor Percentage 1.00%    
The Credit Agreement [Member] | The ABR Loan [Member] | Minimum [Member]      
Debt Instrument, Basis Spread on Variable Rate 1.50%    
The Credit Agreement [Member] | The ABR Loan [Member] | Maximum [Member]      
Debt Instrument, Basis Spread on Variable Rate 3.00%    
The Credit Agreement [Member] | Revolving Credit Facility [Member]      
Line of Credit Facility, Remaining Borrowing Capacity $ 10,800    
Term Loan [Member]      
Long-term Debt, Gross $ 30,723 $ 34,814  
The SOFR Loan and Pricing Grid Credit Agreement [Member] | The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member] | Minimum [Member]      
Debt Instrument, Basis Spread on Variable Rate 2.00%    
The Lenders [Member] | The Credit Agreement [Member] | Revolving Credit Facility [Member]      
Line of Credit Facility, Maximum Borrowing Capacity     25,000
The Lenders [Member] | The Credit Agreement [Member] | Letter of Credit [Member]      
Line of Credit Facility, Maximum Borrowing Capacity     10,000
The Lenders [Member] | The Credit Agreement [Member] | Swingline Loan Facility [Member]      
Line of Credit Facility, Maximum Borrowing Capacity     10,000
The Lenders [Member] | Term Loan [Member] | The Credit Agreement [Member]      
Long-term Debt, Gross     $ 40,000
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Long-term Debt - Breakdown of Borrowings (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Long-term debt, gross $ 37,123  
Less: unamortized deferred financing costs (560) $ (840)
Total debt 36,563 46,824
Less: current portion of long-term debt (6,139) (4,091)
Current unamortized deferred financing costs 280 280
Long-term debt 30,704 43,013
Term Loan [Member]    
Long-term debt, gross 30,723 34,814
Line of Credit [Member]    
Long-term debt, gross $ 6,400 $ 12,850
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Long Term Debt - Debt Maturity (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
2024 $ 6,139
2025 30,984
Total $ 37,123
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Derivatives (Details Textual)
$ in Thousands
Dec. 31, 2023
USD ($)
The Credit Agreement [Member]  
Debt Instrument, Interest Rate, Stated Percentage 4.75%
Interest Rate Swap [Member]  
Derivative, Notional Amount $ 27,375
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Derivatives - Derivative Instruments (Details) - Interest Rate Swap [Member]
$ in Thousands
Dec. 31, 2023
USD ($)
Interest rate swap $ 27,375
Interest rate swap $ (199)
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Amount of loss recognized in OCI on derivatives (effective portion) $ 199
Amounts reclassified from accumulated other comprehensive loss to interest expense $ 120
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member]
$ in Thousands
Dec. 31, 2023
USD ($)
Equity securities - common stock $ 3,511
Interest Rate Swap [Member]  
Derivative liabilities (199)
Fair Value, Inputs, Level 1 [Member]  
Equity securities - common stock 3,511
Fair Value, Inputs, Level 1 [Member] | Interest Rate Swap [Member]  
Derivative liabilities 0
Fair Value, Inputs, Level 2 [Member]  
Equity securities - common stock 0
Fair Value, Inputs, Level 2 [Member] | Interest Rate Swap [Member]  
Derivative liabilities (199)
Fair Value, Inputs, Level 3 [Member]  
Equity securities - common stock 0
Fair Value, Inputs, Level 3 [Member] | Interest Rate Swap [Member]  
Derivative liabilities $ 0
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation (Details Textual) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 4.7   $ 4.7  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     1 year 7 months 6 days  
Vesting Rate of the Targeted Shareholder Return     100.00%  
Minimum Vesting Rate of the Targeted Shareholder Return, Percentage     0.00%  
Maximum Vesting Rate of the Targeted Shareholder Return, Percentage     150.00%  
Share Price (in dollars per share) $ 5.35   $ 5.35  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value     $ 0.6 $ 0.1
Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date     15.00%  
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) 0.1 0.2    
2021 Incentive Plan [Member]        
Employee Stock Ownership Plan, Shares Available for Issuance (in shares) 3.1   3.1  
Employee Stock Purchase Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 0.3   0.3  
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based compensation $ 5,000 $ 4,411
Continuing Operations [Member] | Cost of Sales [Member]    
Share-based compensation 308 121
Continuing Operations [Member] | Selling and Marketing Expense [Member]    
Share-based compensation 746 557
Continuing Operations [Member] | General and Administrative Expense [Member]    
Share-based compensation 3,560 3,487
Continuing Operations [Member] | Research and Development Expense [Member]    
Share-based compensation $ 386 $ 246
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member] - Share-Based Payment Arrangement, Option [Member]
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Volatility 56.80% 62.60%
Risk-free interest rate 4.60% 2.10%
Correlation coefficient 41.70% 41.50%
Dividend yield 0.00% 0.00%
Liquidity discount 14.10% 11.70%
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Outstanding at December 31, 2021 (in shares) 1,238,776 1,404,816
Outstanding at December 31, 2021 (in dollars per share) $ 3.15 $ 3.1
Outstanding at December 31, 2022 (in shares) 924,067 1,238,776
Outstanding at December 31, 2022 (in dollars per share) $ 3.37 $ 3.15
Restricted Stock Units (RSUs) [Member]    
Outstanding at December 31, 2021 (in shares) 1,093,801 1,141,164
Outstanding at December 31, 2021 (in dollars per share) $ 3.94 $ 3.57
Options, Granted in Period (in shares) 1,350,125 918,870
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) $ 2.87 $ 4.64
Restricted Stock Units, Vested in Period (in shares) (1,144,065) (733,611)
Restricted Stock Units, Vested, Grant Date Fair Value, Balance (in dollars per share) $ 3.38 $ 4.08
Options, Cancelled / Forfeited in Period (in shares) (134,865) (232,622)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) $ 3.71 $ 4.44
Outstanding at December 31, 2022 (in shares) 1,164,996 1,093,801
Outstanding at December 31, 2022 (in dollars per share) $ 3.28 $ 3.94
Market Condition Restricted Stock Units [Member]    
Restricted Stock Units Outstanding , Balance (in shares) 646,235 860,155
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) $ 4.51 $ 3.13
Restricted Stock Units, Granted in Period (in shares) 558,958 320,272
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) $ 2.61 $ 5.08
Restricted Stock Units, Vested in Period (in shares) (316,210) (401,308)
Restricted Stock Units, Vested, Grant Date Fair Value, Balance (in dollars per share) $ 4.01 $ 2.11
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) (87,138) (132,884)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) $ 4.64 $ 4.21
Restricted Stock Units Outstanding , Balance (in shares) 801,845 646,235
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) $ 3.37 $ 4.51
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Outstanding at December 31, 2021 (in shares) 1,238,776 1,404,816
Outstanding at December 31, 2021 (in dollars per share) $ 3.15 $ 3.1
Exercised (in shares) (213,644) (40,267)
Exercised (in dollars per share) $ 2.38 $ 2.64
Cancelled/Forfeited (in shares) (101,065) (125,773)
Cancelled/Forfeited (in dollars per share) $ 2.71 $ 2.77
Outstanding at December 31, 2022 (in shares) 924,067 1,238,776
Outstanding at December 31, 2022 (in dollars per share) $ 3.37 $ 3.15
Outstanding and Exerciseable at December 31, 2023 (Year) 3 years 4 months 24 days  
Outstanding and Exerciseable at December 31, 2023 $ 1,836  
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Contract with Customer, Liability, Revenue Recognized $ 2.1 $ 2.5
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 112,250 $ 113,335
Transferred at Point in Time [Member]    
Revenues 108,558 111,927
Transferred over Time [Member]    
Revenues 3,692 1,408
Instruments, Equipment, Software, and Accessories [Member]    
Revenues 105,716 108,165
Service, Maintenance, and Warranty Contracts [Member]    
Revenues $ 6,534 $ 5,170
XML 95 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues - Revenue by Geographic Destination (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Total revenues $ 112,250 $ 113,335
UNITED STATES    
Total revenues 48,205 49,912
Europe [Member]    
Total revenues 32,801 30,687
Greater China [Member]    
Total revenues 18,488 16,393
Rest of the World [Member]    
Total revenues $ 12,756 $ 16,343
XML 96 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues - Deferred Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Deferred revenue $ 4,508 $ 3,370 $ 4,266
Deferred Revenue, change 1,138 (896)  
Service [Member]      
Deferred revenue 2,849 1,530 1,976
Deferred Revenue, change 1,319 (446)  
Customer Advances [Member]      
Deferred revenue 1,659 1,840 $ 2,290
Deferred Revenue, change $ (181) $ (450)  
XML 97 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance, beginning of period $ 191 $ 136
Provision for expected credit losses 29 62
Charge-offs and other (60) (7)
Balance, end of period $ 160 $ 191
XML 98 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Revenues - Warranties (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance $ 268 $ 240
Expense 381 408
Warranty claims (313) (380)
Balance $ 336 $ 268
XML 99 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Percent, Total (33.50%) (3.70%)
Research and Development Tax Credit Carryforwards Offset by Reserve for Uncertain Tax Positions $ 800  
Deferred Tax Assets, Tax Credit Carryforwards, Total 2,700  
Deferred Tax Assets, Valuation Allowance 15,222 $ 14,506
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 700 200
Cash and Cash Equivalents, at Carrying Value, Total 4,283 4,508
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 400  
Non-US [Member] | Subsidiaries [Member]    
Cash and Cash Equivalents, at Carrying Value, Total 2,100 $ 2,600
Expire 2024 [Member]    
Deferred Tax Assets, Tax Credit Carryforwards, Research 7,800  
State and Local Jurisdiction [Member] | Expire between 2024 and 2043 [Member]    
Operating Loss Carryforwards 6,300  
Foreign Tax Authority [Member]    
Operating Loss Carryforwards 7,800  
Foreign Tax Authority [Member] | Research Tax Credit Carryforward [Member]    
Tax Credit Carryforward, Amount $ 400  
XML 100 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax - Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Federal and state $ 570 $ 641
Foreign 61 194
current income tax (benefit) expense 631 835
Federal and state 132 (468)
Foreign 96 (30)
deferred income tax (benefit) expense 228 (498)
Total income tax expense (benefit) $ 859 $ 337
XML 101 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income tax benefit computed at federal statutory tax rate $ (537) $ (1,927)
Permanent differences, net, amount (89) 375
Non-deductible executive compensation 324 346
Global Intangible Low-Taxed Income (GILTI) 537 552
State income taxes, net of federal income tax benefit, amount (19) (295)
Stock-based compensation (329) 69
Tax credits (51) 492
Net operating loss true-ups and expirations 1,140 431
Change in reserve for uncertain tax position 239 688
Impact of change to prior year tax accruals (171) (232)
Change in valuation allowance allocated to income tax 631 (102)
Other (816) (60)
Total income tax expense (benefit) $ 859 $ 337
XML 102 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Domestic $ (2,951) $ (9,099)
Foreign 395 (80)
Total $ (2,556) $ (9,179)
XML 103 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory $ 1,489 $ 1,696
Operating loss and credit carryforwards 11,550 14,883
Research and development 3,908 2,000
Employee retention credit 1,435 0
Lease liabilities 1,317 1,538
Accrued expenses 818 621
Stock compensation 670 675
Deferred interest expense 386 881
Other assets 934 726
Total gross deferred assets 22,507 23,020
Less: valuation allowance (15,222) (14,506)
Deferred tax assets 7,285 8,514
Indefinite-lived intangible assets 1,964 1,914
Definite-lived intangible assets 3,733 4,875
Lease right-of-use assets 959 1,148
Employee benefit plans 569 579
Other liabilities 400 255
Total deferred tax liabilities 7,625 8,771
Deferred income tax liabilities, net (340) (257)
Deferred tax assets (included in other long-term assets) 436 333
Deferred income tax liabilities $ (776) $ (590)
XML 104 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Income Tax - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance $ 1,983 $ 1,332
Additions based on tax positions of prior years 13 534
Decreases based on tax positions of prior years (57) (34)
Additions based on tax positions of current year 245 237
Other decreases, net (76) 86
Decreases based on tax positions of prior years 57 34
Balance $ 2,222 $ 1,983
XML 105 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Commitments and Contingent Liabilities (Details Textual)
$ in Thousands
Dec. 31, 2023
USD ($)
Director [Member] | Indemnification Agreements [Member]  
Liability for Contingent Indemnification Obligations $ 0
XML 106 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Litigation Settlement (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Jun. 10, 2022
Dec. 31, 2023
Dec. 31, 2022
Equity Securities without Readily Determinable Fair Value, Amount $ 3.9    
Preferred Stock, Book Value, Inclusive of Accrued Dividends     $ 4.1
Harvard Apparatus Regenerative Technology, Inc. (“HART”) [Member]      
Investment Owned, Fair Value   $ 3.5  
Equity Securities, FV-NI, Unrealized Gain (Loss)   $ 0.6  
Case in Suffolk Superior Court [Member] | Convertible Preferred Stock [Member]      
Stock Issued During Period, Shares, Issued For Settlement (in shares) 4,000    
Stock Issued During Period, Value, Issued for Settlement $ 4.0    
XML 107 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 17 - Product Line Disposition (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Feb. 17, 2023
Dec. 31, 2023
Dec. 31, 2022
Gain (Loss) on Disposition of Business   $ 403 $ (0)
Hoefer Product Line [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]      
Disposal Group, Including Discontinued Operation, Consideration $ 500    
Disposal Group, Including Discontinued Operation, Assets 100    
Gain (Loss) on Disposition of Business $ 400    
XML 108 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 18 - Government Assistance (Details Textual) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Feb. 29, 2024
Dec. 31, 2023
Dec. 31, 2022
Programs Established to Offset the Impact of COVID [Member]      
Government Assistance, Amount   $ 0.2 $ 0.7
Paycheck Protection Program CARES Act [Member] | Subsequent Event [Member]      
Government Assistance, Amount $ 3.1    
EXCEL 110 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 111 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 112 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 114 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 206 445 1 true 82 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals) Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals Consolidated Statements of Comprehensive Loss (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995454 - Disclosure - Note 1 - Organization Sheet http://www.harvardbioscience.com/20231231/role/statement-note-1-organization Note 1 - Organization Notes 10 false false R11.htm 995455 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 11 false false R12.htm 995456 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss Sheet http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss Note 3 - Accumulated Other Comprehensive Loss Notes 12 false false R13.htm 995457 - Disclosure - Note 4 - Goodwill and Intangible Assets Sheet http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets Note 4 - Goodwill and Intangible Assets Notes 13 false false R14.htm 995458 - Disclosure - Note 5 - Balance Sheet Information Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information Note 5 - Balance Sheet Information Notes 14 false false R15.htm 995459 - Disclosure - Note 6 - Restructuring and Other Exit Costs Sheet http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs Note 6 - Restructuring and Other Exit Costs Notes 15 false false R16.htm 995460 - Disclosure - Note 7 - Employee Benefit Plans Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans Note 7 - Employee Benefit Plans Notes 16 false false R17.htm 995461 - Disclosure - Note 8 - Leases Sheet http://www.harvardbioscience.com/20231231/role/statement-note-8-leases Note 8 - Leases Notes 17 false false R18.htm 995462 - Disclosure - Note 9 - Long-term Debt Sheet http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt Note 9 - Long-term Debt Notes 18 false false R19.htm 995463 - Disclosure - Note 10 - Derivatives Sheet http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives Note 10 - Derivatives Notes 19 false false R20.htm 995464 - Disclosure - Note 11 - Fair Value Measurements Sheet http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements Note 11 - Fair Value Measurements Notes 20 false false R21.htm 995465 - Disclosure - Note 12 - Stock-Based Compensation Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation Note 12 - Stock-Based Compensation Notes 21 false false R22.htm 995466 - Disclosure - Note 13 - Revenues Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues Note 13 - Revenues Notes 22 false false R23.htm 995467 - Disclosure - Note 14 - Income Tax Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax- Note 14 - Income Tax Notes 23 false false R24.htm 995468 - Disclosure - Note 15 - Commitments and Contingent Liabilities Sheet http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities Note 15 - Commitments and Contingent Liabilities Notes 24 false false R25.htm 995469 - Disclosure - Note 16 - Litigation Settlement Sheet http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement Note 16 - Litigation Settlement Notes 25 false false R26.htm 995470 - Disclosure - Note 17 - Product Line Disposition Sheet http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition Note 17 - Product Line Disposition Notes 26 false false R27.htm 995471 - Disclosure - Note 18 - Government Assistance Sheet http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance Note 18 - Government Assistance Notes 27 false false R28.htm 995472 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies 28 false false R29.htm 995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies 29 false false R30.htm 995474 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables Note 3 - Accumulated Other Comprehensive Loss (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss 30 false false R31.htm 995475 - Disclosure - Note 4 - Goodwill and Intangible Assets (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables Note 4 - Goodwill and Intangible Assets (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets 31 false false R32.htm 995476 - Disclosure - Note 5 - Balance Sheet Information (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables Note 5 - Balance Sheet Information (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information 32 false false R33.htm 995477 - Disclosure - Note 6 - Restructuring and Other Exit Costs (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables Note 6 - Restructuring and Other Exit Costs (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs 33 false false R34.htm 995478 - Disclosure - Note 7 - Employee Benefit Plans (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables Note 7 - Employee Benefit Plans (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans 34 false false R35.htm 995479 - Disclosure - Note 8 - Leases (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables Note 8 - Leases (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-8-leases 35 false false R36.htm 995480 - Disclosure - Note 9 - Long-term Debt (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables Note 9 - Long-term Debt (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt 36 false false R37.htm 995481 - Disclosure - Note 10 - Derivatives (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables Note 10 - Derivatives (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives 37 false false R38.htm 995482 - Disclosure - Note 11 - Fair Value Measurements (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables Note 11 - Fair Value Measurements (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements 38 false false R39.htm 995483 - Disclosure - Note 12 - Stock-Based Compensation (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables Note 12 - Stock-Based Compensation (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation 39 false false R40.htm 995484 - Disclosure - Note 13 - Revenues (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables Note 13 - Revenues (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues 40 false false R41.htm 995485 - Disclosure - Note 14 - Income Tax (Tables) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables Note 14 - Income Tax (Tables) Tables http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax- 41 false false R42.htm 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables 42 false false R43.htm 995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Details 43 false false R44.htm 995488 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) Details 44 false false R45.htm 995489 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) Details 45 false false R46.htm 995490 - Disclosure - Note 4 - Goodwill and Intangible Assets (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual Note 4 - Goodwill and Intangible Assets (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables 46 false false R47.htm 995491 - Disclosure - Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) Details 47 false false R48.htm 995492 - Disclosure - Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) Details 48 false false R49.htm 995493 - Disclosure - Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) Details 49 false false R50.htm 995494 - Disclosure - Note 5 - Balance Sheet Information (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual Note 5 - Balance Sheet Information (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables 50 false false R51.htm 995495 - Disclosure - Note 5 - Balance Sheet Information - Inventories (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details Note 5 - Balance Sheet Information - Inventories (Details) Details 51 false false R52.htm 995496 - Disclosure - Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) Details 52 false false R53.htm 995497 - Disclosure - Note 5 - Balance Sheet Information - Other Current Liabilities (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details Note 5 - Balance Sheet Information - Other Current Liabilities (Details) Details 53 false false R54.htm 995498 - Disclosure - Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details) Details 54 false false R55.htm 995499 - Disclosure - Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) Details 55 false false R56.htm 995500 - Disclosure - Note 7 - Employee Benefit Plans (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual Note 7 - Employee Benefit Plans (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables 56 false false R57.htm 995501 - Disclosure - Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) Details 57 false false R58.htm 995502 - Disclosure - Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) Details 58 false false R59.htm 995503 - Disclosure - Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details) Details 59 false false R60.htm 995504 - Disclosure - Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) Details 60 false false R61.htm 995505 - Disclosure - Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details) Details 61 false false R62.htm 995506 - Disclosure - Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) Details 62 false false R63.htm 995507 - Disclosure - Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) Details 63 false false R64.htm 995508 - Disclosure - Note 8 - Leases - Lease Expense (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details Note 8 - Leases - Lease Expense (Details) Details 64 false false R65.htm 995509 - Disclosure - Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Details 65 false false R66.htm 995510 - Disclosure - Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) Details 66 false false R67.htm 995511 - Disclosure - Note 8 - Leases - Future Minimum Lease Payments (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details Note 8 - Leases - Future Minimum Lease Payments (Details) Details 67 false false R68.htm 995512 - Disclosure - Note 9 - Long-term Debt (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual Note 9 - Long-term Debt (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables 68 false false R69.htm 995513 - Disclosure - Note 9 - Long-term Debt - Breakdown of Borrowings (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details Note 9 - Long-term Debt - Breakdown of Borrowings (Details) Details 69 false false R70.htm 995514 - Disclosure - Note 9 - Long Term Debt - Debt Maturity (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details Note 9 - Long Term Debt - Debt Maturity (Details) Details 70 false false R71.htm 995515 - Disclosure - Note 10 - Derivatives (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual Note 10 - Derivatives (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables 71 false false R72.htm 995516 - Disclosure - Note 10 - Derivatives - Derivative Instruments (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details Note 10 - Derivatives - Derivative Instruments (Details) Details 72 false false R73.htm 995517 - Disclosure - Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) Details 73 false false R74.htm 995518 - Disclosure - Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 74 false false R75.htm 995519 - Disclosure - Note 12 - Stock-Based Compensation (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual Note 12 - Stock-Based Compensation (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables 75 false false R76.htm 995520 - Disclosure - Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details) Details 76 false false R77.htm 995521 - Disclosure - Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details) Details 77 false false R78.htm 995522 - Disclosure - Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details) Details 78 false false R79.htm 995523 - Disclosure - Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details) Details 79 false false R80.htm 995524 - Disclosure - Note 13 - Revenues (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual Note 13 - Revenues (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables 80 false false R81.htm 995525 - Disclosure - Note 13 - Revenues - Disaggregation of Revenue (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details Note 13 - Revenues - Disaggregation of Revenue (Details) Details 81 false false R82.htm 995526 - Disclosure - Note 13 - Revenues - Revenue by Geographic Destination (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details Note 13 - Revenues - Revenue by Geographic Destination (Details) Details 82 false false R83.htm 995527 - Disclosure - Note 13 - Revenues - Deferred Revenue (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details Note 13 - Revenues - Deferred Revenue (Details) Details 83 false false R84.htm 995528 - Disclosure - Note 13 - Revenues - Allowance for Doubtful Accounts (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details Note 13 - Revenues - Allowance for Doubtful Accounts (Details) Details 84 false false R85.htm 995529 - Disclosure - Note 13 - Revenues - Warranties (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details Note 13 - Revenues - Warranties (Details) Details 85 false false R86.htm 995530 - Disclosure - Note 14 - Income Tax (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual Note 14 - Income Tax (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables 86 false false R87.htm 995531 - Disclosure - Note 14 - Income Tax - Income Tax Expense (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details Note 14 - Income Tax - Income Tax Expense (Details) Details 87 false false R88.htm 995532 - Disclosure - Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) Details 88 false false R89.htm 995533 - Disclosure - Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) Details 89 false false R90.htm 995534 - Disclosure - Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) Details 90 false false R91.htm 995535 - Disclosure - Note 14 - Income Tax - Unrecognized Tax Benefits (Details) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details Note 14 - Income Tax - Unrecognized Tax Benefits (Details) Details 91 false false R92.htm 995536 - Disclosure - Note 15 - Commitments and Contingent Liabilities (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual Note 15 - Commitments and Contingent Liabilities (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities 92 false false R93.htm 995537 - Disclosure - Note 16 - Litigation Settlement (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual Note 16 - Litigation Settlement (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement 93 false false R94.htm 995538 - Disclosure - Note 17 - Product Line Disposition (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual Note 17 - Product Line Disposition (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition 94 false false R95.htm 995539 - Disclosure - Note 18 - Government Assistance (Details Textual) Sheet http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual Note 18 - Government Assistance (Details Textual) Details http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance 95 false false All Reports Book All Reports hbio-20231231.xsd hbio-20231231_cal.xml hbio-20231231_def.xml hbio-20231231_lab.xml hbio-20231231_pre.xml hboi20231231_10k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 117 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hboi20231231_10k.htm": { "nsprefix": "hbio", "nsuri": "http://www.harvardbioscience.com/20231231", "dts": { "schema": { "local": [ "hbio-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "hbio-20231231_cal.xml" ] }, "definitionLink": { "local": [ "hbio-20231231_def.xml" ] }, "labelLink": { "local": [ "hbio-20231231_lab.xml" ] }, "presentationLink": { "local": [ "hbio-20231231_pre.xml" ] }, "inline": { "local": [ "hboi20231231_10k.htm" ] } }, "keyStandard": 405, "keyCustom": 40, "axisStandard": 38, "axisCustom": 0, "memberStandard": 52, "memberCustom": 30, "hidden": { "total": 46, "http://xbrl.sec.gov/ecd/2023": 9, "http://fasb.org/us-gaap/2023": 28, "http://xbrl.sec.gov/dei/2023": 6, "http://www.harvardbioscience.com/20231231": 3 }, "contextCount": 206, "entityCount": 1, "segmentCount": 82, "elementCount": 688, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 935, "http://xbrl.sec.gov/dei/2023": 37, "http://xbrl.sec.gov/ecd/2023": 10 }, "report": { "R1": { "role": "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R3": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "longName": "003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R5": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "longName": "004 - Statement - Consolidated Statements of Comprehensive Loss", "shortName": "Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R6": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "longName": "005 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)", "shortName": "Consolidated Statements of Comprehensive Loss (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": null, "uniqueAnchor": null }, "R7": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R8": { "role": "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "hbio:AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization", "longName": "995454 - Disclosure - Note 1 - Organization", "shortName": "Note 1 - Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "995455 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss", "longName": "995456 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss", "shortName": "Note 3 - Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets", "longName": "995457 - Disclosure - Note 4 - Goodwill and Intangible Assets", "shortName": "Note 4 - Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information", "longName": "995458 - Disclosure - Note 5 - Balance Sheet Information", "shortName": "Note 5 - Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs", "longName": "995459 - Disclosure - Note 6 - Restructuring and Other Exit Costs", "shortName": "Note 6 - Restructuring and Other Exit Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans", "longName": "995460 - Disclosure - Note 7 - Employee Benefit Plans", "shortName": "Note 7 - Employee Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases", "longName": "995461 - Disclosure - Note 8 - Leases", "shortName": "Note 8 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "longName": "995462 - Disclosure - Note 9 - Long-term Debt", "shortName": "Note 9 - Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "longName": "995463 - Disclosure - Note 10 - Derivatives", "shortName": "Note 10 - Derivatives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements", "longName": "995464 - Disclosure - Note 11 - Fair Value Measurements", "shortName": "Note 11 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "longName": "995465 - Disclosure - Note 12 - Stock-Based Compensation", "shortName": "Note 12 - Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues", "longName": "995466 - Disclosure - Note 13 - Revenues", "shortName": "Note 13 - Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "longName": "995467 - Disclosure - Note 14 - Income Tax", "shortName": "Note 14 - Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "longName": "995468 - Disclosure - Note 15 - Commitments and Contingent Liabilities", "shortName": "Note 15 - Commitments and Contingent Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "longName": "995469 - Disclosure - Note 16 - Litigation Settlement", "shortName": "Note 16 - Litigation Settlement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "longName": "995470 - Disclosure - Note 17 - Product Line Disposition", "shortName": "Note 17 - Product Line Disposition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "longName": "995471 - Disclosure - Note 18 - Government Assistance", "shortName": "Note 18 - Government Assistance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:GovernmentAssistanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:GovernmentAssistanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies", "longName": "995472 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "hbio:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "hbio:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables", "longName": "995474 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Note 3 - Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables", "longName": "995475 - Disclosure - Note 4 - Goodwill and Intangible Assets (Tables)", "shortName": "Note 4 - Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables", "longName": "995476 - Disclosure - Note 5 - Balance Sheet Information (Tables)", "shortName": "Note 5 - Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables", "longName": "995477 - Disclosure - Note 6 - Restructuring and Other Exit Costs (Tables)", "shortName": "Note 6 - Restructuring and Other Exit Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables", "longName": "995478 - Disclosure - Note 7 - Employee Benefit Plans (Tables)", "shortName": "Note 7 - Employee Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfCostsOfRetirementPlansTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfCostsOfRetirementPlansTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables", "longName": "995479 - Disclosure - Note 8 - Leases (Tables)", "shortName": "Note 8 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables", "longName": "995480 - Disclosure - Note 9 - Long-term Debt (Tables)", "shortName": "Note 9 - Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables", "longName": "995481 - Disclosure - Note 10 - Derivatives (Tables)", "shortName": "Note 10 - Derivatives (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables", "longName": "995482 - Disclosure - Note 11 - Fair Value Measurements (Tables)", "shortName": "Note 11 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables", "longName": "995483 - Disclosure - Note 12 - Stock-Based Compensation (Tables)", "shortName": "Note 12 - Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables", "longName": "995484 - Disclosure - Note 13 - Revenues (Tables)", "shortName": "Note 13 - Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables", "longName": "995485 - Disclosure - Note 14 - Income Tax (Tables)", "shortName": "Note 14 - Income Tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "hbio:PercentageOfCashAndCashEquivalentsHeldByForeignSubsidiaries", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "hbio:PercentageOfCashAndCashEquivalentsHeldByForeignSubsidiaries", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "longName": "995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-MachineryAndEquipmentMember_RangeAxis-MinimumMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "hbio:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-MachineryAndEquipmentMember_RangeAxis-MinimumMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "hbio:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details", "longName": "995488 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R45": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details", "longName": "995489 - Disclosure - Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details)", "shortName": "Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-AccumulatedTranslationAdjustmentMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R46": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual", "longName": "995490 - Disclosure - Note 4 - Goodwill and Intangible Assets (Details Textual)", "shortName": "Note 4 - Goodwill and Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "hbio:WriteoffOfFullyAmortizedIntangibleAssetsRelatedToExistingTechnologyAndDiscontinuedProductLines", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "hbio:WriteoffOfFullyAmortizedIntangibleAssetsRelatedToExistingTechnologyAndDiscontinuedProductLines", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details", "longName": "995491 - Disclosure - Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details)", "shortName": "Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R48": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details", "longName": "995492 - Disclosure - Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details)", "shortName": "Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "longName": "995493 - Disclosure - Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details)", "shortName": "Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual", "longName": "995494 - Disclosure - Note 5 - Balance Sheet Information (Details Textual)", "shortName": "Note 5 - Balance Sheet Information (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "hbio:FullyDepreciatedAndDisposedOfPropertyAndEquipmentRemovedFromFixedAssetRecords", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R51": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details", "longName": "995495 - Disclosure - Note 5 - Balance Sheet Information - Inventories (Details)", "shortName": "Note 5 - Balance Sheet Information - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details", "longName": "995496 - Disclosure - Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details)", "shortName": "Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details", "longName": "995497 - Disclosure - Note 5 - Balance Sheet Information - Other Current Liabilities (Details)", "shortName": "Note 5 - Balance Sheet Information - Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details", "longName": "995498 - Disclosure - Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details)", "shortName": "Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:NoncurrentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:NoncurrentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details", "longName": "995499 - Disclosure - Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details)", "shortName": "Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:RestructuringReserve", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31", "name": "us-gaap:RestructuringReserve", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R56": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual", "longName": "995500 - Disclosure - Note 7 - Employee Benefit Plans (Details Textual)", "shortName": "Note 7 - Employee Benefit Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details", "longName": "995501 - Disclosure - Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details)", "shortName": "Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedBenefitPlanInterestCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCostsOfRetirementPlansTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R58": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "longName": "995502 - Disclosure - Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details)", "shortName": "Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R59": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "longName": "995503 - Disclosure - Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details)", "shortName": "Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R60": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details", "longName": "995504 - Disclosure - Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details)", "shortName": "Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember", "name": "us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R61": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details", "longName": "995505 - Disclosure - Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details)", "shortName": "Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "longName": "995506 - Disclosure - Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details)", "shortName": "Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R63": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details", "longName": "995507 - Disclosure - Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details)", "shortName": "Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R64": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details", "longName": "995508 - Disclosure - Note 8 - Leases - Lease Expense (Details)", "shortName": "Note 8 - Leases - Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details", "longName": "995509 - Disclosure - Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)", "shortName": "Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "hbio:SupplementalBalanceSheetInformatonRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R66": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details", "longName": "995510 - Disclosure - Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)", "shortName": "Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "hbio:SupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "hbio:SupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details", "longName": "995511 - Disclosure - Note 8 - Leases - Future Minimum Lease Payments (Details)", "shortName": "Note 8 - Leases - Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual", "longName": "995512 - Disclosure - Note 9 - Long-term Debt (Details Textual)", "shortName": "Note 9 - Long-term Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2020-12-22_DebtInstrumentAxis-TheCreditAgreementMember", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R69": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "longName": "995513 - Disclosure - Note 9 - Long-term Debt - Breakdown of Borrowings (Details)", "shortName": "Note 9 - Long-term Debt - Breakdown of Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R70": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details", "longName": "995514 - Disclosure - Note 9 - Long Term Debt - Debt Maturity (Details)", "shortName": "Note 9 - Long Term Debt - Debt Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "longName": "995515 - Disclosure - Note 10 - Derivatives (Details Textual)", "shortName": "Note 10 - Derivatives (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2023-12-31_DebtInstrumentAxis-TheCreditAgreementMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DebtInstrumentAxis-TheCreditAgreementMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "longName": "995516 - Disclosure - Note 10 - Derivatives - Derivative Instruments (Details)", "shortName": "Note 10 - Derivatives - Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2023-12-31_DerivativeInstrumentRiskAxis-InterestRateSwapMember", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DerivativeInstrumentRiskAxis-InterestRateSwapMember", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R73": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details", "longName": "995517 - Disclosure - Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)", "shortName": "Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "longName": "995518 - Disclosure - Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "shortName": "Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2023-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual", "longName": "995519 - Disclosure - Note 12 - Stock-Based Compensation (Details Textual)", "shortName": "Note 12 - Stock-Based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R76": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details", "longName": "995520 - Disclosure - Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details)", "shortName": "Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "longName": "995521 - Disclosure - Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details)", "shortName": "Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackScholesOptionPricingModelMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackScholesOptionPricingModelMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "longName": "995522 - Disclosure - Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details)", "shortName": "Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R79": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details", "longName": "995523 - Disclosure - Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details)", "shortName": "Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R80": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual", "longName": "995524 - Disclosure - Note 13 - Revenues (Details Textual)", "shortName": "Note 13 - Revenues (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details", "longName": "995525 - Disclosure - Note 13 - Revenues - Disaggregation of Revenue (Details)", "shortName": "Note 13 - Revenues - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_TimingOfTransferOfGoodOrServiceAxis-TransferredAtPointInTimeMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R82": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "longName": "995526 - Disclosure - Note 13 - Revenues - Revenue by Geographic Destination (Details)", "shortName": "Note 13 - Revenues - Revenue by Geographic Destination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_StatementGeographicalAxis-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R83": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "longName": "995527 - Disclosure - Note 13 - Revenues - Deferred Revenue (Details)", "shortName": "Note 13 - Revenues - Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details", "longName": "995528 - Disclosure - Note 13 - Revenues - Allowance for Doubtful Accounts (Details)", "shortName": "Note 13 - Revenues - Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R85": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details", "longName": "995529 - Disclosure - Note 13 - Revenues - Warranties (Details)", "shortName": "Note 13 - Revenues - Warranties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R86": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "longName": "995530 - Disclosure - Note 14 - Income Tax (Details Textual)", "shortName": "Note 14 - Income Tax (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details", "longName": "995531 - Disclosure - Note 14 - Income Tax - Income Tax Expense (Details)", "shortName": "Note 14 - Income Tax - Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details", "longName": "995532 - Disclosure - Note 14 - Income Tax - Income Tax Rate Reconciliation (Details)", "shortName": "Note 14 - Income Tax - Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details", "longName": "995533 - Disclosure - Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details)", "shortName": "Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "longName": "995534 - Disclosure - Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details)", "shortName": "Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsInventory", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsInventory", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details", "longName": "995535 - Disclosure - Note 14 - Income Tax - Unrecognized Tax Benefits (Details)", "shortName": "Note 14 - Income Tax - Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R92": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual", "longName": "995536 - Disclosure - Note 15 - Commitments and Contingent Liabilities (Details Textual)", "shortName": "Note 15 - Commitments and Contingent Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": null, "uniqueAnchor": null }, "R93": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual", "longName": "995537 - Disclosure - Note 16 - Litigation Settlement (Details Textual)", "shortName": "Note 16 - Litigation Settlement (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "i_2022-06-10", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-06-10", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual", "longName": "995538 - Disclosure - Note 17 - Product Line Disposition (Details Textual)", "shortName": "Note 17 - Product Line Disposition (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-02-17_DisposalGroupClassificationAxis-DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-HoeferProductLineMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "unique": true } }, "R95": { "role": "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual", "longName": "995539 - Disclosure - Note 18 - Government Assistance (Details Textual)", "shortName": "Note 18 - Government Assistance (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_GovernmentAssistanceTypeAxis-ProgramsEstablishedToOffsetTheImpactOfCOVIDMember", "name": "us-gaap:GovernmentAssistanceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:GovernmentAssistanceTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_GovernmentAssistanceTypeAxis-ProgramsEstablishedToOffsetTheImpactOfCOVIDMember", "name": "us-gaap:GovernmentAssistanceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:GovernmentAssistanceTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hboi20231231_10k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35", "r856" ] }, "hbio_AccountsReceivableAllowanceForCreditLossChargeoffsAndOtherReoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "AccountsReceivableAllowanceForCreditLossChargeoffsAndOtherReoveries", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details" ], "lang": { "en-us": { "role": { "label": "hbio_AccountsReceivableAllowanceForCreditLossChargeoffsAndOtherReoveries", "negatedLabel": "Charge-offs and other", "documentation": "Amount of charge-offs and other recoveries to allowance for credit loss." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r304", "r305" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Professional fees", "label": "us-gaap_AccruedProfessionalFeesCurrent", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r9", "r23", "r46", "r899", "r900", "r901" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r70", "r200", "r651" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r222", "r231", "r232", "r560", "r820", "r899" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r45", "r46", "r125", "r211", "r647", "r672", "r676" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r23", "r46", "r565", "r568", "r619", "r667", "r668", "r899", "r900", "r901", "r909", "r910", "r911" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r7", "r23", "r46", "r231", "r232", "r589", "r590", "r591", "r592", "r593", "r899" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r116" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r515", "r516", "r517", "r686", "r909", "r910", "r911", "r988", "r1014" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Shares withheld for taxes", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r80", "r81", "r482" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r513", "r522" ] }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } }, "auth_ref": [ "r59", "r920" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r212", "r306", "r314", "r315", "r317", "r1009" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of deferred financing costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r129", "r374", "r601", "r904" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "terseLabel": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r63", "r67" ] }, "hbio_AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of intangible assets", "label": "hbio_AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets including portion attributable to discontinued operations, not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Shares excluded from diluted loss per share due to their anti-dilutive effect (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r277" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r557" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r171", "r204", "r245", "r282", "r294", "r298", "r309", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r558", "r562", "r582", "r642", "r730", "r856", "r870", "r941", "r942", "r999" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r195", "r216", "r245", "r309", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r558", "r562", "r582", "r856", "r941", "r942", "r999" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "terseLabel": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r5", "r108", "r109", "r150", "r193", "r194" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r874", "r875", "r876" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r874", "r875", "r876" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r874", "r875", "r876" ] }, "us-gaap_AutomobilesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AutomobilesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Automobiles [Member]", "documentation": "Vehicles that are used primarily for transporting people." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r484", "r485", "r486", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r508", "r509", "r510", "r511", "r512" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r91", "r95" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "hbio_BlackScholesOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "BlackScholesOptionPricingModelMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Black Scholes Option Pricing Model [Member]", "documentation": "Represents Black Scholes Option-pricing model." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r106", "r139", "r140" ] }, "us-gaap_CapitalizedComputerSoftwareNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CapitalizedComputerSoftwareNet", "terseLabel": "Capitalized Computer Software, Net", "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } } }, "auth_ref": [ "r809" ] }, "hbio_CaseInSuffolkSuperiorCourtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "CaseInSuffolkSuperiorCourtMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Case in Suffolk Superior Court [Member]", "documentation": "Information regarding case of Suffolk Superior Court." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r51", "r198", "r814" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r52" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r51", "r136", "r243" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r136" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r190", "r208", "r209", "r210", "r245", "r268", "r272", "r274", "r276", "r280", "r281", "r309", "r350", "r352", "r353", "r354", "r357", "r358", "r377", "r378", "r379", "r380", "r381", "r582", "r680", "r681", "r682", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r718", "r739", "r757", "r789", "r790", "r791", "r792", "r793", "r886", "r905", "r912" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies - Note 15", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r43", "r103", "r644", "r717" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r152", "r343", "r344", "r795", "r934" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r74", "r796" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r859", "r860", "r861", "r863", "r864", "r865", "r868", "r909", "r910", "r988", "r1011", "r1014" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r115" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r115", "r718" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r115" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r24", "r115", "r718", "r736", "r1014", "r1015" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,394,509 shares issued and outstanding at December 31, 2023; 42,081,707 shares issued and outstanding at December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r115", "r646", "r856" ] }, "hbio_ComprehensiveIncomeLossPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ComprehensiveIncomeLossPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss) [Policy Text Block]", "documentation": "Disclosure of the accounting policy for comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r47", "r226", "r228", "r234", "r637", "r656" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r124", "r233", "r636", "r655" ] }, "hbio_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Computer Equipment and Software [member]", "documentation": "Represents information related to computer equipment and software." } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r249", "r558", "r559", "r562", "r563", "r620", "r806", "r940", "r943", "r944" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r249", "r558", "r559", "r562", "r563", "r620", "r806", "r940", "r943", "r944" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r86", "r821" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r948" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r383", "r384", "r403" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r383", "r384", "r403" ] }, "hbio_ContractWithCustomerLiabilityCustomerAdvancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ContractWithCustomerLiabilityCustomerAdvancesCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Customer credits", "label": "hbio_ContractWithCustomerLiabilityCustomerAdvancesCurrent", "documentation": "Represents current customer advance for contract with customer liabiltiiy." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r377", "r378", "r379", "r863", "r864", "r865", "r868" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r131", "r632" ] }, "hbio_CostOfRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "CostOfRevenuesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "Cost of Revenues [Member]", "documentation": "Represents the Cost of Revenues." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details" ], "lang": { "en-us": { "role": { "label": "Federal and state", "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r896" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r896", "r908" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "current income tax (benefit) expense", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r168", "r546", "r552", "r908" ] }, "hbio_CustomerAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "CustomerAdvancesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details" ], "lang": { "en-us": { "role": { "label": "Customer Advances [Member]", "documentation": "Represents customer advances." } } }, "auth_ref": [] }, "hbio_CustomerPaymentsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "CustomerPaymentsTerm", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_CustomerPaymentsTerm", "terseLabel": "Customer Payments Term (Day)", "documentation": "Represents payments term from customers." } } }, "auth_ref": [] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DE", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "GERMANY" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r33", "r110", "r111", "r172", "r174", "r249", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r602", "r834", "r835", "r836", "r837", "r838", "r906" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt, gross", "label": "us-gaap_DebtInstrumentCarryingAmount", "terseLabel": "Long-term Debt, Gross", "totalLabel": "Total", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r33", "r174", "r375" ] }, "hbio_DebtInstrumentCurrentMaturitiesExcessCashFlowSweep": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DebtInstrumentCurrentMaturitiesExcessCashFlowSweep", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_DebtInstrumentCurrentMaturitiesExcessCashFlowSweep", "terseLabel": "Debt Instrument, Current Maturities, Excess Cash Flow Sweep", "documentation": "Information on the excess cash flow sweep." } } }, "auth_ref": [] }, "hbio_DebtInstrumentInterestRateStateFloorPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DebtInstrumentInterestRateStateFloorPercentage", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_DebtInstrumentInterestRateStateFloorPercentage", "terseLabel": "Debt Instrument, Interest Rate, State Floor Percentage", "documentation": "Represents the stated floor percentage rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r40", "r360" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r41", "r249", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r602", "r834", "r835", "r836", "r837", "r838", "r906" ] }, "hbio_DebtInstrumentQuarterlyPaymentThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DebtInstrumentQuarterlyPaymentThereafter", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_DebtInstrumentQuarterlyPaymentThereafter", "terseLabel": "Debt Instrument, Quarterly Payment, Thereafter", "documentation": "Amount of the required quarterly payments including both interest and principal payments thereafter" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "terseLabel": "Federal and state", "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r981" ] }, "us-gaap_DeferredFinanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsCurrentNet", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Current unamortized deferred financing costs", "label": "us-gaap_DeferredFinanceCostsCurrentNet", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r102" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "terseLabel": "Debt Issuance Costs, Net, Total", "negatedLabel": "Less: unamortized deferred financing costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r102", "r946" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r168", "r908", "r985" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets (included in other long-term assets)", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r528", "r529" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "totalLabel": "deferred income tax (benefit) expense", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r14", "r168", "r187", "r551", "r552", "r908" ] }, "hbio_DeferredIncomeTaxExpenseBenefitIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredIncomeTaxExpenseBenefitIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "hbio_DeferredIncomeTaxExpenseBenefitIncludingDiscontinuedOperation", "negatedLabel": "Deferred income taxes and other", "documentation": "Represents deferred income tax expense (benefit) including discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "totalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r112", "r113", "r173", "r540" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 }, "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax liability", "negatedLabel": "Deferred income tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r528", "r529", "r643" ] }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred interest expense", "label": "us-gaap_DeferredTaxAssetInterestCarryforward", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": [ "r984" ] }, "hbio_DeferredTaxAssetsEmployeeRetentionCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxAssetsEmployeeRetentionCredit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee retention credit", "label": "hbio_DeferredTaxAssetsEmployeeRetentionCredit", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee retention credits." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total gross deferred assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r541" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory", "label": "us-gaap_DeferredTaxAssetsInventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r983" ] }, "hbio_DeferredTaxAssetsOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxAssetsOperatingLeases", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liabilities", "label": "hbio_DeferredTaxAssetsOperatingLeases", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating leases." } } }, "auth_ref": [] }, "hbio_DeferredTaxAssetsOperatingLossAndTaxCreditsCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxAssetsOperatingLossAndTaxCreditsCarryforwards", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating loss and credit carryforwards", "label": "hbio_DeferredTaxAssetsOperatingLossAndTaxCreditsCarryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss and tax credits carryforwards." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r84", "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r84", "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock compensation", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other assets", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other." } } }, "auth_ref": [ "r85", "r984" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r542" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Deferred income tax liabilities, net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r82", "r983" ] }, "hbio_DeferredTaxLiabilitiesDefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxLiabilitiesDefiniteLivedIntangibleAssets", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Definite-lived intangible assets", "label": "hbio_DeferredTaxLiabilitiesDefiniteLivedIntangibleAssets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from definite lived intangible assets." } } }, "auth_ref": [] }, "hbio_DeferredTaxLiabilitiesEmployeeBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxLiabilitiesEmployeeBenefitPlans", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee benefit plans", "label": "hbio_DeferredTaxLiabilitiesEmployeeBenefitPlans", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from employee benefit plans." } } }, "auth_ref": [] }, "hbio_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite-lived intangible assets", "label": "hbio_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from indefinite lived intangible assets." } } }, "auth_ref": [] }, "hbio_DeferredTaxLiabilitiesOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DeferredTaxLiabilitiesOperatingLeases", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease right-of-use assets", "label": "hbio_DeferredTaxLiabilitiesOperatingLeases", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating leases." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "us-gaap_DeferredTaxLiabilitiesOther", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r85", "r984" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Actual return on plan assets", "label": "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r421", "r845" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details" ], "lang": { "en-us": { "role": { "label": "Actuarial loss (gain)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r414" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses", "negatedLabel": "Net amortization loss", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r408", "r446", "r468", "r845", "r846" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "terseLabel": "Other long-term assets", "totalLabel": "Net funded status", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r76", "r77" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r453" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected return on assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r454", "r473" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details" ], "lang": { "en-us": { "role": { "label": "Benefit obligation", "periodStartLabel": "Defined Benefit Plan, Benefit Obligation, Balance", "periodEndLabel": "Defined Benefit Plan, Benefit Obligation, Balance", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r409" ] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r457", "r843", "r844", "r845" ] }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r843" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details" ], "lang": { "en-us": { "role": { "label": "Employer contributions", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r423", "r433", "r472", "r843", "r844", "r845", "r846" ] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanEquitySecuritiesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Equity Securities [Member]", "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r843", "r845" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r440" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r440" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r440" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r440" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r440" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r440" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "terseLabel": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r441", "r846" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets", "negatedLabel": "Expected return on plan assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r408", "r445", "r467", "r845", "r846" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Fair Value of Plan Assets", "periodStartLabel": "Defined Benefit Plan, Fair Value of Plan Assets, Balance", "periodEndLabel": "Defined Benefit Plan, Fair Value of Plan Assets, Balance", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r420", "r431", "r433", "r434", "r843", "r844", "r845" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "terseLabel": "Currency translation adjustment", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r415" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details" ], "lang": { "en-us": { "role": { "label": "Interest cost", "terseLabel": "Interest cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r408", "r412", "r444", "r466", "r845", "r846" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "totalLabel": "Net periodic benefit expense (credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r442", "r464", "r845", "r846" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid", "negatedLabel": "Benefits paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r425", "r954" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsCategoryTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Table Text Block]", "documentation": "Tabular disclosure of defined benefit plan asset investment. Includes, but is not limited to, fair value of category of plan asset and its level within fair value hierarchy." } } }, "auth_ref": [ "r951", "r952" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Currency translation adjustment", "label": "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r422" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Actual Plan Asset Allocations", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r950" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r476" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r14", "r69" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r705", "r708", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r731", "r732", "r733", "r734", "r745", "r746", "r747", "r748", "r751", "r752", "r753", "r754", "r775", "r776", "r779", "r781", "r859", "r861" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate swap", "label": "us-gaap_DerivativeFairValueOfDerivativeNet", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r581" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r92", "r94", "r96", "r98", "r705", "r708", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r731", "r732", "r733", "r734", "r745", "r746", "r747", "r748", "r751", "r752", "r753", "r754", "r775", "r776", "r779", "r781", "r819", "r859", "r861" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeLiabilities", "negatedLabel": "Derivative liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r217", "r218", "r581", "r698", "r699", "r700", "r701", "r703", "r704", "r705", "r707", "r708", "r731", "r733", "r734", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r819", "r1012" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate swap", "label": "us-gaap_DerivativeNotionalAmount", "terseLabel": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r986", "r987" ] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesAndFairValueTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives" ], "lang": { "en-us": { "role": { "label": "Derivatives and Fair Value [Text Block]", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } } }, "auth_ref": [ "r169", "r170" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r25", "r87", "r88", "r90", "r100", "r248" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r915", "r1013" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r949" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r193" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r15", "r28" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r107", "r147" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r847", "r850" ] }, "hbio_DistributionAgreementscustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "DistributionAgreementscustomerRelationshipsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Distribution Agreements/Customer Relationships [Member]", "documentation": "Represents distribution agreements or customer relationships." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r874", "r875", "r876" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r874", "r875", "r876", "r878" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r877" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCorporateDebtSecuritiesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Debt Security, Corporate, US [Member]", "documentation": "Debt security issued by corporation domiciled in United States of America (US)." } } }, "auth_ref": [ "r845", "r916", "r917", "r951" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Loss per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share (in dollars per share)", "terseLabel": "Basic loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r235", "r255", "r256", "r258", "r259", "r261", "r266", "r268", "r274", "r275", "r276", "r278", "r572", "r573", "r638", "r657", "r824" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EarningsPerShareDiluted", "terseLabel": "Diluted loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r235", "r255", "r256", "r258", "r259", "r261", "r268", "r274", "r275", "r276", "r278", "r572", "r573", "r638", "r657", "r824" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r990" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r531" ] }, "hbio_EffectiveIncomeTaxRateReconciliationChangeInReserveForUncertainTaxPositionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInReserveForUncertainTaxPositionAmount", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "hbio_EffectiveIncomeTaxRateReconciliationChangeInReserveForUncertainTaxPositionAmount", "negatedLabel": "Change in reserve for uncertain tax position", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in reserve for uncertain tax position." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Global Intangible Low-Taxed Income (GILTI)", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": [ "r982" ] }, "hbio_EffectiveIncomeTaxRateReconciliationNetOperatingLossTrueUpsAndExpirationsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossTrueUpsAndExpirationsAmount", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Net operating loss true-ups and expirations", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to net operating loss true-ups and expirations." } } }, "auth_ref": [] }, "hbio_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible executive compensation", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for executive compensation." } } }, "auth_ref": [] }, "hbio_EffectiveIncomeTaxRateReconciliationPermanentDifferencesNetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesNetAmount", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Permanent differences, net, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences, net." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r887", "r982" ] }, "hbio_EffectiveIncomeTaxRateReconciliationTaxCreditAmountDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditAmountDeduction", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "hbio_EffectiveIncomeTaxRateReconciliationTaxCreditAmountDeduction", "negatedLabel": "Tax credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Compensation", "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r514" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r514" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "hbio_EmployeeStockOwnershipPlanSharesAvailableForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EmployeeStockOwnershipPlanSharesAvailableForIssuance", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_EmployeeStockOwnershipPlanSharesAvailableForIssuance", "terseLabel": "Employee Stock Ownership Plan, Shares Available for Issuance (in shares)", "documentation": "Number of shares available for issuance under an employee stock ownership plan." } } }, "auth_ref": [] }, "hbio_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Member]", "documentation": "Information on Employee Stock Purchase Plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r872" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information", "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables", "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r872" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r872" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r884" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r872" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r872" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r872" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r872" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r885" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r24", "r191", "r230", "r231", "r232", "r250", "r251", "r252", "r254", "r262", "r264", "r279", "r310", "r313", "r382", "r515", "r516", "r517", "r547", "r548", "r564", "r565", "r566", "r567", "r568", "r569", "r571", "r587", "r589", "r590", "r591", "r592", "r593", "r619", "r667", "r668", "r669", "r686", "r757" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Equity securities - common stock", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r205", "r580", "r641" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss", "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r658", "r918" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Unrealized loss on equity securities - Note 16", "negatedLabel": "Unrealized loss on equity securities - Note 16", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r308" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r307" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details" ], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "auth_ref": [ "r1016", "r1018", "r1020", "r1022" ] }, "hbio_ExistingTechnologyAndSoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ExistingTechnologyAndSoftwareDevelopmentMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Existing Technology and Software Development [Member]", "documentation": "Represents existing technology and software development." } } }, "auth_ref": [] }, "hbio_Expire2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "Expire2024Member", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Expire 2024 [Member]", "documentation": "Represents expiration in 2023." } } }, "auth_ref": [] }, "hbio_ExpireBetween2024And2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ExpireBetween2024And2043Member", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Expire between 2024 and 2043 [Member]", "documentation": "Represents the expiration date between 2024 and 2043." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r367", "r433", "r434", "r435", "r436", "r437", "r438", "r576", "r622", "r623", "r624", "r835", "r836", "r843", "r844", "r845" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r575", "r576", "r577", "r578", "r579" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r574" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r367", "r433", "r438", "r576", "r622", "r843", "r844", "r845" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r367", "r433", "r438", "r576", "r623", "r835", "r836", "r843", "r844", "r845" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r367", "r433", "r434", "r435", "r436", "r437", "r438", "r576", "r624", "r835", "r836", "r843", "r844", "r845" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r367", "r433", "r434", "r435", "r436", "r437", "r438", "r622", "r623", "r624", "r835", "r836", "r843", "r844", "r845" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r574", "r579" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r19", "r32" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Total amortizable intangible assets", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r202", "r329" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "terseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r145" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r145" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r145" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r145" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r145" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r327", "r328", "r329", "r330", "r633", "r634" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r144", "r634" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r64", "r66" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r144", "r633" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r583" ] }, "hbio_FullyDepreciatedAndDisposedOfPropertyAndEquipmentRemovedFromFixedAssetRecords": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "FullyDepreciatedAndDisposedOfPropertyAndEquipmentRemovedFromFixedAssetRecords", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_FullyDepreciatedAndDisposedOfPropertyAndEquipmentRemovedFromFixedAssetRecords", "terseLabel": "Fully Depreciated and Disposed of Property and Equipment Removed From Fixed Asset Records", "documentation": "The amount of fully depreciated and disposed of property and equipment removed from fixed asset records." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSaleOfBusiness", "terseLabel": "Gain (Loss) on Disposition of Business", "negatedLabel": "Gain on sale of product line", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r561", "r904" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r132", "r741" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r128" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodStartLabel": "Carrying amount", "periodEndLabel": "Carrying amount", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r201", "r322", "r635", "r829", "r856", "r922", "r929" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r143" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r321", "r326", "r829" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details" ], "lang": { "en-us": { "role": { "label": "Effect of change in currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r325" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillImpairmentLoss", "terseLabel": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r14", "r323", "r324", "r326", "r829" ] }, "us-gaap_GovernmentAssistanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceAmount", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GovernmentAssistanceAmount", "terseLabel": "Government Assistance, Amount", "documentation": "Amount of government assistance recognized." } } }, "auth_ref": [ "r596" ] }, "us-gaap_GovernmentAssistanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Text Block]", "documentation": "The entire disclosure for government assistance." } } }, "auth_ref": [ "r595", "r597", "r598", "r599", "r600" ] }, "us-gaap_GovernmentAssistanceTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTypeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Axis]", "documentation": "Information by type of government assistance." } } }, "auth_ref": [ "r596" ] }, "us-gaap_GovernmentAssistanceTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Domain]", "documentation": "Type of government assistance." } } }, "auth_ref": [ "r596" ] }, "hbio_GreaterChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "GreaterChinaMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details" ], "lang": { "en-us": { "role": { "label": "Greater China [Member]", "documentation": "Represents greater China." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r130", "r245", "r282", "r293", "r297", "r299", "r309", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r582", "r826", "r941" ] }, "hbio_HarvardApparatusRegenerativeTechnologyIncHartMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "HarvardApparatusRegenerativeTechnologyIncHartMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Harvard Apparatus Regenerative Technology, Inc. (\u201cHART\u201d) [Member]", "documentation": "Represents Harvard Apparatus Regenerative Technology, Inc. (\u201cHART\u201d)." } } }, "auth_ref": [] }, "hbio_HoeferProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "HoeferProductLineMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "Hoefer Product Line [Member]", "documentation": "Relating to the Hoefer Product Line." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r874", "r875", "r876" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment of Long-Lived Assets Held-for-use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r14", "r68", "r149" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r151" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Domestic", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r246", "r553" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r126", "r176", "r282", "r293", "r297", "r299", "r639", "r653", "r826" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r246", "r553" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r847", "r850" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r331", "r336", "r742" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r336", "r742" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r21" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r247", "r524", "r532", "r537", "r544", "r549", "r554", "r555", "r556", "r685" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Income tax expense", "totalLabel": "Total income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r179", "r188", "r263", "r264", "r285", "r530", "r550", "r659" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r229", "r526", "r527", "r537", "r538", "r543", "r545", "r679" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance allocated to income tax", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r982" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Income tax benefit computed at federal statutory tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r531" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r982" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Impact of change to prior year tax accruals", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r982" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "State income taxes, net of federal income tax benefit, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r982" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes, net of refunds", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r53" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and other current liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred Revenue, change", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r627", "r903" ] }, "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEquitySecuritiesFvNi", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi", "negatedLabel": "Convertible preferred stock received in litigation settlement - Note 16", "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r178", "r239" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r903" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "terseLabel": "Dilutive effect of equity awards (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r269", "r270", "r271", "r276", "r483" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived intangible assets:", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r146" ] }, "hbio_IndemnificationAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "IndemnificationAgreementsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Indemnification Agreements [Member]", "documentation": "Represents indemnification agreements." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r879" ] }, "hbio_InstrumentsEquipmentSoftwareAndAccessoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "InstrumentsEquipmentSoftwareAndAccessoriesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Instruments, Equipment, Software, and Accessories [Member]", "documentation": "Represents instruments, equipment, software, and accessories." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r66", "r629", "r630", "r631", "r633", "r822" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total intangible assets, Net", "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r62", "r65" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r238", "r241", "r242" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r811", "r866", "r867" ] }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InternalUseSoftwarePolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Internal Use Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": [ "r2", "r3" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r142", "r816" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details" ], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r214", "r815", "r856" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r180", "r197", "r213", "r318", "r319", "r320", "r628", "r823" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r142", "r818" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r142", "r817" ] }, "us-gaap_InvestmentIssuerNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerNameAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Investment, Issuer Name [Axis]", "documentation": "Information by name of issuer of investment." } } }, "auth_ref": [ "r1017", "r1019", "r1021", "r1023" ] }, "us-gaap_InvestmentIssuerNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Investment, Issuer Name [Domain]", "documentation": "Name of issuer of investment." } } }, "auth_ref": [ "r1017", "r1019", "r1021", "r1023" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentOwnedAtFairValue", "terseLabel": "Investment Owned, Fair Value", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r678", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r706", "r709", "r710", "r721", "r722", "r761", "r763", "r764", "r765", "r770", "r771", "r772", "r773", "r774", "r783", "r784", "r786", "r787", "r788", "r861", "r870", "r1012" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r609", "r855" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r993" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r148" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information", "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables", "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement" ], "lang": { "en-us": { "role": { "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r153" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r608" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r994" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r604" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r37", "r245", "r309", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r559", "r562", "r563", "r582", "r716", "r825", "r870", "r941", "r999", "r1000" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r120", "r175", "r649", "r856", "r907", "r919", "r989" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r39", "r196", "r245", "r309", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r559", "r562", "r563", "r582", "r856", "r941", "r999", "r1000" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "hbio_LiabilityForContingentIndemnificationObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "LiabilityForContingentIndemnificationObligations", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_LiabilityForContingentIndemnificationObligations", "terseLabel": "Liability for Contingent Indemnification Obligations", "documentation": "Represents liability for contingent indemnification obligations." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r36", "r906" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd", "terseLabel": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r36" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod", "terseLabel": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r36" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r36", "r906" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r36" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Litigation settlement - Note 16", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables" ], "lang": { "en-us": { "role": { "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total debt", "label": "us-gaap_LongTermDebt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r33", "r174", "r366", "r376", "r835", "r836", "r1008" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtCurrent", "negatedLabel": "Less: current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r206" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r249", "r370" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r249", "r370" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "label": "Long-term debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r207" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r154" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r41" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r41", "r75" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "hbio_MarketConditionRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "MarketConditionRestrictedStockUnitsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Market Condition Restricted Stock Units [Member]", "documentation": "Represents information related to market condition restricted stock units." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r104" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r479", "r626", "r666", "r707", "r708", "r762", "r766", "r768", "r769", "r785", "r807", "r808", "r828", "r839", "r853", "r858", "r945", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "hbio_MaximumVestingRateOfTheTargetedShareholderReturnPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "MaximumVestingRateOfTheTargetedShareholderReturnPercentage", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_MaximumVestingRateOfTheTargetedShareholderReturnPercentage", "terseLabel": "Maximum Vesting Rate of the Targeted Shareholder Return, Percentage", "documentation": "Represents the maximum vesting rate percentage of the targeted shareholder return." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r479", "r626", "r666", "r707", "r708", "r762", "r766", "r768", "r769", "r785", "r807", "r808", "r828", "r839", "r853", "r858", "r945", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "hbio_MinimumVestingRateOfTheTargetedShareholderReturnPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "MinimumVestingRateOfTheTargetedShareholderReturnPercentage", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_MinimumVestingRateOfTheTargetedShareholderReturnPercentage", "terseLabel": "Minimum Vesting Rate of the Targeted Shareholder Return, Percentage", "documentation": "Represents the minimum percentage vesting rate percentage of the targeted shareholder return." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r880" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r240" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r240" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r136", "r137", "r138" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r127", "r138", "r177", "r194", "r224", "r227", "r232", "r245", "r253", "r255", "r256", "r258", "r259", "r263", "r264", "r273", "r282", "r293", "r297", "r299", "r309", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r573", "r582", "r654", "r738", "r755", "r756", "r826", "r869", "r941" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r880" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r880" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1016", "r1018", "r1020", "r1022" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_NoncurrentAssets", "terseLabel": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r302" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r133" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Other (expense) income:" } } }, "auth_ref": [] }, "hbio_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "hbio_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r914" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Operating income (loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r282", "r293", "r297", "r299", "r826" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r610", "r855" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total operating lease liabilities", "label": "us-gaap_OperatingLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r606" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion, operating lease liabilities", "label": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r606" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities, long-term", "label": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r606" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r607", "r613" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease right-of-use assets", "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r605" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average discount rate", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r616", "r855" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average remaining lease term (years) (Year)", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r615", "r855" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r84" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r215", "r856" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r203" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r8", "r125", "r584", "r585", "r586" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Derivative instruments qualifying as cash flow hedges, net of tax of $-0-", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r219", "r220" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals" ], "lang": { "en-us": { "role": { "label": "Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r221" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details" ], "lang": { "en-us": { "role": { "label": "Amount of loss recognized in OCI on derivatives (effective portion)", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r219", "r220" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "negatedLabel": "Amounts reclassified from accumulated other comprehensive loss to interest expense", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r220", "r223" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r31", "r225", "r228", "r233", "r587", "r588", "r593", "r636", "r655", "r899", "r900" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit pension plans, net of tax benefit of $137 and $566, respectively", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r10", "r125" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals" ], "lang": { "en-us": { "role": { "label": "Tax Benefit", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r11" ] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables" ], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "totalLabel": "Total", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38", "r856" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Other (expense) income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r134" ] }, "hbio_OtherPlanAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "OtherPlanAssetsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Other Plan Assets [Member]", "documentation": "Represents information related to other plan assets." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r830", "r831", "r832", "r833" ] }, "hbio_PaycheckProtectionProgramCaresActMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "PaycheckProtectionProgramCaresActMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program CARES Act [Member]", "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRestructuring", "negatedTerseLabel": "Cash payments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r335", "r902" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Taxes paid related to net share settlement of equity awards", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r237" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireIntangibleAssets", "negatedLabel": "Capitalized software development costs", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r135" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Additions to property, plant and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r135" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r406", "r430", "r432", "r438", "r456", "r458", "r459", "r460", "r461", "r462", "r474", "r475", "r476", "r845" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details" ], "lang": { "en-us": { "role": { "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r457", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r477", "r480", "r845", "r846", "r850", "r851", "r852" ] }, "hbio_PercentageOfCashAndCashEquivalentsHeldByForeignSubsidiaries": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "PercentageOfCashAndCashEquivalentsHeldByForeignSubsidiaries", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_PercentageOfCashAndCashEquivalentsHeldByForeignSubsidiaries", "terseLabel": "Percentage of Cash and Cash Equivalents Held by Foreign Subsidiaries", "documentation": "Percentage of cash and cash equivalents held by foreign subsidiaries." } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r457", "r843", "r844", "r845" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "hbio_PreferredStockBookValueInclusiveOfAccruedDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "PreferredStockBookValueInclusiveOfAccruedDividends", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_PreferredStockBookValueInclusiveOfAccruedDividends", "terseLabel": "Preferred Stock, Book Value, Inclusive of Accrued Dividends", "documentation": "Represents the book value of preferred stock inclusive of accrued dividends." } } }, "auth_ref": [] }, "us-gaap_PreferredStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNoParValue", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r114", "r947" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r114", "r718" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockSharesIssued", "terseLabel": "Preferred Stock, Shares Issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r114", "r377" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockSharesOutstanding", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r114", "r718", "r736", "r1014", "r1015" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value $0.01 per share, 5,000,000 shares authorized", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r114", "r645", "r856" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r897" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of product line", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Borrowing from revolving line of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r49", "r906" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options and employee stock purchase plan", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r12", "r27" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r300", "r632", "r660", "r661", "r662", "r663", "r664", "r665", "r812", "r840", "r857", "r893", "r935", "r936", "r949", "r1010" ] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Warranty costs", "label": "us-gaap_ProductWarrantyAccrualClassifiedCurrent", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r937", "r939" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r300", "r632", "r660", "r661", "r662", "r663", "r664", "r665", "r812", "r840", "r857", "r893", "r935", "r936", "r949", "r1010" ] }, "hbio_ProgramsEstablishedToOffsetTheImpactOfCOVIDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ProgramsEstablishedToOffsetTheImpactOfCOVIDMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Programs Established to Offset the Impact of COVID [Member]", "documentation": "Represents the programs established to offset the negative impact of COVID." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r148", "r199", "r652" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r16", "r640", "r652", "r856" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r16", "r183", "r186", "r650" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r148" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment useful life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "hbio_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Lives [Table Text Block]", "documentation": "Tabular disclosure of useful lives of property, plant and equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details" ], "lang": { "en-us": { "role": { "label": "Provision for expected credit losses", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r236", "r316" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r430", "r479", "r509", "r510", "r511", "r625", "r626", "r666", "r707", "r708", "r762", "r766", "r768", "r769", "r785", "r807", "r808", "r828", "r839", "r853", "r858", "r861", "r932", "r945", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r430", "r479", "r509", "r510", "r511", "r625", "r626", "r666", "r707", "r708", "r762", "r766", "r768", "r769", "r785", "r807", "r808", "r828", "r839", "r853", "r858", "r861", "r932", "r945", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized." } } }, "auth_ref": [ "r60" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Repayment of revolving line of credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r50", "r906" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Repayment of term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r50", "r683" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r105", "r523", "r1007" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "hbio_ResearchAndDevelopmentTaxCreditCarryforwardsOffsetByReserveForUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ResearchAndDevelopmentTaxCreditCarryforwardsOffsetByReserveForUncertainTaxPositions", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_ResearchAndDevelopmentTaxCreditCarryforwardsOffsetByReserveForUncertainTaxPositions", "terseLabel": "Research and Development Tax Credit Carryforwards Offset by Reserve for Uncertain Tax Positions", "documentation": "The amount of research and development tax credit carryforwards offset by reserve for uncertain tax positions." } } }, "auth_ref": [] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r83" ] }, "hbio_RestOfTheWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "RestOfTheWorldMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Rest of the World [Member]", "documentation": "Represents the rest of the world." } } }, "auth_ref": [] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r250", "r251", "r252", "r261", "r262", "r278", "r571", "r572", "r888", "r889", "r890", "r891", "r892", "r894", "r895" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r192", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r278", "r311", "r312", "r548", "r570", "r571", "r572", "r573", "r603", "r618", "r619", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r192", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r278", "r311", "r312", "r548", "r570", "r571", "r572", "r573", "r603", "r618", "r619", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r332", "r333", "r335", "r337", "r342" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring and other exit costs", "label": "us-gaap_RestructuringCharges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14", "r338", "r340", "r933" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r334", "r335", "r340", "r341" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringReserve", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r335", "r339" ] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringReserveSettledWithoutCash2", "negatedTerseLabel": "Non-cash charges", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r335", "r341" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r117", "r156", "r648", "r671", "r676", "r684", "r719", "r856" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r191", "r250", "r251", "r252", "r254", "r262", "r264", "r310", "r313", "r515", "r516", "r517", "r547", "r548", "r564", "r566", "r567", "r569", "r571", "r667", "r669", "r686", "r1014" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r457", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r477", "r478", "r480", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r457", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r476", "r477", "r478", "r480", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r283", "r284", "r292", "r295", "r296", "r300", "r301", "r303", "r401", "r402", "r632" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r189", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r810" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r189", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r405" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets obtained in exchange for lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r614", "r855" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r880" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r880" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r46", "r991", "r992" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r452" ] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements." } } }, "auth_ref": [ "r158" ] }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits." } } }, "auth_ref": [ "r157" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r165" ] }, "us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCostsOfRetirementPlansTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Costs of Retirement Plans [Table Text Block]", "documentation": "Tabular disclosure of the costs related to the various types of retirement plans including defined benefit pension plan cost, defined contribution plan cost, other postretirement benefit plan cost, and net periodic benefit cost." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r164" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r25", "r87", "r88", "r89", "r90", "r93", "r96", "r99", "r101" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r913" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r79" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r575", "r576" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r829", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r908" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r34", "r121", "r122", "r123" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r71", "r72", "r73" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r66" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current portion of long-term debt", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r110", "r172" ] }, "hbio_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate based on U.S. Treasury repurchases between banks." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r871" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r873" ] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentContinuingOperationsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r301", "r302", "r700", "r702", "r704", "r763", "r767", "r772", "r787", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r813", "r841", "r861", "r949", "r1010" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r301", "r827" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expenses", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r128" ] }, "hbio_ServiceMaintenanceAndWarrantyContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "ServiceMaintenanceAndWarrantyContractsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Service, Maintenance, and Warranty Contracts [Member]", "documentation": "Represents service, maintenance, and warranty contracts." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r840" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date", "documentation": "Discount rate from fair value on offering date that participants pay for shares." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Restricted Stock Units, Cancelled / Forfeited in Period (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units, Granted in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r499" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r499" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel": "Restricted Stock Units Outstanding , Balance (in shares)", "periodEndLabel": "Restricted Stock Units Outstanding , Balance (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r496", "r497" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)", "periodEndLabel": "Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r496", "r497" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Restricted Stock Units, Vested in Period (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r500" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units, Vested, Grant Date Fair Value, Balance (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r500" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r510" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r511" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r503" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Options, Cancelled / Forfeited in Period (in shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r961" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r961" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Cancelled/Forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Options, Granted in Period (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r492" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Outstanding and Exerciseable at December 31, 2023", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Outstanding at December 31, 2021 (in shares)", "periodEndLabel": "Outstanding at December 31, 2022 (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r488", "r489" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding at December 31, 2021 (in dollars per share)", "periodEndLabel": "Outstanding at December 31, 2022 (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r488", "r489" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r484", "r485", "r486", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r508", "r509", "r510", "r511", "r512" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r493" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Cancelled/Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Options, Granted in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r492" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r481", "r487", "r506", "r507", "r508", "r509", "r512", "r518", "r519", "r520", "r521" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "hbio_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCorrelationCoefficient": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCorrelationCoefficient", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Correlation coefficient", "documentation": "The correlation coefficient assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "hbio_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLiquidityDiscount": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLiquidityDiscount", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Liquidity discount", "documentation": "The liquidity discount given to holders that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r854" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Outstanding and Exerciseable at December 31, 2023 (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r161" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r155", "r160" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation", "negatedLabel": "Shares withheld for taxes (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r611", "r855" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r139", "r244" ] }, "us-gaap_StandardProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_StandardProductWarrantyAccrual", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": [ "r937", "r939" ] }, "hbio_StandardProductWarrantyAccrualClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "StandardProductWarrantyAccrualClaims", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details" ], "lang": { "en-us": { "role": { "label": "Warranty claims", "documentation": "The claims relating to the standard product warranty accrual." } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details" ], "lang": { "en-us": { "role": { "label": "Expense", "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties." } } }, "auth_ref": [ "r938" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r190", "r208", "r209", "r210", "r245", "r268", "r272", "r274", "r276", "r280", "r281", "r309", "r350", "r352", "r353", "r354", "r357", "r358", "r377", "r378", "r379", "r380", "r381", "r582", "r680", "r681", "r682", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r718", "r739", "r757", "r789", "r790", "r791", "r792", "r793", "r886", "r905", "r912" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r24", "r44", "r191", "r230", "r231", "r232", "r250", "r251", "r252", "r254", "r262", "r264", "r279", "r310", "r313", "r382", "r515", "r516", "r517", "r547", "r548", "r564", "r565", "r566", "r567", "r568", "r569", "r571", "r587", "r589", "r590", "r591", "r592", "r593", "r619", "r667", "r668", "r669", "r686", "r757" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r301", "r302", "r700", "r702", "r704", "r763", "r767", "r772", "r787", "r794", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r813", "r841", "r861", "r949", "r1010" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables", "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r251", "r252", "r279", "r632", "r678", "r697", "r709", "r711", "r712", "r713", "r714", "r715", "r718", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r731", "r732", "r733", "r734", "r735", "r737", "r740", "r741", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r757", "r862" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-1-organization", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-derivative-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-compensation-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-allowance-for-doubtful-accounts-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-deferred-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-warranties-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-income-tax-rate-reconciliation-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-pretax-income-from-continuing-operations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement", "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition", "http://www.harvardbioscience.com/20231231/role/statement-note-17-product-line-disposition-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-inventories-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-other-current-liabilities-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-property-plant-and-equipment-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-weighted-average-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-future-minimum-lease-payments-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-9-long-term-debt-debt-maturity-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables", "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r250", "r251", "r252", "r279", "r632", "r678", "r697", "r709", "r711", "r712", "r713", "r714", "r715", "r718", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r731", "r732", "r733", "r734", "r735", "r737", "r740", "r741", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r757", "r862" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock purchase plan (in shares)", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r24", "r114", "r115", "r156" ] }, "hbio_StockIssuedDuringPeriodSharesIssuedForSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "StockIssuedDuringPeriodSharesIssuedForSettlement", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_StockIssuedDuringPeriodSharesIssuedForSettlement", "terseLabel": "Stock Issued During Period, Shares, Issued For Settlement (in shares)", "documentation": "Amount of stock shares issued during period for settlement." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Vesting of restricted stock units (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r24", "r156" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-stockbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Stock option exercises (in shares)", "negatedLabel": "Exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r24", "r114", "r115", "r156", "r493" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r24", "r114", "r115", "r156" ] }, "hbio_StockIssuedDuringPeriodValueIssuedForSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "StockIssuedDuringPeriodValueIssuedForSettlement", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-16-litigation-settlement-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_StockIssuedDuringPeriodValueIssuedForSettlement", "terseLabel": "Stock Issued During Period, Value, Issued for Settlement", "documentation": "Represent the value of stock issued for settlement." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Vesting of restricted stock units", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r24", "r114", "r115", "r156" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Stock option exercises", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r24", "r44", "r156" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets", "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details" ], "lang": { "en-us": { "role": { "label": "Balance", "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r115", "r118", "r119", "r141", "r720", "r736", "r758", "r759", "r856", "r870", "r907", "r919", "r989", "r1014" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Other adjustments", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r18", "r760" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_SubleaseIncome", "negatedLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r612", "r855" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r594", "r621" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r594", "r621" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance", "http://www.harvardbioscience.com/20231231/role/statement-note-18-government-assistance-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r594", "r621" ] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SubsidiariesMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]" } } }, "auth_ref": [ "r953", "r995", "r996", "r998" ] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Income Tax Contingencies [Table Text Block]", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r22", "r166", "r167" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r898" ] }, "hbio_SupplementalBalanceSheetInformatonRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "SupplementalBalanceSheetInformatonRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]", "documentation": "Tabular disclosure of supplemental balance sheet information related to operating leases." } } }, "auth_ref": [] }, "hbio_SupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "SupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information related to operating leases." } } }, "auth_ref": [] }, "hbio_SwinglineLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "SwinglineLoanFacilityMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Swingline Loan Facility [Member]", "documentation": "Information pertaining to the swingline loan sub-facility." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-11-fair-value-measurements-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-3-accumulated-other-comprehensive-loss-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-7-employee-benefit-plans-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-8-leases-tables", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r84" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r83" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r83" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-", "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [] }, "hbio_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TermLoanMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-breakdown-of-borrowings-details", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "Represents information related to term loan." } } }, "auth_ref": [] }, "hbio_TheABRLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TheABRLoanMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The ABR Loan [Member]", "documentation": "Information pertaining to the ABR loan." } } }, "auth_ref": [] }, "hbio_TheCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TheCreditAgreementMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives", "http://www.harvardbioscience.com/20231231/role/statement-note-10-derivatives-details-textual", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The Credit Agreement [Member]", "documentation": "Information pertaining to the credit agreement." } } }, "auth_ref": [] }, "hbio_TheLendersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TheLendersMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The Lenders [Member]", "documentation": "Information pertaining to the lenders." } } }, "auth_ref": [] }, "hbio_TheSOFRLoanAndPricingGridCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TheSOFRLoanAndPricingGridCreditAgreementMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The SOFR Loan and Pricing Grid Credit Agreement [Member]", "documentation": "Information pertaining to the SOFR loan and pricing grid credit agreement." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r842", "r949" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r842", "r949" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r915", "r997" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "hbio_TradeNamesAndPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TradeNamesAndPatentsMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Trade Names and Patents [Member]", "documentation": "Information pertaining to trade names and patents." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r842" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredOverTimeMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r842" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_TrdArrAdoptionDate", "terseLabel": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r882" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_TrdArrIndName", "terseLabel": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r881" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_TrdArrIndTitle", "terseLabel": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r881" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_TrdArrSecuritiesAggAvailAmt", "terseLabel": "Trading Arrangement, Securities Aggregate Available Amount (in shares)" } } }, "auth_ref": [ "r883" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_TrdArrTerminationDate", "terseLabel": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r882" ] }, "hbio_TwentyTwentyOneIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "TwentyTwentyOneIncentivePlanMember", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "2021 Incentive Plan [Member]", "documentation": "Information on the 2021 Incentive Plan ." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities", "http://www.harvardbioscience.com/20231231/role/statement-note-15-commitments-and-contingent-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r557" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r334", "r335", "r340", "r341" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-13-revenues-revenue-by-geographic-destination-details", "http://www.harvardbioscience.com/20231231/role/statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r525", "r533" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "Decreases based on tax positions of prior years", "negatedLabel": "Decreases based on tax positions of prior years", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r534" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "Additions based on tax positions of current year", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r535" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "Additions based on tax positions of prior years", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r534" ] }, "hbio_UnrecognizedTaxBenefitsOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "UnrecognizedTaxBenefitsOtherIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "hbio_UnrecognizedTaxBenefitsOtherIncreaseDecrease", "negatedLabel": "Other decreases, net", "documentation": "The amount of increase/(decrease) in unrecognized tax benefits resulting from other decreases." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r536" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r56", "r57", "r58", "r181", "r182", "r184", "r185" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-14-income-tax-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r539" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r26" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt", "http://www.harvardbioscience.com/20231231/role/statement-note-9-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "hbio_VestingRateOfTheTargetedShareholderReturn": { "xbrltype": "percentItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "VestingRateOfTheTargetedShareholderReturn", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-12-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_VestingRateOfTheTargetedShareholderReturn", "terseLabel": "Vesting Rate of the Targeted Shareholder Return", "documentation": "Represents the vesting rate percentage of the targeted shareholder return." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "terseLabel": "Weighted average shares outstanding - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r267", "r276" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Weighted-average common shares:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-consolidated-statements-of-operations", "http://www.harvardbioscience.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in shares)", "terseLabel": "Weighted average shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r266", "r276" ] }, "hbio_WriteoffOfFullyAmortizedIntangibleAssetsRelatedToExistingTechnologyAndDiscontinuedProductLines": { "xbrltype": "monetaryItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "WriteoffOfFullyAmortizedIntangibleAssetsRelatedToExistingTechnologyAndDiscontinuedProductLines", "crdr": "debit", "presentation": [ "http://www.harvardbioscience.com/20231231/role/statement-note-4-goodwill-and-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "hbio_WriteoffOfFullyAmortizedIntangibleAssetsRelatedToExistingTechnologyAndDiscontinuedProductLines", "terseLabel": "Write-off of Fully Amortized Intangible Assets Related to Existing Technology and Discontinued Product Lines", "documentation": "Represents the amount of write off of fully amortized intangible assets related to existing technology and discontinued product lines." } } }, "auth_ref": [] }, "hbio_statement-statement-note-10-derivatives-derivative-instruments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-10-derivatives-derivative-instruments-details", "lang": { "en-us": { "role": { "label": "Note 10 - Derivatives - Derivative Instruments (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-10-derivatives-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-10-derivatives-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Derivatives" } } }, "auth_ref": [] }, "hbio_statement-statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-10-derivatives-the-effect-of-derivatives-designated-as-cash-flow-hedging-instruments-details", "lang": { "en-us": { "role": { "label": "Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-11-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-11-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-11-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Fair Value Measurements" } } }, "auth_ref": [] }, "hbio_statement-statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-12-stockbased-compensation-activity-of-restricted-stock-and-restricted-stock-units-details", "lang": { "en-us": { "role": { "label": "Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-12-stockbased-compensation-black-scholes-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-12-stockbased-compensation-black-scholes-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-12-stockbased-compensation-stockbased-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-12-stockbased-compensation-stockbased-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-12-stockbased-compensation-stockbased-payment-awards-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-12-stockbased-compensation-stockbased-payment-awards-details", "lang": { "en-us": { "role": { "label": "Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-12-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-12-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Stock-Based Compensation" } } }, "auth_ref": [] }, "hbio_statement-statement-note-13-revenues-allowance-for-doubtful-accounts-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-13-revenues-allowance-for-doubtful-accounts-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenues - Allowance for Doubtful Accounts (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-13-revenues-deferred-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-13-revenues-deferred-revenue-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenues - Deferred Revenue (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-13-revenues-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-13-revenues-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenues - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-13-revenues-revenue-by-geographic-destination-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-13-revenues-revenue-by-geographic-destination-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenues - Revenue by Geographic Destination (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-13-revenues-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-13-revenues-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Revenues" } } }, "auth_ref": [] }, "hbio_statement-statement-note-13-revenues-warranties-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-13-revenues-warranties-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenues - Warranties (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-14-income-tax-deferred-tax-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-14-income-tax-income-tax-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-14-income-tax-income-tax-expense-details", "lang": { "en-us": { "role": { "label": "Note 14 - Income Tax - Income Tax Expense (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-14-income-tax-income-tax-rate-reconciliation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-14-income-tax-income-tax-rate-reconciliation-details", "lang": { "en-us": { "role": { "label": "Note 14 - Income Tax - Income Tax Rate Reconciliation (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-14-income-tax-pretax-income-from-continuing-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-14-income-tax-pretax-income-from-continuing-operations-details", "lang": { "en-us": { "role": { "label": "Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-14-income-tax-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-14-income-tax-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Income Tax" } } }, "auth_ref": [] }, "hbio_statement-statement-note-14-income-tax-unrecognized-tax-benefits-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-14-income-tax-unrecognized-tax-benefits-details", "lang": { "en-us": { "role": { "label": "Note 14 - Income Tax - Unrecognized Tax Benefits (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-property-plant-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-basic-and-diluted-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "hbio_statement-statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-3-accumulated-other-comprehensive-loss-changes-in-each-component-of-other-comprehensive-loss-net-of-tax-details", "lang": { "en-us": { "role": { "label": "Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-3-accumulated-other-comprehensive-loss-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-3-accumulated-other-comprehensive-loss-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Accumulated Other Comprehensive Loss" } } }, "auth_ref": [] }, "hbio_statement-statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-4-goodwill-and-intangible-assets-change-in-carrying-amount-of-goodwill-details", "lang": { "en-us": { "role": { "label": "Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-4-goodwill-and-intangible-assets-future-amortization-expense-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-4-goodwill-and-intangible-assets-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-4-goodwill-and-intangible-assets-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-4-goodwill-and-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-4-goodwill-and-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "hbio_statement-statement-note-5-balance-sheet-information-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-5-balance-sheet-information-inventories-details", "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Information - Inventories (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-5-balance-sheet-information-longlived-assets-by-geographic-area-details", "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-5-balance-sheet-information-other-current-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-5-balance-sheet-information-other-current-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Information - Other Current Liabilities (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-5-balance-sheet-information-property-plant-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-5-balance-sheet-information-property-plant-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-5-balance-sheet-information-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-5-balance-sheet-information-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Information" } } }, "auth_ref": [] }, "hbio_statement-statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-6-restructuring-and-other-exit-costs-restructuring-and-other-exit-charges-details", "lang": { "en-us": { "role": { "label": "Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-6-restructuring-and-other-exit-costs-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-6-restructuring-and-other-exit-costs-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Restructuring and Other Exit Costs" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-change-in-benefit-obligations-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-change-in-fair-value-of-plan-assets-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-defined-benefit-pension-expense-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-fair-value-and-asset-allocations-of-pension-benefits-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-fair-value-of-plan-assets-by-fair-value-hierarchy-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-recognized-in-consolidated-balance-sheets-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans" } } }, "auth_ref": [] }, "hbio_statement-statement-note-7-employee-benefit-plans-weighted-average-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-7-employee-benefit-plans-weighted-average-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-8-leases-future-minimum-lease-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-8-leases-future-minimum-lease-payments-details", "lang": { "en-us": { "role": { "label": "Note 8 - Leases - Future Minimum Lease Payments (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-8-leases-lease-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-8-leases-lease-expense-details", "lang": { "en-us": { "role": { "label": "Note 8 - Leases - Lease Expense (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-8-leases-supplemental-balance-sheet-information-related-to-operating-leases-details", "lang": { "en-us": { "role": { "label": "Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-8-leases-supplemental-cash-flow-information-related-to-operating-leases-details", "lang": { "en-us": { "role": { "label": "Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-8-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-8-leases-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Leases" } } }, "auth_ref": [] }, "hbio_statement-statement-note-9-long-term-debt-debt-maturity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-9-long-term-debt-debt-maturity-details", "lang": { "en-us": { "role": { "label": "Note 9 - Long Term Debt - Debt Maturity (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-9-longterm-debt-breakdown-of-borrowings-details": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-9-longterm-debt-breakdown-of-borrowings-details", "lang": { "en-us": { "role": { "label": "Note 9 - Long-term Debt - Breakdown of Borrowings (Details)" } } }, "auth_ref": [] }, "hbio_statement-statement-note-9-longterm-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-note-9-longterm-debt-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Long-term Debt" } } }, "auth_ref": [] }, "hbio_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.harvardbioscience.com/20231231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "SubTopic": "50", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-6" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "SubTopic": "40", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "b", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(a)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(b)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//820/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r886": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 118 0001171843-24-001239-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-001239-xbrl.zip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

S!1;#;"'NU,)_SO\JZ#I,8%\A2$(KLF_!;. M3()C MG+*"<7(>5_A$E!IK,+FH(]11CGX'/)O1 0XR"V)"EX^>:X4GN8.1NG_0AX./!C.4O@Q M(@=G/6Y9V@YCE-<7-#0X=@VMS5(N"E]>B_*7\0V)GE^BB/]35)7,SD@6<;HZ MK-WSDJ66PQCFE:T(SS?729B*2U?"%5T)PG"2J-O=*&\PZP1\'MC\&1B8,0'Z MIOF"\.W>R9[^/DD2]B"@4#!3SUAQG\^*9-=*J5^&^(3A.8(#JB 7G"V%GR[V MG'@R\13$$PP@CI."=H.835*J0@DW9,7X'CY"JENMOF:Y$D[P"9S.L0#Y"+A4 M0I%,2W52^AX1T WVGMB>:D'N,))/^3R&E$]18';!DICP3"CQ'+LWL/V,<@.^ MPG1VGN5T"1,KDY#Z1J-/.D194BYEL(THX= G!_CD@#$E!S3I@L/'A9&1->=X M1!#^O'P\,I#C7&:@'J.JT\UL1E7_:Z@?.45RW%-%\=XYQL)82#8_.LKF<-XT M;AJ8VEE:6"9=NK"]B+Y=U5.PP9B\:RZ:H=IIDX@&775>NJ M9;8.EFU7[:WNN3O8&7#5^,+F1&+Y=-7X:I%FB&7955.L!&8=C8#P,YH4.8F5'/&8S0Z2"%_E%Q9YP>/(F>':$U%GY_P'I;WL+R'Y3TL[V%Y#^LM>%@-YM&H8SLM#21LHJ"# M//=O"5ESGW\*[L-$7/0-L@4A.3B2,\:7)=GM/&?\@.:=9EW:O+_L_655O<_G M5WE.-I^(>!IJM:#1A),0%[)J-XA1/BM,L+QT"\=W>$^3LD "BCVMOFY49FQ= MD]$-)$ ._!>P_>>_#>@W\+'KS.J3A"=U[7J!FA M]]["%$5R:>XF9S.77?P):RC$SP$GXKI\E!=<7,T3(>TJVY0\TCR(6-8VD-]B M9/.X1&LB/4#A 0J42WAS*%^@WF](F>US*B0+[QEJC>(=1.\@>@?1.XC>0?0. MXEMP$%L5' F81/Q_Y62?@M3-&=^@K*7V ]FZH)>4GQ3EW69/I.K>Q],8Q!:? MRUT1=#9/Z=\BL^.D2A>X%=D"N@RW&E"BL;4,MQG,-M_7G/V'1/E>WTSO$SJO:F2WY5Y[2%MS("PO89?EE)=& M05F+4I=KC4$\XN$1#X]X>,3#(QX>\7@+B(?^V3C"P'@?YM\(@^7]V7TCC*'W MXL4A^397!UF+;[Q/A^33W.,46GQJPQ)(=LT]2M',;E?$R1I,_6N0E ]WM8.E M);W-P]!*0CSL?-2P26+J-'MVQ*?@/H:A77KUA MUUQ^NN^Q>V97O"IZD;"'RZ>[5_WPVGE@LW>'!"'"@,9=$E*W-DRY>%'Q^8SN MTBDWGT,1_\QQD9 .(WFHS4-M'FKS4)N'VCS4=KQ0&^K8'Q&F-J!].B*(;2C+ M=81 6V<+T!HT\5N0L'2>$[X$M7J?MT,HU(.8!RHP]'B\XJCQBO[2+\Y @C23 M+>1=+/&P54&49-7#O7>P-5KPI3>,]VV];^M]6^_;>M_6^[;'Z]OB3_T1.;C] M'/W6G)IW/\(^XG0=BI?;6T9=E6.8=VD0Y'B/QGLTN(3R+4[S.XG+A*@H*6*1 M$33,"U:#?,V:+[C;@I>IN"4I]J=&W0%<=^\W>;_)^TW>;_)^D_>;WH;?A#\5 M1^U##6@)V7.UW@6SD/)@+>X1P$R%65'=H6CK=F''L^""Z9'FW3'OCJ& M]'YTVK/5WP=9#N3"()/9X%6UV/-&^K'[6M7G^;ZR0)HV^P MST%\LFEY1_B:TPAV\&<6D^3S,_5Q>%E+IY\EE^)\6R[PEO U%7G)(2@\D#?LS1[3^1?AQNA4R8/H'YNA3ZIUCL3YT'%T]/] M-"#G2G16<4[\![!]X8G7LE=D>B14K_ C/Z]3F/:VR9[EK3"=M\C+3K MF($>^'F;P(^:$>2^9KK[:'3@EHZ"S"XX;PC=%V*%@HH MZF-(HW-P"A86#Z/\3YHO3HLL9TO"R_CL07@6ARUW&,GLNSTT"^=S3N9[DZ;4 M("@>M?H:Y6I+R04<8N>@]7@:)KM%P#[Y^X+7'D:T% JXYBPN0!!#SL,TW^B) M<=MA?## !P,\J.M!70\=>>CH>*&C%@;0"&&@WDR?$6(^GA<^GC\*W)YL'WW1K3W2=D1K]45FA'/Q3M%CW6T#[3*4+4:SE;$\FY$HW]]W M!I)O0,V(N!V<8PFMHNQZ[+D!GC3S2#UB!9#D9;&L,Q3^A<=QHZ MC>KAH2. AVZ+Y3+DFP,5**QEL [AA!=ZH$F4-+M[Z,M#7Q[Z\M"7A[[<\I,[ M&L,C!,3ZLP5'B(CU:@&.$!WKQ0\:(S#6RERS!HB]#[**X(#-@@S$D,YH%,)? MPR@2;Q8#X<&*)530#J=/'M(D"\0Y481[-8\$SOKXE'F K3^J/1!WU$!<_2WW M73!DFP^)^.#O)(E/-MNS MZ+:XSVA,0T[)R^GJ:[CN;FK&\P,7%?[UM.KPCW]_#A_ILEC6%A*0_GUXJD!+ M*:FJ^_O@5-V$<#[5[(W:OYFA1CI#-7]UAZ+>M!J:,K(_KR;Q?T")B)_DE#:W M-DJQ1.+J6YBDK/8(4[9QD[K^Y5$G4QI76/4+R:,S(KDBLYD,+I.5Z,\?6(L?J!) M*/4R];*U8D\+SL%GW-SQ,,W"J,0@TKC\5U(B6)] X0J! MFG": 2]GA:A'5]UX;-!Q!K_LQ(PBU+ZSNEY%V'6%]K*\.T]##UXS.W#7?(H'EUMW5,67%^'ABJ8Y\RN4-MB-:PHHZ=."7(;*[23_/64A>ASP0?,!9?N MJ&/+!3>7#ZUFJ=^T*>?RH1',-V>X.9?EC)-2_=BXUG9X\U?*NE'JKY&]P6MD?W)P,=EL-IU=%$FRF2P9SX6% M^L+AS&Y(J17NV#E\7Q@*Y=,X+&'S#9P*9S2+RLNH8/QMR[8)/5-[Q6XN1S3MLK8GTOMH;]-5*;7Y&5IQ$5"CN2DFOA+(IJV6#(9,+ MS2W"OBLA9#=DR=8D%H7C+^CC-NXDBF/QN-8U&^0#1BWI/?$'9MS+1Y-JFGCO MQ'LGWCOQWHGW3HR8IG(5/#)W8NA3TYI=_DM MF\Q!_=5*#18B5AH1Z-<=UCS M%GD["KTY?M3F>'>K%*25Q =)!:(\K[BZ<%'D!=]5Z=TE,%[0-;F@610F_R(A MS^X6A)-PEDLOGO<]O,MS\P6VVMT#2=;D,QS/"YGIW-.H+L^$6#RQE/W,P,O1 MG.><%3UMAY>CN<[Y'7RZQT5_-ISSO#^P'CE_&LPIOL\K X273]_1^T)8.:6& M>E+:+2=!8V0;,W)(EB#^E&6E63Q/%65\M/IZG,?C/![G\3B/QWD,X3S:NGED M -!@)^](@\Z]^ETCOPI;A\(6;T@K^,HO;-P"7X.)V![PT8H51M\DO&G MVA'-Y&-'Z)WT_[<(.7PZV6RUJ#0FTJIO#^3>D@A4?3Q=$Y[2^0+L^C1,(YK. MRZEB,UY;.KA-USZ(?8#1H1FY8F%Z$8J7$O.-@L#FYCT0)G M%V1R=*G'8\4Y)1VZ:?S]].+\J9 M%N7+.!5;X1.GLI4UYE5-QT2S53E^;D\JY$/>T"*]L,%H=KL"FS>>IG^$ MG(KX@MAQ[U!<-'>WR-MIR/D&3O?)4CR9B^*GOHM%'AK?B6AJ/D;:+>_GJK)3 MY6D1$8_*Y!?<&UH;I?R*Y+FHUU2I2.6YJFIJEF;P''=D(,[8IN;6:3\$029Y M5?#H/)7EI[08P2D.#\LZM62Q;@CK/%;NJU)W8;L= R]6]7$=<5MO^(1QS@3^ M=!JNX"_Y1H._IB&L\WA#Q-0#95VX;![$+)_;J(HX^%]6MW_)C:*I59K5.TG9 M>&QT6]WW-V3-DK60V.?[5OW*'J*/S_,TG^?9.YV'OJ9"B\B:6:-5N0OE#<=" MKX[&\+F_G1DYGM?1%. 8TP4[7.1/X;(R'4#61=Z4IAK3,XYQ MZK-@+Z>*K!XWI;3367@D+_!A(Y[.266C?7F@/Q'Y0DY*:#=+^TC>Z,/F;#@G MH4H/X=D#J&@DS$DI;>\ON7"V][B0S9%:YVY%-K&FES=L]J)?C[I%C3TZIUD4 M'NQ^S=HDHSNI7MJY]"-1+>J5W+52I58ZQQ+67>B0W&WV5FU?[US7ISL[HUQD M.#1KS!]W2FU@<7;'%433:LCO&#AG8R!.*_6E'"1'/=TC]R55VMMG3<2"%A+V< M@F36M;(J=?*,RZQ&,NQ:+94FAJ79\DA^77EDO$.9 JPAXA>EU]Q- M[$GB3+!92_J8GNIV*K@VQ+9T(73M4X]]ZO% JRR1H$1FCI"\8OLZP0*2UU48DNX_3-QG7! MHP4(O_BZ/(Z"[-(#<=MTIS] 9VX3_:;0^8G /,.2F^M\I'(:I^ 29G M30?_WG',7I4-!#I[^RO13E;6V X11N=9[&KA32O"1W5-K-"H#-C5-W*=3JNA MQ'IYGG N;H.4N9*;IR;;'+-2R,]H%@E7\ (\K\\A_T9R<:L*E/",B.S",U#( MLH"-@4^.8PZ_%.(HG&Y.?H*\L%#KTY\8Q=]-5^1KJ^2-8330CV65:*=12 M]UZ*]U+3C$9_A$G1NQRV^+3Y.2VWAHKS9PU\&/H(2E^6/I]P0TE\F.)=;7>I M8RB?_$ZC^0"\D9!TK6'&<";1:$/0B=9/Y92T?;J1!0.QET(9[&T M<+;1!YK^ +DG=7[COW&DM#\N[:]6<9NH%DQ[7+S>9A*N1$N7(KVCRNC#6A7+E, MW2ND@V7>-0/2#&QN+SGL0\#)FJ1%]_OFS2-92/_"$N7SO8XZWZLK1KZ[W_ G MS1>G19:S)>%7-+S?%OTI):PQS:+=(#[&XJ_Z24&ID2/S'C#T@*%C]EX7)6W/ MBOL8T!1:D2 /'[O:<9BQ+%AR>+*\+7?4MIPDZ?UQ13F!WW]49+E+VO3V^1.2 M/Q"2BB],TOC]CQ\_-!'3U*,'TFY(1D S+6#\,]!?"5M5&ONQNO99EEF=,5Z" M^]/9+"/@THH^?"V'YB3\*\GP165 MJD'I9RRAL;B_54HG!8_]M01CFEJAM581X!J/A=[^TUT;Z+ZM3*I/A,UYN%K0 M*$RD9#>V'0>UYN=X=\8?TB+9>(UMAZ>VN,]H3$,.0EFKU]6-S (6828TL?C/ M^5\%78<)S%PVV1?55F6X:O4U7/VI*B<-A\0D@Q,DJS]>)'QI]G:1L]TAVXW# MEZ/8Y52(4P6J)PE[J+E3V:*GV0M'LQF)JJHIPD$!\D3P5#B2-"U@OTQ7A(=U M=E/[ 8SR!^89H?/T5 2[^*96\V&:&JZUMIW)29$O&*_W2'"-+=.MO!+4U'R, MM%N]V/2%I5_K#W=%"Z,4;I5!.K]BHHIU\['7W,$H_;O#1SG)]8W,AQ; #+J" MSR7_L^ TBVDDE+"2<&0O']0Y@HLSM<:5LAPIHH<#',@/RL;V]JEOO$6+[#5^ M3JR>HP+&*[.$U-+TNHT=*IOFN:Z5^Y1:E8"O*=^'R8"N$Y*2&06/=!'F?[(B MB2^7JS#*]Z[/UNF1,-9M,*-\OW9*7_JMIPN1.W:9*H^*ML/XM(9!&<$AD4P+ M%G:-O\80!],++KC$']+E9[HNMHL\UI^O#'FP. MW+BG7N8883UJI_+%^M,U+EQ^[E%F%8:_&"+/:L M8IJC%LZQAQ-+6:J3V>O*_6H.# #EHA9!V2('K*H@<%<526_&626<:';' M7#J)9D]%&/R5('\EZ/BN!+5-SS)K9??&+C9?Q*PUUN/[+1UR),V>]/W4=1G\ M8H;9,\:T(+3BU97"/MJ))TC^7"O>HYT:C.33M:H^W:+"2*9=J]#3XCX"UM)P MK=1.'WD.3[R;OH7\DWA@:TES\:LL"%/QX)8PDN:B2;*]1$V[5YKI^AT+MY?[ M(=G?;'Z#-YLO8<67*9W1J-+\NV=:Z]/4=;KT0-R^- *8BJ=[B7[Q_>E]0N>U M-V ZC3'XA;\S"MH8QI9>]JMO,#A==S1/R'0&,T37-"ZD5R:5[9(-9\GSHAO5[7*VCB\3@GUT"=0)^%V M)P'0IP5H;U*?%C!@4+4;9F4/HO\Y$#AS1520D3ROY*(K(J\YK 4 OA6%'F]_ M@WC[:9B1R_2VF,U8\NVV6(DT>]CC!<_E@#NV3P_D_5X)_V2U"GF8%]D- 6%"^BE+]'LZ&V[VFJ6.@[1C#D5]-8"?JFX88')Z_ MVBMZL2TEL1%Y(\/T"<-?&B=H:CH&6JT"W*=)F&7362FJRM(9\H9CH=?N/(M' M(GE.P;A_KI65H1)D+[/5'/\JP*:X)1&H-)&1<;'^0D5:3IB(I)Q/,-$B+U;" MD%YGJWP)3(P5^0T)8YILSDA.^)*FY1-5(>6E$E<6*.D\GN':A.(-4W$,E2<3 M?_GP]*O:A.KFUFEOJ*S8U&&L]%O5<4]DB:=?XTF^%^Q&/F0=[ 1/#\\.Q29H M;.]#U?YI*BFHZ7;H4V'^,QW3VR6^\/N6X>U>%QEL/)V9_EDXRDAUDQ/K3)P/ MM:%8*S#-JEN!]CX$@*SO@T">T=Z=,D!DR3Z!;@,GN6#,HQ+BAF5M_T5R"C'R@8 MR;U3Q16ZAJ"1/+M6.P&+;"+9'N=6]_[.G)^F8F?"#@7'+272%*^FYH934D1%RKU3 P$0L GE7!27:RT5JDQF=S37W<)YOX9!,I-&PU2(/* M6@BUX95A&SRVI[!HTL*L:F:G0N-=A4!I@,$.!58&^WV.[(,&"TX MPNW]HSQ_9"QW9L37A:_DJG:-U6H.:R%0VXI"'Z5]@U':ZW 3+4CT#7RN MG)35K."G.0^7IR)O;!(IZEIH=NVEED4Y?G8.XGR?T&Q!XCM6/:1RMR!5Q?[I M['3ZQ^69@NRV@YB%RO?[=[+?OLI+PLT=K-,OKE\H0&Y,%R=X4,9E<)W&SH7(]6']&/M.X:C#B+0+<: !UKV- M;SK:X!?*J'%N*S>?*G(6[2\?]N9W#Z>LCUKYJ)6/6@T2P$""9M9"&.^#K%@N M0[X)V"S(Z+RJ>"Y _2@29-)T'JQ80B/QH.6*,]BD^298)663- Y G]#R$>H= M]*\9ZQCL^^:#(@.SXJ,G;S!Z,S(KDBLYD$3J-GCX7:A3A0 M3[6:)0(B#,LM%2)K< HYZYHM#P'L&Z] M#[/Y,)L>QS[,AC8_9)ZSM7C;QV#.6/Q DZ2,^<",P,D@"L^+6S0DSX)9(31% M$"X9S^G?U1NWY'$%(DY$7.EUAW9QM\'I,!]_,\22C\,==1RN,_POA)M@2^PG^X>2+(FG^%X7,B@ MQ7X&=7@>>A6"$:U_22HKI,&Q3H,YSO<=?+F_!7\VFNN\>$=J8LZ\@"!AP\\?. 8?-"G<>DNTC.7:LQTXNAA>3= ME?=N^K2ND:R[]NQ-'PX5DG77GL3I#5! \O_+>/A_98-; XI_#CC)8)ZBO'QZ MK(0T6;X@/""/- \BEN590Q/XZIRT!8@'^[YY8'A@5CP@?-2 L.QB1I9/9S=D M3=)"DM_=V,ZHUWP.^XUM"+D%4KBXAJ9,Z6YH;93RJ=B'-X?;4TEZ4W.SR<#A M1NBA[((])TE">U-SH[0_H^"TTH 2NE5-+=(,>V^2QO [PM>JM']D+WN<;(G! MD/^BJ76:J_=1X^T[HJ=AMGBOP8:BM\=(CZ BF$BA$L?CP9]H".#I4OM51Z$S",WYU&-HN=RH,,83$.IXVK;6F6GZ+*Q=RI+$['%9D+7[Q2T"V M9W%P3U+X:%Z6.LJ"64AYL Z3HDRZ%K_;I5O?;P[_N*!P@O-HL6D9P!B. /,1 MC*%Y\2&,HPYA=,4YSH18"1.L/(5G3F?AG%3R5H!Z:ONP(E(%+"Q7F<[?%VFJR+/2F+>J:L0-?>PSL%[;0[>.\;!!VT. M/KC P6<2BA=%*WOCE:@K,<]68QPWE_YM$_N1#(^B]X:B:QZ#K!?=,%J O8W1 MX!S.WF[AZF:AR=IP"O4S+/$C >@'$89:P\TYN&T0UFLM/H_G>SQ?CV./Y[]D MJ14080U _2U(6#H/?4_RU"@O'E;4%1O4/- 9QOZ/'CIP4LE>'F? M7Z8B0"+$[#3D?$/3N?*I6TP7HSQSRGG,,/!IB!8[J: MC[?#K'EI[]X'6SSMJ/Z_^GNV)D)';2D2FJ^J=71J)I&<6DT1^[U:G7P]DWL+. M(*6(GQY(^(1S4?=;;(:33=GD1#399NY-'F K[1&HR9/XGS+.25*.<,K(;"9> M#'SEJYK^K&N3=$7_*F@LM@/-HAI?WN 7C3I8)7GBPH B,:FVC9W;YD+U5_L/ M=]]$ NX'C4>87F_KN^&?S#R8T50*[T?1\ MUG]YO#-Z0[-O%YR02W!@11$44_.I^JY;LYG)V'K2LVDLXD=?PJ7Z[;HA/^7G M#/\IGX%G']+MG4ZA8$K9N"/1(@5C364BJ1M;IENY'YJ:CY%V7__ 2N9FO9_ M3)Y7+DY+@VY@NGMQ=%$@'27I7&YJXYJPUA"14\&O_J35A3S3'J56@7XX)ZR# M*MBZNAAJ?,5) ;=R2G7:$_ZM/A_/]_%\&4NF0;F11OT-@VTC2Q&P$_Y"3I)K MI4(,QQ60L^3*BP#&(X4N)JL<_'Z;5A2$@KT!DE70GW(J6463:I^L)7O)HH^S4CYNGAVF5X33EG<=\RN^4NCFK%ID<-F3V.:SL$(XA31$FXB* [ 4%BY3X#(HCR* HHP.7X,>"=U_6$JUV7"DSV4'H8*\ I49GZX%\ MY-\'#7S0P <-^D(P<7[%6PL1=/$41A8HZ.M(.E;H?T!?9V1Q &.(&7)>7'LV MV*XSAYPTU]X:MNZ2(>?M5Q?G;7CXU5XH[F- 4VA%@CQ\#(J4DXC-4_HWBQ+M.($U (9Z3Z M[PO"6O?WX-81@%N2A9<0W-#:!&5<0=MKEI5J M6Y/-5D.[,">['?R<\-."1]DQ7(9\HUX=C&C0/N,1J'( M"8[*A&]8M&#%$G&'(!,5[DA<).43C?=A1J,@3&,XMY,B)W% 0BY0O"R SW( M!*;5$O0Q2I-YJ,@">QY@.FJ J7,I-OA\*5)4O#(<;>NRGC]&20%"4RIMMEP5 M>0E=3V?G6ZD#%5Y"U\H2]+V.;;;TVPM23L3VDW"I;&N5ZK-*52#I?M':*.7E M"2G49)B 2"Q96H6T)WG.Z3T("/@&=^QUK.0@;"=ALK^!C<['%Y)?EB&%*Y;) M6*MMXU'>(T!Y7P1)JV2?Z6R[02L)/H@-2AAI.8H+G+XB3J5_6XWAL3N/W7GL MSF-W+UA2G*DC1>PZ:,>10G-]FWPC!>8Z'?\C0^ T7+&1YBVBG+61IA<. !-8 MPU0_!G/&X@>:)"58!W,&6H6"RA%/@Y \"Z*%4#/PAR#:/@43A"4# N7;]VT' MG@[S#C4PZ$*A_335G@DON;+/UNA[8)Q.-O3*I@6;>[ <,FJFD^? M8$D5B)'^ !Y.\L]$>OC!PP\>?C!B"=-M9L]Y^"^S )H6F0+0C) MP;R<,;ZL*J?1= WM&!=Q^7;&>L5 2 MV1>23V2!7'1/.QP!*4VD'S2Q0^--^/ 9]CJG8:(WZ8T=[?#S)^/? M+M-KSB*2Z3'4W-.[/M[U\:Z/=WV\ZV,H:J=YOH_4*](^@48;A=4S'48:997; M=DZZL2O.X/#(-\$J*;/.TS@@?Q5T5?;NWZ_5^9Q;CJX^Y=[S/6K/M[Z00Q68 M)OQ\)QN3-+YEL_PAY*3VK7#-7F:O D11L2R24+R+05:<1+3<"_!S0DHUG,:3 M)>,Y_;O\_?5VBX@WIP0'>VXD[D#?PYN=FR)G2W9/$Y(IWX"7MC-*[47!T[)& M%2 MJ^0 T<,H!]+]=[(I'YN3/TNLT=,-CCYQ>W!R%. D[G%JG1."==CZHP-F6Q^AAE>Y&3[162O6P@IR"J$>7JY= M>-ZZ_U5OY0T[!_RV%'6TR^(< MR28:R3Z1P4W)+?!BS [.;U44,?-3R^J*&. M=^["Q'+MC4'Z^-P[<7;UM+O5K*#[&>6FK.VXG64T*[A. MYOG08\ 1RD&VXP+V;RB*-X":$=,:)J=)"/(^HR16\=?4_VYTC=>!W3U#DT&(U4Z!L72%Y=*[ND8],B672M_A+* MZG42#Y MIK*WM_]X,K6WO_CWV?D+\_KU'SKC/CA*OMY**'GZ@QNXF%O4O!&4[H9D^71V MMR!_,E#D\FQX5;ON/FS&\P/_%?[U-$'PCW_?5O;ZI_W.#I/:-42U'0>U_><2 M-E&]T[J'M-2((ZJM453C"TNWD8A)>0A(< U9,X\8><3(2<1(S0AN'S(MI3@Z M1$Q#&3F3>XE;#R:WTYQ"^?H10\<3)[67[*61[PSNA>8$:?3Y]#B/H>MQ[#'T MERRI#5-K<-4O =F"^\%]]4YB>I/@ 21^^NU6@LFC^*GMFX)]?Z70FJG5FHERGM+I:BQ$L7JMQG",H^7<+IR,+=.62;+A,%ULLS'%[)].)A&V]]J<:3N[J$: M#]4X"=5XQ\0[)L?GF.@<.,X@'%U9Q%H*(TWJ:6W]C33#IYV)X9[3S4G$YBG] MF\3E@THLS5A"8Y%S]SP]HNTEI?X_[) CWI$'[Y)[EUQA>)]4(G0K).A*?%)H M1'GAK:;FUFE7ED%J[C!6^JU6;ZH]EHLTSV[VJNLR/:1=!]S!C&/^+M,3['V0 ML:DLOH?MYF$"#Q,X"1/@ZFXU'A!,7QV/#@[1.RV=2>[06)>7>>MHQ>84$-2O MT+J0!^*Q/(_EO04L3\LP= \0>2!TOA >?+@F/)R7KTX7RY6@J'<,1.=;#L$> M^F1[I,,C'7I>ZI-$?04M=QHFD:B"1=-Y/O_:^]=.^M?>=/>F^YLPW7L[$(\F;#_D2>>>\S,+ M*0_685*0\M&S\O)[ #MG"Z9D 9OMLXVW/7MWBOJ@P2%GJ3]VO!-UU$Y4_3WZ M$L)]RA627Z17-K3LI9QL]H2=PJZ9,TY)I@AEMQC!,H>G8;:8I+'XCZA*#/N= M-#U:UFX0VRGS0%>^N251P9OCJKK=+?-V 9KZ#Z&HI[,6-P&4O2US]N<6L)M4 M>%U)V^3I"$+SB!S'++=L2;*<1J>,KQ@'W7!&[G.L@.KT-5O;]+6V4[\BUM1^ MG-3[E\\\0C0*A B7@='&KF':FWQTV%AGL\^Y-(WFE6*=3B&GP,*AI=N%Y(W> MU[R5:>PQSZ:T:Q=$!ZYOSMVW C"@C MH4UDRAN:Q4<6C./]4.^'HCV]_2-U*'?O56L7*&]XY!;5R04^ MGNYVZ['RNI]%;FX$=#F=?(+"'J?'7X/)@EP@_C#N\WA"A M-7=_% ;CNS:\*H;QN(O/^_%XAL8_<>N_?8 MO@S8HEP<;]/9*5!# MJ%*:WB4<7/\'K5<-+U^S;-ZP'0]CX M3@6'^I''D91S;UX\K,5JEC4?LO0AR^,+6>(1A9&&)5&^^EC#CU)'>:R1Q29W M>J3!0QW$:ZRA0@2H8"V0\NY'.)TX78D'BN;@%3?>JLFW4Q00IYD,TYKCR\9RCCN=T3I\5CP*=LN6*DX4P M;M?;:K17+,O$9T' 7/DI0 MFX&^XO9,#3U'3LV.!QL]V.B1 8\,O%UD8- S;J1@PD!GFCV_Z%TP"RD/UN(U M-YB?,"LXJ8SOL'S5+0C3.$BV:7$4[/=MFS@ W1 &7+RJR87=?A]FM+5+-"P5 M%KPA$PQY1\@[0LJ,IIW3?0I') ^CYI@_ILN8>;":O?!$V!/FN1N)KVAJE^N4#T!?K+W0+OD[2N#%;2K>[4=[V3[&>;/8__DX)!XMB ML;DB:Y(HY$NOLRV^/C\=GQ><_%7 $5RG=UOTM,/19;HJ\JR3P<63WQZ^C+7BM:;1X;QSAN+MU;TYN= MNX93)8BN1GFZ3'/"25;6_KY]"%=*+M2-/43O(7HG(7IMFK:U\LQV*DXWO("[D',^C*"C M$9%1R'KS650W"TW @^O"/N0A[H+DVQ*&6@S'N9#N(*S7@C]F6>]1W^$C#,YI M.93)R?0<5R?U69^V>">EU=/M!Y\MY;.ECB];JEV4T+DS$WN=I3&V:R^EZ7V0 MY2SZ=A_"1 70? 5[LWK73O9[\BA^)FVSEWK[H(5$I9YI]SE)/B=)@8!/DO)# M)+X%624G0KA.#V3KO!(M"3*NU]DH7^(^WW1V&R8D4P9/I.V,4ON)I.#Z)' L M36+Q6! 8E:4NW\Z@D@.MOH:C6"(1]^G\8MN$6WFF"**'"QPH(Z>H/N/FPFJ\ M]X9D1* $(/!GPOUG*T$@9J=H]#0;A:Q,?N$;TK2@Z7Q; I6E:MV%[F>#FWT9 MUTD$VJ@T1Y4"A^UV#+S8K=E%DD30E,:?0_Z-"/HPFP?;S><;8.BM$8VMT"A. M1\W>/I/"9U(L]6PKULJ,<9%;W;W"VIY$H\T@:*5-G(LYH!?K]0)C[2:GD&L# M\NU"&+5'.4?[E,[)-DX%,S28X:0@]WDLN2"Y0ZRKGNWM7 1#F]\6D);9@.D0 M3&NC$Z-+(APV;MHE@V(NC?@@X:(:T$$7;:!;.YQSDLPP!LMGN M3VU#IFW&MA =;4^F#X0>=2"T_M6AI_RL3*2#E$?J+9OE#[#;A7D1B2 M*&&G,7H@_Y;P-8W(9U@P$%Y1IQ0^^&?(>9CFFUTNF8+T-OV[PX89SP\@0_C7 MDSS /_Y]S5E<1/F4;ZFK$8JF9J9HS&"ZMI^O1_Q1;<=!K>6@7JFY+^ (WXGE MGS1?G!99#E8T/W^,DB(6+E"6B8<18WF-PPXC^="%>8"_=SKOZ%(@>K,[T''9 MC/#I[!-CL4K9M.CI$D?*2*16W^/BRJH^VU'&23S)KQD(ZV>)C MNB9<'9JAYCD_UY<)JV":.?]MHF M3*3AI<:VXZ"V?_"XB>J=PC^D11(9;6SK0W<^=.?OYHP$KF_>S4Q+M8X2M4:J M-&=P/]QZ,+D1[!0@T(\8C@"M0RV9VLYR)KL>S0_*LG8F?UZ/K69;?71!$8\E M>BS18XE#I,R3*O+09Z9\PY"6$^11U/F\^#<(Q^VV[B1>BTBD(H5-X1MT9M*MZN9' &Z@^IJMR@4V>D3-2_?7?80Q9#Q9YL,B#1=W (@W[TQDL M78_#3C:W$U 82"U[$%HPF#$.-DQQG\^*) BC,ER5]8",:7[!+E#6BEB/F[U! MW&RR%8D;$A&Z%CI[LI.="\9/.8EI?L6R[!0D);ZK7V2A?8%6NJ;!C:DB3<(/IXO$,CV.>&$/51W/RGIP]^2#V;7M6JBRWM1 M;]"+@BV?QB!46_!V=PD:MCDOPN0T">DK8U6[GVG;54&8W)9%='*(CS_W>_DR MRPK8LVWXD@WB?2/O&WG?R/M&WC.CP"0LN4V=JO2/U!AVI\]F,B->;2/7:R%WX M> /R7KI2F!$=Z"@OZX$0'3^N*+;9[^Z<=_B$Z:89T(EP&% P6[9/F9Q_DBB0O0[ M?.BB->NZ'S#$^#7ARS %]7I&H3472CB#9>JVSJA!#3$(OZQPS^KK9]4BM%_( MIO&,NKL8@C_1)*>UZ]EQ%.V(7YD"S9)+\@L7@/ M3OA !9"W>2;%>E/3[1LNS%(9UYK$_RFR7/@/,N12L[<+G%USROB_2,CW?W^5 M+=5A!!?'$DSS\YQG,GZPW)\\^.\3PLT("P3IN5G(UW8O5"9DQ3@[.1IA)\0Q,I(23.XWH^@RWFY^X ^..&#$WO+R &]SEZ./-'%HKH^\ :61C"N$%CSVW]$103I^M0@&K9P<_@ENT?#&_K MI;89VX)3VIY,[X-Z'U1ACY[M16E7X>X./E\[ESI=QLR#U:ZH9FWVJVA$X72SQ\84*YAXDR%;NIN6%\H#K+10SJ M]B%<*4NTJQM[O][[]4[Z]6I&M-0*:W/,C0[%T->TAA>TV3E"K0[34VU.83=# MB*T+U=X]".=!N.,#X7 VWT@1-EW7P@92!**=L83&\.\XN ^3LM9WMB DUX"$ M$(,8Q7[0]'B0QX,\JB+>V^J:U^%&:-S3@G,B=5_5C:W0_505%'0-CGI5%],\ M%,LB$5NXS'D3&=&<+(3%L$L1%>"]2)&=';RJ^IJM-J.8Y32.:77V78!9]DS&'[FB6GS(O4T;SLS]:H*MA&]2UL4?EY#XK71$,M2_; M&J7Z-,P6DS06_SG_JP %DHC(RB0_#3G?T'1>&C\2+K3ZFN4*=A*M\FP%@66, M< [6Q^NW*C1Z&.=@JPN42R!I9IA6Q5-!ZFVKT]4P!%ZEJ^^CR#NJ:'FM3XJ$ MHWH9Y>038_$#360E>U_^V318'Z9S<5VPTH@P1_N7UQOHUNEJF*T3&^#.=/< MP2S]+)W?$;X\(_>Y2/11S[FRL5&ZGZX,BB?XD"S22T$9%B0<-^ NLH;^J0A\TE# ]")]#<<\3!>D]%@L3=W M\$E:/N_#YWWXO(\7+"$B%\ZESJEI/F"N14##N65$,XL/'#N7Q8/F40ZT.G?Y M#)\-R:.Y^GAXD<3#74@FS=6[0S-9'U1" M\F.N@IV&;M0-H"%Y-5>=0Y6U./1?T<'>=,4$WQQ<1EG+-(]7CLB3US MQJ@F>XBHOG.FJ!Z+6KEFSIFIO1PH'5?6G*':3?^,QV1MK8/:,>:J_8-.)G;. M,L#BVKCHD7-6.H+P9]!-0Z: :^4E'\7E=C;E?FS1)WY0H%6&?6WT/TM=-Q- M:'$&P^F\?1Y#Q *SI[= E"7*V@UBB\]/( ?;@U=D45PD[.%W$L_)=<@U&-49 MQ;6[[5@>;3E%=#;*5V4WG.Y4OK).IK+MN*BV6M:S0^D' M9^L][,&1%].=*6I[HOKXG'&?,]Y$K\^Y[LR(WIYD6H>"63Y[+(FIH:"<@W/5 MZU(/%Z&-$\/@+JXX9C^BZT)9S(&65]M'<@[F;L.UCC/A'-#=AF%]#]&L=/O+ M/_[RS_%=_NDI\N!:TFF7")+AJ,/'8+Y-S0["- [H/H<[",LDX)K?M L@=/^0 M^5A 7S1[6/^H8?U7HE^^8G]&LYS3^Z+457-.2KG*HFV^ZPVI7(9L05=9+0[: M;9 >&#B'^1!Y1GB =?+*8? F7 M9<3W&O8T3)JDPL62R M9#RG?Y9II MH2"4,9.6HQP_IU;C1@I:Y761<)T,5P'=FKGU9.&KG+8;QE=Q]5$R!:W^.3;S M4:ZG>Y#TR M#(O=, 4';Y?AF&Y?[7@"Q7"=L0$MQ7:4S!2N0Q;2\QB3M,LY#R8"WN M[(K[2>*OW:*]?7[2?-RW?^I]!/BH(\ ]/ [V(LEP$N5%F-R0O.#I-"U_HWI, M47\ R_R5-:"VZ /XYN?5?I/=!=+N;YF[@U>>6RR=LK=ESIX(VOXR$]40T*RI MNSO#VP7CA,[3JC)+M#E(\=[EB;;@&#^H#TSXP(04RQ@Y$.]Q)H\S.>;*M3J! M1PHUM3441PHZM30<1XHUM;.W1HHZ]6EJN0S-['[/[A,ZKV*RPX$RB(\Y"<>@ MZ?9 C =B]($83L-$V_.3]K3-T7+W3 ^;I_1O =B?A/#[B-PNB.HE^G;C6.9V M^^-TKQC0_$E[>G!I*,Z>']OGCY6"OX'3X+2JM]9^-3N,;7E6+L'OXR3+3UF& MWYQUG9R!U\8.'5Y7D$%9#. YH0?R-@"Z75PUTW>WDIRPY^ M%=(B+PJEW=GLRPH/L-$:P-K:-H9QSM>3=G/[50F2H_J810Y!KY$3H:!.#_33 MA'-AF A5=K)Y:G(=;L2ORKFO*EI>IL!045ZN+^M"WH%!,UV5*0I@]LP(S<7! M=TTX9;)@B 4*CFN&"S@K_@0+G\%AM+>X;$V^%G%'LBXE M@YDUL:___%'.K7MBWY*^(UF=+RQ=PQ%'XB^%XA0T_OUCFUWWQ%Z?M"-9DS]* MKJWI^OK/'^7D;Q^J\-N,F:7S^N**\RD >2N1UOWMQ=OOND:52K\-Q&4Q7T'?!+HYJQ:9%G>9B*\A_#6'9-WQGK;%G8SYI? M=VMF,QES3WA?&HOP2F,9YR$_Y><,_RF[>9RM&<*X\[WLYOXI\)FR/E-V'Z > M7Z9L?62'F=3LHTVN543%G,NI'7096:N8FU/9G%;W@POYNP[(4)=@N4]V]LG. M>AS[9&=MU=8-3QAI:K05A&"D.=:68HTCS=1V+T XTBSPP8'CD>:$6X-#1II7 M;B=+"#E9O[[1R1I&A?WV9F93E;2 -50-XA1.S=8PLO?NV Q_S?0![#0=FR?0 M8^P?.X5OQT%H2#_'3MC;\1':IXS;NS_W,: IM")!'CX>_D@>Q=20MK?A-(>U M<+>M%87^IEHS)CGBFVI=@[/5%>G\@H#F"Y-2'<&Q= 4?3^["Q_-*LK9W;"6A MVS9#6.&QNA2NRU9#+QN<7)9[7Y.1ADZFB_D1("KN(G:MQK##925">JNFU]D* M7^T8S6D49FVYBR(PVV:AFY(PV0:O)F%1Z,M^M1_F/[H*ZH]930\)XF0 YI73VK MZW=L XBM2?:(XE$CBO6UKW:*#;;]]A7V[1-*-P2D00CK*?SUE>O.=!@C.CMV>:. M=D'2:M*^J![$:NA@E_Z#^<5R4-/%&1XT%J*^EQ5.=F*Q+\Q]H-$;V,%TM*QG,I[VN)( M2WH=DL5#>QTG:[(>/O#N ^][E-H'WGW@W0?>3<2XFDS\D879>P131QI\[^:1 MCBPECO2&, 8W' M>EU7&YD8ZX7;9EQV;/=@^PJYCNTZ:S]!?BS7KII?V#@UED]7C+!.:1!89ATV MLM3H))9!5XVEYI@^ED.'K:2NO+UWU0!JRBG!\N>J$81*U;"1DARQ-&,)CGLI:4' M^S@I1)',_5/>B1"H.W9&,P'HT[0@\=9J8B]G=+#Q>TQPE-R=V-.%YK.7 8T& M(B?Q?XHL+[7"'1-OM*<13<@7LKWL)?#U.W8*NN*:LS4%O7"R^9H)!O=6\J1Z MP1MT^^0^RWD8R=):AOR4V3E[)LT7- 6W'J@34)STE69$%[,U*V">Q?^+6D3K M,"'EMMO5\Q9_F*3Q\U\SV9$NNOL$&$X?67%243KM+*JB5$:J^F9S@ZG M;)HZL O=(I0UV&Y)5/#R0+E8?Z%?4Q#OA/Y-XBMYRC.^HU%^/H&Q*CX^ M36]A$::SDR(#%TW*15-S._5>2'8=TEB>#"QO:)K>%_IP$D6EY7H=;D1"R2YN M@TEB[3:8(WR#-4=@]\M3V72Z6N;I%#24,"W_I/GB% Q6D#B^FWE9?GW+42QS M6J?*T RJ.EOF:Y?YI+/I:OI8YF+O]9R&*YJ'28-WI3^ ;?X$'+^M+%)[![)- M5Q=X>HH?M5#^C2,8YK!*PF@ZEFM;&:44OEL''>P][2?H0,*$_@".\M>@)]H/ MY *_E^7C*1W64S& H_RU6T_$0"[P6P/MZ?&I&,!1_MJMIVL8Z#/85L[*ZS9& MJ=Q677^**(#O*"SR!4L$/G'!>'U6I82AKL-9X?V.32*PU3EI*#FAW<\N-[!! M8$OD&Y&VDHLW&^"WJHO=^@.8Y4^D]),XN^!L>49+W2WJ_S\A,V7H?#H3NJ'Z M.Y&5%N@RE#6>KP1E0%-=N2)T>VO4EP^@;A]OV#T-@ED>93^CW-R0U7:#3&>8 MM6AL;X]ZEL[O"%^>D7L4\37-S5X%U3F!'#I?_)7;\F_^RJV_Q#!=@>&&,KM&]GEXUVKX3.7G!.%05E^EBLL2\QP3BD,/24#9THZM_=, MB1@^]\ZY"@&FI@CC5CA72<#(?NPQH]>Y @6FI$LW9F)JI-EH5S=1!, M318NAO'N:T^ ME.SC$T.=L]GZGA*--$OGS*]!]D=SZIASUE6W>6B;%^+D*>@@X7I4OH:#501 @$'.MEF:4F80?8RRXEX! ',E)GT MRE5-"PMEFL12"^#DM+)_0:R?#. 3,F,BUK WELX?86;!Z -KBV]*?/8+2X7E M#$<\D#;?&9,2C@U\T4ZAJ^=)A$KNI:VM% *I:-H2!#/+=F'6YNH@F*Y&>;H" M138OQ>B6Y'EU/4:M-Q ]_"7\UU0>K/4S(9!1W-3>#>J;ZCA@^QGE9I\6L25& M)C72=G:H;91R14NS%(L<'%V!QW4R?*&Z[FE!-1NH/H:Y6).T(#OCX66BV/GC M[C:-2 7(RLZ?S3T+G MBYS$DS6HF#GY4@C$=#HKO=%L6N19'J:E_*H/M;;#.,FKRF-O-88O$^#+!/@R M ;Y,P N6.ML.SN4@X?C&@LW.91GAV)/"<<[E"R%W'M(2="[C![E<.IBOE_?VY>%Z1 ^?J%6?O%(S=1=@&]-Y6I5>BC9W/$PS4-;B4$GC\E]):4;O M*K)-.,W$I2GP(=-Y=2VM8;T,?MF)&16TBFM)%PE[^)W$<[)G8 9^Q0V)DC#+ MZ(Q&X8Y7[:GK\@EGYJBEV-1U=8ZG^ON:#0D8_0WLS'Q<5P%RD,"RU34#.DE. M>6D^;'U/4<4G>RHLV4$L>OB:3XCRKVSLO12?/N/39WSZS,#5FX[L.8F^#W'G M8)\>&41,VV!.@G,;QNR\]FHN.;=5S<]E-V_,N;BC^0GL)%GF8I3#3 P:TG(, M],Y$@3514XSP+"!E>D$OJ+=B7%=@[T826^#>KJRZAQ%MS< =DRQ02>[] M2W)OQ-[*:$ZV.>:5!M)V%HB1B M:ED*ZU ;)$.U'1?5O<7YWEY$:LRQ@1N2P^*3>)?%HMR@ZL9FD=V7"1 M$174[?);FN%2D=1C&3>6,USW)-RXL9SAN@?1;A['/+=;).G\&9!4QTYM0\OT MEN8XFNAGK6WE!?003F]A93D7S%-[W P-)AAF3)TYH+=B^NAF<2XULX%W?!+V ZSMY;>4Y-YU>\>]4D_;B@A)$MJ$,DYK8-=*+5U MYIRZT6"K@WOH7 2_$]M8U\&YR\(]+#86^''N]G#W%4>" DC.7:N[TP?JA63= MM7H\/6 B2,Y=J]33/?"!M3Y<*^;36^X$=@)ZZ'\A&NV7*# MY5^^<])\:T(=FY,IM[\7_R/V OSF_P=02P,$% @ ?8=G6/&'-N%/F M\78( !4 !H8FEO+3(P,C,Q,C,Q7VQA8BYX;6SLO7N3XS:2+_K_C;C? ==G M([8=(8W=MN=AW]T]H:Y'3\7I[JI;56V?N8X;$Q0)E;BF" U)5;7FTU\D0%*4 MQ >0Q(/EW8@9MTHBD3\D,A.)1"+Q;__SRR8ASS3+8Y;^^U=O__#M5X2F(8OB M].G?O_K\,%\\7-SO4O;5__R/__/_^+?_:SY_3U.:!06- MR')/'M>[-*+9)=M0\K_?W7\@<_+MCS_]\*>[C^3SXP7Y[MOO?IA_^_W\VS_/ MY__Q;TF<_O83_&<9Y)1P$&DN_OSWK]9%L?WIFV]>7E[^\&69)7]@V=,WWWW[ M[???5$]_53X.OT9%_4+SX3]^(W^L'SUK^N5[\>S;'W_\\1OQ:_UH'K<]R!M] M^\W__OCA(5S333"/4^!("%CR^*=HRKHE2:\T3#]4E ^'Y56LVZ;A<>=6,:, _WN^[?? M22/[/^";OU^R<+>A:;%(N;$HXF)_DZY8MA'VO2(C8,H6E)Z7L!*8)5A6=OBH MRYKMSI,F-Y68=,[^C.9LEX5R4N6D8=JGZ?SSPU?_4=$FG#B1U$F#_+]]B";;8TS068199Q MKE/ ^FY_>.0NV OX+T$670=Q]G.0[.@BSW>;+;R57WW9TI#K_&7\'$=:+2%TL&9U#HF2[CE-6[W66[X$;F)GW8K58L^>UA MMX6U4G;!V5E\I)LES=K<-M5W,*[;4-NV-0#HDS@E)0)202 " _E5HOC_=!3! M4K^BTE5K\99[[5/MSY&,KW\RB%F1$'K-5AV]_H-[IU59Q!B*OR.5ANLC?637 M<1JD81PD#WP,Q,1]28L@3O)'OHC:!4F;ZNB]B5$@-0JVU0A0D$=&:ARD!D)* M)*2$XEZX- >!C>#L2$%[*%CXVPWW]KB#M\NXILI8EG "Y=?7+'N@19$()&T2 MAVP"(WJ:I&S+( :3MEVWWF>$TR,P$4F=2%1$PIH1 6Q6_0WJ,'I@^]3#S&@YBP;>I"';T,?@RST%5L9)+";Q^FL(7*8Y?4=3NHJ+17%- M(YI)KWK'Q7I_>+\[1&^%!C+N:!2+;0V3Q$@1?"%+"8CP+[8[R$D)"K*2V"!_ M18(33T)$TTO0S,XP,R=C9VMZ^AXT?K?9)6)CFW%'-YO#$&9TS:'&SQP&RU$3 M$ZIEHU.2%@(GD]'W?#):'#"16\!$+IJ8R >.:4+3$&X8!R>@$6/S.G>,[^/\ MM^N,TFICQ]6.<1_=*>P8M^&SK8M <[[B1$G 1M35X_ MS)\8BU[B))D':33G@\GQQ]QBS(,\IP5JVM)LT^B$I4C;R53U Y^JWI=H"$=# M;FHT9"'03&B2TAVTP>D)-1*VQ/R/\V600+[S/%]36G TAUPJA(2K-V=4N(?) M.I'K/W*Y?B>!D < XC>KSL0H#4JS+NMM"?*?YC _9+NP$)%FH5K2]:-?XH+[ M?SG.9B/:-2K:&O2=R/B?N(S?-Q$) RX7&U<<$5]QY).RWY@!')1Z]*C8$O\_ MS^EFF[ ]I?,R6C+?\L%#B;QB6T;%?("F$]'^,Q?MJQ(%*0,IY Y03$B<50=G M4(2U.&Y+;/\R3RA?!Z#$M.-=HV)Y0L.)&/Z%B^$'075"8M?%[$$QZ^6@+;'Z M<9ZP](DO&3?SB"X+C'3U-V%4R-I).9&U'T'6./$Y4">7G/J$9&Y@" 9%3X6O M(R5PL6%9$?]3N+NWJ\,R5JYB;](PV4'RHDR*S>]I(H_,7<8YYTH1ISL:W6[A MH&W'Z2,;[6-DUR0.1UGN3X)=QZ< 3H<3&F0I1YZ3@I$@$8I$11H7N/VMHD;>I"S= MKO=Y' 9)]5U0A M&?F3Y#"UQ(_$%-3/T-&!V;F@AY&9V@"R[0RAB M2O-#'^^'9XA!ACJ;(S[$P1($/Z;YQ2[+:&<=H>X'D1;XO$%797?.*6,*[IC M7W14GNR+[\,K))0427( X642Z)$*ILXJ=QY1N*;1+J&WJX\!I#T!HML5[!X_ MTFP#>\>/H(Q#05]L,UA?19.<]3/3)1[8)SH@@K_$/OQCM0]/?A6XB.^H,7JX MF*DQF,3IZ6T&VU+%7N1(%2+?C_YC%V]%^)C]GRWODQXF,\0PH5GET$>AT(]HCB!,^[S*LMDSO5GGL.JW/X\,Q:1O[D'BWR:\U%3 M(=]!;\2,="E[0ZZJ_*,[FA$1KWG]4]1HR3,[;9D1)\^%%<(UA/7R>9QRQ.%: M/,)2:(7WJO,MJ._/?X?@"L;>>,+FH[B#J3Y,JCP$?^Q"]@MR\:YXO\1#HE]@ MCKK>FY%/5#P :4]3-$>^!--4N0H[TN;M^+SL#O0F#+)L+P[1R=+1'&[]+L8" MV2'M]C"^%L2)G-FO+0<8CHL2=EG(' Q#_?84K8,EH1E?#&"$)#A;28LY07DS M9.!IY/JYHU7;NB&G0^T=!%GE#\D#TV20MRGM_!LKT]<@&;=352>< MZ4Q+Y]^]RBEH>.#'3S>*H^EV:CE:;8*? 243%_+:% M]QL)_^MR!7[),:9\;=^L73$CP8I3(_56WW?Q:SS;_\\4]_FA'>/*3"\9XG M?M();=NM4Q?,]FA[<^%6NV*745AAU<LJ@[;\3]W&T5(WW+LV(RDCK)L M-:0WK^-MWGV_'+H1U%W!NL3L7XMZ $0.B+ZY*"&1(TSX&^D<='SD]3TY%&DX M\"*H04)%@PHH=Q :2#W4+L!+*S,S$C[*E\;I,W^.9;"?BYFFD6T[*VS:@L%_ ME5,1;:EQ37*BQ([KJ%*H@X/E0T.,)[6:(N9,AR:3LCJD5*\O0]68+(S2.XOY MIP85L=R^KW8S#ALF>N@2,4CS-8?60 M]=U^TE64>;B5)USAQ*L\(7LX]:J9)VZ2R.C,=1^3 M:11K\$4'6LV%^PM,B"L.C9:\>\C]$6'3K6W4*)948::&9B M5JH D1H1?G_=;H]';ZWG%1,VITQXJ9@05B ][*JCY)*-9KWS6?%P!*E1UIBM MQ*]C\N!,$G0S.VH \S]#'@[C-:IO\U4F_#[E1#:C8H&?*=%C[2SZ\B(RU*-*RGJD$]FY+H?D9J+#/R^4%QXK04 M2]$; C:*KR/GC)L4EG BY:M..GA@JX)/PS!M+<*0YKE(;NGVXK!M8"R[+BW[ M-\+4>&:'M(T9J3!)IZ8!"^_2V>_Z:+/ M/E[U/5LF\9/,ZK3EW2F0IQ37]A61)USX=]SV&DOJT]VR(+-,7QN#4E@BQ^WC(#?_3 MYI]>Z6#*/',^CV0T9$]I_$\:B9(E7,E8$D>BLM'11K?A.05-ULW\H@W/_UQS M7T,6Y7P:D(\S/U[9O(,7%/P<-'+TG>OP"XV?UH N>*99\"0.XU698F;55H>2 M&TU50>1?.7\I49*%1'F4]?BJ]%%+ O JJ#^LSK6N$66$/7(189R7UTL+F!![ M+'?KRC<-:Z,)!&ZT= Q2_]K;",>+L ^@)XL#>A&D+[>SRW=?F58;D22\MIL3 MC^E?-P?!I6+?B#:)K*5'ONPM,^O>PXYB?I/>B0O?JYFCG#C$CY>,ZYOBS<+VWYKO@R#MW7/1@ M3LIK.4DB>+=O_OC7"OJK=5F0 F3$7QDC%2-UOBK>LHB>80;HVTM MVA;ZNEQ-118?OC;5@=$![+KF3% B\1"\'I /IL&SWX$#_C/WQ&@T70<'$[WSO]# WM/ M-:-[B9T4C-Q6V*M&)KUBL"!#ZLL,6X+Q.UB;?&+ILP@M3&]EH@]MEFU/20?2 M)*]IG+;(XYZ;N4M1)DYM.R.LJ+5 V?'6E082V=::$6M[Q'.Y)<8!'@OHB M._R%SU-CCZ&[*65/R!O ]_6,5&RL^D0:G1)!M4:W"/2K?).4?2.R[39D) MMI4]&.E):35MQU%2@N#>#RKOEOXH8949AZ783-S-T1M4=2\&,5*V=.-'<+J/F=F.X;>SM.G7SPSPJ_K,) M"E$#?(0OI]JD!1=NB+13SXT\-CPW\<_'$LZ$_37EP5-TT_1&Q,/9A$MN-I^Y M)L,>4:V@ZN<,U%X??6:@GXS+VQ:,P/,I*HUHV:JRU$#BQV6^_%3:ZQG3TUY&@3]%TXT9TT(*/&"9'6L'] MJ#E=K6A8P-K_&&P>/Z5BCR_(&YN 7,6?8*_/L!)9 6)3YXP"]J6BCVM*KD0G MCF>FG'^N.D&"O+&Q_E?9B=>FT7;$2]< 6)09:_;B;;,RU(8&^2ZC$D=9.PI* M7R9QL(P3<2U0]4PT9^D\@*+4NTS'M=?^]A MSW\IR[!!$MV' _[JJ8A @AW4ALV""R'Y'03JCTM3.H_3 MMY.?7)C^&*:O(AA5Q=?_"@D>'8+AH5RK(R?@._X-'VMQU'X>-GK4^?V8BE'F MR)F=VD?#-*]MI+I*,/\E7)\.5?10*=.[Z[-, CZ1YN&: M#TH^^O(J$X1N2=VRE42KOU2FZ*D3Y.=! M7IZL!U!TQ 5ZGL26MCEOT=5JNX4T9F$\K@=CUK ?:)[_5%89*M.%TEAXKV<(=<.0!0G;7C5< M4;!)PK80RW)WX5&YNX33-UD"<%Q_[-3P4ZVYY[2GK @23$^/AR\N>PK#Z&=K M4$MW%$H"=K/5Q4P9) E[$47_5RR;1VRW+%:[9!Z$(=NA3R;@V[$SP%Q1JKKQ7-( M^>=?D6VPY]@2#U= Z\HK&S,\+B:TEP 2943._]BYJ[LI:]/4.4DO,](O-8S) M3SX]@Z0USPQQWIKL_C"7/NV\X/Y?X^.H!'#-1LW*LR)Q-Y+] Q?GSC M/R:=L*T[A,/2CAH7YW*?\(PBXT8<>(/YUXYZ#@\.(#7"O M2T]4AAFO,\ICYT9_N'/: A\FW-H19SNX)!C66 >/Q^L=@HI%E=- XTG; MZLTJ^+/CZ/WT]0PSZIHJAAY*-]JU2V&:?4KC?Y80ES2E*W1:.JYMBYHTB,&3 M_GQNX!)?O2MQO0*M41]735W1'*SIGUPM3X9=?:%9&.>T/A?_"-MU-VF1Q6D> MAU9N.4:0=GUB50/BY$^K:O3%Z4E5JSQ&[*\+E&VI]XV^0%)8\[FC//P9*;LT M(W6G#D=;9Z3N$U%@]M3.MV*4UL395K24C'12/@;9;[3@J[0H!@"'8U+B&(8X M)-6]&:C],L;-4"9BVT))(*1&TG6F#+TE:+&GHS<%&U>[D>QP7]Y&\B2L>7(X M_$7$P10B#G]YV/C3ETTV;AA&*B)XJ?DCNX[3( WC('FHW+16_W_X:8RJ=;?J MPD?/R2,C-6UR(.Y>>!38RS1Y9DT\%DLNGT%X>KA*\RVSXE*U[E5LR*\5#+>5 MLG4Y/RQ)[>P<*5'X9;?C_S[F=\19CR%^Y8+BQEJZ6R2 8CLQ;@V!9R6[BU_9-)\ ZQ MXJEPB_!H [F(^DCLY @\D>AA%53B%UE/=0_$BZ^TNSG(X.KKLB(XVKLS[A<9/:][3Q3/-@B=Z3S=\2N3? M0[X)+)5V00(5(+[KV]3Q@V3,'H];Q-:/+S9N0 0/L@I^"W4-"NZJAR+.1KY_ M.R,@3.3-W[CGY+%BIB>).=U@\"D&KV;+M]%3)_N\@_0\;>YVXIJ<>K_*G<+A M83>X/:@XECX\7Y87?+5Z3XM8WE0"/KJVKZO1R'CO5H&84W\6\,BB114BL<:; MH@.K,T[M+JLV\SW(]$($NO+[.B/J)BVO:7Y84UIH"C>JM=%2KD75I;B7P,@! M&:SDJFNP!;CI"3YN#%LU8,3 ^%"%0[7GSWQJTA5]E;?'BWH?%=NB?&Z,V*+1*>1 M\895@9A3UZ'&,_E]$*UQ:C>UVLQ_C1&:DUA4%2JXR^+00;Q&A;K_Z$T?RM>2 MG:_8'1\)^M8XO16)W ]%D!5Z>2M' ;3S>-E;<8M4Q)(DR'+"J<@;I0;"XZ^2 M>5>I9A'S =9]AV+=]".02H;,3CQ2?=C=S4_@#-)H^ *"[@>Q5O^L0=L&^F*2 M]?I[&,O4N34RT?5JM8(*7E4]RL?@"]3^."[](;?0;]+^/"L9LVG+';6>Q)LM\D>_ Y! MF[^3%W%(5C3B\V)"X/3UCNOROMD@%-O)9:5%J 9R7 28@$DEAZ(@Y% 4A+LV M118O=X58]?+W@62H(1$>,FRM64KF1&BGL[C.!WPSWJD5C0L^L]:'26VLLBW! ML+7<-@S7NEL'&T))0J-O2F T>E5+%UO2H;.&L3KD#GQ3#FD3I!ST93V104'U M<XM;K.E?$&XY!/B,I+6;ET18K?I+A/O^W8Z3E&&T[!WVB+I": M?NKX/!H"Z,S)J5)-?XF+]<4N+SCVK*I?MN^/V>B\BG0F5$A8=P!*#*11KEON\#D::]K%';KVG.1,![55Z[$QDSN UA4'!&^O.JQS/.>E*?;FRD5EVP3)3:@8 % MHZM5',;G\Z%KLI@U@0-X]N?AFBIW.6NRVDN%2;("7PL@;&<+"6J0W-L/"A+G M9)?+%-]GW@EY)(0[['*O*B50-XN]I-(J^CCX[U*#F"]9<.99O6HF3A%OC M&RY6Z5/,UV$R<^DRSD.^?..V>BC;#=<(TG?1(V;;VE1HQ$K[@*=*=WOT$?C:Z%%'ZFQE*2!))ZFJI?M[6E5:D!V3VT!8@1BY8GR7!.%O MW!9Q+N<2"=#@#O)'%M&DN_:NSGN8-9M*^[8U0V @)8BRZC0I81"! U]LUT[_ M1M?9;>OR?%MV>0/0/"R.M&2-H1G\>B;:LS+=/N9:% A?TZT66.N'WTIBOZ]< M"IP\F)Q"1PSRR%FTN@SI,?C2N/](',J-"_HA?J9G:\NV275$,Y@Y%D%.7S4X MZY=,MV1JA6&> CND=8A"'F!DO9TZZ2KB+QC!*YI]GUL0DAU2Y;(NZ@VF_?G M&:;!%_F1;K8L"[)],Z%"9F1$9<=(A^QX<&#&Z#4S-8KN3L*7UZ_?RWL:&FC[ M4RJ4W\.>?1]JWY%Q:\YNF,-R%OJA9[F4@?@YQ:\L1@S-4RONPDT:F7$8%!LR MYS(,$'2D5P<4EMT&X]TUYC@,()MJ_Z?C/,3IJW$?5+6\WX'0&LN19@_*>7Y@ M0=H=56Q_ F.HCENRK9) C0 Y?$!P+&!;5VR)$[P)!^9!\#O$@2FPS)FW>TFS M^#F Y&=(_JI3(X:V9U5?0_JZ0\W;KT=6TQ=)!(V[ [RG#"BSGF'YZ4SX[O@Z M B+;4+VR+ %75H!KM;&ZKR&%;ZAY^T=L!'U9FDG-(%L2-65&,RSWG(G:!\H= M GHKS[BD3Q]HD--\R,JIO804L_[&;0N9I Z7T9;TB03@W[XI,IWA.&ENZ2L] MS -5EH-MK2\BRH]N(AI8_:+:&KD UJ+I: U\D$8XHR:FWK:+L,8L!"UW>]Q: M6 OU2F$O&?Y!WS_$H@U[^G:62QQS];-$8UV82'6P.Q< MO@Z7K>7'0N9WI8RS""V+Y1$C[6QR7H2A*.=\%^QAT/KC[/T/(R?C]D9MJW]% ME6PE62_S[0 _F1Z31LZO=QFH:+$']Q$JST)=6G'!W^>'5*AF1.(B IAV^K$G!B /V03+71)D)#JD_/,Y8R?[ MGXC^\[^W-;NV-;MHU0)YA<62 M)7#/E7VQW+-; %D>&?5=]7@<;^S4-U;BS$1K#'0;$3OEB]O&;W2D;5GSZW[06R5U+,&K==B.PTM^W/6>KC)U%GD24IZ';2^1XU( MBAO'[$Q6?/IDO3SME!>OOM@M++4789CM- X2JKV$E*+^QEVE>0$(C)=A&CW. M >M'X44W%&6&X5CI+B&<)7&XK_>D%\M<5+_N4)2!I['IW^VMNA*N#O(8;3'6 M$T2LMLP5@IBD@.&K\/J0C#!-=HT]0Y8%$?T4;(3_>\>7)VF1]YPG&WP:=;:L MLU7KY\R ,A&D16RZ)#[BU)G!KN""]#>-8V=;>0>6N*2#D4)T-JT[NY7P?)Q# M&Q8CILE0=S-"QB![]Y< UIC<^X<)*T@NDB#/XU7,UZ&]KI3FV]@90XV*(^>J M@D%"ENN=F;;>'^2,J ;'S_2B*6!L))>G'T66J0"W*_%KOG@.X@3R#*]9)DI$ MF@X>*Y)S'3,>@#7Y4/$ ?J<18N.\1+BS@O9<0"--^*2!'V[I:CY7]H&(3LR( M[ 9LY\N.D+HGXHI1T9?7&U56U4,3P60M@7!YB 76TMRLKV@.1V"#Y)H.Q7K4 M7L(?:NEIW)$[TJ1.5G1H&>BF)SAKVH_"U^$=%?EA.%9.W]N *PX@SG#-N?(Q MR'ZCA:B.>0MUV"$6VZ$ 1/NWWL &2H?:= MA1*&@*#")09[-R9UY2+8QD60Q/_DFI^S5<%EE9*(/M.$B:-_*@$A6V$290%C M:+XZT[*;-)3I?D'"+<>&I>4ZI%%VX)&=FXY&(? .-337,%)/QP-PIQMNX%&&AQ3- A%V&D)'11"=!T=V_P8XPQ4&.%L M$ <)96[*?4BFFWSC0P9&EP.-SOM/J(1,WBPEZ*\;!Z>B!NZJ3!!+?18!&J?F MIY6 #(R;OV5,9S4+U?7,8 .F%C:=A+RM<#H1&5GJF.CO&#.WB*)8*"ID7/36 M<9G&NF=8$/L60(K<=ANV5;B">7D:0CED_@\?*3+9_IB K D<3J.O)@"C0ZU^ MN(6.JRX5XZK+MKCJ 7=]..AO-,@\[N :U9G3F*GYH1VYTOH8I_%FM_F9YI!O M>L]GD=O5XYH[.]D3Y3.*0+1F242S>UKL,H 0@F_Y=+HW9*@US!H+3]7) @L/ M3WNEX9(3"'M1PB,E/@( JQH-%4;2 $DDRAEY)2P9O?("1FQ*)FUK(.2YY%<& M_&I\7[*NJ%B7-UB7B=YX6(,9L ',\-B-M)'BN ?XC3)TWIUSWOL@QK*U-FC; M: FBLIB )(O/,3>$W]8%)R*<(Q8\_F[XZ9<9ILY(9RN7DZM5CS/*&H6M!DX@ M89M!KD-TR=G6L@K//)" 2"CB[N7>PD]>_%_TD#!3?'8FQ%=B4^>!AKM,G-V[ M?OX4?TXS*O> WP=Q"M6^.T17[V6DP*H1<7;AHQ(:U)V6EOJ)\$\E%'+ ,B/7 M/\\_W9W01Q]HEWS1O>#^)W[DP:M MEP8(\C79[VYRS0C*16;SIRINW3HG@I[6\Q='&;J;'-W/='9">P!SV/X M!>RU1)T-6Y8I/ M+\7B+!@?73W?\1%>4;ILVM9QELYD4*\9G^4=2BNN'UN6!\G[C.VV6@E9:%-WJA!8TO )9Y@ J35/B(0+0C-202!,3J4'-B(H1L:J9.,$]4^,18^$N M"8F/%13"Z"D&V/8(-I&HT93UVZ$@5@S$?);^:^4=4V'(V,WBX(O)S>+1K:$V MB]%4W6P6H^'I[XPZY 1FLUC"<[M9[) E9C:+2R:]KAWB\8K/# ^8V[0_B2B7 M\=A%&IT=K!@.,B";&9/$IT'.>K"A@>=?21FVAY35EA.\4X@Y8$?K-'T,/03. M7;_>"K_M#XUT_]Q4]6TX@#[K^79PL,4)]%K#]VJS3=B>T@>:/<<0*&L[-OZ) MI3!]T4AD.^8BD-+\_8+EQ2=6_(T6]S1D3REL5G5MS-JFA]W+M87+V?:OK0Z@ M=HRGP\V1Q2CJ9.A#%O",U,BK'&F RK\MR)X6Y(!V1N0M5WYVH:UK&G,^X*_? M+,H$\6N6E5_!$%,SH*U@7[U5;>W5I$RM(;[[M;_EB15(XFATP^<) M%D]*[<)6*TB,PS2!94)YIV0.3&"WID5U]BL9GP2,-URA+V!('6YNYZ67S^0YS2T]UMAQ0Q M>Y]VD3G9'[7;!>T-PZEQ%+$>$EV8\S[ 9J'H!:F[00[]J,X"WA^.SU5](8?. MB,GQ* 6G[ _Y??#7R*9M4%]._P+=(R7O5X+W0^/ M:C%M2]XGT%D/&[V.+"'S("S.O*#KF"]UZ8?X^;P?[_8?@_]DF;CVI"?5"M$" MTD_2H&1[LI!0Y@)+BQ5;[HG 0P0@G\E;9D2C[WYO&#I6:5 _S?^2"H0Y@%GSI>_N2$Y<= TS;4733>\R9XA(8$,K.#NGA(:(.ZSGAR*B-63G;OP BFLC,"5'WPL^Y/ .RRRRP MW]#E"9QVH[Y">28P??H >\ZM&Q=:+XZY#*&7@*.[%04QDD&QJCE;S7HJ=[I!04:(V/.MI3'D;7,2N\[(RU*:]M.C4FC M^,X8)3/4D7'VHQ7$!'HURFHL*7!&&A75RNAGMTE>!W'V,Q\^" WO-EMQF<6'^!^[ M..(S07759)M)*%<1E/O0@X=37@$#< ;G<0W3P2DSR%/\3%.P M'.5!3E*L@X+$.=GE,IT+C!%8BH";IJVT4"F)BQPBGF6LU(/Y<*0NS(,(C#1= MR@?/VZR0]LL8@Z),Q(F'H8Q&VVY8["=BUT>S:,64>FLDQ>E5U:/0UT,V;AB< MQ7O?[7)(7(_CQPG[YA2^0J;I,84:#$, MR;9""K@SCR\9A27TD '3)0A,B5%&1/4=+5XH38$&UXSOOOWA^R'! M'7H#+\9=+3L2ZJ4D+X4;O!) ,%;*S?7)R**B(?<1K"M:^^Q-%09%BR%XZRXS MI)YBN@\2M#Z#S=YHMN72T_"7Z=_./J;$$V=R\(D6\D!FS_5'K<\@Y>"H+=MR MP(F1!'E-T4B@B!B23[3Z]>_5T%I2K7:)9$K\&+MY!?>9<;TMCXK]$H _7^P7 M89CM@N0B">)-ZZZXSGNHC22%]JW?<5<2):$@I[\79*4/^!T=V0UY#%.JWX%$ZF/+1D>\&)K?(Y6',_4BHU%<+)XR*M; W0[\T+,8)>EJ MT[9B@#!)PJ2FC'?6S?4"IQHWC=M5MS0K@CAM:$O6HF3I$-A=%Y%JHT*"4=)R-*TGYESM/+8Z9J>7;@Y M[TTZU!M+ZJ0E3&P,&\"H)CEHSC01M8ZV4 M2$A^EDCM L&4&.9L-KBG>9'%(>18P:GYSWS"RN\?/K=*NM8[2/O?V[9M33@0 M+ZM+"/+D#0>0?ZVH&Y:LI1K/&8J14_#2WV?=^R.JKYGWU$7SOGUU 6)J'N\Q MX]5\WA9NCIR:/Z=971;@,?CRCJ9TQ>7\%HJXWJ1A!F=K+JG\MVW:QKR/F=)U MZ#C)&]_AI2F70.X M.'ZW+*$3WO(N$7LO\FC=,9L\^$THC62C!\A*B8"JQDF) S(-->H$]+UMKEA M&Q5'Z^NZDE*3& MYDZ\<$O.'Z,?6)!>!Z$8@^Z@A<+CJ$R)[F:M5^6J2!.@32KB^+"&T;[8B'#D M=8\3Z'&^6\Y7)4P?61(*$L5T63LZH8@O?Z'<'XTN=QFG*>N'R=))\GNH(T2+ M(A$[U.W)1;@V<(E&>K2[:'*]SR&J&7?"VDQC(CH^ LI'9<\U2< M)^R-W0X^CPRB=;;KO1"G!.,W>CO,];8;__I9:;KR5$7VGA:<;W!IH,C<&EBP M*KUKI!)5!PW7B]6L(E\FXHVOX62L8^-6J[U@)M3+5UBQBG8)SR1J5PTI;V<- M*Z4A';_YOGAW#TN$WLWWUF>0F^]';;G8?.<$Y7IUS.[[2-0VUJ;0+UB5^ME^ M;Q<)IL2QD4)[EY6J(J;P=XS])JHHW< ]@WG\3&]7X@@ ]RSCYSBB:=0:%L:W M@A%\?6I.)BA]6-K*XZ+GB,5G#4OF(LP((","&E]U5N!@GBKAD6FSP,B1Y27P M .9KT?%MS2*Y(HV;7 E*KD059 ]F:(0*,T-#XVPE6N7>\54QC9_2BUT&+M#^ MD2_%\D0,^GL^/?0<@]5O +E652=DO=@ =Q1#$5()U[!BA+XM6 MQ'BP\4P>.?6^SVC C>W%.DZ#;H^Q^RG,U'G>FFVY*2D201+O-IH /MJL/S7[ MXL%&]\@"4^33^#7.P^VU<$:A(%$6AY#*G,61SEE.1 O(]9$&)1>K)X CET]0 MLJ1$1 "2V2.A5KMM8_DE&)-4C-F6C'D"QDSC#"E&9)F! 1F]NF-/6;#)KW(( M \7Y&BXFN5VM;;1 6MZN+VY]O+KLU%MT(;FVG2%G98.67F1F7T=L? MR^(FS8M,#-Q-RJ=WSG)XQE=W6=W?9-$$P+N*T0'4J.]@UT("%V M#^SV&!&. 4CD@ E",!*5J$D](P(8$PX_$W9:+OUX3_M-W!4\L]";;; M9 ^,C_CS>1&'9$4CSHU$6)\=E[I]LS%1&)\3XG8*_BQ_>0.C]K4$Q%G+.2EN M RE'E;-O=K:CFZJ/NH_2F):TF;F02X":09<^T"-GOU9 MA6>>B+.)9Z40?O)4. Y+,P4KYT)\@7;;&)Y!2I7KPMAP9ZX38UI#M?O<.NT MR^C071.X1I!"K$?,M@@WT,A[N)MXR &0_]LED(/$S'#>75GD0]6H2UA3A')* MX9\36MZ%T:PF=9?!5%SLX:A, 1/,/W;QMB5)WU;SV&+,AF"XJN%F"B_JDFWW MO!ISD/@#S?.?(+>@ DVB!FH_=;!-"SVS/3K.S$TGGNZB<"JO(,U"7],.(NZ" M]DPF)]$629"'[(T@X^4%^EFC.C%F;+*4M]"4E3FXKZ*A^IO61Z M.G)2]>A@N>]JRWUUL-S^BAXI\ES%>H\I>#16WCZP]*F@V09V-P;NH>E[%"E; M;4W:EBB@.7_D1 E0G7F_GZ:7K4R'5]Z$IO?:QOZ'#0F.FZL3VT7'YR6* \SM M$1\;%QFJ[ JP]' 8[DIN[5Q]H>$.WFM>T(C>I-0E8&V+4A6(]0U*3J)Q )%6 M&,0^6@7"SM:D/1;8W)@\[#3&*?\RA-N'^2MO$OA0K(/TZZEN5+;L4S:'X+#U MRK(..9CJ9J6V5FMM5>+D=*RYY!,X!-\?:;A.6<*>]MPI?&"KXB7(Z"5]I@G; M]N=SXUI &3PM2M;/PY1HR &.6!A4@$@#T9C+..WVV<"%M"4;BF,VY!4;H@-( M+_=SHJ23&6"_,T_XDF;Q07K%?4W;ULD#[4;ZH\]U ME1*?&89Y'J0+]FFS(!Q>;:F\,EJZSIMV*%T5<;\++R4^MTK7$/.<2=@8)AP.) MSB]E*9>X@D*"&HN?-*@1@\/,<=Q=H;-_[.)B_\!]]TS ^24NUFQ7W-,@BI/] M)8402)S"ZN@ZB#-Q1KXU*=I8>]A":5BZKI)!T QNU0.N8$X\R'1D0,\\B+Q MD1(@:2(D +$JT*'"$EO%YD9+-C,^0.[,1)#!&=C\CF:B,N# ##?T.%;).YJU M'\?.KI$<"'I*"]=G/3/ 3X_2N0A#,+7Y7; '"PS)>+(6$$90=1HS)K,J1&V+ M;X6!;"4($6J3-Z'(6CS%!&5;:[1ZQ5Q_"-QM1]."^Q>W*UG3H;>N<=^CV*WH MEB:M3^""ICC8+TMT>"U;W,M4IL,I=R(3IU1-8#H?Q(K+68/6A06N?9B*J'2S MDZGSR.5<*O<,RTW!\DJ6[LFR[VG\;-C6JOUC?:<;V[C+C V!QUX!WKM![VN2 M[I42ILD]9\H@'%W8#<_HFJ.IM]1A-0G!P>N$O?R51D^TJMBW6'%S?T_#),CS M>!7+2MJ\-QWJ8[Q]I,(9PV&]K%GPQ8L$FQ\H9IW[*"W):?B')_;\C?!\L[U4 MDO*/@WZ47_S]\NI$L,]_T)3(0P/6#SYVS&*G0#!E/CE,+5AQ)UN< M_Q;Y@G JD[/V@N7%?7TY:F>.@<:[Z&0#!1JN-$0)#$9K+/425;=,("%-*.+( MS8P &D\Y%CIRQD:Q=1)>]*D7LXC^+6@W7G#&+VXN;.WA%G*<6[=SQ'F6T MB#-1Q+1Y8>@URS[1HO*1<$ZW"S@6?'2;L!VX]*0$,#G7WHDX**X$W(VQNY/4 M'%,6)!!8CS9Q&L,6)^2+E8Y"A_XJOH4]=]W?NO55B20O=EJ"(P!^/3U5IC,D M)]T5CN(+:J@"Q/^!#([G(!%U@8KJD+9(U.B0/*UWL66B5&@XR>T#$0SA SW@ MP'A\EGJ$\/CJ;HD/#3!PB(C4Q_3+1"6QTO)3\DI+SM@H5KM>?C7FH3HOZG8% M?\H"<_T+,-6WQRW!AJC83_V6*Y,21[DH.231P=86?$HRJIXODK5X[N[$GSR[E,JK[(6%RZ5Z M+V/+YRD1T1=;U,6_\G[II;A?&GNNVG;'<,$O-31^2MKIB1D;QV*/SD'Y\7:9 MQ$]MU1$0;QIS"LXHV!;,:EY@-44SLYZ!CAB>[ZN_#I ,3_3&NFQHDD=WV-GL MWJU/O3/[ *,]FI:KLI+%]:[8956&R5VP%Q6"K^-G>AWG89#\C099_KBF&0U@ MOUW9_HQKWIB1PL%PO+\T&J\9H^"*5R-VJ8ZM1@682,2'7R7F&1$ "0 F@%^4 M/_D$E;S%7Z(C$S$O(]6EUP:9&%>/AJJYFY>_VU]MM@G;:UBB@?>-F9H..M9K MHI1T1%V@FOY$Q'J(][URJ\30R\!)=\7LQS;G MT"8 V2E;!<#GRB[@>.':,@QS9$*VX4BJ1UJ'\^&9LGVXYH-OSCPT6W-G'8#J MA(T#P'-D&W"<<&P:AODQ'[NV57 M9KH' BJWVV2/$*=AC^B+.^E]W5$\*#(,P35+AO B+O:+C 87+#KU<;I^1IC! M9C/6#RQ -5(@1H":DH]JU8T[?$I] MHF[Q*4P'[O%XSCAVDV_35^$E=\H[WEON'RIGYN1S3F]75WD1;X*BLU9(^T-( M93]NS+;ND7 =OF1K#W!WO+0\8 MWZ8/0<+QO-OE7-H[KW0=>AQ[H+>C65V&8.;T0A_V\],,Z@)3)=W M#F]8>2G+YL;ITUW&4OXQ% 4(6L,T@Q5N7G&WQ/@4! M!9(DFZ?:"$[ M%(?E\U!QJEK$P 7,<'?T/>6+F?16]X2_';+&X@UFX5E/EJ_6UID@"_Y.H% ] MP-E:VM)@]RZV;8Z@Q\LOJNOVX$:B"VY6V(9FU94%^P[M0[9B[+J+7FJ.#K37 MURPJ7VKAJ7>XA:@FK$GV'!=JI%G&#=\]?:8I%/8)U_QW/RL[K)KUWE.BP6-G M5DD4&!&G$+6J'W>E\#FE9SMJS?C1?GM4F;^)4WBV6#]38MX8;?1)_ M:EW0/EFOW0%+VMTMS$R932X3(S8L?2CXDDI5655>P:=&=#9M??-8T"8Y$)^5 M D38@;YWN5+B.\,PTV'@I)R&M01.\2UT6*2W=5=^V0 ,C"DVWC.$WU5C( ]2 ML20,X[LGH8T?H:+[/)' M^.]0"-Y$DR/*G&%)V];:&@$Y0)B1&K$HM%%>.R;NG/U5P/,>OS0RFLS&$+E; MDH#"KED2<5LF+V\69;*[%B;]3V.7)^VMVA9:>0]M4 >9_03]AEC*-/ED*SM2 M7FUZ./S.UR.70=&:*3GP*"9KLJ-)ZTYP>:%KHP8"X:0)T':?3SG$5Z;#+(<[ M)\OB)LV+;"R5 CXRY%4@T/ M+A?25E]1D]=*AQ9!-I;7KVA;\Y*;&AY28MD_H3?RN 9W8+L'A%/L]Q-RBTAS06@AP*2[SCJD/\0 M/'4KB6X#1F:Z/D)^YKH^1.-G.[/]-3'?58C$_#8C$A11[;.3*4])&CLG/766 M.]/6#[!'"):C0QG/?D?J6MV.*U6J"6(T901:])V="= DH:^K!<\'F@WRP]T5 M@=4=H0+(+S1^6G/E63SS;Y]H<\XK]:E#F+'-8*_DTR3G*(^E D("B81$ZJZ5 MKX[B;( N+K^7Y.H*9=L=NJ@!L!0HNV2AF/5D^$4ZJ]?\N],,3Z5G$:&RSC:M M+U5*PE6P3)(F@K;S6-DP9YD6NSS9_!X7I?M!(W;;A=-24_3M!?3PLM/<&/(+ M= V*K!FE8D[.GAQM3.H679N2LD"8?T-RSM-6,]+!*(=93&G.DC@2IRC4SI:I MO(+.8NINVGX64X/VY,Z(*3&=83CI,*65906D_0_-5]T/HI-:3QNT+4R"XKS@ M)'U/6#W,9.H<,I5D[,6^V<.M:5^3-[ $1!T8LM]]"U'E%EP3".1HB*IJ5'EP "PY0U=IP>W( M=9S03[O-\BP_M^\1A MTVI3U8_B"'@&"1%)T[O=TY] MQEZ*M2@*DI[Z+HI/HV6AM55'8E'1)I(X*:E[$I%^_C)-IOE,]-O ]EA^3T/V ME,;_!$^F/#+ZL*:T*XR#;L= F:E::KSWB!0F>7 B8>F3#(:I ME$SQUS_]S)1/M""K71IQ9R\O@L+QKL-X3>O/K=1AL.70SB-OOB>BT_QY1" ' MFG$6OP%BWH(V1PQC0URPZK0\;((DZ:AM.O 4VDDY:LV1A M++_,[X(X4C;-_:\;,\SM9/Q9K78\9FSTZ+Z.*0A>D23;P?XXL\$#,M9K@568 M:7G][R]6CV'(?T(VW91>I] M!INEUVS+>H*>)$9^E>3\I%>UHHU^F_>3AU%.SMO4D&9%'U1WJ*Q& M!NYVRR0.KQ,6G&X#]CZ#C@LTVG(4%I 4B2#I*2K0QD"FQ!7K.2;9!5\>/K&L M.RS4^M2H3).Z-8?))AFIB'K,-SEGXUG*20=O/!4W67R)NSV K@>-%"N!!JTO M,H[K1;4Y7^O*])MXN93)E#5F7B%YHD_RME+^D##7(&AY;R?-=SB&#@ M>;2,=+3K2%: ^OPW($\J^D0"\"0U0VQFVKSSG//$Z?JYS$.'W<,)2]T\=%?;)-C&19! YC(DS.P*FCVP5?$29/13 MYZD%M9>P]4UZ&W?E)_6CP'A]ION%.&G0@$ J#*0"P==(0QVS5;=%39P8CI?. M5*E9@+QWK=W](%)ESANTK29'5>3]KJM[N,G46>1QJC_9JZK.OP/2"_&IRJBZ MK2L *#L#(]HVYBX@,/C;1T6 -;/-[(1+F#ECS!Z[,R]LC)SW^FFCA\698;G9 M;(,X@S&Y7<'EX1_B9QK)W?"_TB3B'?F<=U7+UWH7:1B4:+A2?"4PJ-NI[?02 MH;@')(2M"&"9"S!$HB$ 9[YB&92@\7-/M9;0L5$\=J:%[QF+7N(D.6#L6;SW M/XS4L_9&72E6.W6,)IGJ!T)U*M(STE B;YE3 U+"]%CF93G4D^/0]9B!I9"+ M_(:3A9"_[(9./G8L@@QE-J \E33,H-[/)97_WJ2+,*R.T9?7>78Y*AJO8OT4 M!1+.W!0%+"@OQ6P?QYR#J@B33+%'MKP1'AGD,I!&TUPL8>[I/W9Q'A>T3*Z7E2G+(A?PP,]!LNO245=D MD?IM&Y[US9"[FXORHO/Y.X!([H*]\% 6608KTNH>+"F/\K)HJ)?; .KG>FA7 M M[$D>.CC)5-EC51I:]^&[?D:/OIL]]W+4O6RV=[*,#?'!TO!^H$]!(JFV!!=[ MGD ,\DE+]N\XX>1(-=KN(XI]S&,*'+&JT'P-QUF7E_]\B%-Z6F=?Z5FTJK>T MZ4CO2Y*SZ@,!XN0V]67W^[C+M%CF;-E\Q9?TQ?Z!AKN,+^%I?OW\*?Z<9E1F MDO5LU*F_B%P<#Q.P+64':C+)EJ]%J !%\AH5F9-/K*#D[9\P06>C?1P3++'O,-FD172?! MTXEV*3VKJ5"];=K6H5[B.BICN!>(+7!.?0[D"="?OVW&E@G*RZJRA(#,=*%W[_!?]XFSVRE^XU?>>38WW^0XNN M/7Z@3%A&@+9?;[^%JVV^?A>K+#D\&B[CV>OH?'.@-'C;KV!R1QPJD3(._7)6AG;YM7T,,S%T(CLB%N ML[N,/<=I."@V'8^/%9R39EV+CB /OF0%P*_P=#&Y37QZ.>N+MBV=YGGP5Q*8]FF5G"NY6AH]%EH!WGM^N'K,(W%[ZI7C' M&_VM11F&'T8H0W>CMI7A([<]H@*)( \AG<I;K7 %7=HU!<4*UCMJ+#>GK$QO'4 MTAPE[=E-&CW&Q9G%Z'X ,1<=-^3"&3NFJ.N C<6+<+I:ID@XF!+%SW$$]R\J M],/"/-DA 6R83;9EMB5CM?/W,1+K(D?UC"!:7G%H+8BK\R3;[L$_%5;#:;5# MLEK%Z&.67G+'N%-F.YY#R^Y)>^YD^(0P3I9'HSVNK[J2^E3Q.]@WUQ)15/\ A'$\FL@B) M@"6*.2PVX+N2-W%*T,QTNK1EF$/(>\CK:' MT":XV9@[R]NDBC.XXW ;\C0J$#[=C%9I8&JL\E@2IRV7NR, JO>RL;(X;43\ M%<9I0V.F-,[(?HXYJ7#!TF>:%2)O=,LEC689C4@.5KBLE\/_Y$Y*PH')XI,D MIT612.WS>X1!4RI[2^H,#X%'3;V%*V'*NY]Z\[AU7C6FI>HG)T? &NVLCA%%SG[66(%LS=JM)%R5\Q]$Y(9DJ> MF^CQ&.O]B18D:![42:9S.?:PW/5?+Z/&6H]>TPWW;%.N,G&G,BJ]8\Q/:K3M MST%J@##C&>%Z-4:IE+O@S"-JDYI>5ZB3:9;BIV7DY&&_6;+D1!DZ?T=$18_: ML2WD53A(4G,>YVSG&1MDA$=GA4]'LLAD');?0ME.94^E_W5C;DH[&7\^2CL> M,PZ*J;X6K @2?=]D6](F2TF!V<*TRH@O6K2S3:/RG'% MS5'('<1[6NRR]#85"X^^ "BF"6.*TTW*W^35CY5&78%5_1:P MX59U2J[T5 ,21DVM]A@Q0P(>401=("(5)$A]+:=.<;?-Y2Z#]=R=OP,*&*%D M!OCNL*P_"W\3%Y%'DML2D$RXN=IL$[:G5#QTQ\=R'>043$W7;#NR-729?Q15 M^^7^8<]\6Y*4DY!R>I_GGB)T6G97@CO6W"H+;48JB#([C50@B4#I+??1E/0R MPP,UF>&AG^," MGB6]:2^@^F5/=>VDP&AG.OL(!_>&\D7;'T+JVG%CKF;(8ZH8W1F+&U5]J^ Z M+PC["?IW##Q3XXKOB4=<-=H9J-";>]3:,CO]]-/T$/J;DD%6')!AFZS#9=\2 M+>>/>[YLSV+8.A./+5Z"+'J?=5_#,ZXQ&RY5)U';0OTS)US6PLIJ#.7)L%T: M%Q,/X X/EJH/HC@"7B,!'X,O\6:W&1,'&&K"8!2@BY3/&$ 7)E,1 '-]-KG^ M+U%->?4_*)<#:W\UQON>KL34:F#A/]R.!<=K0LO^*4U$"F.AZ'--:1G:!4_R9BHH2"HOI5=/155L MQU@^Z@ ]VS)= B(E(I'U,2.+L(!*A_"'O*B,-"!-)%U3=:!ZA!*_&8:)[GP$ M6#B_"[B3&1NV /7PG#7_HX[_F#17Z3RFFBUX.P1PGK M7YA'9%L52LHS(FC+@C^2O/\8C\7Q90X'[=6H'CXL0U:8QA9)VVL&MT6:S5M/O.W:$9 @R*\2AJ?:8*J\'PC]=S/4 MW;U3!RN<E1LRVJ%RSA+[",SVK/ M]*CX+QC)YM^R6&*Q#E)R_))7:<8.'C,T(@Y+<,FJ1OO[X*6ZS2[_1(O;U3W- M:?;<4X=+]45T,:XA K:%F!/F\WE)V5/9*F4F,SSGO$[KBR]QEX@-/6YP&H=F MK4_?/\ I)#E"$$Y$WP/PKH0I=M*90BN+%L'QU M[PU'SIYO'JTOR\+AXO'IP*@@M3&+=/7=F M.NYI$4 "QU60P3G1?!&&N\TN@7T(2.T(XZ[BC.HO(@W', ';PM*@2"))THOM MT& UP_//HMJV'A\IB0MW/#J0][OU MH<9NAN*ANQ#T0>#E%2QLL\WHFB.*G^E-&K(-A0/ OIX1*"/-5H2C\Q-<1XHE M,S0(REJ\C)E0S;?\?T(]X1ONUT9TD\9\&I)[]D\9E5'^UNT@G5A*?-++H(;T!Z<:I"5,#,/. MD;IQP?B2( B+7^)B?;'+"ZZ'617KVE=?+*)G2/S)RWO%VA1F3#L8+<+0TY?# M9YHMF:YMKZB76< GT@\Y-*&^XD,#) &49+DG)4[R>IB"F[^/^1)6?!$?:(,O MZY(OJY(O>0.KAZG;A,8STZ,TTBC67@,G!%X%M\&<^,G2YW:9E!>BMUI";!L8 M\Z=+RXG-TP6EK=/V>XTJM%*"$K[V 18YC6U,N^>CER#)$1_" Q].HQ_L -.# M]4)K*3,R%.ZV (XNZ[V.4[X( L^2Y9VGOE5>P0;W>YJV'LEOWL;,)]J(KBA? M"D9D5<$0U[CYV6Y2XCG#,-+G'6XB">V!AKM,K,YZ#SKHOF[N[K96,GY*9$@L MY !&,?SMK#[&P)CT7V6FP&AWTAKG8<+R77:HRSH0>5%X RN3W2T[NSZP&P+J MMD"3/4+7!"X8*2UCD) '[M+(#0L_JJ0@/0S!0'<'=/F:BZ]&(:'VEGYC)2 ]CZ/ 6'&IM=)4&2X,_&M8_$?(#9?+_H^<=:T[CMKOX<4 MU<'V'>TKUSA( D":FS$SDK#T:!?[LPJ7;:A^SK6Z5 D8]T/*7% W*)&PF> >34F\-D<'GL643N]J=E#_BL^;",.>9-CL].LOMNV&:D325 M1HRYS'W$_$AI]U;SQ*)K2N/4ZSZK,]^W!ZWG-]OQEAWYR/+D.<.ZDY:[A L8 M=I"?DF.LX0Y/(Z;VR.GVQ$$&GC835ZM:=1Y9 \(^(QE#W.T.K[6SS+=];4^+ MUWO)K+5UG? NUT9;V"AEW MP8W\=9;Z?] [6A>C^N;7*+4G<&);ZM-&]*[_! MY\W9:3J4KG[?L M_W5%&D8VAPU$(,G:/TU>@:@6@7R5YSLP-GJ,F&G&>_).[N%BE-O5YUQ>BJ+D MG'2\8\0W.6G;TYY)!BCF;#7?\3_DP9;Q'LGHKHW;+-'NDQ,OI$N6.IV07BZZ MJUA(.7':X1Z59=WSRUU7Z1#=U[$5#!7).*MDJ(@'5='06E_QE0V%WFU+VGYJ M&.H*&AO+T6FHX.O82HH7 E$]5G59CM\NM-W$<0)9]>0R^E*6;2I>Z M>Z]-Y2W\YEI?Z\Z2@_MAH!*$3?<,,6W6!T!B6=>H"+Z0-TL)X.NJ^IBOG4$E MJ6)(ACI3*J@36W"5?P9@!6=^O$RD)YTW3["46!S M=BPO9&MZCN)&G,%_LKE8'=$?NROT&MCTW.%>\4,L;SO&8)(Z>\W'UX#*-IMQ MH+% SIW"_MFVPN*Z8U]? =?DU?5(])#:>CX TU36;I\:VXP+947YBEAE_8MU M976X&-#%-7UE[7",QPW Y)15914\JBW+:CMRG8?+L%5];E MP96N@?&8:(1+>/M6GGK3IN#./LY2':TKJD4)#=I7F2B)EI^QY(X[#JYHO4N5EM5:-C63@!! M! I(.SY46&D F1$)A?Q:_NL[ T]O<-@HCD]Y[NF)LHYLS=W\XS)"B83G: [" M<0(W"PU$GJ8,\UV&2"@Z:DW]G=9!X/3$]AD[0CBCN*^,RV%0)TP&H\T7*?Q M/W9]Y53Z'T;J7'NCMH6QIDH6VVW&@O(R[1J#S[HJ VQF>KQS7I^2K7KFJ>M= MLZ!.X+?=4%%%*G^1> MGOSOH.W6>1=KE%5H6+>V$@2I44QN:U=O*-@H_KHK$E2ZU-PVQQR \TQ M=HCCT./8(C\=S;I:7'71QZP?#?3E^'3WHW[41M2?]5JA85!0F"[')AI75=Q" M,=.HDSBKKWV'<2CMQUW'\P47?QW89)I$_%5E>\4DM]T9 WD1L"P-R:?K+$CS M(!07;2[22/R9"-BYFC\WNCVL"<#2M9[D5UXR72$C36AR =( -S6?!Z.'"+:\E%WMY MRK08Y2X8M XR^H[+='3!-N#I!,T+T$\C,[T/8\,]K8U:C^\4H*A+($O"!EVO M]8\&^,OTF.9XXA664='M5'ACU$3:VK*K"5,2GXQ/J,+KL_E.@8$3"(!\SNEJ MEWR(5_II9.>O&@]F'$A87[0,; ?^0J&<+_]M\API<%W-VI8T29=PPI.3L$%. M,UWV.90I/@&E0<)MZP-;%2^UL'<*U<#S:*GJ:->^6$G",&V2BO0$)6R([4R; MEPYK+F\S&L9]2^VV1]#5E ]-V1:>)BU0Q6!&NHSI@:S6/6P::J7#$;8PH MARCO-!?Z$>0D$V-B2]IDG2UQXS!AE$KRSP84_Y?0B,O M@(@F$5FQ#"J2\Z_>Q"G)Q:]^UFNC9/4T5C>*^AN2"]%ZULE &DN,)$R-XXLLHP_(N\;G,J28,Q@#6ZM:(R VZ4JS0NY@JX2 ME5A:WXC[J?.J09U7QRQ@!T@X61;5W_[EVS]\^Y;P49#NZ8S\Y=O9M]^* M_Y<.*PEVQ9IE\3]I]!/YX?O9]S_^,/OCMS]6O\9YON/&%++)V*[("_X!\FN" M@ES2D&Z6O.7OW\X(L/W_)C]\-_OV+V]G?_[VS_JO?^=%X#N'G:F.I4,3^LPU M#*:QVY>41HNBKGO7:3B'7D";RZZ&7?G%W0@P3K+)_B#B.@?R1-"?D4/Y1D^S MP*#@,'WNN:\0^F[_D09PPS* N\[$#>/AON>\N<:;8ZN#=E.PK4,-NJ0F[//X MN0[7V\I^JK+276@B^L^=U(C\D=U38$&<4.X"2??H \OY]W#0Z"YCSW%$HW?[ MSSGLF->IFXN0N^UQ$=-\L%@)G"SWI/9P25"C_LE/O,.F*#"7X^M^IF@S(+T'V#7>'#M3=%/P M-%/X/,NNP_>VN4*5F5Y%,.=:M'+:LMLXREF$Q/M&GPK3VT,7 M_9ST)V+F""K F: MY5?_V$'U1;6"1:KO8?=KA]IW7%+YZ>L946&&[=)WNH+;5A(/-2+.5/V> M/M-T1Z]Y_R]8*J)JD+UWL>-S_X9F:E,0KA&DFNL1LZWD)1H" D0J/"+7DU2( M)C-'(8>)F>'].)'.LZ(ASORO@RCS/_X.91D9:-NIXG-(6PI24'$A;G M8$39BMQE,S\UP: MS,?+-6Q"O?G4&AI7?'JDK3AIU9>T<,^J1N(G'J[*[A:+TLM#AZ?;CCVY_-S9 MZ_"4--Y$GX4;I.!JX:, !7>"SD(/40?K3EBI[US\*3(^U5DW+Q^!+O-EM.HU+Z^\(\W+4 MCO6$(DG,G[/:SC4VR J[0QVG_4/=]CMFJ)OM6!]J2Z!F.\":E4*:=X;W!Y_%6Y'S-KV8$E]K MZF'.,BUV^8O5=I<,Z'O45#3604F /MI&8I&H/B!JPM0!UB+XXM-(]LI%7Y31 M9KZF2("DKW'OX2)38XU#27CDI#K=HJ%'1TO%H4GGLN'+(1KD::N, M=#'*F3MTEY63U&!IFYXGDC*AQBN^3. LVNG= MG(W;,(;JLJN]AR]OU]^^@]IVI_>\-.]!F5S@7GU &)K+SDLO0E7?X2J+)T^- M+*A8MN8V)2$NB7NMH'C*QY9BB:W,\33'?V)W06\QN:''C9#_"&=$4UGXA2%J? M1&M,A!NY"A4D5P&N\D:Q:GJ=VH0Z9@B9R7%QI@"'ZU(EJ@[A[GH,*;BGS;E: M)9W2Q:R-QF-'K(C.=,>+?G1* 5-EC]4(Y4-U;.,]94]9L%U#1+\C9#WX+")& MV=FF;?%NTO,5O1YF*-/BDEU)H4^G"#J#V8//8B2EJTVWDN(KECW,4J;%)X>K M$2BD6>SAIH)BD4901&,+"(><0_47T2N4(0(.TD<$ N[5 0:11E*C(+\^!A!7 M\>WA:8P#PS/77[+)^XSE73Y<_\.F$DY$H]Y23@1U(TDGR'Z@KR)Z GHDJM;[ M4TH_.9:3O@24%J9YW0T:K ZI]I+!72%W-2+/8DA?SB< MZ!UPCOM>&>DBMS7MVE%NPS#&73;3)[337+O+D+'M^]BVD@BU>,_#/'2X"?_, M5[4LV_?MP)\_@MY^/S1E/[=#TD+*^SBH6/GV=JW6V0 S%58X$]/Z@H*;=+LK M\@_TF2;?JUU"T?T&4HA[6K8MT\TK)R3U&1'TR?<3N7BBA]MM]TT,L=!?7.TF MO3XN?IW>OUO"0#%UMI,9GGY-/Z7&I3S,G+YB;4,J&'4T=-3U# M_UOK7G];WU[_6^GY_6?6Q8M=+ MQ*\#.HDKP%6&H/T6<&6^^G,X^8?JNZLO6YKF%!9WV3.%*CN+,,QV09*+(DVJ M'JE^BZ9<5G7*CGQ:68M+);]G CTTY/>J0YR&8XP0US[/&3M"$[< XE\:J6^N MFFK>J6TXA^'(4)2$"970'!H+$UUV:3G.\;XB,](CYJ-MRM! ^D^<_YS3U2[Y M$*^Z3_0JOVDZ=?Y P5WN_+;.G:=U[OQ.X" )!T+>_(T&F:]$1O614$F>[V*O MN[./M( C^1S@(XINTKJH_B(LXF>A-8ME+BZ?ZY!1?$/8\Y/:!)W4 M-E@E["675Q.R"@H):BP_^3FTB!\<9H[CSH2Z/E[W(4[I#?_8Y91U/X@4RO,& M711N+$LU DTBB/JZC[F3FTR=1N9N!?!P43O:,H_%&"E\X'K MZ\8U@I0N/6*V):^!AI1P2(E'''_+FY?>+8HBBY>[0IR *QBY"S)O=^&-'#MF M9D#<3?$[('Z[JNUT>:*TL\[!T//8";NK76>5#[H H$H@F.L-XLR/I X516KZ M1*TWMCR,0:%AVKQSMR>QR]*XV&64N^;7\1?XE/?O>0V^@-U[Z&S8^GY#15DL MO"K:GC>[AMG,]'GGTL$0-Z[=TY#&SS#S@0?=>\^&RBMXYZ&S:0>N@KQ[+JN) MST@Z5!K?WK0_S&.&89S+!4X:!5E47OSP2Y!E05KLRY!7]V)'X27\PJ>G<5T*>U1 M7; -_"LOVDVK]4@N3E"_"W(:-1^X8+ERWKY!4O;VKK0A.=K'$J?82=@@;FDG MRP$#K.UJ:6.?Z@X77C'T=KM&#K:/2-O[($X_L#PO8\G7"7OY*XV>J(P'J8;: M=%H9'VM3H>8RV 9XR!M ]/6,<% S(G8> !<1P&93"Z]IC5=[?$U_$'R(]R-W M$O)$*J1V %GAY?'"W$/$I0Q?LXS&3RF1ZZAP_XIBQ2K#U"[#RKR?R$*R_#,> MN%($UXB5A>8I,>M%2.1$/,$U32?;E=7_$[('W_S]:K6B ML%U,Z\H/]UQ#[BGT.TYBH2/\RPON[,3%8@,!F$L*(/GW)V)HK#U-B1Q-U[9P MC@:HLT9QR8T?)3=2^@1656\EQLF34-#7VO;Q,-@1XQ,'GR""6>!-MMLH>]*$&;OP,W2I(5C6@6)"3G7=G!X;EF@QGG8 ZS_#:C\'?Y MTYL$W%N91Q.*"]5WT&Z94L/2G 0G7D)Q&-@_$#Y R2[B;\P(?X2DK"!)O(D! M9L%FG ?E<7SYP@PN(Q'NR*&1&4?R3$N/I/DU<(:)_/4F1:M_"+6VQXD8-W3KA&(NW;F<3H/ M)0@_SK,ZQQF>C3[6>^+ D19,KKF=K%6(-4EG]K[XU=]_72LB^/MQN1#9=NQS6#7=YKDK.=7EGC HRH1 MD0H2J3%-I;8[>K"8J1%P&+K@M-8R?8XY$Z8/-,@I +KA-IP]RYHXO9.XPAM(<>IIV;8\U:1) MD[;?.5J%T0S!/?_GOM3NU--]W?0),,=WY_5>H3*Y.N':@Z-R*&P:M^()G_83 M2^M33-*E+2/>'<*J]A)21/L;MRV8LF;!FS( ]G49J/*7QJC(:H;CGW_K^&[_ MR#'T%(/1>-.T33Q0L#XC'RX]?#RZ/<%G#1@=SJL8O"YVNCLBHVGF;%DX;\9M M$ #REE!3O4%7QY>1>NIQFU;+1$_-.K($V@5%@(;JM5]/O!9 B)'B/@OWFKYZPKA0 KF(+_] M>TXPF?96==9XT[3G=*#@T7/R6;Y9A_=*UV]V,'1J4T15&GW<5'':BMTIHZ(V ML:FC@F5Q"L'WW/Y4HM9]O[/)F9SJSRKM0S V[6ZS3=B>4A& O^/CL0YR"C:E M-=:M\PHJ>:Z_:>O)FR5Y>6\FJ0"(P*-BS-M%IW!Y8#(?P__7UU4?R MDJ)0,0Q3W26""/4MCP(/[#[V/HM-\&AKTWJ5*TFNK-[J9[>QGYE,BT/N*U]? MQGF8,+AZ(Q_:_%%Z9VR=Z[:V'9:W;I GO_K>T%%C>%M5ZV$N.I,T." %_X=% MPG.04%&\@,M^#-F\\ -?0!Q_T7BR3IWE'=JR/$C>9VRWA1N-> =E)BZ-;NL\ MW [!]0$!J0HXLTB'.8L&,=P@=Z@$R"@BSI4YRF(HM] M122)WROKM&M#]#*.0L:]&LLLS0I>K!F;PI@[F[/JFY74LF*&'D?.!5W-VK;; M-=W)9;@,,KKM6MQI9+#(0RVWJZLO?+F8/E$XTG*;3L YF@XPI)KX[X#UV)#H M(4P[M.RC.*E&Y.<<0BHP57E12?_<;U-^_ZA>XVKK3C@UO*,9Y*U>4OEOW?$F M,R6#;:RWT"!\K+BTP;Z*-9=VKYPO'1SP'9'E4^$@L33(K8N(U[=FP&NDJ57# MR.$>N4_U^,(Q[.5_;U,@RS_%SP-;5>IO87:KAENW;6DXG]Z2FN[(?2H;W3&R M506U ]IZZF&;2D.@&)*M[HXX#5Y19NZ6,0^W9BE??&4!,3H[-?%\6]? A5O^ M[\SJN'+F.DZ#-#RZ4.V!:6BYN=0=0_CV# W1B[J+NFRN$GY>E.L$-+2IKG57'7AQ=*MVV+/'PKF$6?/C4G5?WT86FO#UWT')4LO"S( =>, M5/EH!V@S(L$URB)/EP7&ELQ4]OG_K^Y:?R/'D?N_0B!!,@-X-K>+! CN/O78 M,[,.9L?&V)M%L!\.LL2VE9/%#J7V8__ZL*A'J]L2'\67%MB[F;$EUD_%(EE5 MK$<^-*$D#0!*8#0[+%#FB?'QDN2/D_6@0/6"UJ-X$IL._W;$X#GP8[.QHS*- M:?+?%0QE%ER*J"G7,OSTM[)].-\WK4##QY)*W^D3K?>RXN)]7?ZQ6&L9-PA: MG[8A%NV>Q0H5ZIXD\'GKWVB2VHS?\UT/)U:RVWS1KS1);^;,-BDHDS@9;OZDLM*<@BA-:14- M?UH3NIO&+28&J\_?G[1UF*B"Z4KD:>1&JSBM2V>ZE/TH''0FQ0!^=:890HEU MIAE$'G4F+]_KX]*['("L5%]22:!>7]*R.6JR4M<:1K;&XM^R1W7%)?T+#@E+ M\P/'2%GJ*)^1CC8!XFFK*QGPF=DS+ZE<*2J@ZA[W*%,Q:ITN2E2Z2J=:#FND M*6%-TR^<-8W80K?EDO4V\P128B8CQ3KH)R0Q)[D38L11+>F!;T.+-Y DSTTV M,^!'-'F%AM603:#LNC#_$%)JCP<++;A C0"YM.T4%CC(S-@2\;*T::^V7Q@K M( CMAO*G,J?-#:N6+T9U+Z O09<&#A]3V,@,5-Y=>25*8]+SE=DS*Z*?B9=/ M&21@-&:%!?0OH/U-2P,'#SD\4%Y=>0$#=C-['D9W8XYM,R?>(V'%:OR9FK<< M'9L+HX>7MMX;.'4#OKIX-MT_Q*5AL,:[F=2QJ1.@&0^G$3/7$1.%"8$*&?&T MB@ G[_%,<4O\]KK,^B*3K .1DBLT)O=FBF>=U9@DMV8SQ'%'B]M7N!TH ^T5 MG",J 9E5O )=CVFR@6[V=TU9E!D79!I 9U9L+ ?ZE] ;HK+ X<6F@-E"9@'[^Z>ZE2!FKF),'D7L/DM#AGB2@7"*"Q@COC(;9D67EMD+ M8;.'/4E,G(O@!9E)<0ULR%V%W"2]_KW.7A^[*DU5%XHES'2P/:"=<5G??V;\ MYB'C%!STQ3E[A#B^H[3!DU/)=3AL[R/*]/D&$#* "M3 MKB])I(Z5:Q Z962H\7O^!2^.>: 1O931HN:\-Q._I,;#=]H*XL*2R3@T&5$? M_>J'D:(V/VAH^1JHDH%LVO-7PUEFQZZ(TB/OY3Z+;YF[]?KTTM?]A89JXC]( ME%D4+?1(:+FSIA@I+;ZK\FD6OY7PVVP77,)P-!?I8A[9&L\GQ%E.:=$ 5-G] M\FHG->Q/+Y3G9;-8*,;X/:R71S=^:#$< ! 0$$)[LF"D-;+%*>OPR&J,=.A^ MVOUJ-W0_W8D14W4!-YP=AF9Y4(?W;=E6]&I[61?E4UGLLPJ6CW2E **'5^+@[XOD/"1UG0Y=\KP+6P8HGKTT.+4TTT3 MI&?(6(;D5O30\![6&'=K)%YV+SL&BJN)Q*Z(H4;C$D?N^SL1<; I5Y:E3,W$ MCMLP,-HZVQ1%"=I&5EUG97%9GV>[4EC=2O>7T3O(5:4<._1B.A G0/U#69.> M?EJOF!G#&8J+45L=L%I:7DKI6GS.H:W!T7@QFAFPFDB*:>5FF97,F#_1Y..F MS5H9+/%)!DI T "K91N%Y5M'HW>022FQTS]DZ?]DY?S59FQ:MHWE#]"WXL% M<9E[!"DETZ&B7H06@B"J.:,38-Q!,:69IC?CW(0S$Z9$=YTZ*"28(1R=JFM0 M1]9Q)J.8/^-X7?&)W$.T\[Z:O>0FAHF]K6H4J"(#GK\+460M[UN!32IUO+OK MZ+\G?0WOE O-PN5JP\UXZJUL]%X^T1$6U F#5BQU7E:EO/3]4E9MN7ED^WII M=2%'P:K$=M1"K[\O%;L3^_YEW8J?EI"V^Y4]?X \G()<]CVUOEQ^O;U,TU0+ M.S?,$\.CB;(L[/]-0.K6V:2J@=*U:_H:4EAUP\=I=W 0"8(TCJ"C1G/L-R, M6.1W:$0WA!^6];ZL[P_9,Q_IEO'#^J%-?_&V()3N Z(+!6,)1S([C:Y;TW\; M3H7#(TQ42ME92IG_Z5GSJO_TTO*,\:*L,_YZV=+'!C8S"%=F527[N;14R,F2 MGA6!8KQ]PQ193']6I&TEW*='VW=,/^%/SU&$T0K(R9V$.#%<$Z57Q-@SW'9Q MW-RM>9N_$']IVC+WMXV?CAAOFQXH1]J&!W*1]@W\UT7;:(0#S0'QVCL!6\A](KE/R>NJ2A\00P+%?C^D)GL &[O]'V M:BNVUFO*2P;%PSG-&GI!NS\U[6']#>SB3W4"$,?CFA^)>V\%O*M W-/TFO4X MJENCW>MK=EF@*8L;%C_$A?S7GI=-4>:@=2EOV@S?<@F- M7QX]N' #>1G\(P&0*8*T]VRF;#^-E3?E932INRT?P53&6_+/X3&50R]>[82$&P8.6!*FT:RL!;F$D94?(QW'O7; MD "T::]9";%]8HM2MSLU>PE[ BD'#W[T'*B3K"62/K2P!P1I52!#IC,<)U,( MW-43Y3:R-O^\NY@=CQM3PIB@O"[16N#QO%2I&!>OT,*^98_LKJPT,9*+SV$+ M*IR.%[R(PH%@XJH)BYQDQNR)?/-]F[T(0 ^,E^VK(NU=_;#3??7IH,%OPCKG MDR!+1KHI<]TUK'USOZKFE['XW)5,RL2/XC\I%_"3O_^<\:>,%YO=+N-9NV^^ MTWM:R]O;)WI+\X>:5>S^50 1#[:SNXKK,):RA"476LIZ2&3$1*:@R '5&7A# M?R#O_N6?_O.GG_[RMY\WWV_E7W_\VWO#S2P50PJ6[Z'DPDP/&F4UVIWXK2PP MX8-'/T1=L\["S7Q-4%+71Y_L9.?N21T?(8?!(D4P]00^&=YR/].?T.:!8 MC4-A1K0T?H4E5B;4OI0>;MWCWC2P.'[L>1TLI=M:RV"E'I;6.5TVV?T]!^>A M.(BOMGVM=*,K;:MW\1U-]#0B=#69@(!;DQ[&6JZ?[6:".;$WFFCV*3SGD#C* M7Y5>"-6C2,&;&S)2*=[3K2VE5T+)66;#KK5^S2BP&"VS8]3=(1)1W5Z$D] M2DXR4_9$V[M^R?*'LJ;\=5,74%MR![B4)HK!&\@=2C%R:.$92L/RCA#^$1ZQF1:*7@=VD* Q1R>.J,C)C)5EA7 ^KQ MV3/2 2>_]W^F/\$#" :+,=OQDCBSYD' AC]@OWC**CI"TF9RVKR+3>+I&$R4 YI4]+RV!FR[6DHJ2\;M2_X%& MGN[Z@L+=)Q=6FZ0N,\GZ^X)S5M 9\]KB+82U;3!Z\&X*$@(YPG!&NH1!!HFO M$@D!*-$M>1I!#[22=8+-+-D4;?U^D6'9U:8N-L5C69=0U@:" MM/O^#LK[ JMWD6O;B$;P)@D=".DL.H9!>AQIKQ/L)H(Y<3?UR7+[D+6_L7U5 M7#[NLKP=NSOT?1WL#A[#P?R>2QJBB8\M#3J/!X-W/B"TV"DT&=,X@".M0$&7&/&E-1UI]$5O,2+]NWNU<1^JYT7Y>TT13[T[^ S?]='#AX M(O!(F0RDR>\#\40IP7HN,WO6Q:L%5@KQWY9Y5K=OL6GKY5F]C*T,9D0D>(&P M PHR*X6IK\@LYX*Y,3AP2)>,#R[!-ZD-ZUIZU"&TZW3(:.%=!\*I0[P6N6^S5]RD)SEP:/)4)<$60IC3;KUY<\D'G( M1'X'2''W*N^DP_P$THYO:+Z'+/A/+_F#F#SZ+7N&"Z^@=#3)0)0 U>C* MKY*3S)0]J;?1H95(@&T4-;3?;=0*0G#OP #&QS:Z"C:XI(9[Y4;<0P4GV/I# MQ6&:4F\C\^=A;]Z'T<>T@\?0R!9!K$$GR_OJ>;" UK1^L/.)5W95NIE++31QP4LF&H\$5RVJX;U8\_O;M[3P;RR;2Q-RQD)GR)EQ+)FO9J M>Y/IJH4O/H=-=3P=+WA:HR (8B%)IO4:+O.2&3/(L>#SYWU5O5Y 3=Z\!%5I M4Q<792,V:UI<;:\YVU'>'J75?Z>/[(D6L'M]+E_$"TU#Q0]SQHO3PS,< 4R1 M:*] 0@NI?\36-:03\POAX)2(R02RO"D80,.:'V"?U+KHD1. 3B1V(L&3/RGO M<)6Y;Q\HR:0_%5BUE)?1.QZO?J(%<\U>E*0/X3+CM^;")'55 V'^")LOAZH+%_2) M5DRN")/+;8LWT65LM!3"5Z?I('0GUP'$.FZY;:: .? U[;8GB"OJ;)B\XG/3 MZX=.LN>=$2"?LNB&$;=U6]XL"Y/+F+( A]E+GN4L3B$.I:2EK,9AR',#:7.J MRC%OIW=>@+[ YKR'1OL&R^6AV:@BN^#Y >]UD5[?Z_JN\_5,VY?$_,.;$]P(@>*35!&17GQ)@D@E.T@,E+2,C5-)A MM>[YLQXV(5V[V=V^RCBX;_.*-7LN+T:;*1-S8.(6F%A.F,@/3&0C$ROY)0D4 M&+]K@X6;R6BG&%@;5]L-YQ##)PT116L8'V%D0GQK@#) MY-]=5>?V(:O)\4LI>^,HIX%9\3:>G&4O79"*4C]:> HK6\>C!8\7R5Y(1R^M MTK/$1&;(F8A):O<@E>.VN('DN;(M::,4$M/7T$EJZN%#B]%!USA03BM0Q@QG M6"[&%CEH+E/6>^@5U@%DM3IHR?@]-Z%;'C_\D3A0)@?2J5,B37G^5NY,&>G1 MB)M65QZT/U]VG(^Q74TY%PQ1K;GC0MT'J#$-NKC,"F;3W?6L;"0K_QQVG9>U M,F?:^9O30.'8FWU1BK6]D!XW\UM$$/9DE.!Y !VI-"EP<]QB&A;$TV+VCX\9 M?[W:CHW$N_/NGM9&9;4L7\?J-(9DPA\.$@=L;I.V\4=8UM+#VWIFF"N[XSL M5 ZFN6=5NG%B*4M C5Q>I-*73IC&M)P(.\?# M_>WR+)\^@9_G8:18,SW02S75;SC'#-@14]TXYU0@D4T\A+'VG/%"687*X V\ M*K(TENJEJ!^$K:YKS MAXS?4[;=-D,[UN\4HE/% 3WGG?0X+,8QZ8%\E Q,#SBM_9!Q>>-2**5#\ $@ MR)MW!B!6_KU.+M?-F!V9SWVZS'#L$(%C-3OJ&YUW^UTEOB2!A]7G>F>A)BZ> M$2L0T6M>YDOM4-X^@#5%QX%BJ0H'BAC-P 4O0A&0Y(BD1]Z5-2D@2(KS'9,F3VSJMBS*:@_A M;GV)&;'A?GK)JWW1Y9Z?L\?=OCL!K[:?,EZ7]7US3;F4;Z6MY75LI$AZP1!K M4_8"%K.?)^(2]BAH".VA=>4C)'3Q#]":#H<"*?84%"RA2I1ML>K[44WR9T 7.U; MR*,L!.B%S09J$B KI+GL%<[JYVGXM:P%IVZEMB[JIYGFTFKHP;JQEN0@ LP!]?(V+ M>V>D#PX/3I]8]22CQ 04Z0(Q^+!@*KA.?I@U&Q-?;2BC*M3/>[W6B!1M,6O5 M)0V]T/!8Z_I/FIOS%@^$M^ER=4S>\BE=P"TQ,YK8 M?6/UK^JLBYDGD.(T&2FTZ A2XL^T+J8YQC$#;D2;^T.P-/CW)U*Y=(CI7T!* MQO+ L72^9008I<_G]R ,K$EB!;A<+#XGT%(P$!QFS[UH"^6:LYS2H@''C(EE MI'T>N4P6QPV]2CXRSMDS")1TZ*W*C- SFUES,'X@K@Q]7[K'G'W(-:Q6#A8\ M['^L1=,%]R>.F3UFX%QH[ Q7$D1E;\<&OT,OB=-^\TNS:O"JI@E(U-?B;UQ['_,FC*WNQ!3C^'W.FR>5G#=$HCT M;0DL;WR2?%VP"Z\[R8B57G=IY%!_V67"_GBGFHPO*)_HF*;Y79S <_4JE@XZ MZP&P9Y\QH6C'H3$BU D9\'L1*W>$,\U:!D2RJ8Q0U*I2HCF#S--<:'!GY):U M697F_+072N;.^62JJ.HT53[K20U-=#IZT-^"?A]BE74?^>=13!?//@,61ELN ML'+!1@)N=00%&/4Y@)(Y%E@ M(@.H,S+^7.*;_'O$>2:7[R&_8BUU+ERFE7F8DT96\TT>S:&6;5%\[V.Z'D5WLPP\5/\T['I\6HXHL] MO2F+_A\+TNHZ'%* L61CF<=8?!B-/1XO4/[F#AR1Z,[(B(], 1X*G4K5R90? M@=:]LTPSWY.3JI.*YJC2/.VG>TJLX^A-WY3$IX^.N3NE1SP$0EP+1XD'_/) DQ2S!H.+=_G[9Z+!0P% _C3 M4A"?ZE%\/8Y^,;=K*@JMB'>6M[\R!W[-3(/]6667U&N,.5 MSEB69&;#H#2N#]V1JTVZOB!5--P@2)&V(Q9:D@'-!PFGN\M;M>J%G"?FA_E)%:P;VK85+>"^D>U; MN/CYR4+G4KSM40V;H9)2,YN!XTOE9DCTE$U/NUJ.:=+;;.5, MHR1I61KU2!&3\GA![]I?LK:O4S2MQ7 M<.?E+JLNZV]BK[A]IM43_465;VV((?D6@>X$[&_UC_R7@JB-@#<9:S\>JE0-7S\SWG M<0V5IJNLBB MWL5643&A$;Q?EJRAWZ,@$QAK\9S8S01S8F^\L-/\@1;[B@Z-!S_2+>.'3)X+ M\4?3EOFF+CZ+GY?WM9'0>AH5&ZKJ1CUX$&L/;]+2\DXBG*2*"8VL1RES 'J< M:UD)OJ:7!9JS!*L'RBZSNCMW1M2?7G:T;L2WU'1;MI8K!SVB\ZJQIAQSQ1S MG;2$[0&2=SW$]^M;+?@IG5TICO.48)57@\/$)%@*\UG3Q\GAENL!/Z3SHK G'7-E MF";CKV]Y.$SI[!IQG:@YB*ND^CH5E=975GWN(LK:&;8.-Z?(\)IBS!K^7OJ MX-$R+5Y%>$'H:GN$1UT+7O<\M@K\TKC!Z[^+!V"G.Q&GI'7?M3QFUHR+5T#G M<5>Q5TIO*)3F$M^JW)DT3V.+Z,R/&EJ4!K)DI)MV6](QEUER+$U GCA[O],* M(KH8D(_3)G.QN7:D8B8H<8*WJ8M]IWI9"WU"3D<", M60!]SIJV,3=AK$9Q-E^,J*43WXX>5T2E]IDPJ]F4U4L[JHY_D:L"@(_JR#\EK:U-\;_[II6!'@L29_FV M4UZ^EDH4\SEA#KTYF]\DP5OR+EZ#*RHCZ*\Y>RH+6GQ\_;6AQ67=U]D7V_*H M;FA*GN 'PK;+LB88O 8B)%IL9:4XF:V^':"0;,3RUS2]MO"3P_QQW%BH[THF M)?5'\9^45OC)WV4G:%I<"3NOAAK:(UUP[M^P+9^UUS&O6DJD#8G@+O .!AEQ MD!%(=Q?T[N;J\_?WAN9]S.\L6+Z'G7"F"IJR.%%+Q:];PN'C[C(AD835Y-OA-.=>/U!_+(A=[1]IK06C];_:'Z(NAI1HLA<^)[ ORWUFJ$]1F#52O<]OW*NV"=AO@J]=>*[JLDWY@LMUV^S <2[<*DA=%^?$ M(ZD.(-+=MZE9?'KC9L"WU+;J-2\9A^2#\??4TEY5C>#79IVC%+R"XN,.2IY# M(\@'\7-*6D9V@(.\"B"DS5Z$A9#S?5:ED4K,I.@M7#VG4\OMN9R-R_I-3!UL M^/*)327,.;A5LA-GQ,!^I=P"0'"KN!/YLB9/ VV2#<3EWW+IYQ9KHNSBUL1Z M6-,RP$RF?G6@9RAQ%ZCCKQC:>(#7_A%"LN5//[WDM!%*T$L?G[UY9/M%K2,4 M&:\=I?!PPA>+!PVS,WSS"9H5M5CR,)?:1DR^)BA>U0#*RZ<,OF.T,""X>_CA M-[JT7LQ?Q&;^:PG8R_03Y7?,-GGWV+?3/&<[5!7X )]CMT3-D:2I1& N4 S/ M5D?G[\\,SLEKSHI]WGXMZ_G@+)-',<[=A2%#"TY'EO1T"1#&.VZ]?0/.42LO M]\&1)/0\8=:2F6]+X(W5R0JS85[,WF5B0VTARON:]_JCU .4$8N&;^%[DJE& MC]!_;"!/1OI=\YRTH8RF7&=(5D83.B'\.:5% _6G+\0.W[1EN^=BT_^X;\2" M$+9+(S;]KM54]_O%/N@N0R'%$T,RM,P.F+K;XB;K//2[?D<48Z0I8.PT.\PG MRR.V)3MM1K5T![7X(+KAV.F X5NFHFMZ^P#;0O]?.SM M@PFS5$C-"K)I_J( M% 75_>'^4Y535ZPX9LX<1^L#O B==*H?'"@(YQGY$ZD:M=(Q$+=3^=PWX6E-J^ M>=AU7TH4R,VJL(KG4 KKS'BA!6"1L+TBZ@4]HI3M0)@,E F0)N\NLM?WB;X" M>Q,@U,E&?L%0Q9;(M2G=8/G0TBZ%@JR2=&;,NA1UMC)>"]NCN:9\N/N6920O MRFH/G4,L2VQA1G.OKF5#-6IAK1X8$?GK=5P<7\N6+//]/BGGX1ZB/\\#O-0:TLMV7>Q5MMQ2YTF[TL+ _OXSN5 ML?: (U;8@S? &'TS!;>.NS;9G?)=3%)#^ A#;"WR8,QR<=CNNYH 3(:U'WN7 MP*O4!5'V43.TJY&:L(JXS\7RIM*X]SF-&/IU'/(YQ#F=9YR_;AE_SOC2S:G- MJ^CP+SV)2.;F6.O53J9C?A=N2S3!DB@6S$*^F MSUZL7R-WAS991%QY5 P,2 ML;0#!93@+9S&:$&QP*$T1V<+_M\^J\KMJ\R;;T@^)-63!X#=2.>-O'7)7N"/ M?_[PEP]_CB/.9-)=3CGCF8R8=M/M C)%^3G;*[S4<5S+C M'NBFC4'3L);9\\[>P=^CJT6/0E!S;__B$U74UC"@$ %RTD$G W9( ML9R@)WVK,55@SMI4?'+AX[Q@&IYG)O+=:-X:2[&#@V,YFZ MM(",;X)B,4*^*W19#-TH?HL&+%$+G\(,9M(A^7]BY&^I6!Q9-?DEN>N2=\]( M)I?6FBH%:*=+7Q; ; YBNJK+FA9]PO2UF#;X7U>HX%P@O6?\U4@=Q ^$=V-; M$@SO[I*(2 ^) )XS^?]]):XS,@!;BV;F,&O,WU2<2ON4%5_%W\0/AQ^)_X-2 M".(G_P]02P,$% @ ?8=G6/*,=3^S<0 C1\* !4 !H8FEO+3(P,C,Q M,C,Q7W!R92YX;6SMO6MSXSC2+OA](_8_]/9^YG37I6]OO',V9-FN]CFNDM=V M=9_9+Q,T"4F8H@@U2,I6__I-D)(LVR28X T@A(B9KBH; #,3"2#SR43BO_^? MIU7TW8;PA++XG]^_^\>/WW]'XH"%-%[\\_NO=][D;GIU]?UW2>K'H1^QF/SS M^YA]___\C__S__CO_\OS/I&8<#\EX7_V=]]V/ MO_W7QY]O/G_W]7[ZW?L?WW_T?OS@_?B+Y_V/_XYH_.V_Q'\>_(1\!T3$2?[/ M?WZ_3-/U?_WPP^/CXS^>'GCT#\87/[S_\<A_ M)?D/KUG@I[D8:UGXKK*%^)>W;^:)'WGOWGL?WOWC*0F_!ZE_]UTA.LXBO?CFTN<;GX4'(#\E*Q*G7LQ2 MXKU[Y\U]RKV-'V7$6Q$_R7C^ZP0XS#^XY&0.7X%!O?U(@J;_6WF@=+L&)4KH M:AV1[W\X8FG-20(-PP]V[06Y_;-74$6>4@(ZO)/TGK"(!2^% +0D>XU+ M2/"/!=O\$!*:TR#^DDLHEP[\X]\7<4K3+2P+G\;[ST7^ XG^^7W5KPMJ(J%0 MC.^$U!$UUV3A1\4W)T\T*2&HHH4236_41/SDWU]@+I)[=DEC6#O4C^[VLY1, M'I*4^T'ZBAS%7HW%-O>3AWP-9HFW\/UU(3L2I MU.8,QO]6P85"C_%RX+W7PL,E+.L_Q*I^)BTYT%;!!:K/H%P<5!KV/7(%?WV] M+NL;ZJ'WWG^(2!VM+QK)Z#P^ 28\^(YQL"?^^3W8)/";.>&[C:'J_,QW M_YP0^&!N _R7F&(2_O/[E&<'*GP>O#E77@ZT:_'#VN?B& F6- KWO>>SA/[[AU(/HS]_ZE#J'I/K[OI\)7*:7">D?., MG&Z])5#*I%!*5U[@&VVWA=N/%SH,D)=0[9""T*YY YA\PY9,XA90GL8TER3I* MTW6^1\7AF9_09#:_.=+?.C>J^4#C=4O&SX%SK)QCY1PKYU@YQ\HY5LZQ,M&Q M:FM7Z7&U0A9D^5]$;A[)==NC\9SQE:+;A1QH8!=,B:I>W+$)?#X4)%Q&_J+$ M_2G]?8\.V20+*0QZ2?GJ*BRCI^SW_=-SO2LC4TW1ZQ;]T_3%7[TV(2M^VR,M M4W':<.)/65A&3-FO^Z0FXV+;O(2MT8_^17Q^$8?GL-C***MIVB.5Y[M5/XGC MS(]NR9KQURY77;,!J /3_"Y=I1><,SYE(*Q J'?%-H'O- CE8DYO"*EMLS#QC0=@,I"VZJW)FF[ >B[ MYWZ<4"&9VKVIJND05,(G9)0=_;I':G;^5AB"?9CL_A":_ZX2VY:T'8I.<2K/ M^#U[K$;@*UL.1>,- S,Y^O_HNL*RJ&\\%*6YPSGC-YQM:%%]4$IK1?/>J9W" MHN!^= 4NQ-/_(MM*,BO:]4\?6ZT86 _@>=Z!%T6269;F%2YI7&9QX#OU3WEA M2A8[('Q8S'#I<8YIWCNUIH3>BL]=K A?@! ^_6[42HF7->Z?V)GN(:' 9,;^:Q)(VO=-U2Q94@))Q6@%7 MR)KU3MW=DD11W:93UJA_RE9^%.TQVVK2REKU3MN]_W05"K1R3@O,JV93K&G? M.[U_L BV#Y\7FV"U-"O:]4[?GZ!?_RL&&_N.^ F+27B5))E$GC7M>Z3W*ICS M';XX25.2%'AX!294WWCTB3V*-#$!-2UAQBH73%63'JFZ(T'&00COWC_F!1"5FEO[;[EE:-#%4D6I$8G,)4!+Y+T=$I%$X=&B^&"'*'!Q6[14 M/MHA%60X$RV6GVP42T7\%"V4G^T2RML(&5H2O]@EB>H,"[1$?K5+(I+0,UHD MO]DE$GFH&V^C666W5L4[\.*PRF95B%S@)62)#:N !>-E8XE1B\P,P%%88N/*8RQX<5ABW\J#.WBD MS1*[5A*ZPX'-B,9+QA*+%IMXA@^=6F+;JM[2 MQ O($H/WHB;A%R\0J\S=RL1QO#RL,G'QMX[P K+$WI749\#+PA(#M[(2 UX2 MEMBSTAH9S](8LK),P.*$133,'Q%X\",?.GC)DI T\0K&ER2E@1\I/*"@/N; M]6::$N@J@?9P8:#AVP3[D^?&YS.>1W_"/_PH(S>$YX?1*\H;]-3%47&63K)T MR3C]F[PN_Z/00R\'.1B(IOYE:[V45U^Y5NDR* \W^^,QI^D+ ^7.E;J"_KKF M&FE'JC^NDRO#BJ%W-C\4(+UA17)730U7]9=VAI>,4[O MNI:KH-JLR#+.8K!..Q1D(K=!\.$'&R2C[&;AL2#+Q-.1UAB*F[842YE3B!:) MH?!I2Y$@,'9M^.'AQXG'YB6/D7:#*#;\BDZ,L17)#G4T!'6MS[3Q5N:>?C&R.=US1.PO]D M29K'X&%/G,RF5S>B2UZ+/Q]'Y*QS6 T\7S5G)"9SFMY$?IQ<,OZ%I'L)-!/F M$.0XY F'/!6S H(NF2L\"*4RBL.CM)L\BA/FH"D'33EHRD%3%3Z2&4>]==K7 M6.8M;-4NG-@7/@<)PD*(5T DB']WKVG"N;C)D[MDWU>?^,>C%(=]$#Z?\?5# MMO(YF_+1VFLLYQ;^\>\W'Z^R-W&-6WN4U91^3GET3_@JF0@?KWIP%=>X M1TJ_L/@VB\B['Q]^>@>?GH1LG9*PI)BHO'$'3X\JTWK/5W&*)/6Y[2"4XD6J M4YYH86J49+$B>]8UK0>D5FS'-/9K5>Y5.QR%XS*&D6#L>;1@E.]R&RL8M->(EHWR;6YC98.R>/6D@<1,4.(EV6KE M\ZU(=X6#6%]:T'I;AB M7LM;#$E9Z3XK;3-H*LKD$0XS4>V^1(+2-H-2>4X386UEG!R JYHT($2/\7+0 M >3:A >AL9P&Z>YJP]>8ILGMW=?2/4*IS[#)5R)C^LP'TUU$JDF<['R#YYCI MV?:YS8V_S7UT$Z+@@-B!6KZ.PA$S]N2QDTZCE)G"#&6-6B&!-TX>J_&VQLZU MW(!G0QHJMHBR.@U7@B.,/0M4NGHD:,[8KS?+^:[&UL8^W_B<QJX6:+27'1JVK;]#C]9RQU#(X^>LY&.25M4.'-(:S/WH+ MQL)'&D6>'X<>A8_&"PI3[OE)0M[<&ZD+86.'TQ&V5J/-A:I//%3MPCDC"^=\ MVJUN\-RO#FM[DB_M$F(KV&HVB /Y'VA@U:T.!' M9\7F>2?VSF<-J$]<:S"$\\"!.0_,>6"-PF&-SQR-_M6A3'4W2^ZH;1X7GA:')NEW.[G-LU)K<+4^!3(0S6=CCG_'*"\G#@4>D1U;16X'$+'[UCTKDE1-E3;72+-<5:>.!2PYN6+0! M]^&EYM:4'$3T<0$W"W(\__ Y%1\7AK5D%58UTT:K=/55-W3!3!?,?"T.%\S< M2\3N8.9I%["3>,M,U3NU1282?X2I(".VR$-J:S,UZ]86F51:/@QO;]@BBUHO MGC7UEFV14'V6" X)L25K!J,QB&B<+>) J$R"ML=JXD2U+!F%KH)/!T#(9 M?655.;YKRR8B\^6:YS':LI-@/%U9#HXM[W[T M0.9T Y_:*+^C7MY9QR4O&27NCM>IW_'2=D_'986/*"O\L'],69QK8&V^(Z:+ M)AZ>Q7I+DV]2S:GOHHF'!'S,2Y_R/_PHJRVD@NTVWCS]\7.@Z:;!59P2,#W2 M',YZ]-?2)&!Y8Y?]Z\KMN Q5EZ'J,E3[B(,C+!'6Q/JR1T(NF[5)'@G6PAT[ M2M]T)6%L'EMDX_*.].4=&1KD&1+E-SS>XU#^ABB_&OR@$_!_[R7BM?$''\3G M0?,UB9,F+Q[5#Z0E$("DR@4%>@T*7.QJG^7L!'O MTT#^I.ERFB4I6Q%>!\&H=G?0BX->'/3BH!<'O8S3EQJM.^E\*:DOU>P%2KKJD66DN7)ZYQ M[_3>D868U$^$+;B_7M+ CRK)K6W;/[5[)3RFH4(5:MOV3VWVD-"0^ARFM?+9 MM>I&XP4_QL^!)OCFDG%"%_&496"TR9]GD34=^#ZI,'CN_:=)EBX9E[\!)6^L MF6YIGE5=* 1 MK,=K^%ST/S-.DY &PKN1$H[LY2!>"UYX@F5?W%R:^IQOYXP_@F,KV:9KV^NG MOC8Q%MEK:$YN"*>L1O9OV^BALDZ^9:U-729(;Y"I>E^VR*7+A.KCHQB\Q99H M,7XW47)];1%/O;)(/ ];A%"YLRJ'Y&S)5\>OFGK$V1:98+2D*HILBPQ0VP4& M)+)HZ\";(S)4&"V0T5;'40B_CET[T"YO;5 #+8G1/C2%3]"P02NP3G]= @!: M%J-]*:B[?-;1/ISB\EFE^:SXX+7.'-:?1(6M%4WS\(#GQZ+B%FATO!!-(NH_ MB$<&J?HM0=5QM62^-B/2)<7VFA1[!;)=Q70.!DF^/^SK5I;G7:AT<7FI*6QB MG 0P=F5N7WF#WNFZIVE$9G.82;JA85:9(2EM-SR5XH;"+8ERM4N6='W/) NY MQ0B#QM(GG(L'\PH%C4.P_OWGG]S#WQ(_1Q[EF5 -1QF4T^GS]@\D3O>;?R!B M6.@LM6:#C#?/=/P<:,J4=9EB_= I'@V8S8_V&UFFDJRMRP-R>4"OQ>'R@(XA M#WOS@' ;!.O(OAF[M.I-<=:!O3MV*>'@981+8P.VC%(7F?Y)L(Q9Q!;;JSB AA**6PSC0B3IOZ\/RU1,?44\L@ITD:]D#V&B]X M/GX.M#UBOB%);I-=)4E&>,U3/G7-M=->4WJBKL.@].RRP!]$#.\.V"*4 M6H./J9M7MLA&'D&K<\;''BRIWT(:(%5C%TJ#&('<[+5.(*C-506NL#^RIN9\ MVZ(QF).G&V39_L!D=['9T=Z9=+%9:6RV 9ZD,R3[B[?F+,P"<2,J)EY(DS5+ MJ/BP:E2V?B0M@5DL62XVVVML]G9RHYVRHQ6/O*PE ?=X%.%^AT@4X7Z'2!SE[@$)3) MRAI;AK9(:N SKTK@3U) MU,IUMS]8ZJXANE"7/-35+0"D,PKVJ[=@&\+C_$=B(X$&T%,U!%8SC);X%XHF M%_SJ-?AE5+RIG,0;?QLL2? -3*J4Y)5-X&\+[J^FL&LDDT!R(5&Q:Q?$%N,G M%Z#+#Q%-EB2\9[/Y/"'I_9)TP7(WB0AFEPG5S4P()J@:)V/?DK QHN-O ?^7O# MLK8ZJ:Y9E#6M=5,N78JU[5V,R<682AQ-%V,ZH1A3W0;'E/<36R2#LL=8,\O' M%AG5XWEXJ]86K!RK-UUXQK9 XVHR:P*"V*)=" 0=8[):(X[&QY?-R\E%FERD MJ6FD20%+TQ-&2NBB*& K@BQ!(!ZDI?'"6[.(BHM?A[_@(TJJ(PX<7&I&GHLS M]5L DZU@MII[[!<,4[@Y)AF8#O'(.*CQUY@2>?_ MW#UP@INYUN,-'&!EX2.-(B#M"JS&>"&*QX#53=)D_ROIO"KW'_82W&H->BP/80%G;AI;3.4AHM_]_X3DJ^:Y@/3_E*%8*N@*S86\_>!5@F/XSA:K1_+F U<(!C4@U\1/L$8# MHL>@''SV^3#&GV)O)C<=%*N-%K01AN%:EV'Y0WD#H!?PTVK@2,XY ?;-T2?AN MW2?/OY]$$7L46#"8V.TCG6;1O)=T;^_C$P#*"PS4CEYRM!,8@5IUX>G$* MZ@G&&\=I0;-!ADTO(PNAEK=DS?@!^D(>%4I]A^5*./!G8%F$ GYWQ0 W6"KBN4I5^06([ET5QO2744QUR6+0L(3L8FGV+6![3KXPV?$W(/(N$CN0Q@"S* 48IBP/PWH!-WCVAN56//WW-)OB[)UR7Y M'DNBXK1C'5G(MBA,M9@ZM2\U0@ ?Q+F9K;((?AIZ3*0)>L%Q-H '(F[H_#<: M6X?;WX)0Y_#WZO!7FH&-I@SE)[=0AL$]Y,DSI7F&;T4>CZ*GW&I4YS$[C]ED M.D_/8VZVH3E?V?G*SE=VOK+SE56

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